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The Endosomal Sorting Complex Required for Transport (ESCRT) machinery facilitates 
topologically equivalent membrane remodelling and scission events in an ever-growing 
number of cellular processes, notably MVB biogenesis and endosomal sorting, 
enveloped viral budding and cytokinetic abscission. ESCRTs are recruited in a modular 
fashion to target membranes by site specific adaptor proteins, where they assemble 
within cytosol-filled membranous stalks to mediate bending and scission away from the 
cytoplasm. 
Cytokinesis is the process of separation of the cell cytosol into two daughter cells during 
cell division. During cytokinesis, the inward constriction of cell membrane eventually 
results in the formation of a thin protein rich stalk-like structure termed the midbody. 
Cytokinetic abscission is the final stage of cytokinesis during which the midbody is 
severed leading to the final resolution of daughter cells. The ESCRT machinery is central 
to cytokinetic abscission, during which it is recruited by the adaptor protein CEP55 to 
the midbody where it mediates the final severing event. 
ESCRT-I is a heterotetramer comprised of TSG101, VPS28, VPS37A, B, C or D and 
MVB12A, MVB12 B or UBAP1. In this thesis, I identify UMAD1 by mass spectrometry and 
coprecipitation assays as another novel alternative MVB12 subunit of ESCRT-I, that is 
able to form a functional ESCRT-I complex and is involved in cytokinetic abscission. A 
direct interaction between the midbody adaptor protein CEP55 with TSG101 has been 
described, and coprecipitation assays have shown that TSG101 binds less well to CEP55 
in the absence of UMAD1. Use of microscopy to more directly examine cytokinetic 
defects and differences in the time taken for abscission to occur have also provided 
evidence for both a generalised role for UMAD1 in mediating successful cytokinesis and 
also contribution specifically at the stage of abscission. We hypothesise that UMAD1 
forms part of an ESCRT-I complex that contributes to abscission in one of two parallel 
partially redundant pathways, the other pathway being mediated by the ESCRT 
associated protein ALIX, which also interacts with CEP55. Consistent with this hypothesis 
are synergistic effects on abscission and cytokinetic defects upon co-depletion of 
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Chapter 1 – Introduction 
1.1. Discovery of the ESCRT machinery 
The ESCRT machinery was first identified in budding yeast (Saccharomyces cerevisiae) 
through a series of light, electron and immunofluorescence microscopy experiments 
aimed at characterising 41 vacuolar protein sorting (vps) mutant genes that showed 
defective sorting of proteins to the vacuole – the equivalent of the mammalian 
lysosome1–5. Vps mutants were classified into six classes, termed A-F, according to the 
distinct vacuole morphologies they displayed. Class E vps mutants had vacuoles of 
normal morphology but displayed the presence of a malformed pre-vacuolar endosomal 
compartment termed the class E compartment1,4. In class E mutants, biosynthetic and 
endocytic cargo destined for transport to the vacuole for degradation, such as 
carboxypeptidase Y, vacuole membrane V-ATPase, vacuolar proteinases and the 
pheromone receptor Ste3 did not reach the vacuole and instead accumulated at the 
class E compartment1,3,4,6. 13 class E vps genes were initially identified. Further work 
focussing on sorting of carboxypeptidase S (CPS) and the G protein–coupled pheromone 
receptor Ste2p showed that class E vps genes were required for sorting of such proteins 
into the multivesicular body (MVB) pathway: in addition to localisation to the class E 
compartment, some GFP-CPS localised to the limiting membrane of the vacuole in class 
E vps mutants, rather than localisation to the lumen, as is mediated by the MVB 
pathway7,8. 
The products of the class E vps genes were later shown to assemble into four endosomal 
sorting complexes required for transport (ESCRT): ESCRT-0, ESCRT-I, ESCRT-II and ESCRT-
III together with the ATPase Vps48–11. The composition and functions of each of these 
complexes is discussed in detail in the following sections. Around the same time, it was 
also shown that ubiquitination of cargo provided a signal for sorting into the MVB 
pathway, and that the ESCRT complexes interact with ubiquitin, thus providing a link 
between the requirements for ubiquitination and class E gene products in MVB sorting8–
10. The ESCRT complexes and Vps4 were found to be sequentially recruited to the 
limiting membrane of late endosomes, to facilitate sorting of ubiquitinated cargo into 
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Intralumenal vesicles (ILVs). The resulting MVBs would later fuse with the vacuole, 
allowing degradation of ILV membrane bound cargo. 
 
1.2. Expansion of ESCRT mediated processes in mammals 
The ESCRT machinery shows strong conservation across eukaryotes, and mammalian 
homologues of all of the yeast class E vps proteins have been identified (Table 1). A gene 
expansion in the number of ESCRT proteins can also be seen, to adapt to an ever-
growing number of discovered ESCRT mediated processes.  
In addition to a role in endosomal sorting to the mammalian lysosome and MVB 
biogenesis, the ESCRT machinery was subsequently established to be essential for other 
topologically equivalent membrane remodelling processes, notably budding of 
enveloped viruses12–15 and cytokinetic abscission16,17. The number of discovered ESCRT 
mediated processes in mammals has continued to grow, extending to processes such as 
nuclear membrane reformation18,19, plasma membrane repair20,21, exosome release22 
and others (Figure 1A). In all of these cases, the ESCRT machinery must assembly within 
cytosol-filled membranous stalks to stabilise negative membrane curvature and 
subsequently mediate membrane bending and scission in ‘reverse’ topology, away from 
the cytoplasm. This contrasts with ‘normal’ topology membrane remodelling towards 
the cytoplasm as seen, for example, in clathrin mediated endocytosis. During clathrin 
and coated vesicle mediated processes of vesicle biogenesis, the scission machinery, 
such as BAR/dynamin family proteins must assemble around the outside of the neck of 
budding vesicles to constrict membrane and mediate severing23–26. 
ESCRT-III represents the macromolecular machine that forms filaments that constrict 
and sever membrane (Section 1.3.4.). As such, it is essential for all ESCRT mediated 
processes. The characterisation of numerous ESCRT mediated processes in mammals 
has shown, however, that in contrast to the classical ESCRT-0 – ESCRT-I – ESCRT-II – 
ESCRT-III pathway of recruitment necessary for MVB formation in yeast, process specific 
pathways for ESCRT-III recruitment exist, mediated by site specific adaptors, that recruit 





 Yeast subunits Mammalian subunits 
ESCRT-0 Vps27 HRS 
 Hse1 STAM1, STAM2 
ESCRT-I Vps23 TSG101 
 Vps28 VPS28 
 Vps37 VPS37A, B, C, D 
 Mvb12 MVB12A, MVB12B, UBAP1 
ESCRT-II Vps36 EAP45/VPS36 
 Vps22/Snf8 EAP30/VPS22 
 Vps25 EAP20 
ESCRT-III Vps20 CHMP6 
 Snf7/Vps32 CHMP4A, B, C 
 Vps24 CHMP3 
 Vps2 CHMP2A, B 
 Did2/Vps46 CHMP1A, B 
 Vps60 CHMP5 
 Ist1 hIST1 
 Chm7 CHMP7 
ESCRT associated proteins Vps4 VPS4A, B 
 Vta1 LIP5 
 Bro1 ALIX, HD-PTP, Brox 
 Doa4 UBPY, AMSH 
   
   
   
   
  
Table 1. ESCRT machinery components 
The subunits of each ESCRT complex are shown for yeast together with their mammalian orthologues. 



















































Figure 1. ESCRT mediated processes 
A. Whilst the ESCRT machinery was initially discovered to play a role in MVB formation and vacuolar 
sorting in yeast, an expansion in ESCRT mediated processes is seen in mammals to include an ever-
growing number of processes. The ESCRT machinery is represented by dark blue spirals at each of its 
sites of action. B. Modular system of ESCRT-III recruitment by site specific adaptors and pathways. 
Characterisation of the expanded number of ESCRT mediated processes in mammals has led to a 
modular model for ESCRT-III recruitment to target membranes. Site specific adaptors recruit ESCRT-III 
to target membranes to play a role in membrane remodelling and scission in a growing number of 
discovered ESCRT mediated processes. Site specific adaptors for each process are boxed. Confirmed 
interactions are represented by solid lines. Interactions that require further validation or that are 
speculative are represented by dashed lines. NPC = Nuclear pore complex, NE = Nuclear envelope, PM 
= Plasma membrane, ARMM = Arrestin domain containing 1 (ARRDC1)-mediated microvesicles, MVB 
= Multivesicular body, ART = arrestin-related trafficking. 
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1.3. Components of the ESCRT machinery 
1.3.1. ESCRT-0 
Although conventionally called ESCRT-0, this complex consisting of hepatocyte growth 
factor-regulated tyrosine kinase substrate (HRS) (Vps27 in yeast) and signal transducing 
adaptor molecule1/2 (STAM1/2) (Hse1 in yeast) has so far been shown only to play a 
role in endosomal sorting of ubiquitinated cargo for lysosomal degradation and MVB 
biogenesis28. It is highly adapted for this function by possession of multiple ubiquitin 
binding motifs and would better be described as an endosomal sorting adaptor protein29. 
HRS and STAM1/2 associate via central coiled-coil GGAs and Tom (GAT) domains30,31 
(Figure 2).  
HRS contains a Fab1p/ YOTB/Vac1p/EEA1 (FYVE) zinc finger domain that specifically 
binds the early endosome associated lipid phosphatidylinositol 3-phosphate (PI3P)32. 
This provides both membrane interaction and endosome specificity33. The N-terminus 
of HRS upstream of the FYVE domain contains a Vps27/HRS/STAM (VHS) domain that 
binds ubiquitin, as do two tandem ubiquitin interacting motifs (UIMs) downstream of 
the FYVE domain, forming a double-sided ubiquitin-interacting motif (DUIM)34–38. In 
addition to these domains, HRS contains a C-terminal clathrin binding box (CBB) for 
interaction with clathrin lattices. This interaction with clathrin has been shown to be 
important for clustering of HRS bound ubiquitinated cargo into endosomal 
microdomains, preventing their recycling to the cell surface, thus committing proteins 
to lysosomal degradation39–41. Recent studies have also shown that the HRS-clathrin 
interaction is important for ILV morphology42. As discussed in the following section, a 
PSAP motif in between the DUIM and the GAT domain is essential for interaction with 
ESCRT-I via interaction with the UEV domain of TSG10143–47. 
Like HRS, STAM1/2 also contains an N-terminal VHS domain and a UIM just downstream 
of this. Together with the ubiquitin binding motifs of HRS, this gives a total of five 
ubiquitin binding motifs in ESCRT-0, providing strong binding to ubiquitin moieties and 
clustering of ubiquitinated cargo at endosomal membranes. STAM1/2 also contains an 
SH3 domain just upstream of its central GAT domain, which recruits the deubiquitinases 


















1.3.2. Focus on ESCRT-I 
ESCRT-I is involved in the majority of ESCRT mediated processes described so far, 
including endosomal sorting8,51–53, viral budding12–14,54, cytokinetic 
abscission17,55, arrestin domain-containing protein 1-mediated microvesicles (ARMMs) 
formation56,57, autophagy58–61 and endolysosomal repair62,63. Whilst a complete 
mammalian ESCRT-I structure has not yet been solved, inter-subunit interactions are 
largely consistent with those elucidated in yeast ESCRT-I, suggesting that mammalian 
ESCRT-I structure is likely to be reasonably well conserved with the structure solved for 
yeast ESCRT-I. Whilst this section focuses on yeast ESCRT-I, mammalian ESCRT-I 
composition is discussed in detail in section 3.1. 
In yeast, ESCRT-I is specifically involved in the process of MVB biogenesis and vacuolar 
sorting of ubiquitinated cargo (section 1.4.). It specifically forms a link between ESCRT-
0 and ESCRT-II, coupling endosomal membrane recognition and binding to ubiquitinated 
cargo with the downstream ESCRT machinery.  
Yeast ESCRT-I is a heterotetramer containing Vps23, Vps28, Vps37 and Mvb12 
subunits8,64–67. The yeast ESCRT-I structure supports a “body and appendages” 
arrangement (Figure 3A), consisting of a central core containing regions of all four 
Figure 2. Domain organisation of ESCRT-0 
ESCRT-0 consists of HRS and STAM, which form a complex capable of strong binding and clustering 
of ubiquitin moieties, through binding up to 5 ubiquitin moieties, through VHS and UIM/DUIM 
domains. HRS additionally contains a clathrin binding box and a central PSAP motif mediates 
interaction with ESCRT-I through interaction with the UEV domain of TSG101. HRS = hepatocyte 
growth factor-regulated tyrosine kinase substrate, STAM1/2 = signal transducing adaptor 
molecule1/2 VHS = Vps27/HRS/STAM domain, FYVE = Fab1p/ YOTB/Vac1p/EEA1 zinc finger 
domain, UIM = ubiquitin-interacting motif, DUIM = double-sided ubiquitin-interacting motif, GAT = 
GGAs and Tom domain, CBB = clathrin binding box, SH3 = SRC homology 3 domain. 
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subunits, from which terminal regions of subunits project by connections to the core via 
flexible linkers. These regions include the N-terminal ubiquitin enzyme variant (UEV) 
domain of Vps23 that binds to ubiquitinated endosomal cargo and to the Vps27 subunit 
of ESCRT-0, the N-terminus of Vps37, and, at the other side of ESCRT-I, the C-terminus 
of Vps28 that interacts with the GLUE domain of the Vps36 (EAP45) subunit of ESCRT-II 
and Vps20 (CHMP6) of ESCRT-III8,35,44,46,64,68,69. 
The yeast ESCRT-I core can be further divided into an elongated stalk and globular 
headpiece (Figure 3A). Whilst the headpiece contains regions of all four subunits, the 
core contains regions of Vps23, Vps28 and Mvb1264. Prior to the discovery of Mvb12 as 
a fourth ESCRT-I subunit, the structure of the headpiece alone was initially solved68,70. 
The headpiece was shown to contain three structurally similar antiparallel helical 
hairpins, each consisting of two a-helices from each of Vps23, Vps28 and Vps37 
arranged at 30° angles from each other like blades of a fan. Vps23 formed the central 
hairpin in between those of the other two subunits. Whilst no contact was seen between 
Vps28 and Vps37, extensive contacts between each of these subunits with Vps23 were 
seen, and stable Vps23-Vps28 and Vps23-Vps37 subcomplexes could be formed. The 
discrepancy between the molecular weight of yeast ESCRT-I, at 350 kDa, and that of the 
full-length recombinant ESCRT-I trimer purified from E. Coli, at 200 kDa, in gel filtration 
experiments suggested the presence of additional subunits in the ESCRT-I complex. This 
led to the discovery of Mvb12 (ORF YGR206w) as the fourth ESCRT-I subunit, as a protein 
that when mutated showed defective Sna3 and carboxypeptidase Y (CPY) sorting64–67. 
Mvb12 showed pairing with Vps23 and Vps37 in yeast proteome-wide screens, and gel 
filtration and co-immunoprecipitation experiments confirmed its incorporation into 
ESCRT-I, further demonstrating that both Vps23 and Vps37 are necessary for its 
incorporation and stability.  
The structure of the entire ESCRT-I core, including the stalk, was subsequently solved 
(Figure 3B)64. The headpiece in this structure matched well with that previously 
characterised for the trimer. Mvb12 was found to contribute both an N-terminal a-helix 
and one strand of an antiparallel b-sheet to the headpiece, the other strand provided 
by Vps28. This b-sheet links the headpiece to the stalk.  
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The stalk contains a hybrid region proximal to the headpiece, a triple coiled-coil region 
and a base64. Helices from each of Vps23, Vps37 and Mvb12 come together at the 
central triple coiled-coil region, whilst in the hybrid region Mvb12 contributes to 
stabilisation of a groove between the same two helices of Vps23 and Vps37 as a series 
of unstructured hydrophobic residues. Mutational analysis has shown that the triple 
coiled coil and hybrid regions represent the most important regions necessary for 
ESCRT-I assembly in yeast, and that correct assembly of all subunits is important for 
optimal sorting function. Disruption of binding between Vps23 and Vps28 or Vps37 led 
to clear class E phenotypes, indicating that an intact complex is required for sorting64,70. 
The base of the stalk consists of a four-helix bundle containing the more C-terminal 
region of the same Mvb12 helix within the triple coiled coil, and two other N-terminal 
helical regions from Vps23 and Vps3764. 
The N-terminal UEV domain of Vps23 binds to the ubiquitinated moieties of endosomal 
cargo and to the Vps27/HRS subunit of ESCRT-08,35,46. UEV domains show homology with 
E2 ubiquitin ligases but lack an active site cysteine residue necessary for catalytic 
activity71,72. They generally consist of a 4-stranded anti-parallel b-sheet against which 
four a-helices are packed, and lack an additional two C-terminal helices found in E2 
ubiquitin ligases. The structure of the UEV in complex with ubiquitin has been solved 
and has revealed a “pincer” like binding mechanism whereby loops within a unique b-
hairpin “tongue” between b-strands 1 and 2, and a “lip” region, closer to the vestigial 
active site within helix 3, come together to grasp a single ubiquitin moiety (Figure 3C)73,74. 
Although a structure has not been solved for the same UEV in complex with the Vps27 
subunit of ESCRT-0, binding sites on Vps27 have been shown to comprise at least a 
581PTVP584 and 524PSDP527 motif and possibly a third 447PSDP450  35,46. These PXXP motifs 
are analogous to similar PT/SAP motifs in mammalian ESCRT-0 and viral structural 
proteins that bind TSG101 (Sections 1.7. and 3.1.1.). Interaction with ESCRT-0 is essential 
for membrane localisation of yeast ESCRT-I and sorting, and binding of the Vps23 UEV 
to ubiquitin and Vps27 can occur simultaneously73,74. By analogy to the human TSG101 
UEV structure (Section 3.1.1.), this is most likely due to separate binding sites for 
ubiquitin and PXXP motifs at grooves on opposite sides of the vestigial active site, 
allowing simultaneous binding13,75,76. 
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The C-terminus of Vps28 is another well conserved appendage that is not required for 
ESCRT-I assembly but is crucial for interaction with ESCRT-II and also shows interaction 
with ESCRT-III68,69. The Vps28 C-terminus interacts with the N-terminus of the ESCRT-II 
subunit Vps36 (EAP45) at its Gram-like, ubiquitin binding in EAP45 (GLUE) domain, at 
one of a pair of zinc fingers (NZF-N), the other being NZF-C, which binds ubiquitin68,77,78. 
The Vps28 C-terminus forms a 4-helix bundle, containing a hydrophobic pocket between 
helices 2 and 3 which binds two hairpin loops of NZF-N79. In contrast, helices 1 and 4 
form the interaction surface for the ESCRT-III subunit Vps20 (CHMP6), with the solvent 
exposed side chain of a conserved phenylalanine residue at position 228 being 
particularly important here69. 
In yeast, the VPS37 N-terminal basic region of 34 residues also represents a helical 
appendage (N-terminal helix (NTH)) that has been suggested to provide some 
membrane binding activity. These residues showed binding to acidic phospholipids in 
vitro but not in vivo64. The C-terminus of Mvb12 from approximately residues 74-84 have 
additionally been shown to bind ubiquitin, representing another UBD. Mutations that 
abolish ubiquitin binding here, however, did not display a strong sorting defect, 














































Figure 3. Structure of yeast ESCRT-I 
A. ‘Body and appendages’ structure of yeast ESCRT-I. ESCRT-I contains a core, which represents a body 
containing regions of all four subunits. The core can be further divided into a stalk, containing regions 
of Vps23, Vps37 and Mvb12, and a headpiece containing regions of all four subunits. Terminal regions 
of subunits project from the core via flexible linkers. These include the Vps28 UEV, the membrane 
binding N-terminal helix of Vps37, the C-terminal UBD of Mvb12 and the C-terminal domain of Vps28 
which interacts with ESCRT-II and ESCRT-III. NTH = N-terminal helix, UEV = Ubiquitin enzyme variant, 
UBD = Ubiquitin binding domain, CTD = C-terminal domain, Ub = Ubiquitin. B. Complete structure of 
yeast ESCRT-I core by Kostelansky et al 2007, as described in the text, showing the stalk and headpiece 
and the hybrid, triple coiled-coil and hybrid regions within the stalk. Orange = Vps23, Green = Vps37, 
Purple = Mvb12, Blue = Vps28. C. Vps23 UEV structure by Teo et al 2004. Ubiquitin (shown in green) 
binds the UEV via a ‘pincer’ like mechanism whereby loops (shown in red) within a b-hairpin ‘tongue’ 
and helical ‘lip’ region form contacts with ubiquitin. The vestigial active site loop is shown in blue. A 
second concavity on the opposite side of this most likely represents the site of binding to Vps27 
(ESCRT-0), by analogy to the structure for the UEV of the human homologue TSG101 in complex with 
a PTAP motif. 
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ESCRT-II is a Y shaped heterotetramer consisting of single copies of each of ELL-
associated protein of 45kDa (EAP45, also called VPS36/Vps36) and EAP30 (Also called 
VPS22/Vps22 or Snf8 in yeast), which form the stalk whilst two EAP20 subunits form the 
arms (Figure 4). All subunits have winged helix (WH) motifs, and PPXY motifs within the 
first winged helix of EAP20 contact pockets within the WH domains of EAP45 and EAP30 
mediating interaction between the subunits81–83. ESCRT-II forms a curvature sensing 
supercomplex with ESCRT-I, that recruits and activates ESCRT-III79,84. The stalk is 
required for interaction with ESCRT-I, as described above, which in yeast is mediated 
through a Vps36/EAP45 GRAM-like ubiquitin-binding in EAP45 (GLUE) domain Npl4-type 
zinc-finger 1 (NZF1) zinc finger interaction with Vps28 of ESCRT-I, whilst NZF2 binds 
ubiquitin77,79. The structure of the GLUE domain in humans is not conserved with yeast 
and does not contain these zinc fingers. Instead, interaction with VPS28 is mediated in 
part by an alpha helix just downstream of the GLUE domain of EAP45, although this is 
not sufficient for binding and other interaction sites are likely to be involved83. Ubiquitin 
binding also occurs via another non-conserved site within the GLUE domain85–87. 
In addition to mediating connection to ESCRT-I and binding ubiquitin, the GLUE domain 
also mediates binding to PI3P68,85. Together with a basic helix at the N-terminus of EAP30 
which binds acidic lipids, this mediates membrane recruitment68,83. Both EAP20/Vps25 
subunits are able to interact with CHMP6/Vps20 via their WH motifs, which bind the N-
terminus of CHMP682,88,89. 
Whilst the role of ESCRT-II in MVB biogenesis and vacuolar sorting has been well 
characterised in yeast, its role in mammals is less clear10,90–92. As discussed more in 
relevant later sections (section 1.4.3. and 1.7.1.), initial studies showed endosomal 
sorting and viral budding to remain relatively refractory to ESCRT-II depletion. Despite 
this, some involvement in these processes has later been described, as has a recent role 
in cytokinetic abscission (sections 1.4.3. 1.7.1 and 4.1.), where it forms a parallel 
pathway for recruitment of ESCRT-III together with the ESCRT associated Bro1 domain 



























1.3.4. Focus on ESCRT-III 
1.3.4.1. ESCRT-III structure 
Whilst ESCRT-0, -I and -II represent complexes that stably assemble in the cytoplasm 
prior to membrane recruitment, ESCRT-III represents a more transient complex that 
assembles directly on membranes. ESCRT-III forms the core macromolecular machine 
that drives membrane bending and scission through polymerisation of subunits 
Figure 4. Domain organisation and interaction partners of human and yeast ESCRT-II 
ESCRT-II is a Y-shaped heterotetramer in both human and yeast, consisting of WH domain containing 
subunits. The stalk is composed of EAP45/Vps36 and EAP30/Vps22 (Snf8), whilst the arms are formed 
by two EAP20/Vps25 subunits which interact with the C-terminal WH domains of EAP45/Vps36 and 
EAP30/Vps22. The N-terminal GLUE domain of yeast Vps36 contains two NZF zinc fingers, the first of 
which mediates interaction with Vps28 (ESCRT-I) whilst the second interacts with ubiquitin. The GLUE 
domain also interacts with PI3P. The human GLUE domain does not contain these zinc fingers and 
instead binds directly to ubiquitin and PI3P. Interaction with VPS28 is instead partially mediated by an 
alpha helix just downstream of the GLUE domain, within a helical domain upstream of WH1 and WH2. 
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involving a complex network of homo and heteromeric interactions. ESCRT-III is 
composed of structurally similar charged multivesicular body proteins (CHMPs) that 
exist in a ‘closed’ autoinhibited soluble form in the cytoplasm prior to nucleation 
mediated transition to an ‘open’ polymerisation competent form on membranes9,94–97.  
Yeast expresses five main ESCRT-III subunits: Vps20, Snf7, Vps24, Vps2 and Chm7 and 
three accessory proteins: Did2, Vps60 and Ist1. There has been an expansion in the 
number of CHMP proteins in mammals to include 12 homologues: CHMP6 (Vps20), 
CHMP4A-C (Snf7), CHMP3 (Vps24), CHMP2A, B (Vps2), CHMP1A, B (Did2), CHMP5 
(Vps60), hIST1 (Ist1) and CHMP7 (Chm7) (Figure 5A). CHMPs are highly charged helical 
proteins with a basic, positively charged N-terminus and an acidic, negatively charged 
C-terminus95,96. Structures for CHMP1B, CHMP3, CHMP4, hIST1 and yeast Snf7 have 
been solved and point to a commonly shared architecture, consisting of five a-
helices95,98–102. Secondary structure predictions also predict a sixth C-terminal helix, 
which due to instability has so far only been seen in the crystal structure for hIST1103. 
This a6 helix is responsible for MIM-MIT domain interactions and/or interactions with 
Bro1 domain containing proteins (Sections 1.3.4.5. and 1.3.5.). In their ‘closed’ 
conformation, the first four helices form a structured asymmetric 4-helix bundle, in 
which the two acidic a3 and a4 helices pack asymmetrically against the basic a1 and a2 
helices which form a 7 nm hairpin95,96,98,99,101. The C-terminal a5 helix folds back on this 
bundle via multiple contacts to maintain a polymerisation incompetent state (Figure 
5B)95,96,98,99,104,105. Consistent with an autoinhibitory role for a5 is the finding that 
various CHMPs form filaments when this region in truncated96,102,106. In their ‘open’ 
conformation, a2 and a3 together form a single helix which extends the hairpin with a1, 
to form an elongated structure which forms multiple hydrophobic and electrostatic 
interactions with neighbouring subunits and membrane acidic phospholipids during 








































Figure 5. Structural organisation of CHMP proteins 
A. Structural organisation of the human CHMP proteins. Each of the 12 human CHMP proteins contain 
6 a-helices. The first four helices play a structural role, whilst a5 plays an autoinhibitory role in the 
‘closed’ state. a6 is responsible for MIM-MIT interactions (Section 1.3.4.5.) and interactions with Bro1 
domain containing proteins, such as ALIX, Brox and HD-PTP (Section 1.3.5.). CHMP7 displays a hybrid 
structure with an EAP20/Vps25-like N-terminus and CHMP6-like C-terminus. Schöneberg et al 2016 B. 
Conformational change upon transition from ‘closed’ to ‘open’ conformations. CHMPs exist in an 
inactivated, ‘closed’, soluble form in the cytoplasm in which the first four helices form an asymmetric 
bundle against which the a5 helix folds back to maintain a polymerisation incompetent state. 
Activation of CHMPs can occur through interaction with CHMP6, CHMP7 or Bro1 domain containing 
proteins and is promoted by negative membrane curvature. CHMPs transition to an ‘open’ 
polymerisation competent form, capable of membrane binding and lateral interactions with other 
CHMP proteins. Structural reorganisation involves formation of a single helix from a2 and a3 which 
forms a hairpin with a1. Adapted from Vietri et al. 2019 
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1.3.4.2. ESCRT-III filaments 
The relative simplicity of the ESCRT system and the smaller number of ESCRT-III proteins 
in yeast has facilitated the elucidation of a defined order of assembly of CHMP subunits, 
through genetic and mutant analysis. ESCRT-III subunits are recruited in the order: 
Vps20, Snf7, Vps24 and Vps2. Vps2 then recruits the AAA ATPase Vps4 for disassembly 
and recycling of ESCRT-III subunits9,107. All ESCRT-III proteins were shown to co-localise 
and form a transient 450kDa complex on endosomes. These proteins were proposed to 
form two subcomplexes being Vps20-Snf7 and Vps24-Vps2 which showed separate 
phenotypes upon depletion. Whilst depletion of Vps20 or Snf7 lead to redistribution of 
Vps2 from class E compartments to the cytoplasm in Vps4∆ cells, depletion of Vps2 or 
Vps24 showed an increase in class E compartment associated Vps20 and Snf79. The main 
constituent of this complex was Snf7, comprising around half of the complex, and 
predicted to contribute around 10-15 subunits to the complex. Overexpression of Snf7 
led to increased polymerisation of Snf7 to form a >600kDa structure with a concomitant 
increase in the diameter of ILVs108. Vps24-GFP was seen to decorate larger Snf7 
structures and a similar increase in polymerisation of Snf7 was seen in Vps24∆ cells89. In 
a separate study, Snf7 also formed filaments at the plasma membrane when 
overexpressed97. It has also been observed in vitro that when Vps24 is mixed with Snf7, 
polymerisation is attenuated89. These studied led to a model whereby the role of Vps20 
is to nucleate polymerisation of Snf7 to form filaments. The Vps24-Vps2 subcomplex 
then caps filaments to prevent further growth, and recruits Vps4 for filament 
disassembly and recycling. Importantly, this sequence of events has been observed 
using fluorescently tagged proteins and also in vitro using purified proteins9,89,107,108. 
Myristoylation of Vps20, probably coupled with electrostatic interactions at its N-
terminus, has been shown to be necessary for membrane binding9. In the case of the 
human homologue, CHMP6, myristoylation has also been shown to favour an open 
conformation, consistent with its role as an upstream nucleating subunit, which 
promotes polymerisation of CHMP4 by causing a conformational change that displaces 
the inhibitory α5 helix from the core109. Negative membrane curvature has also been 
shown to contribute to nucleation, and interaction between ESCRT-I - ESCRT-II - CHMP6 
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has been proposed to form a curvature sensing supercomplex that initiates 
polymerisation88,110,111. 
The function of the main ESCRT-III subunits described above is believed to be largely 
conserved from yeast to humans. However, one prominent difference is the existence 
of additional proteins with potential nucleation ability besides the ESCRT-II-CHMP6 
subcomplex, notably the Bro1 domain containing proteins ALIX, Brox and HD-PTP, and 
also CHMP7 (Section 1.3.5.). Bro1 domain containing proteins bind to the most C-
terminal α6 helix of CHMP4, which also harbours a MIM1 domain (Figure 5A). This has 
been suggested to weaken autoinhibitory interactions and/or promote clustering and 
scaffolding of CHMP4 subunits, thus promoting nucleation112. Whilst CHMP7 displays a 
hybrid structure with an EAP20-like N-terminus and CHMP6-like C-terminus (Figure 5A), 
nucleation capability has not yet been shown113. ALIX can dimerise via its V domain and 
in this way bind two CHMP4 subunits, just as each EAP20 subunit of ESCRT-II can 
nucleate filament polymerisation102,104,108,114–117. 6nm spiral filaments form when 
CHMP4B is overexpressed in COS-7 cells, and this filament width is likely to be due to 
bundling of pairs of 3nm filaments, as seen mediated by ALIX in vitro97,114. Nucleator 
mediated bundling is likely to account for some of the variation seen in filament width 
both in vitro and in vivo97,102,118–120. Variation in filament width is required to 
accommodate the observed severing of membrane necks of varying diameter by the 
ESCRT machinery. For example, the necks of nascent ILVs are generally 20-40nm in 
diameter, whilst during cytokinetic abscission, the midbody connecting nascent 
daughter cells is around 1µm wide118,121. 
 
1.3.4.3. Membrane deformation by ESCRT-III 
Both in vitro and in vivo electron microscopy studies have shown formation of ESCRT-III 
polymers of varied morphologies and dimensions, involving both homo and 
heteropolymerisation of CHMPs. Spirals, tubes, coils and cone structures have been 
observed, and this diversity in structure has made it difficult to define a unifying 
mechanism for ESCRT-III action102,104,106,119,120,122. It also strongly suggests that ESCRT-III 
can assume a variety of different structures to accommodate scission at different sites 
of ESCRT action. CHMP4 has been shown to form spirals of approximately 4nm diameter 
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filaments both in vitro and in vivo, at the plasma membrane of COS-7 cells (Figure 
6A)97,104,119,123. Analysis of yeast Snf7/CHMP4 showed that whilst the inner ring of similar 
spirals is overbent, the outer rings are underbent, and the resulting stiffness of the 
filaments is predicted to be sufficient for the spirals to behave as mechanical springs. 
When these spirals covered the entire membrane, they showed buckling activity due to 
release of elastic energy and protruded from the plasma membrane into tubes123. 
Similarly, in the case of human CHMP4A, overexpression in a VPS4 mutant background 
resulted in tubular evaginations from the plasma membrane, consistent with the 
characteristic ESCRT mediated deformation of membrane away from the cytoplasm 
(Figure 6C)97. CHMP2B showed similar formation of tubes when overexpressed124. 
Earlier studies showed Snf7 to form sheets, rings and filamentous structures when 
activated by truncating the C-terminus105,114,123. CHMP2A and CHMP3 have been found 
in vitro to form approximately 50nm membrane associated heteropolymeric tubes, the 
inner surface of which recruits VPS497,106,125. Interestingly, these two subunits also form 
cones and domes closing the tubes, potentially consistent with the role for these CHMPs 
in capping filaments to prevent further growth (Figure 6B). A further interesting 
observation from another study was that the addition of Vps24 and Vps2 to 
recombinant Snf7 caused formation of filaments of a greater diameter to be formed, 
showing an increase from 9nm to around 65nm104.  
A high resolution cryo-EM structure was recently solved for a double-stranded helical 
filament of approximately 7nm consisting of N-terminal domains of hIST1 and CHMP1B 
subunits102. Intriguingly, this structure showed hIST1 to form the outer strand of the 
helix in a ‘closed’ conformation whilst CHMP1B formed the inner strand in an ‘open’ 
conformation (Figure 6D). The resulting tubule had a negatively charged exterior and 
positively charged interior that was capable of membrane binding with normal topology: 
the structure assembled around rather than inside membrane. This structure is 
interesting in that it opens up the possibility that ‘closed’ CHMP conformations may not 
always represent polymerisation incompetent conformations, and that CHMPs could be 
capable of directing membrane scission of normal rather than ‘inside-out’ topology in 





























1.3.4.4. Models for ESCRT-III mediated membrane scission 
A consensus model for the mechanism of ESCRT-III mediated scission does not exist yet. 
Reasons for this include the difficulty in proposing a model that unifies all of the above 
described structures, and it is likely, given the variety of structures seen, that more than 
one mechanism exists. It is also unclear whether or not some of the above described 
structures genuinely exist under physiological conditions, due to the overexpressed 
nature of the CHMPs in these studies. Furthermore, as particularly evident from 
studying ESCRT-III in mitosis/cytokinesis, CHMPs do not show redundant functions, so 
Figure 6. Cryo-EM ESCRT-III polymer structures 
A. C. elegans CHMP4 spirals Shen et al 2014 B. Cone capped tubules of CHMP2A-CHMP3 Effantin et 
al. 2013 C. Buds and tubules of CHMP4A protruding from membranes in a VPS4 mutant background 
Hanson et al 2008. D. Cryo-EM reconstructed hIST1NTD-CHMP1B tube. IST1 = light green outer strand, 
CHMP1B = dark green inner strand. McCullough et al 2015 
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lack of the entire complement of CHMP proteins used in the above studies is also not 
representative of physiological conditions. 
Earlier more simple models proposed for membrane constriction and severing included 
a filament mediated model based on the observed ability of Snf7/CHMP4 to polymerise 
into tight spirals, thus providing the force necessary to constrict membranes (Figure 
7A)97,114. This model, however, does not take the capping role of CHMP2 and CHMP3 
into account. A VPS4 mediated remodelling model has also been proposed, suggesting 
that VPS4 actively mediates constriction of assembled tubular structures within 
membrane tubes by sequential removal of ESCRT-III subunits (Figure 7B)89,97,105,126. This 
would lead to constriction and thinning until opposing membranes are close enough for 
scission to be energetically favourable. Although VPS4 is essential for ESCRT-III 
disassembly and recycling, whether it plays a role in filament constriction, remodelling 
and/or severing remains an open question. Going against a role in constriction would be 
the observation in yeast that ILV formation was not perturbed by the absence of Vps4 
or Vps2, however Vps4 was required for subsequent budding events127. This is more 
supportive for a role in recycling.  
A ‘whorl’ model was originally put forward to account for ILV formation in yeast and 
takes into account the abovementioned upstream ability of ESCRT-I – ESCRT-II – CHMP6 
to sense negative membrane curvature and nucleate polymerisation of pairs of CHMP4 
filaments (Figure 7C)84. These pairs of filaments are stabilised by their interaction with 
ESCRT-I and -II, and form spokes that extent into a whorl, meeting at the point of scission, 
at which VPS4 is involved in clustering the ends of the spokes. Membrane-filament 
interaction would naturally cause membrane to constrict towards the site of scission. 
Consistent with this model is the finding that deletion of one Vps25/EAP20 subunit of 
ESCRT-II in yeast disrupts ILV formation108. 
A dome model has been put forward to account for the abovementioned ability for 
CHMP2 and CHMP3 to form dome shaped caps at the ends of tubes, and represents the 
best supported model so far (Figure 7D)106,128. In this model, membrane is scaffolded by 
tubules which taper to the point of scission at the dome shaped caps. Membrane 
interaction with the progressively narrowing polymers at the cap would constrict 
membrane, pulling opposing membranes together until a diameter narrow enough to 
favour spontaneous fission (approximately 3nm) is reached106,128–130. Whether VPS4 is 
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required for fission in this model is still unclear102,130. This model is more consistent with 
the observation that the ESCRT machinery can mediate scission of tubes of varied 
diameter ranging from 50nm-1µm.  
An inverse buckling model has additionally been proposed based on the overbent inner 
filaments and underbent outer filaments seen in Snf7/CHMP4 conical structures (Figure 
7E)123,131,132. In this model, polymerisation would occur outwards from the centre of the 
spiral. VPS4 mediated severing of the overbent inner ring would then release the spiral 
from upstream ESCRTs such as ESCRT-I, -II and/or viral Gag proteins, and cause 
relaxation of the cone back into a flattened disk129. The concomitant release of energy 




















































1.3.4.5. MIM-MIT domain interactions 
With the exception of CHMP3, all CHMP proteins contain C-terminal MIT-interacting 
motifs (MIMs)96,101,133. In CHMP ‘open’ conformations, these interact with varying 
affinities to microtubule interaction and transport (MIT) domains found in a variety of 
important ESCRT-III associated proteins, particularly those involved in cytokinetic 
Figure 7. ESCRT-III polymerisation 
models 
Proposed models for ESCRT-III 
mediated membrane scission from 
within narrow membranous stalks, 
as described in the text include A. 
Filament mediated model. B. VPS4 
mediated model. Martin-Serrano 
and Neil 2011. C. Whorl model. Red 
= ESCRT-I – ESCRT-II, Green = 
ESCRT-III filaments, Purple = VPS4. 
McCullough et al. 2013 D. Dome 
model. Green = ESCRT-I, Purple = 
ESCRT-II, Blue = CHMP4, 
red/yellow = CHMP2/CHMP3 E. 
Inverse buckling model. Green = 
ESCRT-I, Purple = ESCRT-II,  Red = 




abscission (discussed in more detail in sections 1.5.5. – 1.5.7.) and notably VPS4 and its 
activator LIP5134,135. MIT domains consist of asymmetric three-helix bundles. Two classes 
of MIM motifs have been described according to their structure and interaction surface 
with MIT domains. MIM1 domains were initially characterised as single helices 
containing the consensus sequence (D/E)XXLXXRLXXL(K/R), and with the exception of 
hIST1 are represented by the single a6 helix of CHMPs 1, 2, 4, 5 and 7103,136. A MIM1 
motif in hIST1 is located downstream of a6 towards the C-terminus101. MIM2 domains 
are found in CHMPs 4 and 6, upstream of a6 and a5 respectively126. hIST1 contains a 
MIM2 motif upstream of its MIM1126. The single amphipathic helix of MIM1 domains 
interacts through conserved leucine residues with the groove in between helices 2 and 
3 of MIT domains136,137. MIM2 domains, conversely, form extended structures with the 
consensus (L/V)Px(V/L)P (where x denotes a hydrophilic residue) that bind in the groove 
between MIT domain helices 1 and 3126. As discussed in the context of cytokinesis in 
sections 1.5.5. – 1.5.7., preferences in binding are seen for the MIT domains of certain 
ESCRT accessory proteins for certain CHMPs. 
 
1.3.4.6. VPS4 AAA ATPase 
VPS4 is the AAA ATPase required for ESCRT-III filament disassembly and recycling by 
harnessing the energy from ATP hydrolysis to mechanically disassemble polymers. VPS4 
exists as monomers or dimers in the cytoplasm and depends on binding to both ATP and 
ESCRT-III filaments for assembly and activation138–141. Cryo-EM structures have shown 
that VPS4 assembles to form two asymmetric hexameric rings that combine to form a 
membrane-bound dodecameric structure139–143. Each monomer consists of an N-
terminal MIT domain and an ATPase cassette that can be further divided into a large and 
small ATPase domain144. The large domain is responsible for catalytic activity, containing 
a Walker A motif responsible for ATP binding and a Walker B motif responsible for 
hydrolysis. An arginine finger also facilitates coordination of ATP at subunit interfaces.  
Loops within the large ATPase domain also mediate interaction with ESCRT-III filaments. 
The small domain contains a b-domain within an internal loop structure that binds to 
the VPS4 activator, LIP5145–149.  
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Binding to ESCRT-III filaments is mediated at the exposed C-termini of CHMP proteins 
via MIM-MIT domain interactions, and binding activates VPS4 by relieving autoinhibitory 
interactions previously mediated by its MIT domain138,150,151. Cryo-EM structures point 
to a ‘conveyor-belt’ model of action whereby VPS4 translocates along ESCRT-III 
filaments which pass through the central pore of the hexamers one dipeptide at a time 
(Figure 8). Cycles of ATP hydrolysis lead to the movement of the loops, which force 
conformational changes in CHMP subunits causing them to unfold and disassemble139,141. 
According to this model, when the subunits of the VPS4 hexamer are labelled A-F, the 
subunit in position F of the hexamer detaches from that in position E and re-joins the 
hexamer at position A, binding the next ESCRT-III dipeptide motif. Hydrolysis of ATP is 
proposed to occur at the interface between subunits C and D whilst ADP and ESCRT-III 
subunits are released at the E to F transition139,141. 
LIP5 binds to the VPS4 b-domain through a Vta1–SBP1–LIP5 (VTA) domain and is 
believed to activate VPS4 in two ways. Firstly, from a structural point of view it links the 
b-domain to the ATPase domain of adjacent subunits, around the ring exterior140,141. 
Secondly, it contains two tandem MIT domains that bind to the MIM domains of CHMPs, 
thus facilitating their interaction with VPS4. Since the MIMs of CHMP4 and CHMP3 do 
not bind as strongly to the VPS4 MIT domains as those of CHMPs 1, 2, 5, 6 and hIST1, 
prior interaction of CHMPs 4 and 3 with LIP5 has been suggested to facilitate their 
disassembly. Alternatively, it has been proposed that these CHMPs simply disassemble 
























1.3.5. Bro1 domain containing ESCRT associated proteins 
Although often referred to as accessory proteins of the ESCRT machinery, Bro1 domain 
containing proteins Bro1 in yeast, and ALIX, HD-PTP and Brox in mammals are essential 
in a wide variety of ESCRT mediated processes. These ESCRT associated proteins 
represent important scaffolding platforms that form numerous interactions with 
upstream ESCRT proteins, ESCRT-III, membranes and a variety of other proteins outside 
the ESCRT family. Bro1 domains generally consist of 14 a-helices and 3 b-sheets that 
form a banana-shaped structure, the convex surface of which has been proposed to 
potentially sense negative membrane curvature152–154. Six helices towards the centre 
form three tetratricopeptide repeat-like helical hairpins, organised in a right-handed 
superhelix. This is flanked by a more N-terminal helical bundle and the b-sheets.  
 
1.3.5.1. Bro1 
Yeast Bro1 consists of a Bro1 domain at its N-terminus followed by a central coiled coil 
region, called the V-domain, and a proline-rich C-terminal domain155,156. Bro1 is essential 
for endosomal sorting in yeast, as evidenced by localisation of GFP-tagged CPS to the 
vacuole membrane rather than to the lumen in Bro1 mutants155. Furthermore, 
Figure 8. ‘Conveyor-belt’ model of VPS4 translocation along ESCRT-III filaments 
Hydrolysis of ATP occurs betweensubunits C and D of the VPS4 hexamer, providing the energy to 
disassemble ESCRT-III filaments as VPS4 translocates along a filament one dipeptide at a time. the 
subunit in position F of the hexamer detaches from the subunit in position E and re-joins the hexamer 
at position A, binding the next ESCRT-III dipeptide motif. LIP5 adaptor protein, required for VPS4 
activation, is shown in light brown around the VPS4 ring exterior. Monroe et al. 2017 
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Figure 8. ‘Conveyor-belt’ model of VPS4 translocation along ESCRT-III filaments 
Hydrolysis of ATP occurs betweensubunits C and D of the VPS4 hexamer, providing the energy to 
disassemble ESCRT-III filaments as VPS4 translocates along a filament one dipeptide at a time. the 
subunit in position F of the hexamer detaches from the subunit in position E and re-joins the hexamer 
at position A, binding the next ESCRT-III dipeptide motif. LIP5 adaptor protein, required for VPS4 
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overexpression of Bro1 has been shown to inhibit Vps4 mediated ESCRT-III disassembly 
in vitro and in vivo and this leads to a reduction in the efficiency of ILV detachment from 
late endosome membranes157.  
Bro1 binds Snf7/CHMP4 via a conserved hydrophobic surface in the middle of the 
concave side of its banana shaped Bro1 domain, and this interaction is required for 
endosomal localisation and function153,155. Some endosomal localisation is still observed, 
however, when the Snf7/CHMP4 binding site is mutated, suggesting that other 
mechanisms for membrane recruitment are present153. Bro1 binds a motif in 
Snf7/CHMP4 that is similar to a MIM1 motif and analogous to the site in mammalian 
CHMP4 homologues that binds ALIX (see below)157. Bro1 has also been shown to play a 
seemingly separate role in recruitment of the ubiquitin hydrolase Doa4/UBPY to 
endosomes158. This interaction is mediated by its proline rich domain, which binds to 
the catalytic domain of Doa4 and stimulates its activity159. Doa4 localisation to 
endosomes and deubiquitination is impaired upon deletion of Bro1160. This role appears 
to be separate from the above-mentioned role in inhibiting ESCRT-III disassembly, as 
overexpression of Bro1 has no effect on deubiquitination of CPS, and ILV formation is 
reduced upon deletion of Bro1 but not Doa4157,159. 
The V-domain of Bro1 binds ubiquitin and has also been found to bind Rfu1 – a regulator 
of ubiquitin homeostasis, that inhibits the activity of Doa4161,162. Bro1 binds a YPEL motif 
in Rfu1, analogous to the YPXnL motifs of cellular and viral structural proteins that bind 
ALIX (see below), and is necessary for endosomal localisation of Rfu1162. In addition to 
Rfu1, the proline rich domain of Bro1 binds the ubiquitin ligase Rsp5, which has been 
implicated in the degradation of Rfu1163. A more precise relationship between these 
proteins and Bro1 in ubiquitin regulation remains to be investigated, but it would appear 
from the above findings that Bro1 plays an important role in bringing together important 
regulators of ubiquitin homeostasis in yeast. 
 
1.3.5.2. ALIX 
ALG-2-interacting protein X (ALIX, also called AIP-1), together with HD-PTP (see below) 
is one of two mammalian homologues of yeast Bro1, that shows 22% sequence identity 
with Bro1164. ALIX was initially discovered as an interaction partner for the calcium 
binding protein ALG-2, which is involved in apoptotic signalling165,166. It is an essential 
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ESCRT associated protein involved in a wide variety of ESCRT mediated processes 
including viral budding, cytokinetic abscission, endosomal sorting, exosome biogenesis 
and plasma membrane repair, as discussed in the relevant sections. 
Like yeast Bro1, ALIX consists of a Bro1 domain, a central V domain and a C-terminal 
proline rich domain (Figure 9). As in the case of Bro1, the banana shaped Bro1 domain 
of ALIX binds to CHMP4 proteins at its concave surface via an interaction through the 
same hydrophobic patch as in yeast Bro1 with the most C-terminal amphipathic helices 
of CHMP4 paralogues167. A distinct pattern of hydrophobic residues in these CHMP4 
helices with the consensus M/L/IxxLxxW, differs from that seen in CHMPs 1-3, which 
display the consensus L/I/MxxxLxxL, and thus confers binding specificity to Bro1 domain 
containing proteins rather than MIT domain containing proteins (Section 1.3.4.5)167. In 
addition to binding CHMP4 paralogues, the Bro1 domain has been implicated in binding 
the nucleocapsid (NC) of HIV-1, in addition to the interaction between the V domain 
with HIV-1 p6 (section 1.7.1.)168–170. A unique loop within the Bro1 domain also mediates 
binding to the late endosome associated phospholipid LBPA and an additional conserved 
hydrophobic patch at the tip of the Bro1 domain has also been found to bind the SH2 
domain of Src kinase, implicating ALIX in endosomal sorting as discussed further 
below171,172.  
The V-domain in ALIX consists of two extended 3-helix bundles, forming two helical arms 
that form a V shape, at approximately 30° to each other, hence the name for this 
region152,173,174. This contrasts with the single coiled-coil in the V-domain of yeast Bro1, 
although this also forms a similar V shape, with two arms connected by a flexible 
hinge161,162. Dimerisation of ALIX is essential for its function and this is mediated via the 
V-domain114,161,175,176. The second of these V domain helical arms also binds 
polyubiquitin chains and the YPxnL motifs found in cellular and viral structural proteins 
(sections 1.7.1 and 1.8.)152,173,175,177. A conserved phenylalanine residue at position 676, 
within a conserved FYX2L sequence is particularly important in mediating interaction 
with YPXnL motifs173. 
A number of binding partners have been identified for the C-terminal proline rich region 
of ALIX including CEP55 and TSG101 (sections 1.5.4 and 4.1), ALG-2 (sections 1.8.2. and 
4.1.), endophillins, the SH3 domain of Src kinase, and Cin85 (also known as SETA or Ruk), 
as discussed below172,178,179. In addition to the unique loop in the Bro1 domain that binds 
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LBPA and the necessity for dimerization, a further unique feature of ALIX is 
autoinhibition in its cytosolic form, which is again mediated by the proline rich region. 
The PRR folds back, interacting with the Bro1 domain and renders the Bro1 and V 
domains inaccessible to binding partners180. Activation of ALIX has been proposed to 
occur by a number of mechanisms including dimerization, interaction with the 
abovementioned binding partners and phosphorylation in the PRR114,180–182. 
Depletion of ALIX has not conclusively been shown to block degradation of EGFR, and 
ALIX has not been shown to play as prominent a role in endosomal sorting as HD-PTP, 
or function in classical ubiquitin mediated receptor internalisation into ILVs90,183–185. 
Nonetheless, involvement in negative regulation of EGFR sorting at the plasma 
membrane has been implied through its interactions with Cin85, endophilin and Src 
kinase. ALIX binds to the SH3 domain of Cin85 – an adaptor protein for Cbl E3 ubiquitin 
ligase, which ubiquitinates the cytoplasmic domain of membrane bound EGFR leading 
to its endocytosis186–188. It also binds the SH3 domains of endophilins, which facilitate 
endocytosis189,190. This is believed to prevent association of endophilins and Cin85 with 
Cbl, thus preventing ubiquitination and endocytosis of EGFR188. Conversely, stimulation 
of EGFR activates Src kinase which via its SH2 domain first binds the Bro1 domain of ALIX. 
Its SH3 domain also binds to the PRD of ALIX. Hyperphosphorylation of ALIX by Src kinase 
prevents interaction of ALIX with Cin85, thus allowing Cin85 to interact with EGFR bound 
Cbl172,188. A further example of involvement of ALIX in a non-classical ESCRT mediated 
sorting process is in the ubiquitin independent sorting of PAR1 – the G protein coupled 
receptor for thrombin. Sorting of PAR1 into ILVs does not require recognition of 
ubiquitin moieties by ESCRT-0, -I and -II and instead interacts directly with the V-domain 



























Like the other ESCRT associated Bro1 domain containing proteins, His Domain Protein 
Tyrosine Phosphatase (HD-PTP, also called PTPN23) consists of a Bro1 domain followed 
by a V-domain and PRD. However, it contains an additional C-terminal protein tyrosine 
phosphatase (PTP) domain and PEST domain (Figure 10)192. Unlike ALIX which plays a 
role in the numerous ESCRT mediated processes listed above, HD-PTP has so far been 
shown to play a role specifically in endosomal sorting and MVB biogenesis184,193–197. It is 
highly adapted to this role, as evidenced by interactions with ESCRT-0, ESCRT-I and 
ESCRT-III. HD-PTP has been shown to be essential for the sorting of EGFR, MHC class I, 
PDGFR-b and a5b1 integrin, and its depletion disrupts EGFR sorting and leads to 
accumulation of ubiquitin-conjugated proteins in malformed endosomal 
compartments184. 
In contrast to ALIX, HD-PTP does not dimerise or show autoinhibition, and adopts a more 
rigid extended conformation198,199. The V-domain is considerably different from that in 
Bro1 or ALIX and forms a continuous extended backbone. Like the V-domains of ALIX 
and Bro1, this region also interacts with ubiquitin. Importantly, however, it also directly 
Figure 9. Domain organisation and interaction partners of ALIX 
ALIX consists of an N-terminal Bro1 domain, a central coiled-coil region known as the V-domain and a 
C-terminal proline rich domain (PRD). ALIX mediates interaction with multiple ESCRT and ESCRT 
associated proteins, notably CHMP4, thus ESCRT-III, CEP55, TSG101, and YPXnL containing viral 
structural proteins such as HIV-1 p6 Gag and EIAV p9 Gag (Section 1.7.1.). Approximate central binding 
residue positions, or regions are shown for each interaction partner. Dotted line represents a 
generalised region through which binding occurs, although more precise mapping of shorter 
regions/residues involved have yet to be elucidated. PRD = Proline rich domain, NC = nucleocapsid, 
LBPA = Lysobisphosphatidic acid, PAR1 = Protease-activated receptor-1, CIN85 = Cbl-interacting 
protein of 85 kDa, ALG-2 = Asparagine-linked glycosylation protein 2 homolog, TSG101 = Tumor 
susceptibility gene 101, Centrosomal Protein of 55 kDa 
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interacts with UBAP1 – an MVB12-like subunit of mammalian ESCRT-I that is highly 
adapted for recognition of ubiquitin and endosomal sorting (Sections 1.4.3 and 
3.1.4.)184,199. Interaction with UBAP1 occurs via the same conserved FYX2L motif that in 
ALIX binds the YPXnL motifs of viral structural/cellular proteins, and in this case binds to 
an FPXL motif within the centre of UBAP1 between its UMA and SOUBA domains (section 
3.1.4.)199. The Bro1 domain of HD-PTP binds the ESCRT-0 subunit STAM, via its GAT 
domain, at the same hydrophobic pocket that interacts with CHMP4 proteins197,200. 
CHMP4 proteins and STAM therefore compete for binding to HD-PTP at this site. 
Likewise, the proteins SARA and endofin, which are involved in TGFb receptor signalling, 
also compete with CHMP4 for binding to this site201. STAM also interacts with the PRD 
via its SH3 domain, by recognising a PPRPTAPKP binding motif, that also interacts with 
TSG101197,200. An interaction between the EGFR adaptor Grb2 with the PRD has also 
been described, further highlighting how highly adapted HD-PTP is to its sorting 
function202. The PTP domain of HD-PTP has largely been shown to be catalytically 
inactive, due to divergence of residues that are normally conserved within the 
phosphatase domain203. It does appear to show phosphatase activity towards FYN 
kinase, however204. This suppresses FYN activity and has been suggested to account for 
the identity of HD-PTP as a tumour suppressor. The C-terminal PEST domain 
corresponds to a known proteolytic signal that likely accounts for the short half-life of 
HD-PTP192. The relevance of the PTP and PEST regions have not yet been studied in detail. 
Interactions with the abovementioned subunits of ESCRT-0, -I and -III together with their 
competition for binding to identical sites on HD-PTP has led to proposal of a shuffling 
model for ILV sorting of ubiquitinated cargo205. According to this model, HD-PTP would 
support the sequential recruitment of ESCRT-0, -I and -III, by first binding STAM (ESCRT-
0) at the two interaction surfaces described above. Binding of ESCRT-I via TSG101 and 
UBAP1 subunits would then compete with ESCRT-0 for binding to HD-PTP at the PRD, 
partially displacing ESCRT-0 whilst maintaining the STAM GAT domain interaction with 
the Bro1 domain. ESCRT-III CHMP4 interaction with the Bro1 domain would further 
displace STAM, leaving ESCRT-0 bound to HD-PTP only via any potential interaction with 
EGFR, via Grb2. According to this model, the ubiquitin binding domains of ESCRT-0 and 
ESCRT-I would be located close to the EGFR binding site on HD-PTP, at the opposite side 
of the protein from where ESCRT-III binds, at the Bro1 domain and via the VPS28 (ESCRT-
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I) – CHMP6 interaction. This both supports a model for sequential recruitment of ESCRTs 
and further extends this model to potentially explain how ESCRT-III could be positioned 
at the necks of nascent ILVs, juxtaposed with the ubiquitinated cargo 20-30nm away to 




















































































































Although at an early stage of investigation at present, Brox represents another ESCRT 
associated Bro1 domain containing protein that encodes a short CAAX farnesylation 
motif downstream of its Bro1 domain, in place of the V domain and PRD206. Like ALIX 
and HD-PTP, Brox binds to CHMP4 paralogues but also to CHMP5207. Structural 
characterisation of these interactions has shown that whilst both CHMP4 proteins and 
CHMP5 interact with the same concave hydrophobic surface of the Bro1 domain, The C-
terminal regions of these CHMPs that interact with Brox are completely different. Whilst 
the C-terminus of CHMP4 proteins forms an amphipathic a-helix, as described above, 
that of CHMP5 forms a tandem b-hairpin structure consisting of three short b-strands. 
















Figure 10. Domain organisation of HD-PTP and model for action in endosomal sorting 
A. Domain structure and interaction partners for HD-PTP. HD-PTP contains an N-terminal Bro1 
domain, a V-domain and a PRD like ALIX, however it also contains a largely catalytically inactive PTP 
domain and a PEST domain, suggested to be involved in protein degradation. Approximate central 
binding residue positions, or regions are shown for each interaction partner. Dotted lines represent a 
generalised region through which binding occurs, although more precise mapping of shorter 
regions/residues involved have yet to be elucidated. PRD = Proline rich domain, PTP = protein tyrosine 
phosphatase, SARA = Smad anchor for receptor activation, Grb2 = Growth factor receptor-bound 
protein 2. B. Model for sequential shuffling of ESCRT complexes by competitive binding to HD-PTP. 
HD-PTP first interacts with ESCRT-0 at endosome membranes by binding to STAM1/2 at both its 
binding sites. Binding of TSG101 and UBAP1 would then displace STAM1/2 from its binding site within 
the PRD, but leaving it still able to bind via its GAT domain at the Bro1 domain. Subsequent binding of 
CHMP4 to the Bro1 domain would fully displace STAM1/2 leaving ESCRT-0 only able to interact with 
HD-PTP via interaction with EGFR via Grb. Later recruitment of the deubiquitinase UBPY (Section 
1.4.3.) via STAM1/2 can also be accounted for by this model. Tabernero and Woodman 2018 
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1.4. ESCRTs in endosomal sorting 
1.4.1. Overview of the endosomal system 
The endocytic pathway in mammals comprises a transport system of heterogeneous 
membrane bound compartments that through various morphological changes and 
fusion events serves to sort incoming intracellular cargo back to the extracellular 
environment or to the lysosomes/vacuole for degradation. The system can be divided 
into a recycling system consisting of the plasma membrane, early endosomes (EEs) and 
recycling endosomes; a degradative system consisting of endolysosomes and 
lysosomes; a feeder system connecting the recycling and degradative systems consisting 
of late endosomes (LEs); and a biosynthetic system linked to both the recycling and 
degradative systems represented primarily by the trans-Golgi network (TGN) (Figure 
11)208.  
Cells are constantly sampling their extracellular environment, taking up solutes, 
macromolecules, receptor-ligand complexes, lipids and nutrients. The majority of this 
internalised cargo is returned to the extracellular environment via the recycling pathway. 
Cargo is internalised into primary endocytic vesicles such as those formed by clathrin 
mediated endocytosis. EEs are believed to form from fusion of these primary endocytic 
vesicles, and function to further sort cargo into recycling endosomes and return them 
to the extracellular environment, or to sort them into LEs for entry into the degradative 
system208.  
EEs contain both tubular and vacuolar domains and localise close to the plasma 
membrane. Rab and Arf GTPases are important markers of vesicle identity and act to 
control homotypic fusion events through recruitment of appropriate effector proteins 
and provision of the energy required for fusion209–212. Rab5 is associated with early 
endosomes and associates with its effectors, notably VPS34/p150, early endosome 
antigen 1 (EEA1) and class C core vacuole/endosome tethering (CORVET)209,213–219. 
VPS34 is a phosphatidylinositol 3-kinase complex that catalyses the formation of the 
lipid PI3P - another marker of EE identity213,220. Rab5 and PI3P together recruit EEA1, 
which is yet another marker specific to EEs that is involved in ensuring homotypic fusion 
with other EEs or incoming endocytic vesicles215–218. Likewise, the CORVET complex 
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interacts with Rab5 and soluble NSF adaptor protein receptors (SNARE) proteins 
appropriate for catalysing homotypic fusion of EEs221,222. 
Cargo destined for degradation must be fed into the degradative system via LEs, 
involving fusion of EEs with LEs and accompanying morphological changes. Endosomes 
become larger and more spherical with an increased number of ILVs. They also acidify, 
as mediated by V-ATPases223–226. Importantly, there is a Rab5 to Rab7 switch, and a PI3P 
to PI(3,5)P2 conversion, conferring LE identity (Figure 11)208,227,228. The Rab5 to Rab7 
switch is mediated primarily by the SAND (SAND endocytosis family)1/MON-CCZ1 
(Vacuolar fusion protein CCZ1 homolog) complex229,230. PI3P to PI(3,5)P2 conversion is 
mediated by the PI3P 5-kinase PIKfyve/Fab1p231,232. Just as Rab5 interacts with the 
CORVET complex, Rab7 interacts with the homotypic fusion and protein sorting (HOPS) 
complex – a similar hexameric complex containing two alternative subunits, Vps39 and 
Vps41, in place of Vps3 and Vps8 from CORVET233. This confers specific binding to Rab7. 
Like CORVET, HOPS mediates interaction with SNAREs appropriate for homotypic LE 
fusion events and LE to lysosome fusion events to form endolysosomes, in which the 
majority of cargo degradation takes place. Lysosomes represent more of a storage 
vesicle for degradative enzymes such as acid hydrolases219,233,234. 
Bidirectional vesicle exchange with the TGN ensures delivery of lysosomal components 
to the lysosomes, via LEs, and the delivery and removal of the abovementioned 




































Ubiquitin is a protein of 76 amino acids that acts as a molecular signal most commonly 
associated with proteasomal degradation and MVB sorting when covalently attached to 
proteins. Ubiquitin is attached to lysine residues in the form of either 
monoubiquitination, diubiquitination or polyubiquitination. Ubiquitin chains are formed 
mainly through attachment of ubiquitin to lysine 48 or lysine 63 residues of ubiquitin, 
although a total of seven lysine residues capable of ubiquitination are present235. Whilst 
Lys48-linked chains serve as a signal for proteasomal degradation, Lys63-linked chains 
Figure 11. Overview of endosomal sorting 
Endosomal sorting serves to either recycle internalised cargo back to the extracellular environment 
or sort cargo to the vacuole/lysosome for degradation. It can be divided into a recycling system 
consisting of the plasma membrane, early endosomes (EEs) and recycling endosomes; a degradative 
system consisting of endolysosomes and lysosomes; a feeder system connecting the recycling and 
degradative systems consisting of late endosomes (LEs); and a biosynthetic system linked to both the 
recycling and degradative systems represented by the trans-Golgi network (TGN). Whilst the majority 
of cargo is recycled via the recycling system, cargo destined for degradation passes from EEs to LEs 
and then to vacuoles/lysosomes via fusion events as described in detail in the text. Degradation takes 
place in the resulting endolysosomes by enzymes such as acid hydrolases. Vesicle transition from EEs 
to LEs and vacuoles/lysosomes involves various morphological changes including a switch in surface 
Rab5 to Rab7 GTPase and PI3P to PI(3,5)P2, acidification of the lumen and an increase in size. Vesicles 
also become more spherical and an increase in multivesicular bodies (MVBs) are seen. Vesicle 
exchange with the TGN ensures the delivery of the necessary components to each vesicle to ensure 
progression from a recycling to a degradative identity. Adapted from Huotari and Helenius 2011 
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are associated with sorting into MVBs via the ESCRT machinery, and lysosomal 
degradation. Despite this, it is not clear at the molecular level whether early ESCRTs 
topologically favour binding to polyubiquitin chains or whether polyubiquitin chains 
simply increase avidity by bringing the ubiquitin binding ESCRT subunits together. 
Monoubiquitination is sufficient for MVB sorting, and most structural determination of 
ubiquitin binding motifs of ESCRT proteins has been performed using monoubiquitin236–
238. 
Ubiquitination is mediated by three enzymes: an E1 ubiquitin activating enzyme, an E2 
ubiquitin conjugating enzyme and an E3 ubiquitin ligase235. The E1 ubiquitin activating 
enzyme activates ubiquitin using ATP and transfers it to the E2 ubiquitin conjugating 
enzyme. E3 ubiquitin ligases act as a scaffold binding to both the ubiquitin bound E2 
enzyme and a specific substrate, thus facilitating transfer of ubiquitin to the substrate 
protein. The first mammalian E3 ubiquitin ligase to be discovered in MVB targeting of 
proteins was c-Cbl (as previously mentioned in section 1.3.5.2.) which has been shown 
to function in EGFR sorting239,240. Nedd4-like E3 ligases represent another type of E3 
ligase that interacts with the ESCRT machinery and is involved in MVB sorting, such as 
in that of b2-adrenergic receptor241. Arrestin related trafficking adaptors (ARTs) have 
also been implicated in viral budding (Section 1.7.2.)242.  
 
1.4.3. Sorting of ubiquitinated cargo into MVBs 
According to a model whereby the ESCRT complexes are sequentially recruited to the 
limiting membrane of LEs to facilitate sorting of ubiquitinated proteins into ILVs, initial 
recruitment is thought to occur through recognition of the lipid PI3P by the FYVE domain 
of HRS/Vps27 (ESCRT-0) (Figure 12)8,44,46,243. The multiple ubiquitin binding domains of 
ESCRT-0 generate a high avidity interaction with ubiquitinated cargo, which localise to 
distinct microdomains on the surface of LEs of specific lipid composition. In addition to 
PI3P, these sites are particularly rich in cholesterol and LBPA, and also contain ceramides 
and sphingomyelin244–247. Such a composition is likely to play a role in generating 
membrane curvature and budding. The interaction between HRS and clathrin, which 
enables association of ESCRT-0 with flat clathrin lattices is also thought to help define 
microdomains at which ILV formation occurs where ubiquitinated cargo is captured and 
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clustered favouring sorting and MVB formation. Deletion of the clathrin binding box of 
HRS leads to a more equal distribution of ESCRT-0 on endosome membranes39,40.  
ESCRT-0 then recruits ESCRT-I via the TSG101/Vps23 UEV domain, which also binds 
ubiquitinated cargo once at the endosome membrane45,46. ESCRT-II is recruited to the 
membrane via the interaction of the ESCRT-I VPS28/Vps28 C-terminus with 
EAP45/Vps36 (Figure 12)68,248. ESCRT-II is further able to bind ubiquitin and PI3P via its 
EAP45/Vps36 GLUE domain77,86. Although these early acting ESCRTs bind ubiquitin 
relatively weakly, cargo sorting into MVBs is still impaired when these ESCRTs are 
mutated38,77,80,249,250. ESCRT-II is essential for sorting in yeast, and its overexpression can 
partially suppress the class E phenotype observed upon depletion of ESCRT-I10,251. 
Furthermore, its non-competitive interactions with ESCRT-I, endosome membrane and 
ubiquitin has been shown, in yeast, to be necessary for sorting of cargo into 
MVBs10,68,79,85. In mammals, however, the role of ESCRT-II in endosomal sorting is less 
clear: whilst initial studies showed cargo degradation to be largely refractory to ESCRT-
II depletion, later studies reported some perturbation90,92,194. It is highly likely that ESCRT 
accessory proteins such as HD-PTP can bypass the need for ESCRT-II by interacting with 
ESCRT-0, ESCRT-I and ESCRT-III (Section 1.3.5.3.). HD-PTP has been shown to play roles 
in the sorting of EGFR, MHC class I, PDGFR-b and a5b1 integrin and displays endosomal 
recruitment kinetics similar to ESCRT-0 (Section 1.3.5.3.)42. A study examining ESCRTs 
required for sorting of MHC class I importantly showed that whilst ESCRT-II and CHMP6 
were not required for sorting, components of all other ESCRT complexes and HD-PTP 
were required194. This is consistent with a role for HD-PTP in bridging ESCRT-0 and 
ESCRT-I with CHMP4 proteins. 
ESCRT-I and ESCRT-II are believed to form a transiently recruited ubiquitin sensing 
supercomplex on the endosome membrane84. Support for sequential transfer of 
ubiquitinated cargo from ESCRT-0 to ESCRT-I and -II comes from the fact that all known 
ubiquitin binding motifs bind the same hydrophobic patch on the surface of ubiquitin 
within a b-sheet, centered around Ile44. Simultaneous binding of multiple ESCRT 
ubiquitin binding motifs to ubiquitin would therefore not be possible. Furthermore, 
depletion of ESCRT-0 prevents recruitment and function of ESCRT-I, consistent with a 
role upstream of ESCRT-I/-II44,46. The finding that ESCRT-I and -II contain fewer ubiquitin 
binding sites than ESCRT-0, however argues against sequential transfer of cargo. It has 
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therefore been suggested that perhaps ESCRT-I/-II alternatively act to inhibit diffusion 
of cargo once captured into sites of MVB formation252. Alternatively, as detailed in 
section 1.3.5.3, proteins such as HD-PTP may act as a platform to direct sequential 
shuffling of ESCRT complexes, or the monoubiquitination of HRS may promote transition 
to an inactive state favouring transfer of cargo to ESCRTs I and II. 
In addition to functioning as a ubiquitin binding supercomplex, ESCRT-I and -II have been 
proposed to represent a curvature sensing complex that not only recruits ESCRT-III to 
regions of curvature, but also potentially drives membrane deformation84. This was 
shown in vitro using giant unilamellar vesicles (GUVs), however, which showed 
production of vesicles of varying size, much larger than ILVs formed in vivo253. This 
system was also not able to sort cargo into vesicles. Lipid composition of the membrane 
has gained much plausibility to account for membrane invagination and MVB formation 
from both in vitro and in vivo studies254. LBPA containing liposomes have been shown to 
form ILVs simply by applying a pH gradient across the membrane, suggesting that 
protein composition is not a hugely important factor in mediating bending255. This has 
been proposed to again account for part of the reason why endosomal sorting in 
mammalian cells remain refractory to depletion of some ESCRT proteins. One study, by 
Stuffers et al. 2009 even observed that although cargo sorting was impaired by 
simultaneous depletion of subunits from ESCRT-0, -I, -II and -III, some MVB formation 
still occurred, despite showing an increase in size and containing no cargo256. This 
suggests that the early ESCRTs are more responsible for directing and sequestering 
cargo into MVBs and stabilising the necks of budding ILVs. This would leave a role for 
ESCRT-III strictly in severing of the necks of budding vesicles, despite the previously 
described observation that several ESCRT-III proteins can form tubular evaginations 
when overexpressed (Section 1.3.4.3.) and even form ILVs in GUVs127. 
In the case of the classical pathway for ESCRT recruitment, as essential in yeast, ESCRT-
III is recruited via interaction of the EAP20/Vps25 subunits of ESCRT-II with 
CHMP6/Vps20 (Figure 12). ESCRT-III and VPS4 show rapid recruitment to sites of ILV 
scission upon maximal attainment of early ESCRTs, which are more gradually recruited 
to the membrane42,257,258. ESCRT-III does not contain any ubiquitin binding domains but 
importantly is responsible for recruiting the deubiquitinases (DUBs) associated molecule 
with the SH3 domain of STAM (AMSH) and ubiquitin isopeptidase Y (UBPY)259–263. The 
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equivalent deubiquitinase in yeast is Doa4, and is recruited not by ESCRT-III but by 
Bro1158,159 (section 1.3.5.1.). Interaction with Vps20/CHMP6, however, has been shown 
to be necessary for Doa4 function in MVB formation160. Such DUBs function to remove 
ubiquitin moieties from cargo prior to scission of ILVs, ensuring that ubiquitin is recycled 
back to the cytosol, thus maintaining ubiquitin homeostasis. Whilst AMSH interacts 
preferentially with CHMP3, via a MIT-MIM interaction, it also interacts with CHMP1A, 
CHMP1B, CHMP2A, clathrin and STAM (ESCRT-0) at its SH3 domain48,259–262,264. UBPY also 
interacts with STAM and ESCRT-III and appears to rely more on its interaction with 
ESCRT-0 for its activity263. Another important difference between these DUBs is that 
whilst AMSH removes Lys63-linked polyubiquitin chains, UBPY removes both Lys63 and 
Lys48-linked chains48,49. Depletion of AMSH leads to increased EGFR degradation, 
consistent with prolonged signalling for lysosomal degradation due to the loss of 
removal of ubiquitin261. Likewise, loss of Doa4 leads to a reduction in cytosolic ubiquitin 
levels coupled with an increase in vacuolar levels159,265. Studies on UBPY depletion, 
however have shown both increased and decreased EGFR degradation49,90,266–269. This 
has been suggested to be due to a potential role of UBPY in the deubiquitination of 
ESCRT proteins such as TSG101 and HRS270. UBPY has also been shown to be involved in 
HD-PTP mediated sorting of EGFR where in addition to deubiquitination it helps facilitate 


































































Figure 12. Classical recruitment of the ESCRT machinery to endosomal membranes in yeast 
The ESCRT complexes are sequentially recruited in the order ESCRT-0, -I, -II and -III to the limiting 
membranes of endosomes through a pathway that is largely conserved from yeast to mammals. 
ESCRT-0 is initially recruited to membrane associated PI3P via the FYVE domain of HRS/Vps27. ESCRT-
0 also binds strongly to ubiquitin moieties of cargo to be sorted, through its multiple ubiquitin binding 
domains (UBDs). ESCRT-0 then recruits ESCRT-I via the TSG101/Vps23 UEV domain, which also binds 
ubiquitinated cargo. ESCRT-II is recruited via interaction of EAP45/Vps36 with the ESCRT-I 
VPS28/Vps28 C-terminus. ESCRT-II binds ubiquitin and PI3P via its EAP45/Vps36 GLUE domain. ESCRT-
I and -II have been proposed to form a curvature sensing super complex that drives membrane 
deformation in addition to recruitment of ESCRT-III. ESCRT-III is recruited via interaction of the two 
EAP20/Vps25 subunits of ESCRT-II with CHMP6/Vps20. Whether ESCRT-III directly contributes to 
membrane invagination to form intralumenal vesicles (ILV)s, or whether it simply severs the necks of 
nascent ILVs is unclear at present. Myristoylation of CHMP6/Vps20 facilitates interaction with the 
membrane. Scission is mediated by formation of filaments consisting mainly of CHMP4/Snf7 and 
CHMP3/Vps24. CHMP2/Vps2 and CHMP1/Did2 mediate capping of filaments and recruit VPS4/Vps4 
ATPase to disassemble and recycle filaments. Prior to sorting into ILVs, ubiquitin moieties are 
removed from cargo by the deubiquitinases AMSH/Doa4 or UBPY, which are recruited by ESCRT-0 
and ESCRT-III. Teis et al. 2009 
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1.5. ESCRTs in cytokinesis 
1.5.1. Overview of the cell cycle 
There is huge variation according to how often a eukaryotic cell divides according to cell 
type271. The cell cycle serves to allow time for cell growth and duplication of organelles, 
genetic material and all other components prior to cell division to produce two 
genetically identical daughter cells. The cell cycle can be divided into two main stages, 
being interphase and mitosis. Interphase is the stage during which cell growth and 
duplication of DNA occurs and can be further divided into three phases being Gap1 (G1), 
synthesis (S) and Gap2 (G2) phases (Figure 13). Mitosis is the process whereby replicated 
DNA is partitioned into forming daughter cells and cytokinesis occurs concomitantly 
with the end of this process to separate daughter cells (Figure 13). Mitosis can be divided 
into prophase, prometaphase, metaphase, anaphase and telophase272,273. Cytokinesis 
occurs concomitantly with anaphase and telophase, and the final abscission event to 
separate daughter cells typically occurs during G1 phase, but can occur as late as in early 
to mid G2 phase274,275. Since mitosis and cytokinesis generally last only for about one 
hour, cells spend the majority of their time in interphase276. 
 
1.5.1.1. Phases of the cell cycle 
During the G1 phase of interphase, cells are metabolically active and grow, doubling 
their mass and organelles, and importantly prepare for DNA replication. Cells also 
monitor the environment to ensure that conditions are favourable for DNA replication 
to occur. The majority of cells do not constantly divide and enter a resting phase from 
G1 called G0, during which proliferation ceases but cells remain metabolically active. G0 
can be temporary (quiescence) and last for days to years, or be permanent, in the case 
of senescence caused by permanent DNA damage or attainment of a terminally 
differentiated state such as nerve cells277.  
The synthesis (S) phase typically lasts between 8-12 hours, occupying around half of the 
cell cycle time. During S phase, each pair of chromosomes in the diploid cell (2n) is 
replicated so that each consists of two sister chromatids (4n), held together by the 
protein cohesin – a member of the structural maintenance of chromosomes (SMC) 
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family. Replication of the centrosome, or microtubule organising centre (MTOC) also 
occurs during S phase to form two pairs of replicated centrioles.  
S phase is followed by G2 phase, during which cells continue to grow and importantly 
prepare for mitosis. 
Mitosis begins with prophase, during which condensation of chromosomes occurs, 
making them appear visible in their characteristic X-shaped structure. Condensation is 
largely mediated by the protein condensin, which like cohesin is another SMC family 
protein. Condensin binds chromatids at multiple locations, mediating looping and 
compaction of chromosomes278. Cohesin is removed from the arms of chromosomes in 
preparation for chromatid separation but retained at the centromere279. The 
centromere is a specialised region at the centre of each chromosome that serves to link 
sister chromatids and represents the site of kinetochore assembly. Its identity is 
determined at an epigenetic level, but often contains repetitive DNA sequence and is 
rich in heterochromatin. The mitotic spindle also starts to form during prophase 
following localisation of the duplicated centrosomes to opposite poles of the cell, and 
initiation of microtubule polymerisation271,276.  
Prometaphase begins with breakdown of the nuclear envelope, in eukaryotic cells, to 
allow spindle microtubules access to the condensed chromosomes. Further growth of 
microtubules occurs and attachment of microtubules from each pole to each sister 
chromatid of each chromosome occurs. Attachment occurs at kinetochores, which are 
disc-shaped macromolecular complexes that attach to the centromeres of each 
chromosome. Crucially, the kinetochores of sister chromatids are oriented in opposite 
directions to ensure that each chromatid is captured by microtubules at opposite poles 
of the cell. This is known as bi-orientation, or amphitelic attachment280,281. Whilst 
microtubules that attach to kinetochores are known as kinetochore microtubules, other 
non-kinetochore microtubules from both poles interact to form the mitotic spindle 
framework.    
By metaphase, chromosomes are fully condensed and lined up at the equator of the 
mitotic spindle, equidistant from both poles at the metaphase plate. This is caused by 
pulling of kinetochore microtubules at both poles of the cell, in both directions until 
forces from each pole are balanced. Despite this force, sister chromatids do not separate 
yet, due to their attachment to each other by cohesin. 
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Sister chromatids separate during anaphase, following degradation of cohesin by the 
protease separase282,283. Sister chromatids move towards each pole due to shortening 
of kinetochore microtubules. The later sliding of non-kinetochore microtubules past 
each other, as catalysed by motor proteins, is also an important feature of anaphase and 
serves to separate the spindle poles. 
Upon reaching the poles, sister chromatids begin to decondense during telophase. 
Nuclear envelope reformation also occurs at this stage.  
 
1.5.1.2. Regulation of the cell cycle by Cyclin/CDK complexes 
The cell cycle is an extremely tightly regulated process, ensuring that cells do not 
progress from one stage to the next until both internal and external conditions are 
favourable284. Central to regulation of the cell cycle are cyclin dependent kinases (CDKs) 
(Figure 13). These serine/threonine kinases are activated at specific points during the 
cell cycle, following which they phosphorylate effectors necessary for cell cycle 
progression. Whilst expression levels of CDKs remain constant throughout the cell cycle, 
they are activated by cyclins whose levels rise and fall thereby activating them at specific 
times285,286. Cyclin D, which activates CDK4 and CDK6, is an exception in that its levels 
remain constant as long as there is continued growth factor stimulation. Levels of cyclin 
H also do not vary greatly over the course of the cell cycle (see below)287. Upon binding 
cyclins, CDKs are not only activated but move into the nucleus due to the nuclear 
localisation signal provided by the cyclins. Phosphorylation of transcription factors 
necessary for cell cycle progression can then take place. The most studied substrate of 
CDK4 and CDK6, in complex with cyclin D, for example is the product of the 
retinoblastoma tumour suppressor gene (pRb)288–290. Phosphorylation of this protein 
leads to release of the transcription factor E2F which is responsible for the activation of 
genes necessary for S phase entry, such as cyclins E and A. 
Whilst cyclins D1, D2 and D3 bind CDK4 and CDK6 and mediate entry into G1, cyclin E 
binds CDK2 to mediate entry into S phase291,292. Cyclin A also binds CDK2, as required 
during S phase. The G2 to M phase transition further requires cyclin A, but now in 
complex with CDK1. During mitosis, cyclin B in complex with CDK1 is required293,294. 
CDK7 (also known as CDK activating kinase (CAK)) is activated by cyclin H, which is 
expressed throughout the whole cell cycle, and mediates phosphorylation of CDK1, 
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CDK2 and CDK4 at specific sites285,295,296. Together with binding to their respective 
cyclins, these phosphorylations are also necessary for activation. In addition to 
phosphorylations that activate CDKs, other phosphorylations inactivate CDKs. For 
example, phosphorylation of CDK1 within its active site at tyrosine 15 and threonine 14 
by Wee1 and Myt1 kinases inactivates CDK1 upon its entry into the nucleus until mitosis, 
upon which the phosphatase Cdc25 removes these inhibitory phosphorylations297. CDK 
inhibitors (CKIs) also exist. These can be divided into the INK4 family, which targets CDKs 
alone by competing for binding with cyclins, and the Cip/Kip family which targets CDK-
Cyclin complexes298–301. Both of these families target CDK4 and CDK6, during G1, 
however the Cip/Kip family also targets CDK1-cyclin B complexes. In this way, control of 
cell cycle progression at the level of CDK activity is regulated by both activating and 
inhibitory phosphorylations, CKIs, and specific cyclin pairing. 
 
1.5.1.3. Checkpoint control of the cell cycle 
Another essential feature of the cell cycle necessary for tight regulation is the presence 
of checkpoint mechanisms to ensure that each step is monitored, and errors in DNA 
replication or damage are repaired before progression to the next step. There are three 
main checkpoints in eukaryotic cell division: the G1-S checkpoint, the G2-M checkpoint 
and the spindle checkpoint284. The restriction point is another checkpoint during G1 
phase, that represents the point at which cells are committed to entering the cell cycle 
and do not revert to G0, even if growth factor is removed302.  
The G1-S checkpoint is induced by DNA damage and is dependent on the transcription 
factor p53. DNA damage of a varied nature is recognised by p53, including base pair 
mismatch, single stranded DNA and free DNA ends303. All are recognised by the presence 
of single-stranded DNA, or double-strand breaks. More specifically, damaged DNA 
legions are recognised by the proteins Ataxia Telangiectasia and Rad3-related (ATR), 
Ataxia Telangiectasia Mutated (ATM) and DNA-dependent protein kinase, catalytic 
subunit (DNA-PKcs)304,305. These are kinases which phosphorylate and activate p53. p53 
substrates are numerous. However, an important gene activated by p53 is that encoding 
the Cip/Kip family CKI p21, which leads to CDK inhibition and cell cycle arrest until DNA 
damage is repaired. p21 also inhibits DNA synthesis by inhibiting the DNA clamp protein 
PCNA, which is required for DNA polymerase activity306.  
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The G2-M DNA damage checkpoint appears to be largely p53 independent and relies 
more on an alternative pathway, known as the Chk1 pathway307,308. This pathway again 
relies upon recognition of single-stranded DNA by ATR and its associated DNA-binding 
proteins. ATR then phosphorylates BRCT-domain mediator proteins which recruit Chk1. 
Chk1 is phosphorylated, thus activated, by ATR, following which it is able to 
phosphorylate the previously mentioned Wee1 kinase and Cdc25 phosphatase, leading 
to activation and deactivation respectively, so that CDK1 is maintained in an inactive 
form, preventing transition to M phase309–311. 
The spindle checkpoint serves to ensure that all sister chromatids are correctly attached 
to the mitotic spindle at both poles, in bi-orientation, and are under tension before 
transition to anaphase. The target of the spindle checkpoint is the anaphase promoting 
complex or cyclosome (APC/C). The main targets for degradation by this 
macromolecular E3 ubiquitin ligase are securin, and mitotic cyclins (cyclins A and B)312,313. 
Securin inhibits the enzyme separase, which is necessary for degradation of cohesin, 
allowing sister chromatids to separate314,315. Degradation of mitotic cyclins inactivates 
corresponding CDKs, promoting anaphase and cytokinesis, and ultimately mitotic exit. 
Mad2 inhibits the activity of the APC regulator Cdc20 under conditions of absent or 






















Figure 13. The cell cycle 
The cell cycle can be divided into interphase and mitosis. Interphase can be further divided into G1, S 
and G2 phases, and mitosis into prophase, prometaphase, metaphase, anaphase and telophase, as 
described in detail in the text. The relevant phases of the cell cycle at which activity of each of the 
relevant Cyclin/CDK complexes are involved are shown. Adapted from Ó Clinical tools, Inc. and Pines 
2011 using images from Zhao et al 2006 
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1.5.2. Early events in cytokinesis  
Cytokinesis and mitosis represent the process of cell division to produce two genetically 
identical daughter cells. It is the process whereby nuclei, cytoplasm organelles and cell 
membrane are partitioned into the two newly forming daughter cells and their later 
separation. Cytokinesis requires tight spacial and temporal regulation involving many 
interconnected factors which play overlapping and non-redundant roles. It occurs 
concomitantly with anaphase and telophase, and begins with the process of furrow 
ingression, mediated by contraction of an actomyosin ring. This actomyosin ring forms 
at the cell cortex around the cell equator, midway between the poles of the anaphase 
spindle to ensure equal separation of genetic material and organelles into daughter cells.  
 
1.5.2.1. Central spindle formation 
Central to polymerisation and contraction of the actomyosin ring is the GTPase RhoA, 
which accumulates at the equatorial cell cortex in response to signals from the central 
spindle, also known as the spindle midzone317. This is a specialised structure acting as a 
signalling hub, which forms at the start of cytokinesis at the centre of the mitotic spindle 
where microtubules overlap at their plus ends in antiparallel arrays318. The central 
spindle is derived partly from the metaphase spindle and partly by augmin mediated de 
novo nucleation of microtubules319–321. Its formation depends on removal of prior CDK1 
mediated inhibitory phosphorylations of various components, coupled with other 
phosphorylation events mediated by Aurora B kinase, which relocates to the central 
spindle from chromosomes at anaphase onset as part of the chromosomal passenger 
complex (CPC)322,323. Three essential components of the central spindle are PRC1, the 
centralspindlin complex and the CPC (Figure 14). 
Protein regulator of cytokinesis 1 (PRC1) is a microtubule bundling protein that binds at 
the interface between anti-parallel microtubules as a homodimer. Prior to cytokinesis, 
its dimerization is inhibited by CDK1324–330. The centralspindlin complex is a 
heterotetramer consisting of two kinesin-6 motor protein MKLP1 subunits and two Rho-
family GTPase-activating CYK-4 subunits (also termed MgcRacGAP or RacGAP1)331,332. 
Centralspindlin stabilises the central spindle by binding to it as higher order 
clusters333,334. Removal of CDK1 phosphorylation of MKLP1 subunits promotes 
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interaction with microtubules, whilst Aurora B phosphorylation of MKLP1 triggers 
release from its inhibitor 14-3-3, thus promoting cluster formation. Aurora B itself is a 
component of the CPC complex, which also contains the inner centromere protein 
(INCENP), borealin and survivin335. At metaphase the CPC localises to the centromeres, 
where it facilitates correct kinetochore-mitotic spindle attachment and chromosome 
structure336. At anaphase it re-localises to the central spindle in response to removal of 
CDK1 phosphorylation of INCENP, allowing INCENP to bind MKLP2, which together with 
MKLP1 mediates re-localisation of the CPC to the central spindle337. The CPC has been 
proposed to promote microtubule bundling and actomyosin ring formation in addition 
to phosphorylation of other central spindle components through Aurora B338–340. The 
kinesin KIF4A is directed to microtubule plus ends by PRC1 and other kinesins. KIF4A is 
activated by Aurora B here, where it inhibits microtubule growth, thus stabilising the 
central spindle (Figure 14)324,329. Aurora B phosphorylation also inhibits activity of the 
microtubule depolymerase KIF2A341. 
 
1.5.2.2. Cleavage plane positioning 
A detailed understanding of how the cell division plane is specified at right angles to the 
central spindle remains somewhat lacking, in terms of the role played not just by the 
central spindle but also by astral microtubules. The mechanism by which central spindle 
derived signalling molecules localise to the to the cell cortex to specify the division plane 
is also not so well understood, and has been suggested to be mediated through diffusion, 
actin cables or microtubule transport. However, activation of RhoA GTPase at the 
equatorial cell cortex is known to be critical for cleavage plane determination and is 
regulated by the guanine nucleotide exchange factor (GEF) ECT2 and the GTPase 
activating activity of the CYK-4 subunit of centralspindlin317.  
RhoA is activated by ECT2, which localises to the central spindle through an interaction 
with PLK-1 kinase phosphorylated CYK-4342–345. Prior to this, the interaction between 
CYK-4 and ECT-2 is inhibited by CDK1 phosphorylation at metaphase345. Upon 
interaction with CYK-4, ECT-2 it is activated and travels to the cell cortex where it causes 
localised activation of RhoA (Figure 14)343. ECT-2 activation also depends on 
dephosphorylation of its previously CDK1 phosphorylated C-terminal basic cluster of 
amino acid residues and this enables binding to the cell membrane346. Whilst the GAP 
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activity of CYK-4 has been shown to be necessary for RhoA activation and potentially its 
cycling between GDP and GTP bound states, its mechanism of action appears to be more 
indirect347,348. Whilst CYK-4 has been shown to regulate ECT-2, there is also support for 
a role in the regulation of the GTPase Rac1, which appears to be a preferred 
substrate349,350. Inactivation of Rac1 has been proposed to inhibit formation of a 
branched actomyosin web at the cell cortex, and also reduce cell adhesion, thus 
facilitating furrow ingression349,351,352. Although less well understood, it has been shown 
through laser ablation and genetic studies that in addition to the action of RhoA and the 
central spindle, the more dynamic spindle asters are also involved in cleavage plane 
positioning, in part through inhibition of RhoA at cortical regions353–355.  The exact nature 
of the inhibitory signal mediated by the asters in conjunction with the central spindle 














































1.5.2.3. Furrow ingression 
Mediation of actomyosin ring assembly and constriction by RhoA is so far believed to be 
the most prominent mechanism of furrow ingression. Upon activation, RhoA further 
activates Diaphanous-related formins which stimulate actin polymerisation356–358. RhoA 
also stimulates the activity of Rho-associated kinase (ROCK), which phosphorylates 
myosin light chain, thus activating myosin II (Figure 14)359. In addition to this, ROCK 
mediates phosphorylation of the counteracting MYPT myosin phosphatase leading to its 
inactivation360. Anillin and citron kinase are involved in attachment of the actomyosin 
ring to the cell membrane and central spindle. Anillin is a scaffolding protein which not 
Figure 14. Early events in cytokinesis – central spindle formation and cleavage plane positioning 
The central spindle is a specialised structure that forms at the centre of the metaphase spindle at 
anaphase, where microtubules overlap. It acts as a signalling hub, specifying cleavage plane 
positioning. As shown in a, PRC1, CPC and Centralspindlin are important components of the central 
spindle. PRC1 bundles microtubules where they overlap at their plus ends. Centralspindlin, consisting 
of two MKLP1 subunits and two CYK-4 subunits, also helps stabilise the central spindle, as does the 
CPC, which contains INCENP, borealin, survivin and importantly Aurora B kinase. Aurora B mediated 
phosphorylation of various components, such as MKLP1, is essential for central spindle formation. As 
shown in b, the kinesin KIF4 is recruited to the central spindle by PRC1, where it further restricts 
microtubule growth upon activation by Aurora B. The guanine nucleotide exchange factor (GEF) ECT-
2 is recruited to the central spindle by interaction with CYK-4, where it is activated and travels to the 
cell cortex to specify cleavage plane positioning through localised activation of RhoA GTPase, as 
shown in c. RhoA GTPase stimulates actin polymerisation and activation of myosin II to form a 
contractile actomyosin ring. Anillin, Citron kinase and Septins represent important scaffolding 
proteins of the actomyosin ring which facilitate attachment of the actomyosin ring to the cell 
membrane and central spindle. PRC1 = Protein regulator of cytokinesis 1, CPC = Chromosomal 
passenger complex, MKLP1 = Mitotic kinesin-like protein 1, INCENP = inner centromere protein, ECT-
2 = Epithelial cell-transforming sequence 2 oncogene Green et al. 2012 
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only links actin and myosin to the cell membrane, but also binds RhoA, CYK-4, ECT-2, 
Septins and PtdIns(4,5)P2, facilitating interaction with the central spindle361–364. Citron 
kinase binds to actin, myosin and RhoA and has been shown to be necessary for stability 
of the actomyosin ring and correct localisation of RhoA365. Both Anillin and citron kinase 
are additionally involved in midbody maturation and stability (Section 1.5.3.). 
The mechanism by which the actomyosin ring contracts and generates the force 
necessary to partition the newly forming daughter cells is not well understood, and 
potentially varies across species. Whilst a ‘purse-string’ mechanism has been suggested, 
whereby aligned myosin II and actin filaments slide across each other, as in muscle 
contraction, this would necessitate alignment of actin and myosin filaments, which 
although observed at the equatorial ring is accompanied by many unaligned 
filaments366–371.  Unaligned filaments have also been proposed to generate contraction, 
by potentially forming a network of filaments that contract, mediated by motor activity 
or cooperation of actin depolymerases with filament end-tracking crosslinkers372. The 
extent to which remodelling of filaments contributes to contraction is also unclear.  
Whilst dynamic turnover of actin and myosin to maintain a constant unit length of 
filaments has been observed in urchins and C. elegans, stable pools have also been 
observed, and filament disassembly does not appear to be required for budding in 
fission yeast366,373–376. Despite being well studied in yeast, the role of Septins is less clear 
in mammals, but these GTP-binding proteins are also likely to be involved in mediating 
furrow ingression and formation of membrane bound filaments as another component 
of the actomyosin ring, to which they are recruited by anillin362.  Whilst depletion of 
SEPT2, SEPT7 and SEPT11 causes multinucleation, indicative of early stage cytokinetic 
defects, depletion of SEPT9 causes an increase in midbody connected daughter cells, 
indicative of a role at a later stage, nearer abscission377,378. 
During furrow ingression, the increase in cell surface area necessitates additional 
deposition of membrane at the cleavage furrow. This is brought about by targeted 
fusion of membrane derived from vesicles of both the endocytic and secretory pathways. 
In addition to membrane, these vesicles also serve to deliver further factors necessary 
for actomyosin ring assembly, ingression, and abscission (Section 1.5.3.). Experiments in 
Drosophila have shown that several Golgi associated proteins such as syntaxin 5, Cog5 
and Cog7 and COPI are required for cytokinesis379–386. Proteins of the endocytic pathway 
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such as clathrin and dynamin have been shown to be necessary for cytokinesis in 
mammalian cells387–389. Although the GTPases Rab11, Arf6 and Rab35 have been better 
studied for their role in midbody maturation and stabilisation (Section 1.5.3.), Rab11 has 
also been shown to localise to the cleavage furrow and has been suggested to be 
necessary for furrow ingression in both Drosophila and mammalian cells390–392. Specific 
lipids, particularly those of the phosphatidylinositol (PI) family are also necessary at both 
early and later, midbody, stages of cytokinesis as discussed later. Specialised lipid 
domains containing long chain fatty acids at the cleavage furrow are necessary for 
membrane remodelling during furrow ingression, and PI(4,5)P2 in particular is enriched 
at the furrow where it is believed to be necessary for stability and structure of the 
actomyosin ring, and to promote actin remodelling via its interaction with the actin 
binding proteins Profilin and Cofilin393–400. 
 
1.5.3. Midbody formation and maturation 
Contraction of the actomyosin ring progresses until a diameter of 1-2µm has been 
reached. PLK-1 mediated reorganisation of central spindle components, clearance of the 
cytoskeleton, further vesicle trafficking and membrane fusion events and maturation of 
the contractile ring then mediate formation of another distinct structure known as the 
midbody, or intercellular bridge. Daughter cells remain connected by the midbody for 
between 80 minutes to several hours into G1, before the final abscission event occurs. 
Why the midbody persists for so long and what events take place during this time period, 
together with what eventually triggers abscission remains largely unknown. The 
midbody is a protein rich structure containing more than 100 different proteins, whose 
main role is to act as an assembly platform for subsequent recruitment of the abscission 
machinery. The central electron dense region where the compacted interdigitating 
microtubules of the central spindle overlap at their plus ends is known as the Flemming 
body401. Due to antibody excluding characteristics in immunofluorescence microscopy, 
this region is also known as the dark zone. Midbody microtubules are highly acetylated, 
forming stable bundles402. Both continuous microtubules, that pass straight through the 
midbody, and polar microtubules, which overlap at the Flemming body, are found within 
the midbody403. Cryo-electron tomography and fluorescence microscopy have shown 
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that whilst polar microtubules disappear from the spindle midzone towards the end of 
cytokinesis, continuous microtubules remain next to abscission sites, demonstrating 
that microtubules are an important structural component of the midbody, present 
throughout most of its existence until abscission, and that the midbody is a dynamic 
structure403.  
During midbody formation, KIF4 and PRC1 remain associated with microtubules where 
they overlap at the Flemming body. Centralspindlin, ECT2, RhoA, anillin, citron kinase 
ARF6 and septins re-localise to a ring surrounding the Flemming body known as the 
midbody ring, and MKLP2 and AuroraB kinase re-localise to microtubules flanking the 
Flemming body404–408. These relocalisation events and maintenance of the midbody 
structure are dependent on the activity of PLK-1. PLK-1 has been shown to display 
differing localisation patterns during cytokinesis, localising with KIF4 at the central 
spindle at the start of cytokinesis, with a gradual dissociation from KIF4 during furrow 
ingression. PLK-1 reappears, however, at the Flemming body following midbody 
formation405. 
The lipid composition of the plasma membrane of the midbody is also important for 
midbody stability and successful abscission (Figure 15). PI(4,5)P2 localisation at the 
equatorial cortex is initially important for midbody stability and the relocalisation of 
anillin, septins, RhoA and CYK-4, around the Flemming body by interaction with PI(4,5)P2 
through polybasic or Pleckstrin Homology (PH) domains395–397,409–413. 
Phosphatidylethanolamine (PE) accumulates within the outer leaflet of the midbody 
plasma membrane at telophase and is important for inactivation of RhoA and 
actomyosin ring disassembly (see below)395,410,414. Its depletion prevents abscission, as 
does cell surface immobilisation by PE-binding peptides410,414. This suggests that precise 
spaciotemporal control of PE composition is necessary for successful completion of 
abscission. PI3P is another phosphoinositide that has been found to be required for 
successful completion of cytokinesis, as evidenced by the observed cytokinesis failure 
upon depletion of the VPS34 or Beclin-1 subunits of the class III PI-3-kinase, which also 
localises to the midbody415–417. Transport of PI3P positive endosomes to the midbody 
has been shown to be necessary for the localisation of the PI3P interacting protein FYVE-
CENT and its binding partner TTC19 to the midbody, which also requires kinesin KIF13A 
for transport415,417. FYVE-CENT together with its binding partner TTC19 appears to be 
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necessary for cytokinesis, with depletion leading to multinucleation and delayed 
abscission (Figure 15)415. Interestingly, an interaction between TTC19 and the ESCRT-III 
protein CHMP4B has also been described415,416. This potentially represents an 
interesting link between ESCRT mediated cytokinetic abscission (Section 1.5.4.) with 
membrane lipid composition, although this requires further validation. 
Following furrow ingression, the contractile actomyosin ring must disassemble whilst 
other components must be retained through a maturation process to form the midbody 
ring. The inactivation of RhoA by PKCe and 14-3-3 protein leads to disassembly of 
actin118,418. This is also facilitated by Rab35, which recruits its effector PtdIns(4,5)P2 
phosphatase OCRL to the intercellular bridge where it reduces PtdIns(4,5)P2 levels, in 
contrast to the earlier midbody requirement for increased PtdIns(4,5)P2 levels (Figure 
15)394. Since PtdIns(4,5)P2 promotes actin polymerisation and inhibition of the actin 
severing enzyme Cofilin, its decrease leads to a reduction in actin filaments419. OCRL 
depletion has been shown to cause a strong increase in cortical actin, which delays or 
inhibits abscission. Depletion of Rab35 leads to an identical phenotype394.  
Following disassembly of the actomyosin ring, maturation of the midbody ring ensures 
tight anchorage of the cell cortex to the midbody to prevent furrow regression. Anillin 
appears to play a much more important role at this later stage of cytokinesis, where it 
is involved in anchorage of the midbody ring to the plasma membrane, through binding 
to septins408,420–422. RhoA is required for the correct localisation of anillin to the midbody 
ring and citron kinase is required for the retention of both RhoA and anillin407. Citron 
kinase also interacts with the centralspindlin subunit MKLP1 and KIF14 which interact 
with PRC1 at the Flemming body334,407,408,423,424. An interaction between MKLP1 with 
Arf6 has also been described, and Arf6 is able to bind membrane through its N-terminal 
myristoylated helix425. Furthermore, Arf6 competes with centralspindlin inhibitor 14-3-
3 protein for binding to centralspindlin, thus ensuring that centralspindlin remains 
clustered and stabilises the midbody426. The CYK-4 subunit of centralspindlin also 
contains a membrane binding domain which contributes to membrane anchorage427. 
In addition to delivery of abovementioned components to the midbody, Golgi and 
recycling endosome derived vesicle trafficking plays other essential roles at the midbody, 
such as mediation of further events leading to actin depolymerisation, formation of the 
secondary ingression sites at which abscission occurs, and has also been suggested to 
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mediate abscission itself (below and section 1.5.4). Vesicle trafficking is central to all 
aspects of cytokinesis and has shed light on the overlapping roles of many factors 
demonstrating a great deal of functional interconnectivity392. 
In addition to the previously described function of Rab35 and OCRL in controlling 
PI(4,5)P2 levels necessary for abscission, recycling endosome associated Rab 11 
represents the other most well studied Rab GTPase in cytokinesis, and is transported to 
the midbody via its effector FIP3428. Fusion of Rab11-FIP3 vesicles has been shown to 
contribute to narrowing of the midbody at sites adjacent to the Flemming body where 
abscission takes place, known as the secondary ingression sites, and depletion of Rab11 
or FIP3 leads to abscission delay and furrow regression428,429. Rab11-FIP3 vesicles also 
contribute to actin depolymerisation by transport of the RhoA GAP p50RhoGAP to the 
midbody, to inactivate RhoA (Figure 15)429. Since FIP3 is also an effector for Arf6, and 
both FIP3 and Arf6 bind the centralspindlin components CYK-4 and MKLP1 respectively, 
this represents a link between Rab11-FIP3 vesicle trafficking and the abovementioned 
roles of Arf6 and centralspindlin in membrane anchorage425,430. FIP3, Rab11 and Arf6 
have further been shown to interact with the exocyst complex through interactions with 
its Exo70, Sec15 and Sec10 subunits respectively431–433. The exocyst complex is an 
octameric vesicle tethering complex required for cytokinesis, together with v-SNAREs, 
such as VAMP8, and t-SNAREs such as syntaxin2. The exocyst complex depends on the 
centrosomal protein Centriolin for localisation to the midbody ring, as do SNARE 
components Snapin and Endobrevin434. 
Syntaxin 16 appears to be another important t-SNARE in cytokinesis, which is required 
for accumulation of both the exocyst complex and Rab11-FIP3 vesicles at the midbody435. 
It is also necessary for CEP55 and ALIX accumulation at the midbody representing 
another link between upstream trafficking events with recruitment of the ESCRT 
machinery to mediate abscission (Section 1.5.4.)435. Along the same lines, the post-Golgi 
secretory carrier membrane protein SCAMP3 has been shown to interact with TSG101 
and like SCAMP2 also localises with FIP3 at midbodies429,436. SCAMP2 and SCAMP3 have 
been shown to be necessary for the FIP3 mediated formation of secondary ingression 
sites and recruitment of ESCRT-III429.  
Lastly, the multifunctional ubiquitin ligase BRUCE has been implicated in cytokinesis 
through its interactions with MKLP1, Rab8, Rab11 and exocyst components Sec6 and 
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Sec8437. Its interaction with MKLP1 is necessary for midbody ring localisation, and its 
other interactions further facilitate targeting of Rab11 containing vesicles to the 
midbody. Furthermore, the ubiquitin ligase activity of BRUCE appears to be necessary 
for successful cytokinesis: BRUCE depletion leads to the disruption of an observed re-
localisation of ubiquitin from the tips of microtubules at their plus-ends to the midbody 
ring during midbody constriction437. The role of ubiquitination during cytokinesis is 
unclear as yet but is likely to mediate structural or regulatory functions rather than 
proteasomal degradation, as mono-ubiquitination is mainly seen at the midbody437. 
Another possibility is that ubiquitination generates binding sites for ESCRT machinery as 
in lysosomal sorting. 
There is conflicting data regarding whether vesicle targeting occurs at one or both sides 
of the midbody, or shows initial targeting to both sides followed by targeting to only one 
side nearer abscission. Fluorescently tagged FIP3 and VAMP8 have been visualised at 
the secondary ingression at the side at which abscission occurs and another study 
visualised asymmetric targeting of GFP-tagged secretory vesicles from only one nascent 
daughter cell to a region adjacent to the Flemming body at one side only434,438. 
Abscission later occurred at this side. Another study employed TIRF imaging to show 
that trafficking occurred at both sides of the midbody from both nascent daughter 
cells439. Whatever the case, the observed vesicle fusion within the midbody, and the 
potentially asymmetric nature of trafficking and fusion has led to one hypothesis that 
abscission occurs through SNARE mediated fusion of vesicles with the plasma 
membrane. In disagreement with this model, however, is the observation from other 
studies that vesicles disappear from the midbody before abscission118. Another study 































1.5.4. Cytokinetic abscission 
Cytokinetic abscission is the final membrane cleavage event that separates daughter 
cells following midbody maturation and narrowing. Earlier models put forward for a 
mechanism for this process included the above-mentioned SNARE mediated fusion of 
endocytic and Golgi derived vesicles with the plasma membrane of the midbody, or 
mechanical rupture of the membrane. A mechanical rupture model was largely based 
on the similarity in requirements for cellular wound healing with cytokinesis, including 
formation of an actomyosin ring440. The later discovery of requirement for the ESCRT 
machinery in abscission, together with examples of its adaptability to this process and 
links to upstream factors in mitosis and cytokinesis has led to ESCRT mediated models 
of abscission gaining the most plausibility.  
Figure 15. Vesicle trafficking and contribution of phosphoinositides to midbody maturation and 
ESCRT recruitment 
Whilst PI(4,5)P2 is initially required for midbody stability and reorganisation of its components, its 
levels must later decrease to allow actin removal, recruitment of the ESCRT machinery and 
cytokinetic abscission. This is brought about, in part, by PI(4,5)P2 phosphatase OCRL, which is 
recruited to the midbody by Rab35. Rab35 also recruits and activates MICAL1, which plays a role in 
actin clearance prior to abscission (Section 1.5.5.). Rab11-FIP3 vesicles contribute to actin 
depolymerisation by transport of the RhoA GAP p50RhoGAP to the midbody, to inactivate RhoA 
kinase. Rab11-FIP3 vesicles also contribute to narrowing of the midbody at the site of abscission. PI3P 
positive endosomes are transported to the midbody by KIF13A. FYVE-CENT and its binding partner 
TTC19 interact with PI3P positive vesicles, and are required for successful cytokinesis. An interaction 
between TTC19 and the CHMP4B has been shown, potentially linking such trafficking events with 
ESCRT recruitment. Frémont and Echard 2018 
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1.5.4.1. ESCRT recruitment to the abscission site 
Initial suggestions for involvement of the ESCRT machinery in abscission came from 
studies showing that TSG101 localisation was cell cycle dependent and localised to 
centrosomes and midbodies during mitosis441. Inactivation of expression or mutation of 
TSG101 led to mitotic abnormalities and an increase in multinucleation. Support for the 
role of the ESCRT machinery in abscission ultimately came from the identification by 
yeast two-hybrid and mass spectrometry of an interaction between TSG101 and ALIX 
with the centrosome and midbody protein CEP5517,442. During interphase, CEP55 shows 
centrosome localisation. At anaphase, CEP55 moves to the central spindle where it is 
phosphorylated by PLK-1443. This prevents it associating with the centralspindlin 
component MKLP1 at the midbody. At mitotic exit, PLK-1 is degraded by the APC/C 
allowing re-localisation of CEP55 from the mitotic spindle to the midbody. CEP55 was 
shown to be essential for cytokinesis, causing abscission failure and furrow regression 
upon depletion, as did depletion of TSG101 and ALIX17,442,444–446. Co-localisation of both 
TSG101 and ALIX with CEP55 at both the centrosome and later the Flemming body was 
observed, and localisation of both proteins was shown to be dependent on CEP5517,442. 
By analogy to the similar dependence on viral Gag proteins for recruitment of the ESCRT 
machinery during viral budding (Section1.7.), CEP55 was identified as the ESCRT adaptor 
protein for cytokinetic abscission. Importantly, neither CEP55 depletion nor mutation of 
TSG101 at its CEP55 binding site had an effect on TSG101 or ALIX mediated viral budding, 
demonstrating functional/site specific adaptation17,55,442. 
ESCRT-III proteins including CHMP2A, CHMP4A and CHMP5 were subsequently 
identified at the midbody forming two concentric rings adjacent to the Flemming body17. 
Midbody localisation of VPS4A also showed a similar localisation at a later stage closer 
to abscission following further midbody thinning, consistent with its more downstream 
role17. ALIX mutants unable to bind CHMP4 proteins failed to rescue cytokinetic defects 
caused by endogenous ALIX depletion, and overexpression of all YFP-CHMP4 isoforms, 
a dominant negative CHMP3 1-179-GFP protein and VPS4 (in both ATP binding (K173Q) 
and ATP hydrolysis defective (E228Q) dominant negative mutants and as wild type 
protein) inhibited cytokinesis17,55,442,447. Interestingly, CHMP4 and VPS4 homologues 
have been identified in Archaea of the genus Sulfolobus and have been shown to play a 
role in cell division448–450. Since these organisms lack an endosomal system, cytokinesis 
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has been suggested to represent the original, anscestral role of the ESCRT proteins. This 
discovery also refutes the possibility that the ESCRT machinery contributes to 
cytokinesis via an endosomal sorting function, rather than directly in abscission. 
CEP55 consists of two coiled-coil ‘arm’ regions from residues 19-156 and 237-402 
separated by an unstructured ‘hinge’ region from residues 156-237 (Figure 16)445,446. 
The N-terminal ‘arm’ mediates homodimerization whilst the C-terminal ‘arm’ mediates 
interaction with MKLP-1444–446,451. Part of the ‘hinge’ region from residues 160-217, 
termed the ESCRT and ALIX binding region (EABR) was found to be necessary for binding 
to both TSG101 and ALIX, and both proteins were found to interact with CEP55 via a GPP 
motif451. The binding of TSG101 to CEP55 was mapped to residues 157GPPNTSY163 of 
TSG101, within an unstructured linker in its proline rich region between the UEV and the 
core17,442,451. Binding to ALIX was mapped to residues 800GPP802 of ALIX within its C-
terminal proline rich region. Residues 805TY806 were also found to be equally important 
for mediating interaction17,442. Mutation of these binding sites in both TSG101 and ALIX 
suggested specificity of these sites for involvement in cytokinesis: TSG101 d158-162 still 
interacted with its other main binding partners such as other ESCRT-I subunits, viral Gag 
proteins and endosomal proteins, and could still support viral budding17,442. Similarly, 
mutation of residues in ALIX known to mediate binding to other known partners, or 
expression of fragments lacking such regions were still able to function in 
cytokinesis17,55,442.  
Dimerisation of CEP55 was shown to be necessary for binding to TSG101/ALIX, and 
competition binding assays showed that TSG101 and ALIX compete for binding to CEP55 
at the same site within the EABR451. The EABR becomes structured upon binding to 
TSG101/ALIX forming a non-canonical coiled coil, which cannot bind simultaneously to 
both TSG101 and ALIX. This led to a model suggesting multiple CEP55 dimers are 
required in cytokinesis to recruit both TSG101 and ALIX to the midbody for efficient 























In addition to their role in abscission, ESCRTs appear to be important for maintenance 
of the midbody, centrosomes and mitotic spindle. Depletion of CEP55 or ALIX, or 
expression of ALIX mutants that are unable to bind ESCRT-III leads to an abnormal 
midbody staining pattern in which a-tubulin staining can be seen at the Flemming 
body55,442,446,452,453. Since protein density at the Flemming body normally masks tubulin 
epitopes, hence appearing as a ‘dark zone’, this suggests ALIX and ESCRT-III represent 
important midbody components. Localisation of both TSG101 and ALIX with CEP55 at 
centrosomes during interphase has been observed, and TSG101 depletion led to the 
appearance of multiple mitotic spindles and centrosomes, in addition to 
multinucleation441,454. A study in 2010 in which each of the 11 human CHMP proteins 
and VPS4A/B were individually depleted showed that each protein displayed non-
redundant, differing effects on abscission, centrosome number and nuclear 
morphology454. Whilst CHMP3 depletion displayed a phenotype in cytokinesis similar to 
that seen upon depletion of ALIX/CEP55 without any striking mitotic effects, other 
CHMPs such as CHMP1A, CHMP2B, CHMP4B, CHMP4C and VPS4B displayed less severe 
cytokinetic defects but very prominent rapid increases in centrosome number and 
multipolar spindles. It is still unclear how ESCRTs may regulate centrosome duplication. 
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However, CC2D1A has been shown to control centrosome duplication, and an 
interaction with CHMP4 proteins has been uncovered264,455. Defective chromosome 
alignment or perturbed nuclear morphology was also observed in the case of CHMP1A, 
CHMP1B, CHMP2B, CHMP4B, CHMP4C, CHMP7, VPS4A and VPS4B. In contrast, CHMP2A 
and CHMP5 displayed an increase in cells with a single centrosome, hence a monopolar 
spindle. In both cases, this led to failed chromosome segregation, failed abscission, and 
aberrant nuclei454. In addition to these increases or decreases in centrosome number, 
cells depleted of VPS4A/B displayed smaller centrosomes whilst those depleted of 
CHMP2A displayed larger centrosomes and pericentriolar material. Localisation of 
endogenous VPS4 proteins to centrosomes and spindle poles from interphase to 
metaphase was also observed in this study454.  
More recent studies have built on this, showing dynamic association of VPS4 with both 
mother and daughter centrioles, within the pericentriolar material, in the absence of 
other ESCRT-III components. Decreased centrosomal γ-tubulin levels were seen upon 
expression of the catalytically inactive dominant negative VPS4 E228Q mutant. This led 
to a reduction in microtubule polymerisation, altered centrosome positioning, hence 
spindle orientation, and defective ciliogenesis due to the abolishment of centriolar 
satellites456. Similarly, another recent study using Drosophila and human stem and 
epithelial cells showed ALIX localisation to the pericentriolar material where it was 
required for correct mitotic spindle orientation, accumulation of γ-tubulin, and 
nucleation of astral microtubules necessary for anchorage of the spindle to the cell 
cortex457. VPS28 has also been suggested to be involved in aster microtubule 
organisation via interaction with the heterodimer Gβγ, and formation of a complex with 
the microtubule associated proteins Eg5 and TPX2, which help maintain spindle 
bipolarity and balance of pole to pole forces458. A role for CHMP4C, again in the absence 
of other ESCRT proteins, has been suggested in the spindle checkpoint (section 1.5.1.3.), 
by maintaining stable kinetochore-microtubule attachments by recruiting the Rod–
ZW10–Zwilch (RZZ) complex to unattached kinetochores459. The RZZ is required at 
kinetochores, in metazoans, together with Mad1-Mad2 for a functional spindle 
checkpoint.  
The striking phenotypes seen in the above studies strongly suggest a role for the ESCRT 
machinery in control of mitosis and centrosome/spindle maintenance and function, in 
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addition to cytokinetic abscission. Involvement in the spaciotemporal control of 
progression from mitosis to cytokinesis is also implied. Despite this, a unifying model for 
ESCRT activity at the centrosomes and mitotic spindle is lacking at present, and the 
above studies likely suggest roles for individual ESCRT proteins in processes such as 
centrosome clustering, independent of their canonical function in reverse topology 
membrane remodelling.  
Whilst the effect of ALIX depletion has consistently been shown to be more detrimental 
to cytokinesis than that of TSG101, binding of each protein to CEP55 and subsequent 
recruitment of ESCRT-III has been suggested by Christ et al. 2016 to represent two 
partially redundant parallel arms of ESCRT-III recruitment: CEP55-ALIX-ESCRT-III and 
CEP55-TSG101 (ESCRT-I)-ESCRT-II-CHMP6-ESCRT-III93. The same study also described 
the interaction between VPS28 and CHMP6 (thereby bypassing ESCRT-II) as contributing 
to CHMP4B recruitment during cytokinesis. This study is discussed in more detail in 
section 4.1. 
 
1.5.4.2. Models of abscission 
Although initial confocal microscopy studies showed localisation of TSG101 and ALIX to 
single bands at the centre of the Flemming body, more detailed structured illumination 
microscopy (SIM) and high-resolution temporal imaging showed localisation of TSG101 
as two distinct hollow rings either side of the Flemming body about 0.25µm apart121. 
The Flemming body, or ‘dark zone’, was shown to be around 0.6µm wide with a diameter 
of around 1µm. The TSG101 rings were around 0.28µm wide and likely contacted the 
membrane, judging from the diameters of the inner and outer rings, being around 1µm 
and 1.7µm respectively. CEP55 and MKLP1, in contrast, were shown to concentrate at 
the Flemming body as a solid disk around 0.75µm wide, penetrated by microtubules, 
which electron microscopy showed to form a dense bundle. CHMP4B also showed 
similar localisation to two membrane associated concentric rings, as previously 
observed in earlier studies by confocal microscopy (section 1.5.4.1.). These rings were 
located slightly further away from the centre of the Flemming body, around 0.45µm 
apart, but still showed 50% overlap with the TSG101 rings. Whilst CEP55 and MKLP-1 




Due to the density of the overlapping microtubules at the Flemming body, the actual 
abscission event to sever the midbody membrane cannot occur here and instead takes 
place at a separate site at one side of the Flemming body approximately 1µm adjacent 
to it. This site is known as the secondary ingression and forms approximately 10-20 
minutes before abscission118,429,452. Midbody thinning occurs to create the secondary 
ingression, narrowing the membrane from approximately 1-2µm to 50-100nm. In 
addition to localisation at the Flemming body, ESCRT-III and VPS4 have been observed 
at this site in late stage midbodies closer to the time of abscission (Figure 17)118,121. 
Electron microscopy has revealed that membrane at the secondary ingression appears 
rippled due to 17nm membrane associated filaments, which although unproven are 
likely to be those of ESCRT-III since these disappear upon depletion of CHMP2A118. 
Electron tomography revealed these cortical filaments to be regularly spaced around 
35.3nm apart, as single or intertwined helices, perpendicular to the microtubules 
passing through the midbody. Depletion of the ESCRT associated microtubule severing 
enzyme spastin (section 1.5.5.) delayed abscission but did not prevent formation of 
these filaments118. 
A model put forward by Guizetti et al. 2011 suggests that ESCRT-III is responsible for 
thinning to create the secondary ingression, by continuous polymerisation and 
constriction away from the Flemming body towards the secondary ingression where 
further constriction mediates abscission118. In agreement with this model, CHMP4B, 
CHMP2A, CHMP2B and CHMP6 appeared to extend from the Flemming body to the 
secondary ingression in a continuous band, and depletion of CHMP2A prevented 
constriction to form the secondary ingression118. Furthermore, Sherman et al 2016 also 
observed continuous polymerisation of nested spirals between the Flemming body and 
secondary ingression by soft-X-ray cryo-tomography460. 
Elia et al 2011, meanwhile, observed that continuous fluorescence of CHMP4B-mCherry 
was not so obvious between the Flemming body and secondary ingression, and instead 
was seen to localise to separate pools, either side of the Flemming body and at the 
secondary ingression121. Closer examination of the dynamics of CHMP4B-mCherry 
showed that prior to abscission, CHMP4B shows an increase in intensity at one of its 
rings near the Flemming body, overlapping with TSG101. This is promptly followed by 
appearance at the secondary ingression around 20 minutes prior to abscission.  VPS4B-
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GFP similarly appeared to re-localise from the Flemming body to the secondary 
ingression even closer to the time of abscission, around 10 minutes beforehand, 
consistent with its downstream role in ESCRT disassembly/recycling. This study led to 
proposal of another ‘cut and slide’ model for abscission, whereby VPS4 mediates 
breakage of part of the initial ESCRT-III polymer ring overlapping that of TSG101/ALIX at 
one side of the Flemming body461. This is followed by constriction of the polymer to its 
spontaneous diameter of around 50 nm, and since the polymer is membrane-bound, 
membrane constriction with an associated increase in elastic energy occurs. This 
increase in elastic energy leads to sliding of the ESCRT-III polymer away from the 
Flemming body until the equilibrium position is reached at the secondary ingression 
(Figure 17)461. VPS4 activity then catalyses membrane scission. In addition to the 
observed co-localisation of VPS4 with both ESCRT-III pools, at the Flemming body and 
secondary ingression, inhibition of VPS4 activity by ATP depletion was seen to induce 
spreading of CHMP4B from the Flemming body to the secondary ingression as one 
continuous band. This suggests disruption of spaciotemporal localisation and supports 
this ‘cut and slide’ model. Also in favour of this model was the observation that further 
constriction of this ESCRT-III pool did not lead to further sliding, suggesting the 
equilibrium position had been reached, around 0.7µm away from the initial pool 
adjacent to the Flemming body461. 
In contrast to this model and potentially more consistent with the continuous 
polymerisation model proposed by Guizetti et al. 2011 is a recent study by Mierzwa et 
al. 2017117. This study used FRAP to examine the dynamics of ESCRT-III subunit turnover 
with a focus on cytokinesis. It appeared to show high dynamic turnover of midbody 
membrane bound ESCRT-III subunits with the cytoplasmic pool of ESCRT-III subunits, 
during ESCRT-III polymerisation. VPS4 was suggested to be continuously necessary for 
this turnover, required for continuous ESCRT-III polymerisation, remodelling and 
constriction. Contrary to the specific appearance of VPS4 following that of CHMP4B, 
shown by Elia et al. 2011121, VPS4 was seen to localise at the midbody together with 
CHMP4B at early stages. Also, potentially in agreement with the model of ESCRT-III 
mediated formation of the secondary ingression was the observation in this study that 
neither 17nm filaments nor secondary ingressions formed upon VPS4 depletion117. 
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Another recent more detailed higher resolution study of ESCRT localisation by Goliand 
et al. 2018 used 3D stochastic optical reconstruction microscopy (STORM) to principally 
examine the localisation of the CHMP-like protein hIST1, required in abscission (section 
1.5.6.)462. Whilst consistent with earlier studies that examined localisation mainly of 
CHMP4B, this study provided a more in-depth picture of hIST1 localisation, identifying 
five different localisation patterns at the midbody. Examination of antibody stained 
endogenous hIST1 revealed localisation similar to that of other ESCRT-III proteins as 
179nm wide, 1.11 diameter rings at both sides of the Flemming body. A second 
localisation pattern as thicker 390nm wide rings of slightly smaller diameter were also 
observed at the rims of the Flemming body. A series of between 3-5 parallel rings of 
successively smaller diameter ranging from 1.08µm to 0.62µm diameters, likely forming 
a continuous spiral of around 846nm was seen as a third localisation pattern. An even 
more extended fourth localisation pattern was observed as another continuous 
deformed spiral extending to the secondary ingression. These spirals consisted of rings 
of irregular diameters and pitch angles but generally decreased in diameter from 
0.82µm – 0.28µm at the abscission site. In agreement with previous studies, the fifth 
localisation pattern consisted of two pools of hIST1: one of large diameter rings at the 
rims of the Flemming body and another as two small diameter rings at the secondary 
ingression462. Midbody narrowing was used as a measure of abscission progression, and 
began to occur during the third localisation pattern for hIST1. Calculations taking into 
account spiral length and the radius and pitch of each turn revealed that whilst early 
constriction of the midbody, represented by the third type of hIST1 localisation, involved 
polymerisation, later constriction, represented by localisations 4 and 5, represented 
filament depolymerisation.  
These observations and calculations led to a model whereby initial polymerisation and 
elongation of ESCRT-III filaments, represented by hIST1 localisations 1-3, is followed by 
more acute constriction of the midbody membrane in stage 4. At this stage, ESCRT-III 
filaments form the distorted spiral due to mechanical stress caused by continued 
constriction to their preferred diameter, at the abscission site, whilst remaining 
anchored to the Flemming body. This stress leads to VPS4 mediated filament breakage 
and depolymerisation leading to the Flemming body and abscission site localised bands 
seen in localisation 5. Further polymerisation and capping of the filament at the 
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abscission site then mediates midbody severing. This model is more consistent with that 
suggested by Guizetti et al. 2011, involving continuous polymerisation from the 
Flemming body to the secondary ingression118. 
In addition to proposing this model, this study using 3D STORM provided a more detailed 
study of the effects of depletion of Spastin and various ESCRT-III proteins on filament 
morphology during abscission. Spiral formation was largely unperturbed in spastin 
knockout cells. However, midbody constriction was perturbed, likely due to lack of 
microtubule clearance. VPS4A/B depletion led to the appearance of large diameter 
hIST1 filaments at the centre of the midbody that did not elongate or constrict the 
midbody. This is consistent with a model for VPS4 in continuous remodelling of filaments 
to drive constriction, as described by Mierzwa et al 2017117. CHMP2B depletion led to 
the formation of elongated hIST1 spirals, but of constant small diameter, of around 
210nm. These spirals also appeared to be internal and not membrane associated. This 
suggests a role for CHMP2B in maintaining correct spiral morphology or membrane 
binding of ESCRT-III filaments. CHMP4B depletion led to disordered partially circular 
hIST1 structures, unaligned with the rims of the Flemming body. Only the hIST1 
localisation pattern seen upon CHMP2B depletion was also observed for CHMP4B 
localisation, implying that these phenotypes are generally specific to hIST1. Nonetheless, 
such studies highlight differential contribution of individual CHMPs to filament 
composition and their lack of redundancy in cytokinesis462. 
Another model proposed by Schiel et al 2012 involves initial formation of the secondary 
ingression in an ESCRT independent manner by fusion of FIP3 positive endosomes with 
the membrane429. The secondary ingression is later stabilised by ESCRT-III filaments, 
which mediate abscission. This model was primarily based on the observation that 
CHMP4B depletion did not perturb secondary ingression formation and arrived at the 
secondary ingression following its formation. Possible continuous polymerisation of 
ESCRT-III from the Flemming body to the secondary ingression was observed in this 
study in 27% of cases whilst in the remaining 73% of cases, distinct CHMP4B puncta at 
the secondary ingression were seen. This together with the well-established importance 
of both vesicle trafficking and the ESCRT machinery in cytokinesis suggests that in reality, 
features of all three models could be involved in abscission.  
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On a related note, the observance of vesicles exterior to the midbody and vesicles 
budding from it in a process analogous to viral budding suggests that the ESCRT 
machinery contributes directly to midbody thinning by expulsion of vesicles463.  
Finally, another recent study related to spaciotemporal control of the ESCRT proteins at 
the midbody showed that septins may play a role here464. Septins 9, 2, 7 and 6 were 
shown to form membrane bound double rings either side of the Flemming body, similar 
to those of ESCRT proteins. It was reported that these rings appeared at the same time 
as those of TSG101 and partially overlapped with the rings of ESCRTs I, II and III subunits. 
The septin rings were shown to demarcate the sites of ESCRT-III recruitment and showed 
an inverse temporal recruitment pattern with ESCRT-III, with disassembly prior to the 
spreading of ESCRT-III to the site of abscission464. Co-precipitation experiments 
suggested a potential interaction between SEPT9 and TSG101 via two N-terminal PTAP 
motifs, and whilst its depletion did not prevent recruitment of TSG101, recruitment of 
EAP20 (ESCRT-II) and CHMP6 were prevented. This was proposed to be dependent on 
the interaction between the TSG101 UEV domain and SEPT9 PTAP motifs. Although 
depletion of SEPT9 did not prevent recruitment of CHMP4B/CHMP2B, an increase in 
failure to form cones towards the secondary ingression was seen, as were abnormal 
distorted accumulations as single bands at the Flemming body, as opposed to concentric 
rings. An increase in the time between furrow ingression and abscission was also 
reported. Involvement of the septins in ESCRT-III organisation and remodelling, was 
therefore proposed via the ESCRT-I – ESCRT-II – CHMP6 axis of recruitment. This study 
may provide some insight into why ESCRT-I and ESCRT-III form spatially separate rings 






































1.5.4.3. CEP55 in human disease and animal models 
Three genetics studies to date have shown disruption of CEP55 to result in lethal foetal 
disorders in humans, displaying perturbed brain and kidney development resembling a 
Meckel-like syndrome465–467. Meckel-Gruber syndrome (MKS) is a ciliopathy 
Figure 17. Midbody localisation and action of ESCRT proteins in cytokinetic abscission 
ALIX and TSG101, hence ESCRT-I, are recruited to the Flemming body via direct interaction with the 
adaptor protein CEP55. The Flemming body is a protein rich structure at the centre of the midbody, 
derived from the central spindle where microtubules overlap. Recruitment of ESCRT-III has been 
proposed to occur via two partially redundant arms of recruitment involving a CEP55-ALIX-CHMP4B 
branch and a TSG101 (ESCRT-I)-ESCRT-II-CHMP6-CHMP4B branch. ESCRT-III proteins appear as two 
concentric rings immediately adjacent to the Flemming body. However closer to the time of 
abscission, they are also observed at sites approximately 1µm away from the Flemming body known 
as secondary ingressions, at which the diameter of the membrane tube is thinned from 1.5-2µm to 
around 100 nm. One of these ingressions represents the site at which abscission occurs. The 
membrane at these sites appears rippled due to 17nm filaments beneath the membrane, which are 
likely to be those of ESCRT-III. A ‘cut and slide’ model for abscission has proposed breakage of 
Flemming body adjacent ESCRT-III filaments by VPS4. These filaments are then propelled away from 
the Flemming body by constriction of the filaments, constricting the membrane as they move until 
they reach the secondary ingressions, representing their equilibrium positions at which their 
spontaneous diameter of around 50-100nm is reached. Further polymerisation at the secondary 
ingression would then mediate membrane scission. Continuous polymerisation and constriction of 
ESCRT-III filaments from the Flemming body to the secondary ingressions has also been proposed, as 
has an ESCRT independent mechanism of secondary ingression formation, followed by independent 
nucleation and scission by ESCRT-III. Membrane thinning to form the secondary ingression in the latter 
case is proposed to be mediated by fusion of FIP3 positive vesicles with the membrane. Microtubule 
severing is a rate-limiting step of abscission and has been proposed to be mediated by the enzyme 
AAA ATPase Spastin, which interacts with CHMP1B and hIST1 via MIT-MIM interactions.  
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ingression would then mediate membrane scission. Continuous polymerisation and constriction of 
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characterised by renal cystic dysplasia, perturbed formation of the central nervous 
system and polydactyly. Stillborn foetuses from these three studies were homozygous 
for nonsense mutations in CEP55 that removed the EABR (R86X)465, disrupted midbody 
localisation (S425X)466 or were homozygous for an Amish founder frameshift variant 
(I172Nfs*17) that also resulted in a premature stop codon within the EABR467. Although 
there were differences in phenotype, even between the two foetuses homozygous for 
the same R86X mutation, all showed features such as hydranencephaly and occipital 
encephalocele, indicating perturbed brain development, and dysplastic, cystic or 
degraded kidneys, indicating perturbed kidney development. In keeping with in vitro 
studies, multinucleated neurons and hepatocytes were also observed in the case of the 
S425X cases465.  
Studies in zebrafish models of CEP55 knockout have shown that, as seen in humans, 
heterozygous knockouts are still viable and fertile but display reduced brain size, 
craniofacial abnormalities and renal dysplasia or atrophy. Apoptosis and cell cycle 
dysregulation were also observed466,468,469.  
A recent publication described the first mouse knockout model for CEP55 and provided 
a more detailed study of its relationship with the ESCRT machinery in vivo470. 
Interestingly in this case, mice that were homozygous for the knockout were born live 
but died postnatally. Such mice presented with microcephaly, due to apoptosis in the 
brain cortex, and kidney dysmaturity. Multinucleated cells were observed in the brain 
cortex, however no increase in midbody connected cells was observed, in contrast to 
the previously described in vitro work (section 1.5.4.1.). Established cultures of knockout 
mouse neural progenitor cells also displayed an increase in multinucleation, which was 
not seen to the same extent in cultured primary tail tip fibroblasts. This was consistent 
with the observation that knockout mice did not show obvious anatomical defects and 
changes in cell proliferation and apoptosis in tissues other than that of the brain. In 
keeping with these observations, CEP55 was shown to be necessary for both mChmp2B 
and mChmp4B to the midbodies of mouse neural progenitor cells and fibroblasts. 
However, only around 30% fibroblasts showed localisation of CEP55, mChmp2B and 
mChmp4B compared to over 60% of neural progenitor cells. Furthermore, CEP55 
knockout mouse fibroblasts were still able to complete abscission, in the absence of the 
ESCRT machinery, in contrast to neural progenitor cells, over 60% of which failed 
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abscission upon depletion of Chmp4B470. A similar observation was made in C. elegans: 
abscission is delayed but not prevented when the ESCRT machinery is disrupted471. 
Taken together these animal models suggest that the CEP55 and the ESCRT machinery 
are essential for cell division in neural progenitor and kidney cells during development, 
but that CEP55 and ESCRT independent pathways for abscission exist in other cell types. 
In contrast to CEP55, MKLP1 depletion in mouse fibroblasts led to a significant increase 
in multinucleated cells, and Drosophila, which do not express a CEP55 homologue, have 
been shown instead to recruit ALIX and TSG101 via direct interaction with the MKLP1 
homologue, Pavarotti275,470,472,473. Studies performed using cultured embryonic cells or 
female germline stem cells in Drosophila showed both ALIX and TSG101 to be 
individually required for ESCRT-III recruitment, rather than the partial redundancy seen 
in mammals472. This highlights a further difference compared to the most commonly 
studied context, of cancer cell lines in culture. The requirement for the ESCRT machinery 
in Drosophila somatic cells is unclear, as is the case for C. elegans, embryonic cells of 
which show retarded but successful abscission upon ESCRT depletion471. 
 
 
1.5.5. Cytoskeleton remodelling at the site of abscission 
In order for abscission to occur, both F-actin and microtubules must be removed from 
the midbody. These have been proposed to act as a physical barrier, blocking access of 
ESCRTs and vesicle trafficking to the secondary ingression. Alternatively, excess actin has 
been proposed to alter membrane tension, hence the ability of ESCRT-III to translocate 
to the secondary ingression via the ‘cut and slide’ model detailed above.  
In addition to the more indirect roles of OCRL and p50RhoGAP in preventing actin 
polymerisation, as previously described in section 1.5.3., a more direct role in actin 
depolymerisation mediated by the MICAL family of oxidoreductases has been 
uncovered474. Mammals express three of these enzymes, being MICAL1, MICAL2 and 
MICAL3, together with the MICAL-like proteins MICAL-L1 and MICAL-L2475–482. MICAL1, 
-2 and -3 possess an N-terminal flavoprotein monooxygenase domain followed by a 
calponin homology domain and a (Lin-11, Isl-1 and Mec3) LIM domain. MICAL1 and -3 
also possess C-terminal Rab binding domains483–487. MICALs have previously been 
implicated in several processes where they mediate actin cytoskeleton remodelling474. 
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Actin depolymerisation has been suggested to occur via oxidation of methionine 
residues in actin, upon binding to it. This has been suggested to weaken longitudinal 
interactions between actin subunits, thus increasing fragility of actin filaments, leading 
to a high rate of depolymerisation from both ends of the filament474,488,489. Alternatively, 
the production of reactive oxygen species by MICALs, such as hydrogen peroxide, have 
been suggested to modify amino acid residues within actin, leading to 
depolymerisation484,490,491. 
A role for MICAL1 has been shown in clearance of actin from the secondary ingression 
prior to cytokinetic abscission. Like ESCRT-III, MICAL1 has been shown to initially localise 
to the Flemming body prior to the secondary ingression, prior to abscission. Depletion 
of MICAL1 abrogates CHMP4B recruitment to the secondary ingression, but not initial 
recruitment to the Flemming body. Its depletion also delays or inhibits abscission492–494.  
Just as Rab35 controls localisation of OCRL to the midbody, Rab35-GTP also interacts 
with MICAL1 and mediates its Flemming body and secondary ingression 
localisation492,495,496. Binding of Rab35 to MICAL1 has also been shown to relieve its 
autoinhibition. MICAL1 exists in an autoinhibited state in the cytoplasm, in which its C-
terminus folds back, interacting with its N-terminus. Binding of Rab35 to its binding site 
at the C-terminus prevents this interaction492. 
Roles for MICAL3 and MICAL-L1 in cytokinesis have also been described, although these 
proteins seemingly play redox independent roles, in contrast to MICAL1. MICAL3 has 
been suggested to act as a midbody associated scaffold for vesicle targeting that 
interacts with MKLP1 and tethers Rab8 positive vesicles at the midbody497,498. MICAL-L1 
also appears to be involved in membrane trafficking498. MICAL-L1 is another Rab35 
effector that also interacts with Rab8 and Arf6499. Importantly, it directs Rab11-FIP3 
endosome targeting, hence delivery of p50RhoGAP, to the midbody. This prevents 
excess accumulation of actin500,501. 
In order for abscission to occur, central spindle microtubules must be removed from the 
midbody. Microtubule severing at the secondary ingression coincides closely with 
abscission and has been shown to be a rate-limiting step of abscission, like recruitment 
of ESCRT-III118. The mammalian microtubule severing AAA ATPase Spastin plays an 
important role in this process, and mutations in this protein are the most common cause 
of hereditary spastic paraplegia – a disease caused by length-dependent degeneration 
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of the distal ends of long axons502. Spastin, like VPS4, forms a hexameric ring structure 
with a central pore through which microtubules are pulled and broken by the force 
generated. Depletion of Spastin leads to an increased number of cells connected by long 
tubular structures, although no increase in multinucleation is seen, indicating a role 
during late stages of cytokinesis503,504. Spastin was found to possess an N-terminal MIT 
domain upstream of its microtubule binding and ATPase domains, that forms a non-
canonical high affinity interaction specifically with the MIM domain of CHMP1B (Figure 
18)504–506. This MIM-MIT interaction surface is twice that of other MIT-MIM domain 
interactions of ESCRT-III proteins, and Spastin localises to the midbody in a MIT domain 
and CHMP1B dependent manner505. Whilst Spastin has been proposed to mediate 
microtubule severing at secondary ingressions prior to abscission, another model 
proposed by Schiel et al. 2011 proposed a non-essential role for Spastin in microtubule 
severing438. This study suggested that Spastin contributes to microtubule release from 
centrosomes and their appropriate bundling within the midbody, which they suggested 
was required for appropriate trafficking of FIP3 positive vesicles to the midbody. This 
study suggested that microtubule buckling and breaking, as occurs during interphase, 
was necessary for abscission, rather than spastin mediated severing. 
 
1.5.6. Adaptation of the ESCRT machinery to cytokinesis and associated 
accessory proteins 
In contrast to their role in viral budding (Section 1.7.3.), which appears to require only a 
small subset of ESCRT-III proteins, cytokinetic abscission and/or mitosis appears to 
require all 12 ESCRT-III proteins, with CHMP1A, CHMP2A, CHMP3 and hIST1 showing the 
most obvious cytokinetic defects upon depletion454,507. In addition to interaction with 
various accessory proteins, as outlined in this section, another possibility for 
requirement of a larger complement of ESCRT-III proteins could be to drive formation of 
intermediary structures, such as filaments at the midbody of a diameter much larger 
than the 50-100nm diameter filaments required for MVB formation. The cytokinesis 
specific CHMP-like protein hIST1, for example, has been shown to spontaneously 
polymerise into approximately 700nm diameter tubular structures, suggesting it may be 
a subunit necessary for generation of the larger diameter filaments that form rings 
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adjacent to the Flemming body98. Another example of adaptation to cytokinesis is the 
CHMP1B-Spastin interaction described above. 
hIST1 is an ESCRT-III associated regulatory protein that is essential for cytokinetic 
abscission, as indicated by the strong increase in multinucleated cells and midbody 
connected cells upon its depletion507. Closer examination of this phenotype by time-
lapse microscopy showed that furrow regression leading to multinucleation always 
occurs following an extended period of midbody connection of the nascent daughter 
cells507,508. This indicates that midbodies are very stable and that hIST1 depletion causes 
a late cytokinesis defect consistent with a role specifically in abscission. hIST1 shows 
functional specificity in cytokinesis and nuclear envelope resealing (Section 1.6.1.) but 
not lysosomal sorting or viral budding507. hIST1 is a CHMP-like protein, that shows similar 
localisation to the midbody in two concentric rings, like other ESCRT-III proteins507. 
Structurally it contains a conserved N-terminal ELYC domain (named after this conserved 
sequence of residues) which like other CHMP proteins forms a 4-helix bundle and 
another 3 helical regions involved in autoinhibition509. Downstream of the ELYC domain 
is a central proline rich linker, predicted to be largely unstructured, and tandem C-
terminal MIM2 and MIM1 domains, that mediate interactions with MIT domain 
containing proteins such as VPS4, LIP5, UBPY, AMSH, MITD1, ULK3 (Section 1.3.4.5.), 
Spartin and Spastin (Figure 18)507,509,510. Unlike other CHMP proteins, these MIM 
domains are both located downstream of the a6 helix, presumably ensuring that both 
MIM domains are available for MIT domain binding regardless of whether hIST1 is in an 
open or closed, autoinhibited conformation.  MIM domains of other CHMPs are 
occluded when these CHMPs are in an autoinhibitory conformation. Perhaps this, 
together with its binding to nearly all MIT domain containing proteins identified so far, 
explains why hIST1 plays such a prominent role in cytokinesis. 
hIST1 interacts with CHMP1A and CHMP1B through its N-terminal ELYC domain at 
surface exposed residues within both the a2 helix of its characteristic 4-helix bundle, 
and the autoinhibitory helix a598,507,508. The binding surface for hIST1 on CHMP1B has 
been mapped by yeast two-hybrid to approximately residues 61-156, encompassing the 
majority of helices a2 - a5 (Figure 18)507. Like hIST1, depletion of CHMP1 proteins leads 
to an increase in both multinucleation and midbody connected cells, and the hIST1-
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CHMP1 interaction is necessary for successful abscission, as shown by experiments using 
hIST1 mutants that are defective for CHMP1 binding: the ability of hIST1 mutants to 
rescue abscission (midbody arrest) correlated with how well they bound CHMP1507,508. 
Along the same lines, both hIST1 and CHMP1 are required for efficient recruitment of 
VPS4 to the midbody, and hIST1 and CHMP1 proteins are less stable upon VPS4 
depletion, indicative of formation of a complex between hIST1, CHMP1 proteins, VPS4 
and probably other MIT domain containing proteins509. Interestingly, both MIM1 and 
MIM2 domains in hIST1 have been shown to be necessary for optimal binding of VPS4, 
and the MIM1 domains of hIST1 and CHMP1 proteins bind overlapping but non identical 
regions of the VPS4 MIT domain508. It is therefore conceivable that the MIM domains of 
CHMP1 proteins, hIST1 and other ESCRT-III proteins act together to form a network of 
MIM domains to recruit VPS4 and its effector LIP5 with high affinity to function during 
cytokinesis. Binding of the MIM-MIT interaction mediates strong activation of VPS4 
ATPase activity (Section 1.3.4.6.). This network of MIM domains also likely functions to 
recruit the other, abovementioned MIT domain containing proteins to function at the 
end stages of cytokinesis, tethering them to the ESCRT-III polymers and bringing them 
into close proximity to act together in abscission. Spartin is another MIT domain 
containing protein that depends on its interaction with hIST1 for midbody recruitment. 
Its function is unknown, but depletion leads to abscission failure, manifested by 
increased multinucleation and midbody connected cells, and increased abscission 
time510. 
MIT domain containing 1 (MITD1) is another MIT domain containing protein that is 
specifically involved in cytokinesis and binds the MIMs of CHMP1A, CHMP1B, CHMP2A 
and hIST1511,512. Only CHMP2A, however, appears to be essential for its midbody 
recruitment511. In contrast to hIST1, which so far appears to function specifically at a late 
stage close to abscission, MITD1 appears to act at an early stage in midbody stability in 
addition to abscission511. It thereby represents an important example of ESCRT 
adaptability to cytokinesis and spaciotemporal coordination with more upstream events. 
MITD1 contains an N-terminal MIT domain and a C-terminal phospholipase D (PLD)-like 
fold. Characterisation of its structure revealed a homodimer511.  
In contrast to depletion of hIST1, depletion of MITD1 causes an increase in 
multinucleation but no concomitant increase in midbody connected cells, consistent 
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with a role at an early stage of cytokinesis. This was further characterised as a role in 
midbody stability, by time-lapse experiments using cells depleted of MITD1, which 
showed furrow regression within time frames shorter than the average time taken for 
abscission in wild type cells. Since an additional small population of cells remained 
connected by midbodies for an extended period of time prior to abscission, like hIST1, 
an additional function in abscission was implied511. Consistent with a function in 
midbody stability, depletion of MITD1 also caused increased plasma membrane 
blebbing, and in cells that successfully divided, abscission was on average 10 minutes 
faster, possibly due to a reduction in midbody tension caused by blebbing at the 
midbody. Blebbing also suggests MITD1 could be playing a role in actin clearance at the 
midbody511.  
An exposed basic patch on the surface of the MITD1 dimer was found to mediate 
interaction with membranes by binding to phosphoinositides, and this interaction was 
also found to be important for localisation to the midbody. Taken together these 
observations have led to a model whereby MITD1 binds ESCRT-III and midbody 
membrane simultaneously to facilitate cortical stability at the midbody and anchorage, 
whilst coordinating this with ESCRT-III recruitment and stability. By competing with VPS4 
for binding to hIST1, but not with Spastin due to the particularly strong hIST1-Spastin 
MIT-MIM interaction, it has also been proposed that MITD1 could act to inhibit ESCRT-



































Aside the above described interactions mediated by MIT-MIM motifs, and the potential 
interaction between CHMP4B with midbody membrane via an interaction with 
TTC19/FYVE-CENT, which binds PI3P, BRCA2 has also been suggested to facilitate the 
interaction between CEP55 with TSG101 and ALIX. BRCA2 has been proposed to show 
interaction with all three proteins and contribute to abscission513. Tsg101 has also been 
shown to interact with several proteins that show midbody localisation and are involved 
in upstream cytokinetic events. Such proteins include CD2AP, which is involved in 
endocytic protein trafficking, ROCK1 and IQGAP1, which are both involved in 
cytoskeletal remodelling and actomyosin ring assembly and contraction, and SCAMP3, 
as previously mentioned in Section 1.5.3.17. Perhaps this partly explains why Tsg101 and 
ALIX do not show complete redundancy in cytokinetic abscission: each could be 
Figure 18. MIT-MIM interactions of the ESCRT machinery in cytokinetic abscission 
The microtubule severing AAA ATPase Spastin interacts with CHMP1B through an especially strong 
non-canonical MIT-MIM interaction. Spastin localises to the midbody in a MIT domain and CHMP1B 
dependent manner. hIST1 interacts with CHMP1A and CHMP1B through its N-terminal ELYC domain 
(named after this conserved sequence) at surface exposed residues within helices a2 - a5. Both MIT1 
and MIT2 domains of hIST1 have been shown to be necessary for optimal binding to the MIT domain 
on VPS4, and most likely its other MIT domain containing interaction partners such as Spastin, LIP5, 
MITD1, ULK3, UBPY, AMSH and Spartin. hIST1 is essential for cytokinetic abscission and interacts with 
nearly all MIT domain containing proteins identified so far. 
 
Figure 18. MIT-MIM interactions of the ESCRT machinery in cytokinetic abscission 
Th  microtubule s vering AAA ATP se Spastin interacts with CHMP1B thr ugh an especially strong 
non-canonical MIT-MIM interaction. Spastin localises to the midbody in a MIT domain and CHMP1B 
depende t manner. hIST1 interacts with CHMP1A and CHMP1B through its N-terminal ELYC domain 
(named after this conserved sequence) at surface exposed residues within helices a2 - a5. Both MIT1 
and MIT2 domains of hIST1 have been shown to be necessary for optimal binding to the MIT domain 
on VPS4, and most likely its other MIT domain containing interaction partners such as Spastin, LIP5, 
MITD1, ULK3, UBPY, AMSH and Spartin. hIST1 is essential for cytokinetic abscission and interacts with 
nearly all MIT domain containing proteins identified so far. 
 
Figure 18. MIT-MIM interactions of the ESCRT machinery in cytokinetic abscission 
The microtubule severing AAA ATPase Spastin interacts with CHMP1B through an especially strong 
non-canonical MIT-MIM interaction. Spastin localises to the midbody in a MIT domain and CHMP1B 
dependent manner. hIST1 interacts with CHMP1A and CHMP1B through its N-terminal ELYC domain 
(named after this conserved sequence) at surface exposed residues within helices a2 - a5. Both MIT1 
and MIT2 domains of hIST1 have been shown to be necessary for optimal binding to the MIT domain 
on VPS4, and most likely its other MIT domain containing interaction partners such as Spastin, LIP5, 
MITD1, ULK3, UBPY, AMSH and Sparti . hIST1 is ess ntial for cytokine ic abscission and interacts with 
nearly all MIT domain containing proteins identified so far. 
 
Figure 18. MIT-MIM interactions of the ESCRT machinery in cytokinetic abscission 
The microtubule severing AAA ATPase Spastin interacts with CHMP1B through an especially strong 
non-canonical MIT-MIM interaction. Spastin localises to the midbody in a MIT domain and CHMP1B 
dependent manner. hIST1 interacts with CHMP1A and CHMP1B through its N-terminal ELYC domain 
(named after this conserved sequence) at surface exposed residues within helices a2 - a5. Both MIT1 
and MIT2 domains of hIST1 have been shown to be necessary for optimal binding to the MIT domain 
on VPS4, and most likely its other MIT domain containing interaction partners such as Spastin, LIP5, 
MITD1, ULK3, UBPY, AMSH and Spartin. hIST1 is essential for cytokinetic abscission and interacts with 
nearly all MIT domain containing proteins identified so far. 
92 
 
specifically involved in binding to other factors required for coordination of abscission 
with more upstream events. 
 
1.5.7. ESCRTs in the abscission checkpoint 
In contrast to the various phosphorylations mediated by CDK1, AuroraB and PLK-1 in 
temporal control of cytokinesis during mitotic exit and early stages of cytokinesis, the 
involvement of the ESCRT machinery in the AuroraB dependent abscission checkpoint, 
(also known as NoCut) represents a role for the ESCRT machinery in control of 
cytokinesis at a later stage, closer to abscission. The discovery of ESCRT proteins as part 
of the abscission checkpoint pathway represents another important example of 
adaptability of the ESCRT machinery to cytokinetic abscission and the importance of 
MIT-MIM interactions. 
NoCut was originally identified in yeast as a surveillance mechanism to ensure that 
abscission does not take place until chromatin from unsegregated chromosomes has 
been cleared from the intercellular bridge514–516. This prevents cutting through 
chromatin, causing DNA damage. This phenomenon was later identified in eukaryotes, 
where it prevents genomic instability arising from furrow regression and 
tetraploidisation, in addition to DNA damage335,516. Anaphase chromatin bridges that 
persist through the midbody arise from defects in chromosome architecture leading to 
incomplete separation of sister chromatids. The NoCut pathway in yeast is different 
from that in mammals, involving inhibition of septin mediated abscission by localisation 
of the bud-neck proteins Boi1 and Boi2 to the cleavage site, in response to chromatin 
mediated activation of Lpl1 kinase activity515,517. Despite this, the key kinase in this 
process in mammals, AuroraB, is the homologue of Lpl1, demonstrating evolutionary 
conservation of this checkpoint. The abscission checkpoint is also activated in 
mammalian cells in response to defective nuclear pore complex assembly and high 
levels of midbody tension, resulting from cell growth at low densities518–520. 
AuroraB activity at the midbody is sustained specifically by chromatin515,516,521. Although 
the mechanism for this has not been elucidated, AuroraB mediated phosphorylation of 




In terms of the ESCRT machinery, CHMP4C has been identified as an important 
regulatory protein in the abscission checkpoint, and AuroraB specifically phosphorylates 
CHMP4C at residue 210, within a unique insertion (INS) from residues 201-217 that is 
not present in CHMP4A or CHMP4B (Figure 19)521,522. This phosphorylation is facilitated 
by interaction of CHMP4C with Borealin (a subunit of the CPC, which contains AuroraB, 
INCENP, borealin and survivin) and is necessary for localisation of CHMP4C to the 
Flemming body rather than the midbody arms during late cytokinesis521. Interestingly, 
dephosphorylation at residues 214 and 215 also accompanies CHMP4C Flemming body 
localisation suggesting control of the checkpoint by unknown phosphatase activity in 
addition to kinase activity523. Involvement of CHMP4C in the abscission checkpoint was 
first demonstrated by the inability of depletion of the nuclear pore protein NUP153 to 
trigger the abscission checkpoint, manifested by an increase in midbody connected cells, 
upon codepletion with CHMP4C521. Mutation of residue 210 or the unique insertion 
from 201-217 produced a similar phenotype521. CHMP4C was thus identified as a 
negative regulator of abscission, even though it did not appear to be essential for 
abscission, likely due to redundancy with CHMP4A and CHMP4B. Interaction of CHMP4C 
with ALIX was later also shown to be necessary for a functional checkpoint, even though 
ALIX was not necessarily required for midbody localisation of CHMP4C. This was 
demonstrated in a recent publication, by a polymorphism in CHMP4C represented by a 
mutation that confers susceptibility to various cancers. This mutation reduces binding 
of ALIX to CHMP4C and does not support the abscission checkpoint524.  
CHMP4C interacts with VPS4 via a MIT-MIM interaction as does Abscission/NoCut 
Checkpoint Regulator (ANCHR) - another ESCRT associated protein involved in the 
abscission checkpoint (Figure 19)525. In an Aurora B dependent manner, ANCHR has been 
proposed to form a complex with VPS4 and CHMP4C, retaining VPS4 in an inactive form 
at the Flemming body, and preventing its localisation to the secondary ingression to 
mediate abscission525. 
ULK3 kinase represents another important signalling node of the abscission checkpoint 
that acts downstream of AuroraB in a CHMP4C dependent manner520. ULK3 also 
phosphorylates CHMP4C, but at different sites from those phosphorylated by AuroraB. 
Its preferred substrate, however, is believed to be hIST1, through which it interacts via 
an especially strong MIT-MIM interaction (Figure 18)520. Like CHMP4C depletion, 
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checkpoint activation also fails upon ULK3 depletion or mutation of hIST1 at its 
phosphorylation sites. 
Whilst retention of VPS4, its effector LIP5, ANCHR and ESCRT-III proteins such as hIST1 
at the Flemming body could explain one mechanism by which the abscission checkpoint 
delays abscission, the various phosphorylations could also prevent transition of CHMPs 
from their closed states to open polymerisation competent states as another means of 
inhibiting abscission (Figure 19). CHMP4C has also been proposed to delay abscission by 
competing with CHMP4B for binding to ALIX, thus preventing polymerisation of CHMP4B 
filaments167. Further details of the pathway and mechanisms involved in maintenance 
of the checkpoint remain to be characterised for a more complete understanding. It 
would also appear that there are differences in the pathway depending on how the 
checkpoint is triggered. For example, when the ULK3 phosphorylated residues of hIST1 
are mutated, the checkpoint is still activated in response to midbody tension, even 






































































Figure 19. The ESCRT machinery in the NoCut Aurora B-dependent abscission checkpoint.  
Activated aurora B kinase, as part of the chromosomal passenger complex (CPC), stabilises the cleavage 
furrow, by phosphorylation of MKLP1. Aurora B also phosphorylates the ESCRT regulatory protein 
CHMP4C at residue 210 within a unique insertion (INS) not present in CHMP4A or CHMP4B, located 
between its MIM and ALIX binding regions. This leads to retention of CHMP4C at the Flemming body 
during late cytokinesis. ULK3 kinase also phosphorylates CHMP4C and other ESCRT-III subunits, but its 
preferred binding partner and substrate is hIST1, with which it interacts through an especially strong 
MIT-MIM interaction. Such phosphorylations have been proposed to render CHMP proteins in their 
inactive ‘closed’ forms, thus inhibiting polymerisation and abscission. Alternatively, such 
phosphorylations have been proposed to sequester VPS4, its effector Lip5 and and other ESCRT-III 
proteins at the Flemming body, thus preventing their polymerisation and activity at the secondary 
ingression. In line with this, ANCHR has been proposed to act in concert with CHMP4C to bind and 
sequester VPS4 at the Flemming body in an aurora B dependent manner. Question marks represent 
speculative interactions that have not yet been validated. 
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1.6. ESCRTs at the nuclear envelope 
1.6.1. ESCRTs in nuclear envelope reformation 
The nuclear envelope mediates nucleo-cytoplasmic compartmentalisation and is 
continuous with the ER, forming a double membrane structure consisting of an inner 
nuclear membrane (INM) and outer nuclear membrane (ONM)526. In contrast to budding 
yeast which undergoes a ‘closed’ mitosis, mammalian cells undergo ‘open’ mitosis in 
which the nuclear envelope (NE) and lamina must be broken down at prophase and 
incorporated into the ER to allow chromosomes access to the mitotic spindle526–529. NE 
breakdown is mediated by a dynein mediated microtubule tearing process under the 
control of CDK1, Aurora B kinase and PLK-1528. Aurora B associates with chromosomes 
to prevent decondensation and NE reformation until anaphase, when chromosomes 
have segregated530. The NE is reformed from ER membrane at anaphase by recruitment 
of ER membrane to the rims of decondensing chromatin disks531. Membrane then 
flattens and encapsulates chromatin; however, gaps still exist in the double membrane 
where ER tubules have not fused together, particularly where spindle attachment 
persists531–534. Spindle severing and annular fusion of membrane must therefore take 
place to seal such holes, and this has been shown to involve the ESCRT machinery. 
Involvement of ESCRTs in annular fusion was initially demonstrated in studies by Olmos 
et al. 2015 and Vietri et al 2015, who showed recruitment of CHMP2A and CHMP4B to 
nucleo-cytoplasmic channels in the reforming nuclear envelope18,19. Both studies also 
made use of correlative light electron microscopy to strengthen their findings. 
Localisation of other ESCRT-III proteins, such as CHMP3, CHMP1A, CHMP1B, VPS4 and 
hIST1 was additionally observed, and knockdown of these subunits led to reduced 
nuclear integrity and DNA damage caused by loss of compartmentalisation, hence 
protection from cytoplasmic nucleases. Vietri et al. 2015 showed that as in cytokinesis 
(Section 1.5.5.), the microtubule severing AAA ATPase Spastin was recruited in a hIST1 
dependent manner, via a MIT-MIM domain interaction, to disassemble microtubules, 
and that microtubule severing is a rate-limiting step of NE resealing: expression of 
dominant negative Spastin led to retention of CHMP4B-GFP at open fenestrations in the 
NE19. In contrast to cytokinesis, however, CHMP1B knockdown did not perturb Spastin 
recruitment, suggesting an alternative mechanism of recruitment. 
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Ubiquitin fusion and degradation 1 (UFD1) and CHMP7 have been suggested as adaptor 
proteins that recruit ESCRT-III to the nuclear envelope. UFD1 is an adaptor protein that 
associates with the p97 AAA ATPase, which has been shown to play a role in directing 
fusion of Golgi and ER membrane, removal of ubiquitinated Aurora B from 
chromosomes, ER membrane recruitment to the NE and NE resealing18,535,536. An 
interaction between UFD1 with CHMP2A was seen by yeast two hybrid and UFD1 was 
shown to be necessary for ESCRT-III recruitment to the reforming NE18. 
CHMP7 shows features of a hybrid ESCRT protein with a C-terminus similar to CHMP6 
showing typical CHMP structure, consisting of 6 helical regions, and an N-terminus that 
resembles the tandem winged helix domains of ESCRT-II subunit EAP20537,538. 
Knockdown of CHMP7 led to abolishment of ESCRT-III and VPS4 to the NE, and 
interaction with CHMP4B has been shown19,539. The first of the two winged helix 
domains at the N-terminus contains an extended loop of hydrophobic amino acids that 
anchor CHMP7 to the ER membrane538. Given the continuity of the ER membrane with 
the NE, this suggests a possible mechanism of recruitment for ESCRTs to NE 
fenestrations, and membrane binding is necessary for further ESCRT-III assembly113. 
Assembly of ESCRT-III at the NE, with potential specificity for sites at which annular 
fusion occurs, however, has been shown to depend on interaction between CHMP7 with 
the LEM domain containing protein LEMD2540–543. This INM protein binds CHMP7 via its 
C-terminal MSC (MAN1/Src1-C-terminal homology) domain, and bridges chromatin with 
the nuclear envelope. CHMP7 also contains a nuclear export signal at its C-terminus that 
ensures localisation to the cytosolic side of the NE, thus preventing ESCRT-III 
polymerisation until required, perhaps by interaction with LEMD2540,541. This together 
with coincidence detection of ER derived membrane, LEMD2 and possibly spindle 
microtubules has been suggested to specify assembly of ESCRT-III at sites where the INM 
meets the ONM and direct annular fusion.  
Fission yeast undergoes a ‘semi-open’ mitosis, in which the MTOC enters the nucleus 
through a fenestration in the NE during mitosis. Whilst it is unclear whether the ESCRTs 
are involved in resealing such fenestrations, studies have shown that, loss of function 
mutations in Cmp7 or Lem2 in fission yeast suppresses defects in NE resealing seen upon 
depletion of Vps4542. This suggests that as in mammalian cells, the aforementioned 
CHMP7 and LEMD2 homologues are important for nuclear integrity, even if they play 
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slightly different roles in yeast. A recent publication studying the fission yeast S. 
japonicus probed further, showing that the ESCRT machinery remodels INM localised 
Lem2-Nur1 complex attachment with heterochromatin, mediating its release from 
heterochromatin, as required during mitosis, and for proper nucleocytoplasmic 
compartmentalisation following mitosis540. 
A recent study by Ventimiglia et al. 2018 shed light on the role of coiled-coil and C2 
domain-containing protein B (CC2D1B) as a regulator of NE reformation, by preventing 
premature recruitment of ESCRTs to the NE. CC2D1B must later be removed prior to 
ESCRT recruitment544. CC2D1B is a member of the Lgd/CC2D1 family that also includes 
CC2D1A and the Drosophila homologue Lgd. These proteins have been shown to bind 
CHMP4 paralogues, and CC2D1A has been shown to inhibit polymerisation of 
CHMP4B545–547. An interaction of CC2D1B with CHMP7 and CHMP2A, in addition to 
CHMP4, was discovered, and CC2D1B was shown to localise to the NE in a CHMP7 
dependent manner, where it also binds the lipid PI(4,5)P2. Depletion of CC2D1B led to 
premature recruitment of ESCRT-III to the NE, around 5 minutes earlier than usual, at a 
time closer to furrow ingression, before more complete coverage of NE around the 
nuclear perimeter. It also led to reduced accumulation of CHMPs and disruption of 
coordination of their recruitment at the NE, as demonstrated by an approximate two-
minute lag between recruitment of CHMP7 and CHMP4B544. Observations were 
extended to spastin in this study, and both premature recruitment and a reduction in 
spastin was observed at the NE upon CC2D1B depletion, potentially due to the 
asynchronous recruitment of CHMPs. Persistence of microtubules and delayed 
disassembly was observed as a result of this, accounting for aberrant NE morphology544. 
Aside the role of ESCRTs in NE reformation during mitosis, increased hydrostatic 
pressure causes NE rupture to occur in interphase during the migration of cells of the 
immune system and cancer cells through confined spaces548,549. Studies have shown that 
the ESCRTs play a similar role here in NE repair, to lessen DNA damage548,549. In these 
cases, rupture occurs at localised regions of NE extrusion where excess pressure causes 
loss of lamins and NPCs. As expected, depletion of ESCRT-III subunits leads to disrupted 
repair and cell death.  
A role upstream of ESCRT-III for barrier to autoantigen factor (BAF) in membrane 
recruitment to NE ruptures has recently been described. BAF interacts with cytosol 
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exposed chromatin, through nuclear ruptures, and recruits membrane to the exposed 
chromatin550. Recruitment of membrane occurs via interaction of phosphorylated BAF 
with LEM domain proteins, which bind the INM. Recruitment of LEMD2 in this way 
recruits CHMP7 and the ESCRT machinery to the rupture to direct sealing550. 
 
1.6.2. ESCRT function in yeast nuclear pore complex surveillance  
Budding yeast undergoes a closed mitosis in which the NE is not broken down, and the 
mitotic spindle instead forms within the nucleus. Nuclear pore complexes control entry 
and exit of proteins and RNA, thus maintaining nucleocytoplasmic 
compartmentalisation. The ESCRTs have been implicated in removal or sequestration of 
defectively formed nuclear pore complexes (NPCs) in yeast as a quality control 
mechanism, since the NE is not broken down and reassembled as in mammalian cells551–
554.  
NPCs are macromolecular structures that consist of around 600-700 subunits called 
nucleoporins (Nups)555–557. Epistasis screens initially uncovered genetic interactions 
between Vps4, Snf7 (CHMP4), Vps24 (CHMP3) and Vps2 (CHMP2) with nucleoporin 
POM152 and Nup170551. Nup170 interacts with the inner nuclear membrane LEM 
domain proteins Heh1 (LEMD2 homologue) and Heh2, and further interactions between 
Snf7 and Chm7 (CHMP7) with Heh1 and Heh2 were subsequently uncovered558,559. In 
addition to this observed interaction with Chm7, the identity of Heh1 and Heh2 as 
putative adaptors for ESCRT-III recruitment to defective NPCs was suggested by the 
observed necessity of the Chm7-Heh1/2 interaction for recruitment of Chm7 to 
defective NPCs551. Furthermore, defective NPCs accumulated in a structure at a single 
site at the NE, within INM invaginations in the perinuclear space, known as the storage 
of improperly assembled nuclear pore complexes (SINC) upon deletion of Heh2, ESCRT-
III or Vps4. Deletion of Chm7 prevented this551,558. This demonstrated a role for Chm7 in 
SINC formation. The SINC is formed to ensure that only one daughter cell inherits the 
defective NPCs rather than both, thus representing a further feature of NE quality 
control551,552.  
The exact mechanism by which defective NPCs are dealt with by the ESCRT machinery is 
not clear. Models put forward include direct disassembly by Vps4, or indirectly via 
100 
 
disassembly of NPC bound ESCRT-III551,552,558. In a similar parallel with the role of CHMP7 
in mammalian NE reformation, yeast Chm7 has also been shown to seal the NE above 
defective NPCs to prevent unfavourable nucleo-cytoplasmic mixing558.  
 
1.7. ESCRTs in viral budding 
1.7.1. Late domain mediated viral budding 
CHMP4 and VPS4 homologues are required for replication and budding of Sulfolobus 
turreted icosahedral virus (STIV) in Archaea of the genus Sulfolobus. This suggests that 
whilst cytokinesis may represent the ancestral function of the ESCRT machinery, viral 
budding is also a well conserved ESCRT mediated process448–450. 
A study by Gottlinger et al. 1991 demonstrated that removal of HIV-1 p6 led to the 
tethering of nascent virions to the plasma membrane by membranous stalks, 
representing a defect at the late stages of the virus lifecycle560. Follow up experiments 
by Huang et al. 1995 showed that this phenotype was largely due to a p6 7PTAP10 motif54. 
Additional conserved tetrapeptide late budding domains (L-domains) were 
subsequently discovered in other viruses, most importantly an LYPxnL motif in Equine 
infectious anaemia virus (EIAV) p9(Gag) and a PPxY motif in Rous sarcoma virus (RSV) 
p2b(Gag) (Figure 20)561,562. Prior to further elucidation of the mechanism by which these 
L-domains mediated viral budding, it was found that despite variation in budding 
efficiencies from wild type levels, such L-domains from EIAV, RSV and Murine leukaemia 
virus (MLV), which also contains a PPXY motif, were able to function in exchangeable 
and position independent manners561,563,564. Whilst PT/SAP motifs were later shown to 
recruit TSG101 (ESCRT-I) via its UEV domain, mimicking the interaction with HRS (ESCRT-
0)12–15,75,565, LYPXnL motifs were found to recruit ALIX, via the second arm of its V 
domain152,566–568, and PPXY motifs were found to recruit Nedd4-like HECT domain E3 
ubiquitin ligases notably WWP1, WWP2 and Itch via their WW domains569,570. Since 
these initial studies, L-domains have been discovered in a wide range of other enveloped 
viruses571.  
The discovery of ESCRT usurpation for viral budding represented an important step in 
understanding how the ESCRT machinery functions. The conserved requirement for 
ESCRT-III in budding regardless of the L-domains employed helped give rise to the 
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concept of the ESCRT machinery as a modular system, that uses site-specific adaptor 
proteins to recruit ESCRT-III to various sites/viral structural proteins to mediate 
membrane remodelling13,565,572–574. Together with this conserved requirement for 
ESCRT-III, viral budding was the second ESCRT mediated process to be discovered, 
following endosomal sorting, and the shared membrane remodelling topology helped 
reinforce its membrane remodelling function.  
Viruses often encode more than one L-domain. In such cases the activity of one L-
domain displays dominance whilst the others display more of an auxiliary role. Whilst 
the 7PTAP10 motif in HIV-1, for example, is primarily responsible for mediating budding, 
an ALIX binding 35LYPLTSL41 within p6 also shows L-domain activity, as evidenced by the 
ability of ALIX overexpression to rescue budding of a PTAP mutant HIV-1 virus (Figure 
20)566,568,575. In addition to this, the ability of HIV-1 Gag to recruit Nedd4-2 in a PPXY 
independent manner has been elucidated, via the naturally truncated C2 domain of 
Nedd4-2576,577. This has been proposed to explain why overexpression of Nedd4-2 can 
rescue L-domain mutant HIV-1578. Both Ebola VP40 and MLV Gag encode all three 
classical PPXY, PTAP and LYPXnL motifs14,569,579–581. In the case of MLV, the PPXY motif 
shows dominance579, whereas in Ebola the PTAP and PPXY motifs which overlap in a 
7PTAPPEY13 sequence are both required for optimal budding (Figure 20)14,569,580. A more 
downstream IYPXnL motif was later identified in Ebola VP40, and shown to display some 
L-domain activity: ALIX overexpression showed some rescue of a budding deficient Ebola 
virus, containing a mutated PTAPPEY motif, as previously shown for HIV-1581. There is 
some evidence that the activity of different L-domains is employed in different cell types, 
such as potentially a more prominent role for the 35LYPLTSL41 motif of HIV-1 in T cells582. 
In this way, multiple L-domains would broaden viral tropism. However, another 
possibility would be to confer an evolutionary advantage to viruses, such that 
propagation can still occur, albeit to a more limited extent, if the dominant L-domain 

































Whilst ALIX is able to directly bridge viral YPXnL motifs with CHMP4 proteins, hence 
ESCRT-III, pathways for ESCRT-III recruitment are less clear in the case of PT/SAP and 
PPXY L-domain mediated budding. One reason for this is the observation that budding 
in these cases appears relatively refractory to ESCRT-II depletion, suggesting that other 
unidentified bridging factors are present91,583. Although ESCRT-II is essential for 
recruitment of ESCRT-III to HIV-1 Gag by ESCRT-I using purified ESCRT proteins and a 
giant unilamellar system (GUV)584, ESCRT-II was originally shown to be dispensable for 
Figure 20. Late domain motifs in viral structural proteins recruit the ESCRT machinery to sites of 
budding 
Late domains (L-domains) are short peptide sequences in structural proteins of enveloped viruses, 
so called because they function during the late stages of enveloped virus assembly to mediate 
envelopment at the plasma membrane and budding from the cell by usurping the ESCRT machinery. 
PT/SAP motifs directly recruit TSG101 (ESCRT-I), LYPXnL motifs recruit ALIX and PPXY motifs recruit 
Nedd4-like HECT domain E3 ubiquitin ligases notably WWP1, WWP2 and Itch. HIV-1 budding is 
mediated predominantly by a PTAP motif, however an auxiliary LYPXnL motif also shows some L-
domain activity. EIAV depends on a LYPXnL motif for budding whilst RSV depends on a PPXY motif 
for budding. MLV and EBOV are further examples of viruses that encode all three of these classical 
L-domains. In the case of MLV, the overall picture so far is that its PPXY motif shows dominance, 
whilst in the case of EBOV, overlapping PTAP and PPXY motifs (PTAPPEY) are both required for 
optimal budding, whilst a later discovered auxiliary IYPXnL motif was shown to mediate some 
activity. HIV-1 = Human immunodeficiency virus 1, EIAV = Equine infectious anaemia virus, RSV = 
Rous sarcoma virus, MLV = Murine leukaemia virus, EBOV = Ebola virus, MA = Matrix protein, CA = 
Capsid protein, NC = Nucleocapsid protein. 
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HIV-1 and MLV budding in siRNA knockdown experiments91,583. Later studies suggested, 
however, that although not essential for budding, ESCRT-II shows signs of contributing 
to overall HIV-1 budding levels585,586. Such studies used shRNA knockdown, CRISPR/Cas9 
knockout HAP1 cells and dominant negative protein expression together with siRNA 
knockdown to come to such conclusions. ESCRT-II has also been suggested to be 
necessary for RNA trafficking in HIV-1587. 
 
1.7.2. Ubiquitination in viral budding 
Although the catalytic activity of Nedd4-like E3 ubiquitin ligases is required for PPXY 
motif mediated budding, this process is also not so well understood. The role of 
ubiquitination in viral budding is complicated, and whilst it would seem logical to assume 
that ubiquitination of viral structural proteins generates sites for attachment of ESCRT-
0, -I and -II, studies in varied viral contexts have implied requirements for ubiquitination 
of viral structural proteins and/or trans-acting factors. The importance of ubiquitination 
of viral structural proteins is perhaps most obviously implied by studies showing that 
mutation of ubiquitin acceptor sites in HIV-1 and RSV Gag abolishes budding588,589. In 
contrast, however, is the observation that increased ubiquitination of HIV-1 Gag by 
introduction of a PPXY motif does not enhance budding590. Fusion of ubiquitin to L-
domain deficient EIAV and HTLV has also been shown to rescue budding, and viruses 
that exhibit PPXY dependent budding display increased budding efficiency upon Gag 
ubiquitination590–592.  
Several lines of evidence have demonstrated the importance of ubiquitination of trans-
acting factors. Two studies made used of an engineered prototypic foamy virus Gag 
protein devoid of its single lysine residue, hence ubiquitination site593,594. This did not 
disrupt budding mediated by the single PSAP motif present. When the PSAP motif was 
mutated but the PPPY motif and surrounding sequence from MLV was C-terminally 
fused to the Gag protein, budding was still able to proceed. Furthermore, 
overexpression of a catalytically active YFP-WWP1 enhanced budding593,594. This clearly 
demonstrates the substrate for ubiquitination to be a trans-acting factor. A further 
finding implicating trans-acting factors as ubiquitination substrates includes the 
observation that hydrophobic surface mutations of ubiquitin rather than mutation of 
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residues that disrupt the TSG101 UEV interaction display a more potent disruption of 
HIV-1 budding591,594.  
The arrestin-related trafficking (ART) proteins are highly likely to represent 
ubiquitinated trans-acting factors involved in ESCRT mediated viral budding. These 
proteins have been shown to interact with TSG101, ALIX and ubiquitin in addition to 
Nedd4-like ubiquitin ligases, including WWP1, WWP2, Itch and Nedd4569,595. 
Furthermore, recruitment to sites of viral budding is observed, as is ability to perturb 
MLV budding when overexpressed595. It has been difficult to convincingly prove 
involvement in PPXY motif mediated budding, however, due to lack of specific 
knockdown phenotypes595. This suggests that functional redundancy amongst these 
proteins, and additional binding partner requirements are likely to be seen. 
 
1.7.3. ESCRT-III requirements in viral budding 
In contrast to mitosis and cytokinesis (Section 1.5.6.), which have been shown to require 
the full complement of ESCRT-III proteins, the smaller number of CHMPs identified as 
necessary for viral budding represents yet another example of how studying the role of 
the ESCRT machinery in viral budding has facilitated general understanding of ESCRTs – 
in this case the core ESCRT-III subunits necessary for all ESCRT mediated processes. A 
prominent role for CHMP2A and CHMP4B is apparent, as evidenced by preferential 
recruitment of these subunits for MLV and EIAV budding573,574,586. Requirement of these 
two proteins in HIV-1 budding appears less specific: as long as both a CHMP2 (2A or 2B) 
and a CHMP4 (4A, 4B or 4C) are expressed, viral budding is not drastically reduced573,586. 
Depletion of other ESCRT-III proteins generally has been shown to result in weaker 
perturbation of viral budding573,574,583,586. Taken together, these studies demonstrate an 
essential role for CHMP4 and CHMP2, whilst that of the other CHMPs appears to vary 
depending on the virus. 
 
1.7.4. Models for ESCRT mediated viral budding 
Variations of the dome model for ESCRT-III assembly and membrane remodelling 
(Section 1.3.4.4.)  have been proposed to account for structures observed at the necks 
of budding virions by deep-etch electron microscopy (DEEM), and the capture of ESCRTs 
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inside released virions129. The attractiveness of the original dome model as described in 
section 1.3.4.4. in viral budding lies in its ability to explain the presence of ESCRTs inside 
budded virions, as observed by photo-activated localisation microscopy (PALM)596. In 
this model, ESCRT-III filaments would polymerise away from Gag, tapering to a point 
towards the cytosol. In this way, the polymerisation of ESCRT-III filaments away from 
the virion would mean that following disassembly by VPS4 and scission, ESCRTs would 
become trapped within the virions (Figure 21). This original dome model, however, 
would not support the observation that VPS4 is steadily observed in bud necks597,598. 
The observation of VPS4 inside bud necks suggests a more active role for VPS4 in 
membrane remodelling, in more than just the disassembly and recycling of filaments. 
The dome model also does not explain the tapering of the dome/cone towards the virion, 
rather than the cytosol, as seen by DEEM122. Other models have therefore been put 
forward such as the reverse dome model and the inverse buckling model (section 
1.3.4.4.)129. In a reverse dome model, filaments would still nucleate on the virion side of 
the membrane and form successively narrower rings, tapering to a point (Figure 21). 
However, in order to account for tapering towards the virion, inversion of the direction 
of growth would have to occur soon after polymerisation is initiated. This has been 
suggested to potentially be mediated by VPS4129. The reverse dome model would not 
account for the observed entrapment of ESCRTs inside budded virions but would be 
more consistent with the classical view that ESCRTs are released back into the cytoplasm. 
The inverse buckling model would also be consistent with tapering of the dome/cone 
towards the virion (Figure 21). Unlike the reverse dome model, a buckling model would 
not require the direction of filament growth to change, as filaments are predicted to 
form successively wider rings away from the virion123,599. The severing of the overbent 
inner ring would then cause relaxation and flattening of the polymer, together with 
detachment from upstream ESCRTs. This would also drive scission and release of most 








































1.8. Additional ESCRT mediated processes 
1.8.1. ESCRTs in autophagy 
Autophagy refers to any of the recycling processes that employ lysosomal degradation 
to remove damaged or excess cellular components under basal conditions or upon 
induction by stress stimuli. Autophagy is important in protection against cancer, 
neurodegenerative diseases, pathogen infection and ageing600,601. Broadly speaking, 
there are three types of autophagy being microautophagy, macroautophagy and 
chaperone mediated autophagy. Endosomal microautophagy represents an additional 
form of microautophagy.  
Figure 21. Models for ESCRT-III polymerisation in viral budding 
Models for ESCRT-III polymerisation and severing of budding virions have been put forward to account 
for the presence or absence of ESCRTs inside released virions, the direction of tapering of ESCRT-III 
cones and the presence or absence of VPS4 in bud necks. The dome model would involve tapering of 
ESCRT-III filaments towards the cytosol, contrary to tapering towards the virion, as seen by Deep-etch 
electron microscopy (DEEM). However, it would explain the capture of ESCRT-III and VPS4 inside 
released virions. The inverse dome model is more consistent with filament tapering towards the virion 
and the classical view that ESCRTs are released back into the cytosol following severing. Reversal of the 
direction of filament tapering following nucleation at the virion side, has been proposed to explain this. 
VPS4 has been proposed to be involved in mediating this change in direction of tapering. This is 
potentially consistent with the more persistent localisation of VPS4 in bud necks. An inverse buckling 
model (Section 1.3.4.4.) would also be consistent with the observed tapering of filaments towards the 
virion and would not require change in the direction of filament tapering. In this model, the majority of 
ESCRTs would be recycled to the cytoplasm, however a few, notably upstream ESCRTs, would become 
entrapped in the virion. Yellow = ESCRT-III, Green = ESCRT-I, Orange = ESCRT-II, Purple = ALIX, Pink = 
VPS4, Grey = Viral Gag. Adapted from Schöneberg et al. 2016 
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Microautophagy refers to the process whereby organelles such as mitochondria and 
peroxisomes are directly engulfed by lysosomes through invagination of the lysosome 
membrane. Endosomal microautophagy meanwhile refers to the process whereby 
cellular components are first internalised into MVBs prior to the fusion of MVBs with 
lysosomes. Given the role of ESCRTs in MVB formation, it comes as no surprise that 
ESCRTs have been implicated in this process61. Macroautophagy is the process by which 
organelles are sequestered by a double membrane structure known as a phagophore to 
form an autophagosome, which subsequently fuses with the lysosome, leading to 
degradation. ESCRTs have also been implicated in this process58,59. Chaperone mediated 
autophagy is the process whereby proteins interact directly with the chaperone protein 
hsc70 and are directly transported into the lysosome via the lysosomal transporter 
LAMP2-A.  
During microautophagy, ESCRTs have been implicated in the sorting of KFERQ motif 
containing proteins into ILVs, following endosomal targeting of such proteins by 
interaction of this motif with hsc7061. 
Involvement of the ESCRT machinery in macroautophagy has been implied by the 
observed increase in autophagosomes upon depletion of various ESCRT proteins 
including subunits of ESCRT-I, -II and -III and VPS458–60,602. This has been observed in 
mammals, yeast, C. elegans and Drosophila, and is either due to inhibition of autophagic 
flux or promotion of autophagosome biogenesis. The role played by ESCRTs in 
autophagy, however, is still not entirely clear, and has until recently been hampered by 
the technical limitations involved in distinguishing between sealed and unsealed 
autophagosome membranes, when investigating whether ESCRTs are involved in sealing 
phagophore membranes. A role in sealing phagophore membrane would appear 
plausible, given the shared topology in sealing the double membrane with that of other 
ESCRT mediated processes. Consistent with this is the observation of numerous, 
enlarged unclosed phagophores in chmp1 mutant Arabidopsis603. However, ESCRTs have 
also been proposed to potentially facilitate fusion of autophagosomes with MVBs to 
form amphisomes, prior to fusion with lysosomes, or directly with lysosomes to form 
autolysosomes58,59,604,605. It has also been suggested that although ESCRTs appear to be 
playing a role in autophagy, this is simply a consequence of disrupted lysosome 
biogenesis or induction of cellular stress upon their depletion606.  
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Although the identification of relevant site-specific adaptor proteins and specific 
pathways for ESCRT recruitment remain to be elucidated for macroautophagy, progress 
has recently been made in strengthening evidence for a potential role in phagosome 
closure. Novel assays have been developed for measuring phagosome closure, involving 
the use of protease protection assays, a HaloTag-LC3 autophagosome completion assay, 
and an optogenetic closure assay607,608. Two separate studies have shown a particularly 
prominent role for CHMP2A in phagosome closure. CHMP3 and CHMP7 were also 
identified as potentially important contributors to this process607,608. CHMP4B/Snf7 has 
been observed in both human and yeast cells at autophagosomes, by examining co-
localisation with autophagosome markers LC3 and Atg17, and VPS4 depletion has 
consistently shown strong defects in phagosome closure608,609. Amphisome formation 
also appears to be disrupted upon VPS4 depletion606. 
 
1.8.2. ESCRTs in plasma membrane repair 
ESCRTs have been described to play a role in calcium influx triggered repair of plasma 
membrane (PM) wounding20. PM wounding can occur in nature by bacterial pore 
forming toxins and mechanical stress610–613. ESCRT-III has been shown to rapidly 
accumulate at sites of wounding at the PM, induced by a variety of techniques including 
laser ablation and use of detergents21,614. Here they mediate extrusion of damaged 
regions followed by scission and shedding of the region21,614. Localisation of Tsg101, ALIX, 
CHMP3, CHMP2A, CHMP2B, CHMP1A and CHMP4B has been observed at sites of PM 
wounding, and a prominent role for ALIX has been described in this process, by 
interacting with its earlier described binding partner calcium sensing protein apoptosis-
linked gene-2 (ALG-2)21,614 (sections 1.3.5.2. and 4.1.). ALG-2 is therefore likely to 
represent the site specific ESCRT adaptor in this process. Strengthening the dependence 
of this process on ALIX is the finding that ESCRT-0 and ESCRT-II appear not to be required, 
and an increase in the nucleating factor CHMP6 at the PM is not observed. These 
findings support a role for ALIX as a bridging factor between ALG-2 and CHMP4, 
providing nucleation of ESCRT-III.  
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1.8.3. ESCRTs in microvesicle release   
In a process analogous to the shedding of damaged PM legions, the ESCRTs have also 
been implicated in microvesicle shedding at the PM in C. elegans embryos upon loss of 
the P4-ATPase TAT-5615. TAT-5 is a lipid flippase that maintains 
phosphatidylethanolamine symmetry. Its depletion therefore causes 
phosphatidylethanolamine to accumulate on the cell surface and this causes a loss of 
cell adhesion, vesicle shedding and thickening of the PM. Whilst ESCRT-0 and ESCRT-I 
were suggested to be required for vesicle shedding, as shown by loss of membrane 
thickening in TAT-5 mutant cells upon their depletion, localisation of ESCRT-III to the 
membrane was not observed. The function of the ESCRT machinery in this process 
therefore remains to be established. 
Arrestin domain containing 1 (ARRDC1)-mediated microvesicles (ARMMs) are a type of 
microvesicle of unknown function, that use the ESCRT machinery to bud from the PM 
with a striking similarity to viral budding56,57. ARRDC1 is a ubiquitin ligase adaptor for 
ESCRT recruitment in this process, that directly recruits TSG101 via a central PSAP motif. 
In addition to this motif, ARRDC1 encodes an N-terminal arrestin domain that mediates 
membrane localisation, and two C-terminal PPXY motifs that recruit WWP2 ubiquitin 
ligase. WWP2 ubiquitinates ARRDC1, which has been shown to be necessary for optimal 
ARMM budding56,57. Multimerisation of ARRDC1 at the plasma membrane has also been 
observed, as for HIV-1 Gag56. Mutation of the PSAP motif and expression of dominant 
negative VPS4 were shown to inhibit microvesicle release56. Although functional 
characterisation of ARMMs is lacking, the observed transfer of ARRDC1 between cells 
hints at a possible role in intercellular communication56.  
 
1.8.4. ESCRTs in exosome release 
In contrast to the direct involvement of ESCRTs at the PM in microvesicle release, a more 
indirect role for the ESCRT machinery has been elucidated in exosome release, 
i.e. vesicles shed from the PM as ILVs within MVBs that fuse with the plasma 
membrane22. Exosome identity is characterised by presence of the tetraspanin CD63. 
ESCRTs have been implicated in formation of exosomes that contain syndecans, which 
are heparan sulphate presenting proteins616. For this they require the adaptor syntenin, 
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with which an interaction with ALIX via a YPXL motif has been described616,617. Whilst 
ESCRTs are responsible for the formation of the initial ILVs in this process, they are not 
required for fusion of the resulting MVBs with the PM and exosome release. 
 
1.8.5. ESCRTs in axon pruning 
Pruning of axons and dendrites occurs during development of the nervous system to 
remove previously formed synaptic connections as they are replaced with new ones. 
This involves scission of neurons, and ESCRTs have been implicated in this process618,619. 
Both a direct role in severing of membrane necks of neurons has been suggested, as has 
a more indirect role in the endosomal sorting and degradation of the cell surface 
receptors neuroglian (Nrg) and Patched (Ptc), which inhibit pruning618. 
In terms of a more direct role for the ESCRT machinery in neuron pruning, studies in 
Drosophila have shown localisation of Shrub/CHMP4 and Myopic/HD-PTP to sites of 
neuron severing, and direct interaction between the Bro1 domain of Myopic/HD-PTP 
with Shrub/CHMP4 was shown to be necessary for severing. This process was also 
shown to require ESCRT-I but not ESCRT-II, hence a role for Myopic/HD-PTP here as a 
bridging factor620. Identification of adaptor proteins for ESCRT recruitment in this 
process are yet to be elucidated. 
 
1.8.6. ESCRTs in lysosome repair 
In contrast to lysophagy, in which lysosomes damaged beyond repair are removed by 
autophagy, ESCRTs have recently been implicated in membrane repair of less severely 
damaged salvageable lysosomes62,63. Lysosome repair is essential for preventing cell 
death from the release of acidic contents and degradative enzymes. Two studies by 
Radulovic et al 2018 and Skowyra et al 2018 in excellent agreement with each other 
demonstrated that the ESCRT machinery is rapidly recruited to small ruptures in 
lysosome membranes62,63. These studies principally made used of the lysosomotropic 
compound L-leucyl-L-leucine O-methyl ester (LLOMe) to permeabilise lysosome 
membranes. LLOMe is small enough to traverse membranes and enter organelles. Upon 
entry to the lysosome, this compound is cleaved by cathepsin C and condenses into a 
membranolytic polymer, within the acidic environment621.   
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ESCRTs appeared at damaged lysosome membranes at an early time point, associated 
with small membrane ruptures, before appearance of the larger ruptures that trigger 
lysophagy. This was demonstrated by appearance of the ESCRT machinery before 
Galectin-3. Galectin-3 is a cytosolic lectin that recognises the carbohydrate portions of 
glycoproteins found within the lysosome lumen. This triggers lysophagy. Numerous 
ESCRTs were observed at LLOMe generated puncta including subunits of ESCRT-I, -II -III, 
VPS4 and ALIX62,63. Whilst both studies observed no discernible decrease in CHMP4B 
recruitment to damaged lysosomes upon depletion of ALIX, a delay in recruitment was 
seen upon depletion of TSG101 and lack of recruitment was seen upon co-depletion of 
both TSG101 and ALIX. This indicated that these early ESCRTs function upstream of 
ESCRT-III in this process. Skowyra et al. also showed that in a striking parallel with plasma 
membrane repair, calcium efflux from the lysosome mediated rapid recruitment of the 
ESCRT machinery, and that ESCRTs colocalised with ALG-262. Treatment of cells with the 
calcium chelator BAPTA-AM prevented the recruitment of ESCRTs to damaged 
lysosomes. ALG-2 therefore potentially represents the adaptor for ESCRT recruitment 
again in this case.  
Involvement of ESCRTs in early repair of damaged lysosomes was demonstrated by 
measuring the recovery time of the fluorescent compounds Magic red and Lysotracker 
to the lysosome lumen62,63. Following depletion of TSG101 and ALIX and membrane 
perforation by LLOMe, recovery time was delayed demonstrating a role for the ESCRT 
machinery in repair. Consistent with this was also the observation that CHMP1B-GFP 
puncta appeared just after loss of fluorescence but before complete recovery.  
 
 
1.9. ESCRTs in human disease and animal models 
Mutations and dysregulation of ESCRT protein expression levels have been implicated 
in diverse phenotypes and pathologies, notably neurodegenerative disease and cancer. 
Further implications in cell migration, maintenance of cell polarity, development and 
mycobacterial infection have also been uncovered622–624. 
Autosomal dominant mutations in CHMP2B have been found in patients with 
frontotemporal dementia and amyotrophic lateral sclerosis625,626. Accumulation of 
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ubiquitinated protein inclusions in neurons is seen in both these neurodegenerative 
diseases. Given the role played by the ESCRT machinery in autophagy, and the 
accumulation of autophagosomes and ubiquitin positive inclusions in autophagy 
deficient mice and flies627–630, the explanation that has gained most support for this 
pathology is that the accumulation of such aggregates is due to disruption of ESCRT 
mediated autophagy. Mouse neurons, human cell lines and Drosophila expressing a 
CHMP2B splice site mutant corresponding to that uncovered in a case of frontotemporal 
dementia displayed an increase in autophagosomes suggesting a direct link between the 
ESCRT machinery and the disease aetiology58,59,604. The CHMP2B mutant formed 
aberrant complexes with mChmp4B59. p62 binds ubiquitin in the observed protein 
aggregates, and recruits the autophagy marker LC3, providing a link to autophagic 
degradation. Neurons are particularly sensitive to perturbations in endocytosis and 
related vesicular trafficking, since endocytosis is required for reuptake of synaptic 
vesicles and maintenance of the correct membrane protein composition for nerve 
transmission. It is also necessary for membrane repair following damage by delivery of 
membrane. This could account for why perturbation of the ESCRT machinery is 
commonly associated with neurodegeneration as opposed to more generalised 
symptoms. 
Drosophila and mammalian cell models of Huntington’s disease have shown that ESCRT 
depletion increases neurotoxicity by preventing clearance of polyglutamine protein 
aggregates58,604. Conversely, stimulation of autophagy reduces neurodegeneration in 
Drosophila, mouse and human cell models of the disease631,632. A functional MVB 
pathway has also been shown to be necessary for clearance of the aggregates, further 
implicating the ESCRT machinery in preventing neurodegenerative disease604. In mice, a 
null mutation in the gene encoding the E3 ubiquitin ligase Mahogunin causes the prion-
like disease spongiform neurodegeneration633. Mahogunin, like Tal (section 3.1.1.), is 
known to ubiquitinate TSG101633. Spartin and Spastin are mutated in spastic paraplegia 
– another disease characterised by length dependent axon degeneration506,634.  
TSG101, VPS37A and CHMP1A and VPS4B were initially described as tumour suppressors, 
in experiments using mice, Drosophila and expression screens for human cancer cell 
lines635–639. The picture for TSG101, however, was later complicated by the observation 
that its knockout caused cell death in mouse mammary epithelial cells, as opposed to 
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proliferation initially seen in mouse 3T3 fibroblasts and Drosophila epithelial cells640,641. 
In the case of Drosophila, cell proliferation upon TSG101 depletion has potentially been 
attributed to increased Notch signalling which directs interleukin-6-like secretion, 
leading to hyperplasia in surrounding tissue via JAK/STAT signalling, whilst the mutant 
cells themselves display apoptosis636,642–644. Loss of epithelial cell polarity is also seen as 
a consequence of TSG101 depletion in Drosophila, suggesting involvement in 
cytoskeleton rearrangement636,642,643. This is potentially due to a role of the ESCRT 
machinery in E-cadherin turnover and integrin signalling643,645,646. Similar phenotypes 
are observed upon depletion of Vps25/EAP20 (ESCRT-II)642,643. In contrast to a role as a 
tumour suppressor, TSG101 has been proposed to stimulate cell growth in mice by 
interacting with the ubiquitin ligase Mdm2 and stabilising this enzyme which 
ubiquitinates the tumour suppressor p53, thus labelling it for lysosomal 
degradation647,648. 
In terms of development, ESCRT deficiency is commonly associated with embryonic 
lethality. Mouse embryos depleted of ESCRT-0 generally do not progress past day E11, 
showing severe defects in the foregut, heart tubes and ventral region, with enlarged 
endosomes649,650. Drosophila also show pupal lethality and disrupted patterning due to 
disrupted EGF and Torso signalling644. Mice depleted of TSG101 die around day E6.5 
displaying no mesoderm and reduced overall size647. Knockdown of Chmp1a in zebrafish 
causes severe brain developmental defects, and knockdown of Vps37a causes reduced 
mobility651,652. 
Finally, A protective function for the ESCRTs has been implicated in mycobacterial 
infection, using Drosophila and mammalian macrophages. Although not studied in detail, 
this is believed to occur through facilitation of phagosome-lysosome fusion, or 
phagosome maturation, to destroy such intracellular bacteria. This suggests a role for 







1.10. Aim of thesis 
The aim of this thesis is first to identify novel interaction partners of ESCRT-I by mass 
spectrometry. Following identification of such partners, I aim to confirm their 
interaction with ESCRT-I through co-precipitation assays, and then to functionally 









































Chapter 2 – Materials and Methods 
2.1. Cloning and molecular biology 
2.1.1. Protein expression plasmids and retroviral vectors 
To facilitate sub-cloning between vectors, a previously established cloning system in the 
lab ensured that all protein expression plasmids were modified to contain polylinkers 
containing EcoRI, XhoI and NotI restriction sites upstream or downstream of the 
sequence encoding the specific tag/viral protein to be fused to the protein of interest. 
All tagged proteins used in this thesis are tagged at the N-terminus unless otherwise 
stated. 
pCR3.1 (Invitrogen), used for overexpression of tagged proteins by transient 
transfection, was modified to contain an HA-, YFP-, mCh- or Myc-EcoRI-XhoI-NotI poly-
linker in place of the original multiple cloning site. Likewise, pCAGGS (Martin-Serrano 
2003567)was modified to contain a GST-EcoRI-NotI-XhoI poly-linker for overexpression 
of GST-tagged fusion proteins. 
The bi-cistronic retroviral packaging vector pCMS28, derived from pMigRI (Pear et al. 
1998655), was kindly gifted from Professor Mike Malim (King’s College London, UK). This 
plasmid was modified by Dr Chad Swanson (King’s College London, UK) to replace the 
GFP gene with a puromycin resistance gene linked via an internal ribosome entry site 
(IRES) to a multiple cloning site containing OSHA-, mCh- or YFP-EcoRI-NotI-XhoI. In this 
way, puromycin resistance is coupled to mRNA expression of the gene of interest. 
pCMS28 was further modified to create pNG72, which contains a geneticin resistance 
gene in place of that for puromycin. pCMS28 and pNG72 were packaged using murine 
leukaemia virus (MLV) Gag-Pol and VSV-G pseudotyped pHIT plasmid, pHIT-VSV-G, as 
described by Soneoka et al., 1995656. Both these plasmids were kindly gifted from 
Professor Paul Bieniasz (Aaron Diamond AIDS Research Center, New York, USA). 
The full-length X4 strain HIV-1 proviral plasmid pNL-HxB was kindly gifted from Professor 
Paul Bieniasz. The full length proviral pHxB-STOP construct used in section 3.2.2. was 
based on this provirus and modified by Professor Juan Martin-Serrano (King’s College 
London, UK) to containin a termination codon upstream of p6 Gag (Martin-Serrano et 
al., 2003567). The shorter trans-complementing pHxB-ENX plasmid was also based on 
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pNL-HxB but was modified to contain an EcoRI-NotI-XhoI polylinker in place of the p6, 
pol, vif and vpr sequences as outlined by Martin-Serrano et al. 200114. 
 
2.1.2. Constructs 
TSG101, VPS28, VPS37B, VPS37C, MVB12A and MVB12B had already been cloned in 
each of their tagged forms and vectors used in this thesis by Professor Juan Martin-
Serrano (Martin-Serrano et al. 200114, 2003565,567,575, and 2004590, Eastman 2005657). 
VPS37A and D constructs were cloned by Dr Bethan McDonald (formerly King’s College 
London, UK) and UBAP1 by Dr Monica Agromayor (King’s College London, UK) 
(Agromayor et al. 2012658). UMAD1 (NM_001302348.1) was initially cloned from HeLa 
cell cDNA into pCR3.1 as GST-, HA- and Myc-tagged forms by Magdalena Kloc (formerly 
King’s College London), and I subcloned UMAD1 and point mutants into all other 
appropriate vectors. 
Wild type R9, R9∆PTAP, R9∆YP and R9∆PTAP∆YP full-length HIV-1NL4-3 retroviral 
constructs were kindly gifted by Professor Wesley Sundquist (Fisher et al. 2007152, 
Garrus 200113, Strack 2003568). pHxB-p6 was previously cloned by Professor Juan Martin-
Serrano (Martin-Serrano et al. 200114). 
RPA3 (NM_002947.4 ) was cloned from HeLa cell cDNA as pNG72-YFP-RPA3 and also 
without a tag, in pNG72-RPA3. CHMP4B was cloned with a GFP C-terminal tag separated 
by a flexible 25-nm linker as described by Kim et al., 2016659. CHMP4B-Linker was 
generated by gene synthesis (GeneArt, Thermofisher) following which this construct 
was cloned by Dr Leandro Ventimiglia (King’s College London, UK) as the C-terminal GFP 
fusion in pNG72 as pNG72-CHMP4B-Linker-GFP. pCMS28-mCh-Tubulin was previously 
cloned by Dr Monica Agromayor (Agromayor et al., 2009507). 
A list of all plasmids used in this thesis together with restriction sites used for cloning is 
presented in Appendix 1. 
 
2.1.3. Polymerase chain reaction (PCR) 
Lyophilised unmodified oligonucleotide primers were ordered from Eurofins MWG 
Operon using a 0.01µmol synthesis scale, and resuspended in double-distilled water 
(ddH2O) to 100pmol/µl. A list of all primers used in this thesis is presented in Appendix 
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1. Primers for cloning were typically designed to include appropriate EcoRI, XhoI and/or 
NotI restriction sites for ligation into vectors using the pre-established system in the lab 
(Section 2.1.1). Primers were typically designed when possible to be between 20-30 
base pairs in length ending with a C/G cap, with similar melting temperatures and a 40% 
minimum GC content.  
PCR reactions were carried out in a total volume of 50µL, consisting of 10µL 5X Phusion® 
HF Buffer (containing 7.5 mM MgCl2), 0.5µL of each of forward and reverse primers at 
10pmol/µL (0.1µM final conc.), 1 µL of 10mM deoxynucleotide triphosphates (200µM 
final conc.)  (dNTPs: dATP, dCTP, dGTP, dTTP, Roche)), 0.5µL Phusion® High-Fidelity DNA 
polymerase (New England Biolabs), i.e. 1 unit/50µl, and 1ng plasmid DNA/purified PCR 
product, 200ng genomic DNA or 1µL cDNA (Section 2.1.16) template. 10µL 1M Betaine 
solution was also added to reduce template DNA secondary structure thus improving 
reaction efficiency. Reaction volumes were made up to 50µL using double distilled water 
(ddH2O). Reactions were prepared on ice. PCR reactions were performed in an 
Eppendorf® Mastercycler Ep Gradient Thermal Cycler or Eppendorf® Mastercycler® 
Nexus Thermal Cycler. Typical thermocycling included an initial denaturation step at 
98°C for 2 minutes followed by 35 cycles of denaturation at 98°C for 15s, annealing at 
55°C for 30s and extension at 72°C for 120s. This was followed by a final 10 minute 
extension step at 72°C after which completed reactions were incubated at 4°C until 
unloading. 
 
2.1.4. Site directed mutagenesis 
An overlap extension PCR approach was employed to generate site specific point 
mutations in genes of interest. Overlapping forward and reverse primers centred around 
the base pairs to be mutated were designed to include the desired mutation flanked on 
both sides by around 15 nucleotides of the gene. Each of these primers were used in 
separate PCR reactions together with appropriate reverse of forward primers, 
respectively, designed to anneal at the end or start of the gene of interest and include 
appropriate restriction sites for cloning. Following purification of each PCR product, 
10ng of each was used as template in a second PCR reaction, again using the forward 
and reverse primers that anneal at the start/end of the gene of interest. The product of 
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this reaction is the gene sequence with the desired mutation and appropriate restriction 
sites for cloning, so following purification, restriction endonuclease digestion and 
ligation into appropriate vectors could be carried out (Sections 2.1.6 – 2.1.8.). 
 
2.1.5. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to resolve DNA fragments prior to purification for 
downstream cloning, or to check for the presence of DNA fragments of a particular size 
following various steps within the cloning procedure. 1-2% gels were generally used 
depending on the size of the fragment in question. UltraPure™ Agarose 
(Invitrogen) was dissolved in TAE buffer (10X solution: Tris-Base 48.4g/L, Acetic acid 
11.4mL/L, EDTA 3.7g/L) by boiling, following which the solution was cooled until hand 
hot. Ethidium bromide (Fisher Scientific) was then added to a final concentration of 
5µg/mL and the solution was allowed to solidify in a casting tank (BioRad). The gel was 
then transferred to an electrophoresis tank and submerged in TAE buffer. DNA samples 
were mixed with DNA loading dye (10X solution: 50% glycerol, 0.1M EDTA, 
Bromophenol blue, ddH2O) prior to loading, and run at 90V for between 45 – 90 mins 
depending on the fragment size. DNA was visualised under ultra-violet light using a 
Chemi-Doc imaging system (BioRad). 
 
2.1.6. DNA purification by gel extraction 
Following excision of bands from agarose gels containing desired DNA, purification of 
DNA was carried out using a QIAGEN QIAquick Gel Extraction Kit according to the 
manufacturer’s instructions. Bands were weighed and a volume of QG buffer equal to 
3 × mass of the band was added. Bands were then melted at 56°C, with regular vortexing, 
after which a volume of isopropanol equal to the mass of the original band was added 
and the solution vortexed. The solution was transferred to a QIAquick spin column 
placed in a collection tube and centrifuged for 1 minute at 13,000 rpm.  Flow through 
was discarded and the DNA, now bound to the column, was washed by adding 750µL PE 
buffer and centrifuging again twice, with discard of flow-though between runs. 50µL 
ddH2O was then added to the column and incubated at room temperature for 5 mins 
before a final centrifugation step to elute into a clean 1.8 mL Eppendorf tube. 
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2.1.7. Restriction endonuclease digestion of DNA 
Reactions were carried out at 37°C for 2-3 hrs in a total volume of 50µL typically using 
2-3µg plasmid/PCR product/mini prep DNA. 0.5µL each restriction endonuclease (1-2 
units/sample), supplied by NEB, was used with the appropriate buffer, as detailed and 
supplied by the manufacturer. Buffers compatible with both enzymes in the case of 
double digests were typically available. Enzymes used in this thesis included EcoRI-HF® 
(NEB R3101), XhoI (NEB R0146), NotI-HF® (NEB R3189) BsmBI (NEB 0580).  
 
2.1.8. DNA Ligation 
Reactions were carried out at room temperature for at least 1 hour, or overnight at 4°C. 
An approximate 5:1 insert:vector DNA ratio was typically used in a 10µL total volume 
using 1µL 10X T4 DNA ligase buffer (NEB) and 0.5µL T4 DNA ligase. Vector only reactions 
(making up the volume with ddH2O) were carried out side by side as an appropriate 
negative control. T4 ligase was heat inactivated at 65°C for 10 mins following ligation, 
and transformation of bacteria (Section 2.1.11).  
 
2.1.9. Bacteria cells: media and maintenance 
The Escherichia Coli strain DH10b genotype Genotype: F– mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 endA1 araD139 Δ(ara leu) 7697 galU galK rpsL nupG λ– 
was used for plasmid transformations. Autoclaved Luria Broth (LB) agar (37g/L) was used 
for solid phase growth medium, set in Sterilin 10cm Petri dishes. Autoclaved LB broth 
(25g/L) was used for liquid phase growth medium. When required, appropriate 
antibiotics for selection of transformed bacteria (Ampicillin (Fisher Scientific, 100μg/mL 
in ddH2O) or Kanamycin Sulphate (Fisher Scientific, 50μg/mL in ddH2O) were added to 
autoclaved media. In the case of agar, this was done prior to plating once autoclaved 
medium had cooled to around 50°C. A stock of DH10b cells was plated and grown on 
agar plates followed by storage at 4°C for no more than 2 months. Prior to competent 






2.1.10. Generation of competent E. coli bacteria 
A 10mL starter culture of DH10b cells inoculated from the stock plate was grown 
overnight at 37°C shaking at 200 rpm. The following day, the starter culture was diluted 
1:40 in LB broth and further grown until log phase was reached (OD500nm of 0.4-0.5). Cells 
were chilled on ice for 10 mins before pelleting by centrifugation at 300rpm, 10 mins, 
4°C. Supernatant was discarded and cells were resuspended and incubated for a further 
5 mins in 100mL pre-chilled filter sterilised TfB1 buffer (30mM KAc, 100mM RbCl, 10mM 
CaCl2, 50mM MnCl2 and 15% glycerol in ddH2O). Cells were again centrifuged as 
previously and next resuspended and incubated in pre-chilled filter sterilised TfB2 buffer 
(10mM PIPES pH 6.5, 10mM RbCl, 75mM CaCl2 and 15% glycerol in ddH2O). 200µL 
aliquots were dispensed in 1.8mL Eppendorf tubes, snap frozen on dry ice and stored at 
-80°C. 
 
2.1.11. Transformation of competent bacteria 
100µL thawed competent bacteria were immediately incubated with 8µL completed 
DNA ligation reactions (Section 2.1.8.), or less than 100ng of other plasmid DNA for 
replenishment on ice for one hour. A heat shock of the bacteria at 42°C for 1 minute was 
then carried out, following which the bacteria were placed back on ice for 2 minutes. 
250µL LB broth without antibiotic was added, and the bacteria were incubated at 37°C 
for 1 hour. Bacteria were then plated and spread on LB agar plates containing 
appropriate antibiotic using glass beads (Sigma), and grown upside-down overnight at 
37°C, or 30°C in the case of retroviral constructs to minimise recombination. 
 
2.1.12. Small scale plasmid DNA amplification and purification – Mini 
prep 
Buffers for mini prep DNA purification were prepared and filtered in-house but based 
on the QIAGEN P1-P3 buffers.  
Single bacterial colonies were picked and grown in 2mL LB broth + appropriate antibiotic 
overnight, shaking at 37/30°C. The following day, 1.5mL bacterial suspension was 
transferred to an Eppendorf tube, and the bacteria pelleted at 14,000rpm for 1 minute. 
Supernatant was discarded and the pellet resuspended in 100µL of chilled 50mM Tris-Cl 
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pH 8.0, 10mM EDTA and 100 μg/mL RNAse A (QIAGEN P1 resuspension buffer). An equal 
volume of 200mM NaOH, 1% SDS (w/v) (QIAGEN P2 lysis buffer) was added and the 
solution mixed by inverting the tube. The solution was incubated at room temperature 
for 5 mins. 100µL chilled 3M potassium acetate, pH 5.0 (QIAGEN P3 neutralisation 
buffer) was then added and the solution incubated for a further 10 mins on ice. The 
suspension was cleared of cell debris by centrifugation at 14,000rpm for 10 mins and 
the supernatant was transferred to a clean 1.8mL Eppendorf tube. DNA was precipitated 
by adding 300µL isopropanol to the solution, vortexing and incubating on ice for 10 mins 
followed by centrifugation at 14,000rpm 4°C for 10 mins to pellet DNA. The DNA pellet 
was then washed with 350µL 70% ethanol and left to air-dry for 5 mins before 
reconstitution in 30µL ddH2O containing bovine ribonuclease A (1/200 dilution, Sigma). 
Successful cloning of constructs was confirmed by digesting mini prep DNA (Section 
2.1.7.) and checking for the presence of correctly sized bands corresponding to inserts. 
In the case of sub-cloning previously cloned sequence between vectors, the remaining 
0.5mL bacterial culture was inoculated in LB broth for further DNA amplification and 
midiprep purification (section 2.1.13.), whereas in the case of newly cloned constructs, 
DNA concentration was measured and a sample sent for sequencing (Section 2.1.15). 
 
2.1.13. Medium scale plasmid DNA amplification and purification – Midi 
prep 
Midi prep plasmid purification was performed using a Macherey Nagel NucleoBond® 
Xtra Midi Kit according to the manufacturer’s instructions. This kit uses a silica-based 
anion-exchange resin to bind negatively charged DNA under low pH conditions. 
Following washing of bound DNA, to remove contaminants such as protein and RNA, the 
DNA is eluted under high salt, alkaline conditions to neutralise the positive charge of the 
resin. 
100mL LB broth + appropriate antibiotic was inoculated with the remaining 0.5mL 
bacterial culture previously prepared for mini prep purification (Section 2.1.12), or a 
single bacterial colony, in the case of DNA stock replenishment, and grown at 37/30°C 
overnight at 200rpm. Bacteria were harvested in Nalgene 250mL bottles by 
centrifugation at 5000g for 10 mins and the supernatant discarded. 8mL of resuspension 
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buffer (buffer RES) was added and the pellet resuspended by vortexing and pipetting. 
Cells were lysed by adding 8mL of lysis buffer (buffer LYS) and gently inverting the tube 
5 times, before incubating at room temperature for 5 mins. 8mL neutralisation buffer 
(buffer NEU) was added and the suspension was mixed by inverting until the blue colour 
disappeared. The entire suspension was then applied to a NucleoBond® Xtra Column 
filter that had previously been equilibrated with 12mL buffer EQU, and the column was 
allowed to empty by gravity flow whilst DNA bound to the resin. The filter was again 
washed with a further 5mL EQU buffer and then discarded from the column. The column 
was given one final wash with 8mL of buffer WASH before DNA was eluted by adding 
5mL buffer ELU to the column and allowing solution to leave by gravity flow directly into 
a 50mL Falcon tub containing 3.5mL isopropanol for DNA precipitation. This solution was 
vortexed and then centrifuged at 15,000g for 30 mins at 4°C to pellet DNA. Supernatant 
was discarded and the pellet was washed in 2mL 70% ethanol before air-drying and 
reconstitution in typically 500µl ddH2O. DNA yield was subsequently measured (Section 
2.1.15), and was usually between 300-800ng/µL. 
 
2.1.14. Genomic DNA extraction and purification from human cells 
Genomic DNA extraction from HeLa/293T cell clones was required to obtain template 
DNA for PCR to confirm successful generation of homozygous CRISPR/Cas9 knockout 
clones (Section 3.2.5.). Extraction and purification was performed using a QIAGEN 
DNeasy® Blood & Tissue Kit (250) (cat. No. 69506) according to the mini Spin-Column 
protocol for cultured cells.  Spin columns employ a similar silica-based resin that binds 
DNA under high salt conditions, whilst contaminants pass through. DNA is then eluted 
due to decreased salt concentration.  
Cells were grown in wells of a 24-well plate until confluent. Medium was removed and 
cells were lysed in the well by addition of 200µL PBS + 200µL buffer AL + 20µL proteinase 
K and repeated pipetting. 200µL ethanol was added and the suspension was further 
resuspended by transferring to a 1.8mL Eppendorf tube and vortexing. The suspension 
was transferred to a spin column within a collection tube and centrifuged at 8000rpm 
for 1 minute. The collection tube with flow-through was discarded and the column 
placed in a clean collection tube. 500µL buffer AW1 was added and centrifugation and 
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discard of flow through was repeated as previously. The spin column was then washed 
with 500µL AW2 centrifuging at 14,000rpm for 3 mins. The flow-through and collection 
tube was discarded, and the spin column placed this time in a clean Eppendorf tube for 
elution. DNA was eluted by adding 200µL buffer AE to the centre of the spin column, 
incubating for 1 minute and centrifuging at 8000rpm for 1 minute. DNA concentration 
was subsequently measured (Section 2.1.15.).  
 
2.1.15. Determination of DNA concentration and sequencing 
DNA concentrations were determined using a Nanodrop ND-100 Spectrophotometer 
(Labtech International). Calibration was first performed using 1.5µL ddH2O loaded onto 
the pedestal. The pedestal was then dried, and an equal volume of DNA solution loaded. 
Concentration was determined by measuring absorbance at 260nm, assuming that 1 
OD260nm = 50µg/µL dsDNA. Purity was gauged by the OD260/OD280 ratio, which at around 
1.8 is considered pure in the case of DNA.  
Sequencing was performed by Eurofins MWG Operon or Genewiz. A minimum volume 
of 15µL of DNA was generally sent at 100ng/µL for plasmid DNA, 15ng/µL for PCR 
products <1000bp and 60ng/µL for PCR products >1000bp. 5µL for each additional 
reaction over 3 reactions was supplied. Primers were supplied at 10pmol/µL using 
10µL/reaction, minimum volume of 15µL. Sequencing primers used are listed in 
Appendix 1. 
 
2.1.16. mRNA extraction and purification from human cells 
mRNA was extracted and purified from HeLa/293T cells to be used as template for the 
production of cDNA to be used for cloning new constructs or to check for successful 
production of CRISPR/Cas9 knockout clones (Section 3.2.5.). mRNA extraction was 
carried out using a QIAGEN RNeasy® Mini Kit (cat. No. 7410), using spin columns, 
according to the manufacturer’s instructions. This kit again relies on the principle of 
binding nucleic acid under high salt conditions whilst impurities are washed away, but is 
optimised to bind mRNA by excluding RNA < 200 nucleotides in length (e.g. rRNA and 
tRNA). Furthermore, the lysis buffer contains highly denaturing guanidine-thiocyanate, 
which immediately inactivates RNases, ensuring reduced mRNA digestion. Given the 
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inherent instability of RNA, all steps were carried out in a laminar flow cabinet to ensure 
aseptic conditions, and reduced introduction of RNases from the environment. 
Cells were grown to confluency in wells of a 24-well plate and lysed in the wells by 
addition of 350µL buffer RLT + 3.5µL b-mercaptoethanol and repeated pipetting. 350µL 
of 70% ethanol was added followed by continued pipetting. The entire suspension was 
transferred to an RNeasy mini spin column in a collection tube and centrifuged at 
10,000g for 15s. the collection tube and flow-through was discarded, the column placed 
in a new collection tube and 700µL buffer RW1 was added. Centrifugation, discard of 
flow-through and replacement of the collection tube was repeated, and the column was 
washed as previously with 500µL buffer RPE first using a centrifugation time of 15s for 
a first wash and 2 minutes for a second wash. The column was placed in a clean 
collection tube and centrifuged at full speed for 1 minute to remove residual wash buffer 
and dry the resin. To elute RNA, the column was placed in a clean, sterile 1.8mL 
Eppendorf tube, 50µL RNase-free water was added and the tube was centrifuged for 1 
minute at 10,000g. 
RNA concentration was measured using a Nanodrop ND-100 Spectrophotometer by 
measuring absorbance at 260nm, assuming that 1 OD260nm = 40µg/µL ssRNA. Purity was 
gauged by the OD260/OD280 ratio, which at around 2.0 is considered pure in the case of 
ssRNA. 
 
2.1.17. cDNA synthesis from purified RNA 
cDNA synthesis was carried out using a High-Capacity cDNA Reverse Transcription Kit 
(Applied BiosystemsTM, Cat. No. 4368814) according to the manufacturer’s instructions. 
In the case of cDNA production to use as template in PCR reactions to assess knockdown 
of a corresponding mRNA molecule by RNA interference, RNA sample concentrations 
were first adjusted to that of the sample with the lowest concentration. Reactions were 
prepared on ice. 
10µL each RNA sample was mixed gently in a PCR tube with 10µL of 2X reverse 
transcription master mix, consisting of 2µL of 10X RT buffer, 0.8µL 25X dNTP mix 
(100mM), 10X RT random primers, 1µL MultiScribeTM reverse transcriptase and 4.2µL 
ddH2O. PCR tubes were placed in a thermocycler and incubated at 25°C for 10 mins, 
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37°C for 120 mins, 85°C for 5 mins and then held at 4°C until unloading. Completed 
reactions were ready for direct use in downstream PCR reactions. 
 
2.1.18. Generation of CRISPR/Cas9 knockout cell clones 
CRISPR/Cas9 knockout clones were generated by transient transfection of two 
lentiCRISPRv2GFP plasmids (Sanjana et al., 2014660, Shalem et al., 2014661, Walter et al., 
2017662) to direct Cas9 endonuclease cleavage both upstream and downstream of the 
UMAD1 locus (Section 3.2.5.), thus removing the entire locus. This plasmid contains 
expression cassettes for a mammalian codon-optimised Streptococcus pyogenes Cas9 
nuclease (hSpCas9) and a chimeric single guide RNA (sgRNA). The sgRNA consists of a 
custom-designed CRISPR RNA (crRNA), complementary to sequence at sites of cleavage, 
thus guiding the Cas9 endonuclease, together with sequence encoding appropriate 
trans-activating crRNA (tracrRNA), required for maturation of the crRNA and pairing 
with Cas9. Plasmids are designed for crRNA encoding DNA sequence to be ligated into 
the sgRNA scaffold cassette using BsmBI. A transient transfection approach rather than 
generation of cells that stably express the aforementioned components was adopted to 
prevent constitutive expression and potential off-target cleavage by Cas9. 
crRNA sequences to be ligated into plasmids were designed using the Integrated DNA 
Technologies gRNA design tool at:   
https://www.idtdna.com/site/order/designtool/index/CRISPR_CUSTOM 
This tool identifies a selection of appropriate 20bp sequences to use as crRNA, upstream 
of Streptococcus pyogenes protospacer adjacent motif (PAM) sites i.e. NGG 
trinucleotides, together with off-target analysis. The 20bp sequences with the best off-
target scores upstream and downstream of the UMAD1 locus (Section 3.2.5.) were 
selected and each ordered from Eurofins MWG Operon as two custom designed 
complementary oligonucleotides designed to anneal to each other and contain 
appropriate sticky ends (shown in red) for ligation into BsmBI digested lentiCRISPRv2GFP. 
Oligonucleotide sequences were as follows: 
 
















Cloning was performed as suggested by Sanjana et al., 2014660 with some modifications. 
5µg lentiCRISPRv2GFP was digested and dephosphorylated in the same reaction with 
BsmBI (NEB) and Antarctic phosphatase (NEB), respectively, both compatible with NEB 
buffer 3.1.  Successful digestion of plasmid was indicated by release of a 2kb stuffer 
fragment. Digested plasmid was gel purified. Each pair of oligos to encode crRNA were 
phosphorylated and annealed, using T4 Polynucleotide kinase (PNK) (NEB M0201S) and 
T4 ligase buffer. 1µL each oligo at 100µM was used in a 10µL total volume reaction using 
0.5 µL T4 PNK. The reaction was incubated at 37°C for 30 mins, followed by 95°C for 5 
mins, and then a gradually ramped down to room temperature by switching off the heat 
block and leaving samples to cool down. Annealed oligos were then diluted 1:200 in 
ddH2O and ligated into 50ng previously digested lentiCRISPRv2GFP, as described in 
(Section 2.1.8.) using 1µL diluted oligos and T4 DNA ligase. A vector only negative control 
ligation was performed in parallel.  
Following confirmation of successful cloning by mini prep and sequencing (Sections 
2.1.12 and 2.1.15), and further amplification and purification of plasmids by midi prep 
(Section 2.1.13) HeLa/293T cells were transfected with both start and end guide 
plasmids in a well of a 6-well plate using Lipofectamine 3000 (Section 2.2.4.). Medium 
was changed 6 hours later and a further 12 hours later, the cells were trypsinised, 
washed in complete medium and resuspended in 500µL filtered fluorescence activated 
cell sorting (FACS) buffer (1X PBS + 1mM EDTA + 2% FCS). Single GFP expressing cells 
were in-house FACS sorted into wells of 2 × 96-well plates, and following growth, 
individual clones were checked for homozygous knockout, i.e. complete removal of all 




2.2. Human cell culture and nucleic acid transfection 
2.2.1. Cell lines 
HeLa cells, derived from human epithelial cervical adenocarcinoma cells, were obtained 
from the American Tissue Culture Collection (ATCC). HEK293T Human Embryonic Kidney 
cells (293Ts) were kindly gifted from Professor Stuart Neil (King’s College London, UK), 
initially obtained from the ATCC. These are 293 cells, modified to express the SV40 T 
antigen to promote increased replication of plasmids containing the SV40 origin of 
replication. HeLa TZM-bl reporter cells were kindly gifted from Professor Paul Bieniasz. 
These are HeLa cells adapted to express the CD4+, CXCR4+, CCR5+ HIV-1 receptors 
together with HIV-1 LTR-Lac Z for infectious virus release readout (Derdeyn et al., 
2000663). 
 
2.2.2. Cell maintenance 
All work involving cell culture was performed in a laminar flow cabinet, to ensure aseptic 
conditions, and all plastic consumables for cell culture were purchased from Corning 
Incorporated. Cell lines were grown in 10cm dishes at 37°C, 5% CO2 in a humidified 
atmosphere in Dulbecco’s Modified Eagle Medium (DMEM) +4.5g/L Glucose, +L-
Glutamine, +Pyruvate (GIBCO 41966, Invitrogen) supplemented with 10% heat 
inactivated (56°C, 30 mins) Foetal calf serum (FCS) (GIBCO, Invitrogen) and 20µg/mL 
gentamycin (GIBCO, Invitrogen), i.e. complete medium. Cells were split every two days 
by aspiration of medium from the dish, followed by addition of 2mL pre-warmed 1x 
Trypsin substitute (TrypLETM Express + Phenol red) (GIBCO 126050, Invitrogen). 
Following 1 – 5 minutes trypsinisation at 37°C, cells were resuspended by repeated 
pipetting, after which an appropriate volume of cell suspension was transferred to a 
new dish containing 10mL pre-warmed fresh medium. 
 
2.2.3. Cell Freezing and thawing 
At around 60 – 70% confluency, cells were trypsinised and washed in 15mL complete 
medium, following which cells were pelleted by centrifugation at 1000rpm for 10 mins 
at room temperature. Medium was aspirated, following which cells were resuspended 
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in 1mL of cryoprotective medium consisting of FCS + 10% DMSO (Sigma-Aldrich 276855). 
Cell suspension was then transferred to a 1.8mL cryovial and cooled slowly to -80°C for 
at least 48 hours before transfer to liquid nitrogen for long-term storage.  
Cells were revived by rapid thawing at 37°C upon removal from liquid nitrogen. Cells 
were then washed to remove DMSO by gently transferring to 15mL complete medium 
followed by centrifugation at 1000rpm for 10 mins at room temperature. Medium was 
aspirated, and cells resuspended in 10mL fresh medium. Cell suspension was then 
transferred to a clean 10cm dish and were not used for any experimental work until 
confluency was reached.  
 
2.2.4. Transient transfection of DNA 
293T cells were transfected using Polyethylenimine (PEI) (Polysciences), whilst HeLa 
cells were transfected with Lipofectamine 3000 (Invitrogen) in the case of DNA only 
transfections. Lipofectamine 2000 (Invitrogen) was used to simultaneously transfect 
DNA and RNA together, in HeLa or 293T cells (Section 2.5.5.). Transfections were 
generally performed in wells of a 24-well plate using 1µg plasmid DNA, unless otherwise 
stated. Cells were seeded the evening before, to generally reach >60% confluency by 
the following day.  
For PEI transfection, 1µg DNA was incubated with 4µg PEI in 50µL serum-free DMEM, 
for 10 mins before adding dropwise to the 293T cells, in fresh medium (300µl). Cells 
were incubated for between 6-12 hrs with the DNA+PEI after which the medium was 
again changed, and the cells left to grow for another 24 hrs.  
For Lipofectamine 3000 transfection, 1µg DNA was incubated with 2µL p3000 reagent 
in 25µL optimem (GIBCO 31985, Invitrogen) for 5 minutes whilst 1.5µL Lipofectamine 
3000 was incubated with optimem in a separate Eppendorf tube for 5 minutes. Both 
solutions were then combined and gently mixed, following which the solution was 
incubated at room temperature for 20 mins and then added dropwise to the HeLa cells 
in fresh medium. Amounts of DNA and transfection reagents were scaled-up accordingly 




2.2.5. Transient transfection of siRNA 
Both HeLa and 293T cells were transfected with siRNA using Dharmafect1 (Dharmacon). 
siRNA oligonucleotides were ordered from either Dharmacon or QIAGEN at 2nmol/tube, 
5nmol/tube or 50nmol/tube and resuspended with either ddH2O (QIAGEN) or 1X siRNA 
resuspension buffer (Dharmafect), to a final concentration of either 20µM or 75µM. 
siRNA was aliquoted into 20µL aliquots and stored at -80°C until use. A list of all siRNA 
oligonucleotides used in this thesis is presented in Appendix 1. 
All siRNA transfections were performed in wells of a 24-well plate, using a reverse 
transfection procedure, according to the manufacturer’s instructions, using 50pmol 
siRNA per well. 50pmol siRNA was incubated with 50µL optimem for 5 mins. 1µL 
Dharmafect was likewise incubated with 50µL optimem in a separate tube. Both 
solutions were then combined and incubated for a further 20 mins, following which they 
were mixed gently with 6×104 cells and added to the well in a total volume of 400µL 
complete medium. Medium was changed at least 12 hrs later. If a second siRNA 
transfection was required to ensure maximum silencing of gene expression, the cells 
were trypsinised 24 hrs after the first dose and an appropriate volume re-seeded and 
transfected as previously at least another 12 hours following re-seeding. 
Lipofectamine 2000 was used to transfect plasmid DNA and siRNA simultaneously. In 
such cases, cells were seeded >12 hrs prior to transfection. The transfection procedure, 
volumes and amounts of reagents was exactly as for Dharmafect, except DNA and RNA 
were incubated together, and solution was added dropwise to the pre-seeded cells. Due 
to greater toxicity of Lipofectamine 2000, it was also necessary to change medium no 




2.2.6. Generation of stable cell lines 
Stable cell lines were generated using the retroviral packaging vectors pCMS28 and 
pNG72 encoding the gene of interest. 293T cells were seeded in wells of a 12-well plate 
and PEI transfected (Section 2.2.4.) >12 hrs later with 1µg retroviral packaging construct, 
700ng MLV Gag-pol and 300ng pHIT-VSV-G. Medium was changed 12 hrs later, and 
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HeLa/293T cells to be transduced were seeded in wells of a separate 6-well plate, using 
two wells/construct plus at least one well of cells to use as an non-transduced control.  
48 hrs post transfection, supernatant from the 293T producer cells was harvested and 
filtered using 0.22μm Millex PVDF sterile filters (Millipore). 700µL supernatant was used 
to transduce the previously seeded HeLa/293T cells after medium was changed, 
replacing with fresh complete medium and Polybrene reagent (Millipore) at 1:1000 
dilution, to enhance transduction efficiency. Medium was changed again 48 hrs after 
transduction, and appropriate antibiotic for selection of transduced cells was added, i.e. 
200ng/mL of puromycin dihydrochloride (Sigma) for pCMS28 or 500 μg/mL of G418 
(Geneticin, Invitrogen) for pNG72. Stocks of 5mg/mL puromycin and 50mg/mL G418 
dissolved in ddH2O were stored at -20°C Once 100% cell death in the non-transduced 
control wells was attained, successfully transduced stable cell lines were expanded and 
frozen/used for experiments whilst passaged under continual antibiotic selection. 
 
2.3. Protein-protein interaction assays 
2.3.1. Glutathione-S-transferase co-precipitation assay (GST “pull-down” 
assay) 
Initial co-precipitation assays to investigate protein-protein interactions using 
overexpressed tagged fusion proteins were performed using a GST pull-down approach. 
293T cells in wells of a 6-well plate were PEI transfected with 2µg each pCAGGS-
GST/pCR3.1 plasmid encoding alternatively tagged ESCRT proteins (Section 2.2.4.). 
Medium was changed ≥6 hrs later and cells were washed with 1X PBS and lysed in the 
well, 48 hrs post-transfection in pre-chilled lysis buffer (50 mM Tris-HCl, pH 7.4, 150mM 
NaCl, 5mM EDTA, 5% Glycerol, 1% Triton X100 and protease inhibitors (Roche)), using 
1mL lysis buffer per well. Lysates were transferred to 1.8mL Eppendorf tubes and 
incubated at 4°C on a rotating wheel for 15 mins. Lysates were then clarified by 
centrifugation at 14,000rpm for 10 mins at 4°C and supernatants were transferred to 
clean Eppendorf tubes. 100µL supernatants were added to 20µL 6X protein loading 
buffer (Laemmli buffer) (0.5M Tris-Cl, 0.4% SDS pH 6.8, 30% glycerol, 0.11g/mL SDS, 
60µl/mL 2-Mercaptoethanol, 0.12mg/mL Bromopheonol blue) to achieve a 1X final 
concentration of loading buffer. These samples were boiled and kept as input samples 
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to examine protein expression levels prior to co-precipitation. The remaining 900µL 
lysates were each added to 25µL Glutathione-Sepharose beads (GE Healthcare Life 
Sciences), that had previously been washed three times in wash buffer (50 mM Tris-HCl, 
pH 7.4, 150mM NaCl, 5mM EDTA, 5% Glycerol, 0.1% Triton X100) and resuspended in a 
final 100µL wash buffer. Samples were incubated for 3 hrs at 4°C on a rotating wheel. 
Beads were then washed another three times with 1mL wash buffer, and bound protein 
was finally eluted from beads by boiling each sample in 100µL 2X protein loading buffer 
for 10 mins. Input and pull-down samples were analysed by immunoblotting (Section 
2.4.2.) using antibodies appropriate for each tag.  
 
2.3.2. GFP-trap immunoprecipitation assay 
To examine interactions of a tagged stably expressed exogenous protein with 
endogenously expressed cellular proteins, a GFP-trap based co-immunoprecipitation 
approach was employed. The principle is similar to GST pull-down assays but uses 
magnetic agarose beads coated with GFP specific nanobodies to trap and 
immunoprecipitate GFP (or YFP) tagged bait proteins together with binding partners. 
Lysis and wash buffer compositions were exactly as described for GST pull-down assays 
(Section 2.3.1.). 
Following generation of cell lines that stably expressed each YFP-tagged bait protein 
(Section 2.2.6.) , each cell line was grown to confluency in a 15cm dish, following which 
cells were trypsinised and washed three times in 15mL Falcon tubes with 6mL of 1X PBS, 
centrifuging to pellet the cells between each wash at 1000rpm for 10 mins. Cells were 
then lysed in 3.6mL lysis buffer for 15 mins at 4°C on a rotating wheel and sonicated for 
10s using a Branson Sonifier 250 (microtip). Lysates were clarified by centrifugation at 
maximum speed, 4°C for 15 minutes, following which lysates were transferred to clean 
15mL Falcon tubes. Input samples were taken and added to protein loading buffer 
(exactly as for GST pull-down assay) and the remaining lysates were incubated overnight 
on a rotating wheel at 4°C with 35µL washed GFP-trap® Magnetic Agarose beads 
(Chromotek) (previously washed three times using a magnetic rack to pellet beads in 
between washes, rather than centrifugation). Following overnight incubation, beads 
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were washed three times for 10 mins at 4°C following which protein was eluted from 
the beads by boiling in 35µL 2X protein loading buffer. 
In the case of immunoprecipitations for analysis by mass spectrometry, 2×15cm dishes 
of cells per bait protein were used and volumes of buffers and beads were scaled up 
accordingly (70µL beads and 70µL final elution volume). Input samples were not taken. 
All solutions were filtered prior to use and all steps of the protocol, except sonication, 
were performed in a laminar flow cabinet. A clean lab coat, plastic sleeves, mask and 
hairnet were worn. Sterile filter tips were used for pipetting and eluted protein samples 
were transferred to sterile screw cap 1.8mL Eppendorf tubes.  All equipment was 
sprayed with 70% ethanol before use. 
 
2.4. Protein detection and quantification 
2.4.1. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Protein sample mixtures i.e. cell lysates and co-precipitation experiment eluates, were 
resolved according to size on 8%, 10% or 12% SDS-PAGE resolving gels, obtained by 
altering the 40% Acrylamide (Bis-Acrylamide 29:1, (Fisher Scientific)) : ddH2O ratio in a 
polymerisation reaction containing 1.5M Tris-Cl/ 0.4% SDS pH 8.8, 3.3µL/mL 10% 
ammonium persulphate (APS) (Sigma) and 0.6µL/mL N,N,N’N’-
tetramethylethylenediamine (TEMED) (Sigma). A 5% stacking gel made using 0.5M Tris-
Cl/ 0.4% SDS pH6.8, 5μL/mL 10% APS, 1μL/mL TEMED was polymerised on top of 
resolving gels with appropriately sized wells for loading protein samples.  Gels were 
immersed in running buffer (25mM Tris, 192mM Glycine, 0.1% SDS, pH 8.3) in a 
compatible running tank before loading protein samples. 
All protein samples were boiled for 10 mins in protein loading buffer (Section 2.3.1.), 
and 10µL was generally loaded into wells of the stacking gel. 1X protein loading buffer 
was also used to directly lyse cells and release and denature proteins in cases where 
direct analysis of expressed protein levels was required. The negatively charged SDS in 
the protein lysis buffer ensures that proteins have a constant mass/charge ratio and 
therefore migrate according to size. Gels were run at 120V for 90 mins, or until the dye 
front had reached the bottom of the gel. All SDS-PAGE apparatus was supplied by Biorad. 
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The protean II mini gel electrophoresis kit and Precision Plus ProteinTM Dual Colour 
Standard molecular weight protein marker was used. 
 
2.4.2. Immunoblotting, protein detection and quantification 
Following SDS-PAGE, protein was blotted onto 0.45µm nitrocellulose membrane (VWR 
International) using a BioRad Mini Trans-Blot® or Criterion® blotter transfer system, at 
18V overnight in transfer buffer (1X Tris-HCl pH 7.4 + 20% Methanol). Following transfer, 
gels were discarded and blocking of the nitrocellulose membrane was carried out for 1 
hour by incubating in 1% skimmed milk dissolved in wash buffer (50mM Tris-HCl pH 7.4, 
150mM sodium chloride and 0.1% Tween-20 (Fisher Scientific)). Nitrocellulose 
membranes were then incubated with the appropriate primary antibody and dilution in 
1% skimmed milk (see Appendix 1 for a list of all antibodies and dilutions used in this 
thesis). Membranes were next given 3×5 min washes in wash buffer, following which 
they were incubated for 45-60 mins in the appropriate secondary antibody diluted in 1% 
skimmed milk. Fluorophore conjugated secondary antibody incubations were protected 
from light using aluminium foil. Membranes were finally given another 3×5 min washes 
before imaging according to the detection method specific to the secondary antibody 
conjugation.  
Fluorescence using an anti-rabbit Infrared IRDye®-conjugated 800nm antibody (LI-COR) 
was the method of choice used to detect and quantify ALIX depletion in experiments to 
measure cytokinetic defects/abscission time (Chapter 4), to avoid exponential 
amplification of signal over time, as seen with enhanced chemiluminescence (ECL). 
HSP90 signal could also be detected on the same membrane, to ensure better accuracy 
of quantification, using an anti-mouse Infrared IRDye®-conjugated 680nm secondary 
antibody (LI-COR). ECL using horseradish peroxidase (HRP) conjugated secondary 
antibodies was the method of choice for detection of proteins in all other situations, 
except in instances where detection of many proteins from one sample was facilitated 
by being able to image more than one protein on the same membrane by combining ECL 
with fluorescence detection.  Amersham ECLTM Primer western blotting detection 
reagent (GE Healthcare) was used for ECL detection, by mixing equal volumes of reagent 
A and B and applying to the membrane, which was then sandwiched between two 
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transparent plastic sheets and promptly imaged, ensuring that the reagent was 
distributed evenly across the membrane surface. Imaging was performed using a LI-COR 
Odyssey® Fc Imaging system (LI-COR Biosciences). 
Quantification of protein band intensities was performed using the square measuring 
tool in Image Studio Lite version 5.2.  
 
2.5. Functional assays and microscopy 
2.5.1. Clonogenic assays to examine cell viability 
80,000 cells per condition were plated and reverse transfected in wells of a 24-well plate 
with 50pmol of each siRNA oligo as described in section 2.2.5. Medium was changed ≥ 
12 hrs later. 48 hrs following transfection, cells in each well were trypsinised and 
thoroughly resuspended in 200µL trypsin and an equal volume of complete medium. 
10µL of cell suspension was transferred to wells of a 6-well plate, in 3mL complete 
medium and again mixed thoroughly by repeated pipetting. Cells were left to grow for 
10 days, following which medium was discarded and colonies were fixed and stained by 
adding enough crystal violet stain (0.5% w/v in methanol) to cover the base of each well 
and incubating for 1 hour at room temperature. Crystal violet was then washed away 
with tap water and plates were left to dry upside-down at room temperature. Following 
imaging of plates using a Chemi-Doc imaging system (BioRad), area occupied by colonies 
on the base of each well was scored using ImageJ. A constant area of the base of wells 
for each condition was selected and cropped using the square cropping tool. This area 
was then converted to an 8-bit greyscale image and the thresholding to remove 
background, i.e. the sides of the dishes that appeared in the image, was performed. A 
threshold value that was suitable for all wells was selected. The remaining colonies in 
the image were then selected and their area measured. 
 
2.5.2. Fixation, immunostaining and imaging of cells 
Following growth of cells on glass coverslips, cells were fixed to crosslink proteins using 
500µL of 4% paraformaldehyde (PFA) (Sigma) in 1X PBS, for 10 mins at room 
temperature. Coverslips were subsequently washed three times with 1X PBS, and cells 
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were permeabilised with chilled 0.1% Triton X-100 in 1X PBS for 10 mins. Cells were 
washed three times, as previously, and then blocking was performed using 3% w/v 
bovine serum albumin (BSA) in 1X PBS at room temperature for 1 hour. Cells were then 
incubated with the appropriate primary antibody (i.e. mouse anti-Tubulin) diluted in 
50µL 3% BSA for 3 hrs, by placing coverslips face down in a 50µL drop of the antibody 
solution on a parafilm sheet kept in a wet chamber to prevent drying. Coverslips were 
returned to wells of the 24-well plate and washed as previously. Coverslips were then 
incubated for 1 hour with appropriate fluorophore conjugated secondary antibody 
(594l- anti-mouse secondary antibody) and a 1:10,000 dilution of Hoechst chromatin 
stain (VWR International) and then washed, in the same way as for the primary antibody. 
Coverslips were mounted face down on microscope slides (VWR International) using an 
8µL drop of Prolong® mountant (ThermoFisher), ensuring not to introduce air bubbles 
into the mountant. Slides were left to dry overnight in the dark at room temperature, 
and the back of coverslips was cleaned with 70% ethanol prior to microscopy.  
Imaging was performed with a Nikon Ti-Eclipse Widefield inverted microscope (Nikon, 
60x or 100x 0.75 N.A. oil objective lens) and acquired with a CoolSnap HQ2 CCD camera 
(Photometrics) controlled by NIS-Elements (Nikon). Images were acquired using 
excitation and emission filters specific to mCherry, YFP and Hoechst as a series of 
0.15µm spaced Z-stacks and deconvolved with AutoQuant X3 Deconvolution software 
(MediaCybernetics). ImageJ (Fiji) was used to produce maximum intensity projections 
of images. Images from figure 45A were obtained using an Eclipse Ti-E Inverted CSU-X1 
Spinning Disk Confocal (Nikon) equipped with an Ixon3 EM-CCD camera (Andor). Images 
were acquired in a series of 0.1 μm-spaced Z-stacks with a 100x objective. 
 
2.5.3. Live cell imaging 
HeLa cells were plated and reverse siRNA transfected as detailed in section 2.2.5. in wells 
of a 24-well glass bottom imaging plate (Eppendorf), pre-treated with poly-L-Lysine 
(Sigma) for 20 mins at 37°C. Medium was changed 12 hrs later and cells were imaged 
for 24 hours every 10 mins using 12 fields of view for each condition and 3 × 0.6µm Z-
stacks. Imaging was acquired using a Nikon Ti-Eclipse Widefield inverted microscope 
(Nikon, 40X 0.75 N.A. dry objective lens) controlled by NIS-Elements and equipped with 
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a perfect focus system and 37°C microscope chamber (Solent Scientific) supplied with 
5% CO2. The excitation and emission filter for mCherry was used and abscission times 
were scored manually by frame to frame analysis using NIS-Elements. Abscission time 
was taken as the time interval between midbody appearance to midbody scission.  
 
2.5.4. Multi-nucleation/midbody scoring assay 
HeLa cells were transfected with 2×50pmol siRNA doses as detailed in section 2.2.5. in 
the case of assays to score cytokinetic defects upon MVB12/VPS37 protein depletion. 
One dose using amounts of siRNA as detailed in chapter 4 was used in the case of ALIX 
depletion. 24 hrs post-transfection of the second dose of siRNA (or single dose in the 
case of ALIX depletion), cells were trypsinised and a volume appropriate for achieving 
around 40% confluency after 24 hrs was transferred to fresh medium in wells of a new 
24-well plate with glass coverslips placed at the base of wells. Another volume of cell 
suspension, kept the same for all conditions, was re-seeded in wells without coverslips 
for later immunoblotting to check protein depletion. 24 hrs later, the cells plated on 
coverslips were fixed, stained with anti-Tubulin and Hoechst (as detailed in section 
2.5.2.), to visualise midbodies and the cell cytoskeleton, and mounted on slides for 
microscopy. Cells that were not plated on coverslips were lysed in the wells with 1X 
protein loading buffer (Section 2.3.1.), boiled and subsequently analysed by 
immunoblotting.  
Cells were visualised using a Nikon Ti-Eclipse Widefield inverted microscope (Nikon, 60x 
0.75 N.A. oil objective lens), using excitation and emission filters specific to the 594l- 
anti-mouse secondary antibody and Hoechst. Cells with more than one nucleus and 
intercellular bridge (midbody) connected cells were scored blind for each condition. 300 
cells/condition were scored. Midbody connected cells were considered one cell, rather 
than two daughter cells. 
 
2.5.5. HIV-1 infectivity assays 
For viral trans-complementation assays (section 3.2.2.) 293T cells were PEI transfected 
in wells of a 24-well plate (Section 2.2.4.) with 300ng full-length pHxB-STOP proviral 
construct (section 2.1.2) and 200ng pHxB- trans-complementing plasmids (section 
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2.1.2/3.2.2.). Cells were immediately moved to a CL3 (Biosafety level 3) facility. Medium 
was changed ≥7 hrs later. 48 hrs post-transfection, viral supernatants were clarified by 
centrifugation at 1500 rpm for 10 minutes, and 200µL was used to infect previously 
seeded TZM-bl reporter cells at between 40-60% confluency in wells of a 48-well plate. 
In addition to overexpressing the appropriate HIV-1 receptor and co-receptors, TZM-bl 
cells express β-galactosidase, under the control of an HIV-1 LTR which is responsive to 
the HIV-1 tat protein, provided upon infection with virus. Remaining viral supernatant 
was transferred to screw cap 1.8 mL Eppendorf tubes and frozen at -80°C for pelleting 
virus later. The 293T producer cells were lysed in 200µL of 1X protein loading buffer and 
boiled. Immunoblotting (Section 2.4.2.) to detect cellular HIV-1 Gag levels was 
performed using a 12% polyacrylamide gel and anti-p24 HIV-1 Gag (183-H12-5C). TZM-
bl cells were lysed 48 hrs post-infection in 100µL Applied Systems Tropix GalactoStar kit 
lysis buffer. Lysates were clarified by centrifugation at 12,000rpm for 10 mins and 200µL 
of lysates were added to wells of a white 98-well imaging plate (PerkinElmer). Infectious 
virus release readout using a Wallac Victor 1420 workstation counter to measure 
chemiluminescence was employed, following addition of 50µL substrate mix to each 
well (1µL Galacton-Star® substrate + 49µL provided reaction buffer diluent). 
Measurements were taken 2 mins, 5 mins and 10 mins following addition of substrate, 
choosing the time which gave values of between 105 – 106. 300µL of remaining viral 
supernatant, frozen earlier, was pipetted on top of a cushion of filtered 20% sucrose in 
PBS, in a screw cap Eppendorf tube. The tube was marked, to facilitate location of the 
invisible viral pellet following centrifugation, and centrifuged at maximum speed for 3 
hrs at 4°C. The sucrose cushion was aspirated away at the side of the tube opposite the 
viral pellet, leaving around 10-15µL at the base of the tube, with the pellet. Virions were 
vortexed and lysed thoroughly in 75µL of 2X protein loading buffer and transferred to 
regular 1.8mL Eppendorf tubes, before leaving the CL3 facility, to facilitate boiling prior 
to SDS-PAGE and immunoblotting. As for lysates, budded virion samples were resolved 
on a 12% gel and detection using the same anti-p24 HIV-1 Gag (183-H12-5C) primary 
antibody was carried out.  
For experiments to investigate the effect of UMAD1 knockout on HIV-1 budding, using 
CRISPR/Cas9 UMAD1 knockout cells (Chapter 5), 293T cells were given two 50pmol 
siRNA doses (siNT or siTSG101 controls), the first using Dharmafect and the second using 
138 
 
Lipofectamine 2000 to transfect siRNA simultaneously with 150ng proviral constructs 
(pNL-HxB, R9, and R9∆YPXnL) . Since two 50pmol doses of siTSG101 is toxic to HeLa cells, 
experiments using HeLa cells were later performed with one 50pmol siRNA dose co-
transfected with 150ng pNL-HxB (Section 5.2.2.). All other steps for performing a TZM-
bl assay and immunoblotting were as described above, except TZM-bl cells were 
infected with 10µl viral supernatant from 293T producer cells, or 50µL supernatant from 
HeLa producer cells. 
 
2.5.6. Immunoprecipitation – Tandem Mass Tag (IP-TMT) based Mass 
Spectrometry 
Eluates from GFP-trap immunoprecipitation experiments were taken to the King’s 
College London proteomics facility, Centre of Excellence for Mass Spectrometry at the 
James Black Centre, Denmark Hill, where samples were prepared for multiplex TMT 
analysis and analysed by Dr Xiaoping Yang and Dr Steven Lynham.  
30µL of each sample, corresponding to approximately 57µg protein, was run around 
1cm into a commercially available 10% polyacrylamide gel, following which staining with 
Imperial protein stain (Thermo Fisher Scientific) was performed. Background was 
removed by destaining, and gel slices containing all the protein in each sample were 
excised. The proteomics facility in-gel trypsin digestion and isobaric tag labelling 
protocol was then followed, to generate tryptic signature peptides to be used for protein 
identification. This involved reduction of cysteine residues with dithiothreitol and 
alkylation with iodoacetamide to form stable carbamidomethyl derivatives. Trypsin 
digestion was then carried out overnight, followed by isobaric mass tag labelling of each 
sample with a different TMT tag (Thermo Fisher Scientific). TMT tags all have the same 
structure and molecular weight, consisting of a mass reporter and mass normaliser 
region, separated by a cleavable linker, and an amine reactive group which reacts with 
the N-termini and lysine residues within peptides thus labelling them. Alternative 
positioning of 13C and 15N atoms within the mass reporter and mass normaliser regions, 
however, ensures that the mass reporter ions released during fragmentation of peptides 
at the MS2 stage each have different masses. Sample specific information regarding 
differences in protein abundancies between samples can be inferred from these 
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different reporter ion masses. Labelled samples were pooled and desalted using C18 
reversed-phase Zip-Tips (Millipore), before being subjected to LC-MS/MS tandem mass 
spectrometry.  
Peptides were resolved by reversed phase chromatography on a C18 column using an 
Ultimate 3000 NanoLC system (Thermo Fisher Scientific). Eluate was then ionised by 
electrospray ionisation using an Orbitrap Fusion Lumos (Thermo Fisher Scientific) 
operating under Xcalibur v4.1. acquisition using a “Synchronous Precursor Selection 
with MultinotchMS3” method (SPS) was employed. Synchronous Precursor Selection is 
a process of selecting multiple MS2 precursors using a single fill and single waveform in 
a CID or HCD cell, while MultinotchMS3 is to reduce co-isolated interference from MS2 
in an ion-trap cell. This method allows for accurate and sensitive quantitation based on 
isobaric TMT tags.  
Raw mass spectrometry data were processed into peak list files using Proteome 
Discoverer v2.2 (Thermo Fisher Scientific) (PD 2.2) Processed data was then searched 
using Mascot search algorithm and Sequest search engine embedded in PD 2.2, against 
the current version of the reviewed Swissprot Homo Sapiens (Human) database 
downloaded from Uniprot. Data analysis and generation of figures was performed using 










Chapter 3 – Biochemical characterisation of 
UMAD1 
3.1. Introduction 
Although a structure for the core of human ESCRT-I has not been solved, mammalian 
ESCRT-I, as in yeast, is approximately 350 kDa and shows strong conservation with yeast 
ESCRT-I in terms of its subunit organisation and function. In mammals there has been 
an expansion in the number of available subunits to form the heterotetramer, to include 
alternative VPS37 and MVB12 paralogues, and two isoforms of VPS28. The mammalian 
homologue of yeast Vps23 is TSG101, and the two mammalian isoforms of VPS28 are 
termed VPS28 I and II. Mammals have so far been shown to express four VPS37 
paralogues, being VPS37A-D, and three MVB12-like proteins, being MVB12A, MVB12B 
and UBAP1. 
TSG101, like yeast Vps23, represents the central lynchpin-like subunit of ESCRT-I which 
interacts with all of the other subunits. As in yeast ESCRT-I, TSG101 shows independent 
interaction with VPS28, at its C-terminal helical headpiece region51,53,565,665, and VPS37 
subunits, at a more upstream predicted coiled-coil/leucine zipper region (Figure 
22)657,665–667. Also consistent with the structure of yeast ESCRT-I is the finding that 
TSG101-VPS37 dimers provide the minimal binding surface required for MVB12-like 
subunits657,665–667. Like Vps23, human TSG101 also contains a UEV domain at its N-
terminus, which in addition to binding ubiquitin13,76 and ESCRT-044,45,47 binds to PT(S)AP 
L-domain motifs of retroviral Gag proteins, ALIX, HD-PTP and a double PTAP-PSAP motif 
in TSG101-associated ligase (Tal) – a RING E3 ubiquitin ligase involved in control of 
cellular TSG101 levels (Figure 22)17,442,566,668,669. 
 
3.1.1. TSG101  
TSG101 was originally identified in a screen for genes for which homozygous depletion 
led to metastatic cell growth, hence the name tumour susceptibility gene 101635. Whilst 
knockout led to tumorigenesis, its overexpression also led to transformation and 
perturbed cell cycling in mouse NIH3T3 fibroblasts, suggesting that precise control of its 
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expression is required for a normal cell cycle and growth. In addition to its sequence 
conservation with yeast Vps23 (52% sequence similarity), TSG101 was later 
characterised as the mammalian homologue of Vps23 based on its requirement for 
efficient lysosomal sorting51,670,671, its association with dominant negative VPS4 induced 
endosomal vacuoles53 and its ability to rescue L-domain defective viral budding when 
fused to HIV-1 Gag14,565. Specifically, a region from 250-390, encompassing the majority 
of the stalk and headpiece, was largely sufficient to mediate budding, indicating that 
binding to all other ESCRT-I subunits is important for function14. 
Consistent with potentially tight levels of control of TSG101 expression was the finding 
that the level of TSG101 expression is tightly controlled at a post-translational level by 
an intrinsic ‘steadiness box’, mapped to its C-terminal 43 amino acids (Figure 22)669,672. 
Increased expression of exogenous TSG101 causes decreased expression of the 
endogenous protein in an attempt to maintain steady state levels of expression672. 
Further work by McDonald and Martin-Serrano 2008 showed that Tal ligase is recruited 
to the UEV domain of TSG101 but specifically ubiquitinates lysine residues within and 
around the steadiness box, thus targeting excess uncomplexed TSG101 for proteasomal 
degradation669. Since the VPS28 binding site overlaps the steadiness box, these lysine 
residues are occluded when TSG101 is in complex with VPS28, thus preventing 
ubiquitination and degradation of TSG101. In this way, VPS28 is a limiting factor for 
cellular levels of TSG101, hence ESCRT-I. In addition to regulation of TSG101 levels by 
this mechanism, ESCRT-I subunits show mutual dependence on each other for stability: 
a decrease in the levels of VPS28 and VPS37 paralogues is seen upon depletion of 
TSG101666.  
In addition to the other ESCRT-I subunits, TSG101 has been shown to bind a number of 
other proteins, notably CEP55 and other proteins involved in cytokinesis (Section 1.5.6.). 
The structure of the N-terminal UEV domain of TSG101 has been solved both in isolation 
and in complex with the PTAP motif of HIV-1 p675,76,673. Like yeast Vps23 (Section 1.3.2.), 
a characteristic b-hairpin “tongue” consisting of two b-strands represents the most 
important site for mediating interaction with ubiquitin. Residues closer to the vestigial 
active site within a hydrophobic sheet are also involved in interaction with ubiquitin, as 
in yeast73,76. PT/SAP motif binding occurs independently at a different site within a 
groove at the other side of the vestigial active site loop, and binding causes the UEV 
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domain to wrap around the peptide involving more pronounced conformational 
changes75. One potentially significant difference with the yeast Vps23 UEV domain is the 
presence of a six-residue insertion within the N-terminal side of the vestigial active site 
loop. This has been suggested to explain the difference in binding of the yeast protein 
to PXXP motifs and that of mammals to related but similar PT/SAP motifs73. TSG101 
contains an internal PTAP motif within a loop upstream of its coiled-coil/leucine zipper 
motif (Figure 22)76. Interaction between this motif with the UEV domain has been 
suggested to possibly form an “auto-inhibited” conformation of TSG101, preventing 
interaction with other PTAP motif containing proteins such as HRS until required76. In 
addition to interactions with the PT/SAP motifs of ESCRT-0, Tal ligase and viral structural 
proteins, TSG101 has been shown interact with ALIX via both a 717PSAP720 and 852PSYP855 
motif in ALIX55. This ALIX-TSG101 interaction has been suggested to be necessary in 
cytokinetic abscission (Section 4.1.). Interaction with ALIX has also been shown to occur 
via ALG-2 – a calcium binding dimeric protein, each monomer of which interacts with 
TSG101 or ALIX (sections 1.8.2. and 4.1.)674–676. Likewise, HD-PTP interacts with TSG101 
via a 720PTAP723 motif, during the proposed shuttling between ESCRT-0, ESCRT-I and 

























Human VPS28 shows 66% similarity with yeast Vps28, and like TSG101 also showed 
localisation to dominant negative VPS4 induced endosomal vacuoles53. Taken together, 
mapping from two studies has shown the binding site for VPS28 to optimally exist 
between residues 330-385 of TSG101, with residues 368-371 representing the minimal 
region required for binding565,665. Virus work also demonstrated the importance of the 
interaction between VPS28 and TSG101, in that a VPS28 binding mutant of TSG101 
(TSG101 d368-371) was unable to rescue L-domain defective HIV-1 budding when fused 
to Gag. HIV-1 budding was also disrupted when C-terminal regions of TSG101 that 
corresponded to the VPS28 binding site were removed565. Binding to TSG101 was also 
shown to be necessary for cytokinesis, as again evidenced by the inability of a VPS28 
binding site mutant TSG101 to rescue the increase in multinucleation seen upon 
depletion of TSG101565.  
 
3.1.3. VPS37 subunits 
Human VPS37 orthologues VPS37A-D were identified based on homology to yeast Vps37 
and previously uncharacterised Drosophila TSG101 interaction partners657,665,666. A 
Modifier of rudimentary (Mod(r)) domain of approximately 150 residues represents the 
most conserved region amongst the VPS37 paralogues and with yeast Vps37 (Figure 
23)677. The Mod(r) is predicted to contain at least one helical region in each paralogue 
and forms the primary interaction surface with the core of TSG101, which through yeast 
two-hybrid studies has been shown to bind at least part of each Mod(r) domain665. 
Mod(r)-TSG101 core dimers also form the binding site for the various MVB12 subunits 
(see below), as shown by both yeast two-hybrid and immunoprecipitation studies667.  
Figure 22. Domain structure of TSG101 and main binding partner interaction sites 
The overall structure of TSG101 is well conserved with that of yeast orthologue Vps23. An N-terminal 
UEV domain is primarily responsible for mediating interaction with ubiquitin and PT/SAP motif 
containing proteins, such as HRS and viral Gag proteins, as shown. A downstream PRR mediates 
interaction with CEP55, the adaptor protein for cytokinetic abscission. As in yeast Vps23, the stalk and 
headpiece regions mediate interaction with the other ESCRT-I subunits. As described in the text, the 
steadiness box represents an intrinsic mechanism for control of cellular TSG101 levels. An internal 
PTAP motif upstream of the coiled-coil/leucine zipper region of the stalk has been suggested to 
mediate auto-inhibition of TSG101, by interacting with the UEV domain, until binding to other PT/SAP 
motif containing proteins is required.  UEV = Ubiquitin enzyme variant, PRR = Proline rich repeat.  
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Whilst VPS37B, C and D contain ~30% proline rich regions downstream of their Mod(r) 
domains, VPS37A lacks this and instead contains an N-terminal UEV domain (Figure 
23)657,665,666. VPS37A shows preferential pairing with UBAP1 to form an ESCRT-I complex 
that is specifically involved in endosomal sorting (see below). Depletion of VPS37A 
shows decreased lysosomal sorting and degradation of EGFR, hence a marked 
accumulation in its cellular levels666. Given the specific role for VPS37A in endosomal 
sorting, it would seem reasonable to assume that the UEV domain of VPS37A represents 
a specialisation for ubiquitin binding, like the UEV of TSG101. Despite this, the residues 
that bind ubiquitin and PT/SAP motifs in the TSG101 UEV are not conserved in the 
VPS37A UEV, and binding to ubiquitin has not been observed, leaving an open question 
surrounding the function of this region637,665,666. An N-terminal region of VPS37A 
encompassing the UEV, however, did show some weak interaction with TSG101, even 
though binding was stronger using a C-terminal fragment encompassing the Mod(r) 
domain (Figure 23)666. Functions for the proline rich regions of VPS37B-D also remain to 
be elucidated. 
Aside the well-defined role for VPS37A in endosomal sorting (see below), function 
specific roles for VPS37B-D have not been described in detail. However, their identity as 
ESCRT proteins and requirement for ESCRT function has been demonstrated by their 
observed clustering on catalytically inactive dominant negative VPS4 induced aberrant 
endosomes, and their ability to rescue budding of L-domain defective HIV-1 virus when 
fused to Gag657,665. Contribution of VPS37B and C to viral budding is discussed in chapter 
5. 
Notable differences between the VPS37 proteins also include the presence of a 
185PTAP188 motif in VPS37B which provides another site of interaction with TSG101 by 
binding to its UEV domain (Figure 23)665. This is not found in any of the other VPS37 
proteins. VPS37A also appears to show some potential direct interaction with VPS28, as 
shown by both yeast two-hybrid and co-precipitation studies in which an interaction 
between GST-VPS28 with in vitro translated VPS37A was seen666. The same was not seen 
for VPS37B or C. Yeast two-hybrid and co-precipitation studies have also shown VPS37A, 
B and C to bind HRS, although to varying extents for each protein, with binding to 
VPS37C perhaps being more apparent due to the observed co-localisation of YFP-
VPS37C with CFP-HRS657,665,666. This was not observed in the case of YFP-VPS37B. An 
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interaction between VPS37C with ALIX was also observed by yeast two-hybrid, however 






















3.1.4. MVB12 subunits 
Three mammalian MVB12-like subunits have so far been described: MVB12A, MVB12B 
and UBAP1 (Figure 24A)196,658,667,678. Mammalian MVB12A and MVB12B were identified 
by mass spectrometry as proteins sharing around 30% sequence identity that co-
precipitated with One-STrEP FLAG (OSF)-tagged TSG101, VPS28 and VPS37A-D co-
expressed in 293T cells. Although no discernible sequence conservation between yeast 
Mvb12 and the mammalian isoforms MVB12A and MVB12B is apparent, a TSG101-
Figure 23. Domain structure of VPS37 paralogues 
As described in the text, all mammalian VPS37 paralogues contain a Mod(r) region responsible for 
interaction with TSG101 and MVB12-like subunits, hence the rest of ESCRT-I. Each of these Mod(r) 
regions contain at least one predicted helical region shown in blue. Whilst VPS37B, C and D contain 
C-terminal PRRs, VPS37A does not contain a PRR and instead contains an N-terminal UEV, which has 
not definitively been shown to bind ubiquitin, but potentially shows some weak binding to TSG101. 
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VPS37 dimer was found to provide the binding site for incorporation of MVB12A and 
MVB12B into ESCRT-I667. Further mapping studies narrowed down the binding site to 
the regions of TSG101 and VPS37 subunits that corresponded to the ESCRT-I core, i.e. 
the stalk and head forming regions of TSG101 and the Mod(r) regions of VPS37 proteins. 
Mapping studies using recombinantly expressed MVB12 fragments to define the regions 
of MVB12A and MVB12B necessary for incorporation into ESCRT-I identified two non-
overlapping C-terminal fragments from residues 192-233 and 234-273 (Figure 24B) that 
both independently bound ESCRT-I. These were termed ESCRT binding boxes (EBB1 and 
EBB2)667. 
The N-terminus of both MVB12A and MVB12B, upstream of EBB1 and EBB2 forms a 
relatively unique type of β-prism fold known as an MVB12 associated β-prism 
(MABP)679,680. The structure of this fold in MVB12B has been crystallised and shown to 
consists of three antiparallel β-sheets arranged about a pseudo threefold axis679. These 
domains have been implicated in membrane binding, in vitro and in vivo, showing non-
specific binding to anionic lipids via an exposed surface loop and adjacent 
electropositive surface patch. Although binding is weak, such an interaction in 
combination with those of other membrane binding domains of the ESCRT machinery 
has been proposed to facilitate targeting to anionic lipids at late endosomes and the 
plasma membrane679. 
UBAP1 was identified as a fourth alternative mammalian MVB12 subunit by Stefani et 
al. 2011196, as an HD-PTP interacting protein accounting for approximately 10% of 
ESCRT-I complexes, and by Agromayor et al. 2012658 as a protein that shared sequence 
similarity with both vertebrate and invertebrate MVB12 sequences. Its identification in 
a bioinformatics screen in 2010 also defined a more specific region of homology of 
approximately 50 residues shared with MVB12A and MVB12B at its N-terminus, that 
was termed the UBAP1-MVB12-associated (UMA) domain680. UMA domains were 
identified in metazoan proteins only and were characterised by a highly conserved N-
terminal proline residue followed by a hydrophobic residue, and an even more highly 
conserved C-terminal glutamate residue (Figure 24B). The UMA domain corresponds to 
a region of MVB12A and MVB12B encompassing parts of both EBB1 and EBB2 (Figure 
24B) and in human MVB12 proteins, the conserved N-terminal proline residue 
corresponds to the central residue of a shared VPF motif667,680. EBB1 contains this VPF 
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motif whilst EBB2 contains the conserved glutamate residue, consistent with a role for 
these residues in binding ESCRT-I, as shown for UBAP1196,658,681 (Figure 24B). Secondary 
structure predictions for the UMA domains of MVB12A, MVB12B and UBAP1 are 
consistent with that of UMA domains in general, showing an α+β fold680. Both JPRED 4 
and NetSurfP-2.0 predict human MVB12A, MVB12B and UBAP1 to possess a short beta 
strand immediately following or overlapping the VPF motif. Two helical regions are 
predicted to exist downstream of this, the second of which contains the conserved 
glutamate residue (Figure 24B).  
The C-terminus of UBAP1, downstream of the UMA domain forms a solenoid of 
overlapping ubiquitin associated (UBA) domains (SOUBA), which binds to both 
monoubiquitin and K48 and K63-linked diubiquitin chains with equal affinity, around 10 
times stronger than the UEV domain of TSG101 (Figure 24A)658. This confers a process 
specific function to UBAP1 in the ESCRT mediated process of endosomal sorting of 
ubiquitinated receptor proteins. UBA domains consist of small 3-helix bundles with a 
conserved hydrophobic surface that binds ubiquitin moieties via a GF/Y motif682–684. The 
SOUBA consists of three overlapping UBA domains in which the third helices of UBAs 1 
and 2 form the first helices of UBAs 2 and 3 respectively, to form a ridged right-handed 
solenoid structure consisting of seven overlapping helices. Each overlapping UBA 
domain can bind ubiquitin, however simultaneous binding to more than one ubiquitin 
moiety has not been shown658. 
UBAP1 represents a mammalian MVB12 subunit with a clear direct function in sorting, 
as shown by its ability to form an ESCRT-I complex that binds HD-PTP and ubiquitin with 
high affinity to specifically function in MVB formation and lysosomal sorting. Depletion 
of UBAP1 leads to endosomal clustering and accumulation of ubiquitinated proteins and 
EGF on endosomal membranes showing co-localisation with HRS196. Depletion also leads 
to defective lysosomal sorting of tetherin and MHC class I658.  
Functions specific to yeast Mvb12 have been described in sorting and recycling of the 
ESCRT-I complex from membranes, based on analysis of mutants that do not express 
Mvb12 or express of Mvb12 point mutants that disrupt interaction with ESCRT-I. 
Mutation of Mvb12 disrupted sorting of biosynthetic cargo such as CPS and Sna3 and 
endocytic cargo such as Ste2 and Ste364. There is conflicting evidence regarding whether 
Mvb12 plays a cargo selective role, favouring the sorting of one type of cargo over 
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another67. Curtiss et al 2007 also proposed a function for Mvb12 in recycling of ESCRT-I 
from membranes, which is dependent upon ubiquitin binding66. Chu et al. 2006 
proposed a role for Mvb12 in preventing the premature interaction between ESCRT-I 
and ESCRT-II until both complexes are membrane bound65.  In any case, sorting defects 
are less severe upon deletion/mutation of Mvb12 than any of the other yeast ESCRT-I 
subunits, and do not lead to a classic class E phenotype67. Cargo still reaches the vacuole 
limiting membrane, even if not reaching the lumen. Furthermore, deletion of Mvb12 
does not disrupt recruitment of ESCRT-I to membranes and the resulting trimer still 
shows some sorting activity despite being less stable and extended66. Mvb12 is the least 
stable of all yeast ESCRT-I subunits and has the highest turnover79. Whilst a unique role 
for Mvb12 in the fine tuning of sorting cannot be ruled out, all these findings point to a 
less important role for Mvb12 than the other yeast ESCRT-I subunits in ESCRT-I function, 
and suggest its main role to be maintenance of stability and structure, as further 
evidenced by prevention of aggregation and proteolysis upon its co-expression with the 
other recombinant ESCRT-I subunits79. 
In contrast to UBAP1, human MVB12A and MVB12B are similar to yeast Mvb12 in that 
their depletion does not appear to have such a detrimental effect on EGFR sorting, and 
function specific roles remain to be elucidated in detail681. ESCRT identity was again 
shown by localisation of MVB12A to aberrant endosomes caused by dominant negative 
VPS4 expression, and a minor role for MVB12A and B in viral budding is discussed in 
section 5.1.2.667.Both MVB12A and MVB12B show serine, threonine and tyrosine 
phosphorylation patterns667,685,686. Mutation of these phosphorylation sites in MVB12A 
did not disrupt incorporation into ESCRT-I but reduced the ability of the overexpressed 
protein to disrupt HIV-1 budding667. It is also often overlooked that MVB12A was 
originally identified not as an ESCRT-I component but as a protein named CIN85/CD2AP 
family binding protein (CFBP), identified in a screen for proteins that are tyrosine-
phosphorylated upon EGF stimulation686. Phorphorylation was proposed to increase 
binding affinity of CIN85/CD2AP to MVB12A and promote EGF receptor downregulation 
through recruitment of Cbl ubiquitin ligase to the CD2AP/CIN85 complex686. Tyrosine 
phosphorylation at the equivalent positions in MVB12B was also later observed, in 
response to EGF stimulation667,685. These observations potentially suggest a role in 
endosomal sorting, albeit a more minor one compared to UBAP1. 
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Selective subunit pairing between VPS37A and UBAP1 has been well defined196,658,681. 
Like MVB12A and MVB12B, a TSG101-VPS37A Mod(r) dimer has been shown to provide 
the binding interface for UBAP1 incorporation into ESCRT-I, and preferred pairing with 
VPS37A has been shown both in vivo and in vitro. Co-precipitation of VPS37A but not 
VPS37B or VPS37C using UBAP1-strep, and co-precipitation of UBAP1 using Myc-VPS37A 
but not using Myc-VPS37B or VPS37C has been shown681. The same publication also 
showed this selective pairing in vitro, in the absence of any possible bridging factors, 
using tagged proteins expressed at physiological levels in rabbit reticulocyte lysates. A 
predicted neighbouring helical region downstream of the UMA domain in UBAP1 has 
been shown to confer selective binding to VPS37A, specifically by preventing binding of 
VPS37C, and most likely VPS37B. In contrast it was shown that the bare UMA domain of 
MVB12A alone was able to selectively pair with VPS37C, and probably VPS37B, but not 
VPS37A681. These co-precipitations demonstrate that selective pairing is conferred by 
differences both within and flanking the UMA domains of MVB12 subunits.  
Aside the selective subunit pairing between VPS37A and UBAP1, preferred pairing 
between VPS37B and VPS37C with MVB12A and MVB12B has so far not been described, 
and pairing has been suggested to be stochastic, particularly since these paralogues are 
more similar to each other at the level of their primary sequences. In this chapter I 
present a further example of selective pairing between VPS37 and MVB12 subunits for 
UMAD1 – a newly identified alternative MVB12 subunit that pairs with both VPS37B and 


































































Figure 24. Domain structure of human MVB12-like proteins and UMA domains 
A. As described in the text, human MVB12A and MVB12B proteins contain N-terminal MABP domains 
involved in membrane binding. Their C-termini contain UMA domains involved in interaction with 
ESCRT-I, specifically TSG101-VPS37 dimer interfaces. UBAP1 is an MVB12-like protein that is highly 
adapted for endosomal sorting of ubiquitinated cargo. It contains an N-terminal UMA domain, a 
central region that interacts with HD-PTP and importantly a C-terminal SOUBA capable of binding 
ubiquitin moieties of cargo with high affinity. EBB1 and EBB2 regions represent framents of MVB12A 
and MVB12B that were each originally shown to bind ESCRT-I prior to subsequent characterisation of 
UMA domains. MABP = Matric associated b-prism, UMA = UBAP1-MVB12-associated domain, UBA = 
Ubiquitin associated domain, SOUBA = Solenoid of overlapping UBA domains, EBB1 = ESCRT-I-binding 
box 1, EBB2 = ESCRT-I-binding box 2. B. Location of UMA domains with surrounding sequence and 
predicted secondary structures in human MVB12-like subunits. Positions of the UMA domains within 
MVB12A, MVB12B and UBAP1 are shown, based on protein primary structure, together with 
surrounding regions of relevance. Signature UMA domain N-terminal VPF motifs and C-terminal 
conserved glutamate residues are boxed in blue. Secondary structure predictions using JPred 4 are 
shown. These predictions also matched well with those generated using NetSurfP-2.0.  
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3.2.1. Identification of UMAD1 as an ESCRT-I subunit 
As part of an attempt to identify novel ESCRT-I interaction partners, a GFP trap co-
immunoprecipitation assay was performed using lysates from HeLa cells that stably 
expressed the bait proteins YFP-TSG101, YFP-VPS37C or YFP alone, as a negative control. 
Following binding of protein to trapping beads, eluted proteins were digested with 
trypsin and prepared for multiplex tandem mass tag (TMT) based LC-MS/MS mass 
spectrometry, using a different isobaric TMT tag to label the tryptic peptides generated 
for each sample, as detailed in section 2.5.6. of materials and methods. 
To determine binding partners specific to TSG101 or VPS37C, a criterion based on the 
TMT tag reporter ion ratio for YFP-TSG101 or YFP-VPS37C to the YFP negative control 
was introduced. A protein was defined as a specific binding partner if this ratio was ≥3. 
A complete list of identified interaction partners is presented in Appendix 1. Upon 
applying this cut-off, ESCRT-I proteins showed the highest ratios (Table 2) and all known 
ESCRT-I subunits except for VPS37D and MVB12B were identified. This suggests that 
VPS37D and MVB12B do not bind, or more likely are either not expressed or show 
negligible expression levels in HeLa cells, consistent with data from the Human Protein 
Atlas version 18.1 and other publications667,681. Despite being less enriched, CEP55 was 
also identified as a binding partner for at least YFP-TSG101. Reassuringly in the case of 
YFP-VPS37C, values for VPS37A and VPS37B were very close to or at zero (Table 2), as 
would be expected, due to their being outcompeted by YFP-VPS37C. Lack of enrichment 
for UBAP1 can be explained by the preferred pairing between VPS37A with UBAP1, 
rather than VPS37C. 
Besides all previously identified ESCRT-I components, UMAD1 was identified as a 
binding partner for both YFP-TSG101 and YFP-VPS37C (Table 2). UMAD1 was previously 
identified as another UMA domain containing protein, based on homology with human 
MVB12A and MVB12B in the same bioinformatics screen from 2010680 (Section 3.1.4.). 
This strongly suggested that UMAD1 could be a novel unconfirmed ESCRT-I interaction 
partner. Detection of only one peptide could be due to the relatively small size of 
UMAD1 (137 amino acid residues), hence a lower number of tryptic peptides (4 
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theoretically expected) and simpler fragmentation pattern compared to other ESCRT 
proteins. 
Like MVB12A, MVB12B and UBAP1, the C-terminal UMA domain of UMAD1 contains the 
same canonical VPF and glutamate residues, however secondary structure prediction 
using both the full-length protein and a shorter region mainly encompassing the UMA 
domain (Figure 25) predicts a more helical structure (Figure 25). The beta strand at the 
site of the VPF motif appears to be replaced with two helical regions, the second of 
which either overlaps or is positioned just downstream of the VPF motif. The UMA 
domain of UMAD1 encompasses approximately the most C-terminal 50-60 residues, 
whilst the N-terminal 75-85 residues are predicted to be largely unstructured, apart 
from a beta strand from approximately residues 22-29. The primary sequence of this 
predicted strand and that around the conserved UMA domain VPF and glutamate 
residues correspond to the most highly conserved regions of the protein across species. 
According to the Ensembl genome browser, UMAD1 appears in general to be very well 
conserved across vertebrate species, found in mammals, birds, reptiles and even the 
Coelacanth – one of the oldest species of fish to date. UMAD1 also appears to be quite 
ubiquitously expressed, present at substantial levels in all cell lines listed in the Human 
Protein Atlas version 18.1. This thesis provides the first characterisation of UMAD1 as a 














Figure 25. Primary sequence and secondary structure prediction for UMAD1 
Positions of the predicted UMA domain (approximately residues 86-134) and N-terminus 
(approximately 1-86) of UMAD1 are shown, based on the protein primary structure. Signature UMA 
domain N-terminal VPF motifs and C-terminal conserved glutamate residues are boxed in blue. 
Secondary structure predictions using JPred 4 are shown. These predictions also matched well with 


























3.2.2. UMAD1 rescues L-domain defective HIV-1 budding 
An HIV-1 viral trans-complementation assay was performed to test UMAD1’s ability to 
form a functional ESCRT-I complex. This assay exploits the ability of the ESCRT machinery 
to mediate HIV-1 budding. Briefly, ESCRT proteins are fused to a defective HIV-1 Gag 
lacking the L-domains (GagDp6), which is unable to release viral particles. This leads to 
artificial recruitment of the ESCRT machinery to sites of viral budding, thus rescuing 
budding to varying extents14,565,567,575. 
In terms of experimental setup, this assay involves co-transfection of 293T cells with two 
plasmids (Figure 26A). The first plasmid encodes a full-length L-domain defective 
provirus in which a stop codon is placed just upstream of p6 (pHxB-STOP). The second 
plasmid encodes a more truncated proviral construct, which encodes Gag as a fusion to 
various ESCRT proteins. When expressed, Gag proteins encoded by both plasmids are 
processed and multimerise to form a virus with improved budding competency. 
Infectious virus release was quantified in this assay using TZM-bl reporter cells. Upon 
infection, TZM-bl reporter cells express β-galactosidase, which is under the control of an 
Table 2. ESCRT-I subunit enrichment when co-precipitated by YFP-TSG101 or YFP-VPS37C as 
determined by IP-TMT based mass spectrometry 
GFP trap immunoprecipitations using YFP-TSG101 and YFP-VPS37C, in a HeLa cell background, 
together with an appropriate YFP negative control were performed. Eluates were analysed by 
multiplex IP-TMT based mass spectrometry following digestion with trypsin and isobaric TMT tag 
labelling, using a different tag per sample. Following total normalisation of signal values across 
samples to eliminate variation in signal at the level of sample preparation and data acquisition, signal 




HIV-1 tat protein responsive HIV-1 LTR promoter. β-galactosidase readout is therefore 
measured to quantify infectious virus release. 
UMAD1 was tested in parallel with TSG101 and UBAP1, since these proteins have 
previously been shown to rescue budding in this assay14,658. Gag with p6 re-introduced 
(pHxB-p6) or with no fusion present (pHxB-ENX) were used as positive and negative 
controls respectively (Figure 26B). UMAD1 was found to rescue infectious release, 
showing over 4-fold rescue compared to pHxB-ENX (Figure 26B). 293T producer cell 
lysates show reasonably constant cellular Gag expression across all conditions. The 
characteristic p25 (CA-SP1) to p24 (CA) processing defect characteristic of disrupted L-
domain activity is also seen, as manifested by the p25/p24 doublet seen for all 
conditions560. Whilst theoretically the band intensities for Gag for pelleted virion 
samples should mirror the infectious virus release levels seen in the TZM-bl assays, the 
artificial nature of this assay has previously shown this to not always be the case658, as 
seen here. Trans-complementation with pHxB-TSG101, for example, appears to show 
more budded virions than when using pHxB-UMAD1 or pHxB-UBAP1, despite observing 
a better rescue using the latter two constructs than pHxB-TSG101 in the TZM-bl assay.  
A possible explanation for this discrepancy could be that not all the budded virions are 
infection competent using this artificial system due to interference by the bulky Gag 
















































Figure 26. UMAD1 rescues L-domain defective HIV-1 budding when fused to HIV-1 Gag. 
A. Schematic representation of modified trans-complementing HIV-1 proviral Pr55 Gag precursor 
proteins. The stop codon in the pHxB-STOP full length proviral construct is designed to disrupt L-
domain activity but not expression of Pr160 Gag-Pol precursor protein, as generated in 5% of cases by 
frameshifting.  B. 293T cells were transfected with L-domain defective pHxB-STOP full-length proviral 
plasmids together with pHxB-UMAD, -TSG101, -UBAP1, -p6 or HxB-ENX trans-complementing 
plasmids. Viral supernatant was harvested 48 hrs later and used to infect TZM-bl reporter cells. TZM-
bl cell lysates were harvested another 48 hrs later and infectious virus release was determined by HIV-
1 Tat dependent β-galactosidase induction measured by quantification of chemiluminescence. Results 
show the mean numbers obtained for four independent experimental repeats, and error bars 
represent the standard deviation from the mean. Immunoblotting of producer cell lysates and 20% 
sucrose cushion pelleted virions was performed with α-Gag. Blotting with α-HSP90 was also 
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3.2.3. UMAD1 is incorporated into ESCRT-I complexes 
The above viral trans-complementation assay and mass spectrometry results strongly 
suggest that UMAD1 is a novel ESCRT interacting protein and specifically could be an 
ESCRT-I binding partner, given its co-precipitation by both TSG101 and VPS37C and its 
possession of a UMA domain shared with MVB12A, MVB12B and UBAP1680 (Figure 24). 
We therefore decided to test whether UMAD1 could specifically be incorporated into 
ESCRT-I. To this end, a GST co-precipitation assay was initially performed using lysates 
from 293T cells that were transiently transfected with plasmids overexpressing GST-
TSG101, Myc-VPS28, HA-tagged VPS37A, VPS37B, VPS37C or VPS37D and HA-UMAD1 
(Figure 27A), similar to that used previously by Agromayor et al. 2012658 to test UBAP1 
incorporation into ESCRT-I. In this way, both incorporation of UMAD1 into ESCRT-I 
complexes and any potential VPS37 subunit pairing specificity could be examined.  
Three independent experimental repeats consistently showed the absence of a band for 
HA-UMAD1 in pull-down conditions using HA-VPS37A, whilst the presence in the cases 
of HA-VPS37B, HA-VPS37C and less so to HA-VPS37D. This suggested VPS37 subunit 
pairing specificity with VPS37B, C and D (Figure 27A). This result was reassuring in that 
UMAD1 was indeed co-precipitated and that specific VPS37 subunit pairing appeared to 
be seen. Co-precipitation using HA-VPS37C generally showed a more intense band for 
HA-UMAD1 compared to when using HA-VPS37B and even less in the case of VPS37D, 
as quantified in Figure 27B, suggesting a further preference for incorporation into 











































This pulldown system used so far has the caveat that it is somewhat artificial in that 
proteins are exogenously overexpressed at non-physiological levels. In order to address 
the issue of potential formation of aberrant subunit pairings due to protein 
overexpression in Figure 27A, a GFP trap co-immunoprecipitation assay using lysates 
from HeLa cells that stably express YFP-UMAD1 was performed to test co-precipitation 
Figure 27. UMAD1 is incorporated into ESCRT-I complexes containing VPS37B, C or D  
A. GST pull-down co-precipitation assay using transiently overexpressed, tagged ESCRT-I proteins in 
293T cells. 293T cells were transfected with plasmids expressing GST-TSG101, Myc-Vps28, HA tagged 
VPS37A, VPS37B, VPS37C or VPS37D and HA-UMAD1. 48 hrs post-transfection cell lysates were 
incubated with glutathione-sepharose beads and proteins were co-precipitated. 1% cell lysate (input) 
and 10% bead eluate volumes (pull-down) were resolved by SDS-PAGE and analysed by 
immunoblotting with α-HA antibody. B. Quantification of the mean UMAD1 band intensities for three 
independent experimental repeats. Band intensities were measured using Image Studio Lite software, 
and normalised to those for VPS37C, which consistently showed the highest intensity. Error bars 
represent the standard deviation from the mean.  
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of endogenous VPS37 proteins (Figure 28). Results to this assay matched well with those 
shown in figure 27, showing co-precipitation of VPS37B and C but not A using YFP-
UMAD1. A preference for VPS37C over VPS37B was also observed much more clearly 
than in figure 27, with the level of VPS37C co-precipitated by YFP-UMAD1 matching that 
using YFP-TSG101. Since VPS37D was not identified in the mass spectrometry screen 
(Table 2) and is not expressed in HeLa cells, according to the Human Protein Atlas version 





















Altogether, these experiments confirm that UMAD1 binds ESCRT-I specifically when it 
contains VPS37B or VPS37C, with a particular preference for VPS37C.  
 
3.2.4. UMAD1 binds ESCRT-I through its UMA domain 
Given the role of the UMA domains of MVB12 proteins in ESCRT-I binding196,658,667,680,681, 
alignment of the UMA domains of MVB12A, MVB12B, UBAP1 and UMAD1, using Clustal 
Omega687,688, was used to identify evolutionarily conserved amino acid residues that 
might be necessary for binding to ESCRT-I (Figure 29A). Alignment revealed four 
Figure 28. Co-precipitation of endogenous 
VPS37B and VPS37C with a preference for 
VPS37C is seen using stably expressed YFP-
UMAD1 in HeLa cells. 
Lysates from HeLa cells that stably express 
YFP-UMAD1 or YFP-TSG101/YFP alone as 
positive/negative controls respectively, were 
purified by incubation with GFP trap beads. 
1% cell lysates (input) and 10% bead eluates 
(pull-down) were resolved by SDS-PAGE and 
immunoblotting using α-GFP and antibodies 
against each of the proteins shown was 
performed. 
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conserved point residues (M3-M6), including the UMA domain signature C-terminal 
glutamate residue (M6), and the conserved UMA domain signature VPF triplicate motif 
at the start of MVB12 protein UMA domains, which in UMAD1 spans residues 89-91 
(V89P90F91 (M2)). This same motif was found to abolish binding of UBAP1 to ESCRT-I when 
mutated, as did mutation of the three less well conserved residues prior to this658. We 
therefore decided to test this additional mutation in UMAD1 (L86S87D88/AAA (M1)) 
despite lack of conservation.  
The results for three independent repeats of GST co-precipitation results showed only 
mutation of the N-terminal UMA domain signature VPF motif (M2) to completely abolish 
binding to ESCRT-I (Figure 29B). Binding to ESCRT-I containing VPS37B and VPS37C 
appeared to be undisturbed in the case of all other mutants, including the non-
conserved M1 mutant. A trace of a band representing binding to VPS37D was sometimes 
seen, although as previously observed in figure 27, binding to VPS37D containing ESCRT-
I complexes is generally weak even for wild type UMAD1.  
Mutant M6, representing the C-terminal conserved UMA domain signature glutamate 
residue appears to show reduced binding to ESCRT-I, compared to all other mutants and 
wild type UMAD1. Interestingly, the same mutation has been shown to abolish binding 
in the case of UBAP1196,658 and most likely MVB12A, as separate fragments that 
encompassed either the VPF motif (EBB1) or this glutamate residue (EBB2) respectively 
were each able to bind ESCRT-I667.   
In conclusion, these GST co-precipitation experiments show that UMAD1 behaves as a 
novel alternative MVB12 type subunit of ESCRT-I that, like the other three MVB12 
subunits so far characterised, shows binding to ESCRT-I through its UMA domain. Its 
conserved UMA domain N-terminal signature VPF motif and C-terminal glutamate 
residue are necessary for incorporation of UMAD1 into ESCRT-I, as also previously 








































3.2.5. Generation of UMAD1 CRISPR/Cas9 knockout cells 
UMAD1 knockout cells were generated using CRISPR/Cas9 in preparation for loss-of-
function phenotypic studies, and further immunoprecipitation assays with removal of 
potential interference from endogenous UMAD1. Knockout cell lines were produced for 
HeLa and 293T cells, as outlined for HeLa cells in figure 30, by transfecting cells with 
LentiCRISPRv2GFP plasmids encoding appropriate guide RNA (crRNA), followed by FACS 
single cell sorting to obtain single GFP expressing clones. The location of cleavage sites 
together with the guide RNA (crRNA) annealing sites, to direct cleavage, are shown 
(Figure 30B).  
Figure 29. UMAD1 is incorporated into ESCRT-I complexes containing VPS37B, C or D through its 
UMA domain  
A. Clustal Omega protein sequence alignment of the UMA domains of MVB12A, MVB12B, UBAP1 and 
UMAD1 shows the location of conserved residues tested for ESCRT-I binding ability when mutated to 
alanine in UMAD1. M1 represents a triplicate motif which when mutated in UBAP1 displayed loss of 
binding to ESCRT-I, despite not being fully conserved (Agromayor et al. 2012) B. GST pull-down assay 
performed using transiently overexpressed, tagged ESCRT-I proteins in 293T cells to test ESCRT-I 
binding ability of UMAD1 UMA domain mutants. 293T cells were transfected with plasmids expressing 
GST-TSG101, Myc-Vps28, HA-VPS37A, B, C or D and HA tagged wild type UMAD1 or each of the 
UMAD1 mutants shown in A. 48 hrs post-transfection cell lysates were incubated with Glutathione-
Sepharose beads and proteins were co-precipitated. 1% cell lysate (input) and 10% bead eluate 
volumes (pull-down) were resolved by SDS-PAGE and analysed by immunoblotting with α-HA 
antibody.  
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Initial screening of clones for UMAD1 knockout was performed at the level of 
transcription, by extracting mRNA from clones followed by reverse transcription, to 
generate cDNA. A PCR using cDNA template was then performed to screen for the 
absence of a band corresponding to UMAD1 cDNA (Figure 30A). Two separate HeLa cell 
clones were obtained (clone 20 and clone 28).  
UMAD1 is located on human chromosome 7, and HeLa cells show an average copy no. 
of 3.87 for this chromosome, according to CanSAR689, whilst 293Ts show a copy no. of 
between 2 and 3, according to the American Type Culture Collection (ATCC). To ensure 
that complete removal of all copies of the gene had been successful, a diagnostic PCR 
using genomic DNA template was further performed to check for removal of the UMAD1 
locus (Figure 30C). Primer annealing sites to check not only for the absence but also the 
presence of any undesired remaining copies of the gene following transfection of the 
LentiCRISPRv2GFP plasmids are shown. This PCR revealed complete removal of all copies 
of UMAD1 in both HeLa clones (Figure 30D) and was further performed at regular 
intervals to ensure that the clones were still knockout and suitable for experiments. On 
a side note, although other clones that appeared negative for UMAD1 mRNA expression 
were identified by the above described RT-PCR, clones 20 and 28 were the only two 
clones that gave the desired genomic PCR result, i.e. no products using primer 
combinations 1+2 or 3+4 but a product using 1+4. In order to further check that the Cas9 
cleavage was specific to the sites specified by the guide RNAs, without off-target 
cleavage, the PCR products obtained using primers 1 and 4 were sequenced (Figure 30C). 
Results revealed specific cleavage at both cut sites. As later shown in section 3.2.6., 
further confirmation of abolishment of UMAD1 protein expression in these clones was 






















































Closer examination of the UMAD1 locus revealed overlap with that of RPA3, which is 
transcribed in the opposite direction on the complementary strand (Figure 30B). RPA3 
is a protein involved in DNA replication and DNA damage response and repair690–692. 
Generation of UMAD1 CRISPR knockout cells was found to have disrupted the sequence 
for part of this gene, specifically a large part of the 5’ UTR, but none of the actual protein 
coding sequence (Figure 30B). Critically, a side by side comparison of HeLa∆UMAD1 
clone 28 cell lysate with that of wild type HeLa cells resolved by SDS-PAGE and 
immunoblotted with antibody against RPA3, revealed no obvious disturbance of RPA3 
protein expression (Figure 31). As further controls to check the a-RPA3 antibody 
specificity to RPA3, and ensure that the bands observed corresponded to RPA3, lysate 
from 293T cells stably expressing YFP-RPA3 or untagged RPA3 were resolved and blotted 
with the antibody. As expected, bands of the expected size corresponding to YFP-RPA3 
and endogenous RPA3 were seen using lysate from the 293T YFP-RPA3 cells. A band of 
slightly higher intensity than in the previous lanes representing combined exogenous 
untagged RPA3 and endogenously expressed RPA3 was observed using lysate from the 






Figure 30. Generation of UMAD1 CRISPR/Cas9 knockout HeLa cells. 
A. PCR to detect amplified UMAD1 cDNA sequence from cDNA template generated by reverse 
transcription from mRNA extracted from individual HeLa cell CRISPR clones. Clones were obtained by 
FACS single cell sorting of GFP expressing cells following transfection of two lentiCRISPRv2GFP 
plasmids encoding start and end guide crRNA to direct Cas9 endonuclease cleavage and removal of 
the UMAD1 locus. Clones 1-10 were positive for UMAD1 mRNA expression and therefore not shown. 
B. Schematic representation of the UMAD1 gene locus and its overlap with RPA3. Sites of CRISPR 
guide annealing and cleavage are shown. C. Diagnostic PCR strategy to check for complete removal of 
all copies of UMAD1. Sites of PCR primer annealing and expected PCR product sizes obtained following 
successful/unsuccessful removal of the gene are shown. In the case of unsuccessful removal of one 
or more copies of UMAD1, primer combinations 1+2 and 3+4 generate the products of sizes shown, 
whilst PCR using primers 1+4 fails due to inability to amplify such a large region. In the case of 
successful removal of UMAD1, annealing sites for primers 2 and 3 are removed, so no PCR product is 
observed using primers 1+2 and 3+4, but primers 1+4 now generate a product of 163 bp.  D. Agarose 
gel electrophoresis to show PCR products generated using genomic DNA template extracted from 
clones 20 and 28 using the primer combinations shown in C.  
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Having already checked at the level of mRNA transcription for absence of all copies of 
the UMAD1 locus, we next decided to confirm UMAD1 knockout at the level of protein 
expression. A rabbit polyclonal antibody against UMAD1 was custom-made and 
purified for us by Lampire Biologicals with the aim of being able to detect endogenous 
UMAD1.  
Immunoblotting of both HeLa and 293T cell lysates using this antibody did not detect a 
band corresponding to the size of UMAD1 (15.2 kDa) (Figure 32). However, when cells 
were transfected with pCR3.1 HA-UMAD1 to transiently overexpress HA-UMAD1, a 
clear band was observed, indicating that the antibody is functional, but unable to 
detect endogenous levels of UMAD1 expression. We could therefore not use the 
antibody for confirming UMAD1 protein knockout. Further affinity purification of the 
rabbit serum was performed by Lampire Biologicals in an attempt to concentrate and 
improve efficiency of the antibody, however the purified antibody was still unable to 
detect endogenous UMAD1. 
Whilst inability of the antibody to recognise endogenous levels of UMAD1 could simply 
be due to low antibody sensitivity, it could also be due to possible low levels of 
endogenous UMAD1 expression. This could perhaps be another reason for its lower 
enrichment compared to other ESCRT-I proteins in the previous IP-TMT based mass 
spectrometry experiment (Table 2).   
 
 
Figure 31. Confirmation of undisrupted RPA3 
protein expression in HeLa∆UMAD1 clone28 
Lysates from wild type HeLa cells, HeLa∆UMAD1 
clone28 and 293T cells that stably express YFP-
RPA3 or untagged RPA3 were resolved by SDS-
PAGE and subjected to immunoblotting using α-
RPA3 and α-HSP90.  
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3.2.6. Endogenous UMAD1 is co-precipitated using ESCRT-I subunits 
To confirm that UMAD1 is a genuinely expressed protein and confirm its incorporation 
into ESCRT-I, we decided to proceed with a GFP-trap co-precipitation of endogenous 
UMAD1 using lysate from HeLa cells that stably express YFP-TSG101 to co-precipitate, 
thus enriching endogenous UMAD1 (Figure 33). As a negative control, we made HeLa 
UMAD1 knockout cells stably expressing YFP-TSG101, which should not precipitate 
UMAD1. 
Immunoblotting using the rabbit α-UMAD1 antibody showed a clear intense band 
representing co-precipitated endogenous UMAD1 from wild type HeLa cells stably 
expressing YFP-TSG101 (Figure 33). No trace of a band the same size was observed using 
either of the two HeLa UMAD1 knockout cell lines.  
This experiment represents an important finding, demonstrating that UMAD1 is a 
genuinely expressed protein, and that it is incorporated into ESCRT-I. It also removed 
any remaining doubt surrounding the integrity of the knockout cells, proving that no 
endogenous UMAD1 protein is expressed. Although for completeness, the sensitivity of 
a quantitative RT-PCR would further ensure no residual mRNA, hence protein expression, 
the above result shows that UMAD1 expression is abolished or at least reduced to an 






Figure 32. Rabbit polyclonal α-UMAD1 
antibody recognises overexpressed 
UMAD1 
Immunoblotting of lysates from both 293T 
and HeLa cells was performed side by side 
with lysates harvested 48 hours post-
transfection with pCR3.1 HA-UMAD1, to 
overexpress HA-UMAD1. Blotting was 
performed using a custom-made rabbit 
polyclonal α-UMAD1 antibody from 
Lampire Biologicals. 
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Having obtained an α-UMAD1 antibody, a further GFP-trap immunoprecipitation 
experiment was performed to examine the co-precipitation assays in figures 27 and 28 
in reverse, i.e. co-precipitation of endogenous UMAD1 by YFP-VPS37 baits (Figure 34).  
In this experiment, lysates from wild type HeLa cells stably expressing YFP-tagged 
VPS37A, VPS37B, VPS37C, TSG101 or YFP alone, were subjected to GFP-trap 
immunoprecipitation, and immunoblotting using antibodies against each of the proteins 
indicated in figure 34. 
Results from previous co-precipitation assays (Figure 27 and 28) to examine UMAD1 
subunit pairing specificity and preference were very nicely recapitulated here. For 
seemingly equal levels of YFP-VPS37B and YFP-VPS37C immunoprecipitation, a band of 
much higher intensity for endogenous UMAD1 co-precipitated by YFP-VPS37C was 
observed, compared to YFP-VPS37B, for which only trace levels were seen. This result 
also clearly demonstrates genuine preferred pairing for VPS37C over VPS37B, rather 
than tissue specific differences in expression levels of VPS37B and VPS37C. No trace of 
a band was seen using YFP-VPS37A. The intense bands seen when blotting with a-
UMAD1 using input samples are the same non-specific bands seen above and below the 
Figure 33.  Endogenous UMAD1 is co-precipitated using YFP-TSG101 
Cell lysates from wild type HeLa cells or Clone20/Clone28 CRISPR/Cas9 knockout clones stably 
expressing YFP-TSG101 bait were incubated with GFP-trap beads to immunoprecipitate YFP-TSG101 
and associated proteins. 1% cell lysates (input) and 10% beads eluates (pull-down) were resolved by 
SDS-PAGE, and immunoblotting using α-GFP and α-UMAD1 was performed. 
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expected size of UMAD1 for input samples in figure 33. They simply appear more intense 
here since this blot was performed following the previously mentioned additional 
affinity purification of the antibody by Lampire Biologicals in an attempt to increase its 
efficiency and potential ability to recognise endogenous UMAD1. UBAP1 was only co-
precipitated by YFP-TSG101 and YFP-VPS37A, as expected. This result confirms and 
strengthens the finding that UMAD1 pairs preferentially with VPS37C. It eliminates any 
doubt previously caused by differences in α-VPS37B and α-VPS37C antibody sensitivity, 
when using these antibodies to detect their respective proteins co-precipitated by YFP-
UMAD1 (Figure 28). 
The intrinsic TSG101 steadiness box mechanism to control protein levels669,672, can be 
clearly seen for blotting using α-TSG101: in the case of the input sample for YFP-TSG101 
expressing cells, YFP-TSG101 expression without any endogenous expression is seen. In 
other words, the overexpression of YFP-TSG101 causes ESCRT-I uncomplexed 
endogenous TSG101 to be degraded, thus maintaining a constant level of cellular 
TSG101, hence ESCRT-I expression. 
A similar striking observation can be made when examining levels of endogenous 
VPS37A, B and C proteins in the starting cell lysates (Figure 34. Lanes 2,3 and 4 from the 
left). It appears that expression of the YFP tagged form of each of these proteins causes 
a decrease not only in the level of the corresponding endogenous protein, but also in 
the levels of the other VPS37 paralogues. This suggests that a steadiness box type of 
mechanism similar to that seen for TSG101 is operating to maintain a constant total 
cellular level of VPS37 proteins. Given what is known about the steadiness box of 
TSG101, this is most likely to ensure that any ESCRT-I uncomplexed VPS37 proteins are 
rapidly degraded. Whilst it could be argued that the decrease in endogenous levels of 
VPS37 proteins in this experiment could simply be due to less protein in the starting cell 
lysates, this is highly unlikely given that levels of TSG101 in these input samples are not 
less than that seen for YFP alone. Since TSG101 levels are finely controlled by its 





















































Figure 34. Pairing preference of UMAD1 for VPS37C is confirmed in physiological conditions 
Lysates from HeLa cells stably expressing YFP tagged TSG101, VPS37A, VPS37B, VPS37C and YFP alone 
were purified by incubation with GFP trap beads. 1% cell lysates (input) and 10% bead eluates (pull-
down) were resolved by SDS-PAGE and immunoblotting using α-GFP and antibodies against each of 
the ESCRT proteins shown was performed.  
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3.2.7. Compositional changes in ESCRT-I subunit stoichiometry 
Results so far show preferential pairing with VPS37B and VPS37C, with a clear 
preference for VPS37C, by ESCRT-I complexes containing UMAD1. In order to 
characterise this further and potentially identify other differences in ESCRT-I 
stoichiometry and binding partners upon UMAD1 knockout, a further IP-TMT based 
mass spectrometry experiment was performed. GFP-trap immunoprecipitations using 
lysates from both HeLa and HeLa∆UMAD1 cells that stably express YFP-TSG101, 
together with cells expressing YFP alone as negative controls were performed. As for 
previous experiments, eluates were then digested with trypsin and prepared for mass 
spectrometry screening, labelling tryptic peptides from each eluate sample with a 
different TMT tag.  
To determine binding partners specific to TSG101 in both cell backgrounds, a criterion 
based on the TMT tag reporter ion ratio for YFP-TSG101 to the YFP negative control was 
introduced. This time, a protein was defined as a specific binding partner if the ratio was 
≥3 in either or both HeLa and HeLa∆UMAD1 backgrounds (Appendix 1). ESCRT-I proteins 
again showed the highest enrichment (Table 3) and all known ESCRT-I subunits, 
including UMAD1, except VPS37D and MVB12B were identified. Despite again being 
identified with only 1 peptide, UMAD1 was still identified as a binding partner using the 
3-fold cut off value with a value at zero for the HeLa∆UMAD1 YFP-TSG101 repeat. 
Following total normalisation of signal values across samples, signal values for the 
identified ESCRT protein binding partners in both HeLa and HeLa∆UMAD1 backgrounds 
were each divided by the mean values obtained for the corresponding YFP negative 
controls (Table 3). These values were further normalised to the levels of TSG101 protein 
in both backgrounds to facilitate examination of differences in subunit enrichment in 
the wild type vs UMAD1 knockout background (Figure 35). Results showed very clearly 
that UMAD1 is behaving as a novel alternative MVB12 subunit that competes with 
MVB12A and UBAP1 for binding to ESCRT-I, as shown by the obvious increase in signal 
for UBAP1 and MVB12A in the HeLa∆UMAD1 background compared to the HeLa 
background. Whilst signal for VPS37B remained relatively constant in both backgrounds, 
there was a slight decrease seen for VPS37C in the UMAD1 knockout background, 
consistent with the pairing preference of UMAD1 for VPS37C: presumably if UMAD1 is 
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knocked out, slightly less VPS37C binds ESCRT-I. VPS37A signal shows an increase in the 
UMAD1 knockout background because of increased binding of UBAP1, with which it 
specifically pairs. CEP55 shows a decrease in the HeLa∆UMAD1 background, potentially 
implicating UMAD1 in cytokinetic abscission. CEP55 is also actually listed as a potential 
interaction partner for UMAD1 on BioGRID3.5, from data obtained from a next 
generation interaction survey performed by Hein et al., 2015693. Surprisingly, VPS28 also 
shows an obvious decrease in the HeLa∆UMAD1 background. This is a surprising result 
given that incorporation of VPS28  into ESCRT-I has so far been described to be mediated 



















































3.2.8. Further characterisation of affinity purified UMAD1 interaction 
partners 
A further IP-TMT based mass spectrometry screen was performed with the aim of 
identifying further interaction partners for UMAD1 and confirming its interaction with 
ESCRT-I and pairing specificity with VPS37B and VPS37C. HeLa∆UMAD1 and 
293T∆UMAD1 cells that stably re-express UMAD1 as YFP-UMAD1 were made in 
preparation for initial GFP-trap immunoprecipitations using YFP-UMAD1 as bait. Use of 
such cells ensures that only YFP-UMAD1 bait protein is expressed, with no interference 
from endogenous UMAD1. Two repeats of immunoprecipitations using lysates from 
both HeLa∆UMAD1 YFP-UMAD1 and 293T∆UMAD1 YFP-UMAD1 cells were performed, 
and eluates from each repeat, together with those from appropriate HeLa∆UMAD1 YFP 
and 293T∆UMAD1 YFP negative controls, were labelled using a different TMT tag.  
To determine binding partners specific to UMAD1, a criterion based on the TMT tag 
reporter ion ratio for YFP-UMAD1 to YFP control was introduced. Following processing 
of the raw mass spectrometry data, including optimisation of the cut-off value relative 
to the YFP control, a protein was defined as a specific binding partner in this experiment 
if the ratio is ≥2 for both replicates using both HeLa and 293T cell lines. Using this cut-
off, 24 proteins, including the UMAD1 bait, remained (Table 4). Results matched 
extremely well with previous findings regarding subunit pairing, showing identification 
of VPS37B and VPS37C but not VPS37A. As expected MVB12A and UBAP1 were not 
Table 3.  Mass spectrometry determination of differences in ESCRT-I subunit enrichment when co-
precipitated by YFP-TSG101 in HeLa and HeLa∆UMAD1 backgrounds 
GFP trap immunoprecipitations using YFP-TSG101, in both a Hela and HeLa∆UMAD1 background, and 
together with appropriate YFP negative controls were performed. Eluates were analysed by multiplex 
IP-TMT based mass spectrometry following digestion with trypsin and isobaric TMT tag labelling. 
Following total normalisation of signal values across all 10 samples to eliminate variation in signal at 
the level of sample preparation and data acquisition, signal values for YFP-TSG101/YFP control were 
calculated for both HeLa and HeLa∆UMAD1 backgrounds. 
 
Figure 35. Enrichment of ESCRT-I subunits is consistent with the identity of UMAD1 as a novel 
alternative MVB12 type subunit that pairs with VPS37B and VPS37C 
A.  Side by side comparison of fold enrichment of ESCRT-I proteins and CEP55 identified by multiplex 
IP-TMT based mass spectrometry using YFP-TSG101 as the bait protein in both a wild type HeLa and 
UMAD1 knockout background. Fold enrichment is calculated using the signal values presented in table 
3 normalised to TSG101, given that this is the core ESCRT-I subunit present in all ESCRT-I complexes.  
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identified, as they are outcompeted by UMAD1.  TSG101, VPS28 and CEP55 were also 
identified. These expected binding partners showed the highest number of peptide 
spectrum matches (PSM) with good protein coverage and signal compared to controls. 
Once again, VPS37D was not identified at all in the screen, further confirming that this 
paralogue is either not expressed in HeLa and 293T cells or expressed at negligible levels. 
Aside from the expected ESCRT proteins, 8 of the 24 proteins were mitochondrial 
membrane carrier or transport proteins, involved in the transport of a variety of proteins, 
peptides, amino acids, small molecules and other metabolic intermediates across the 
inner or outer mitochondrial membrane (Table 4). The five mitochondrial carrier 
proteins (SLC25A6, SLC25A13, SLC25A3, SLC25A12 and SLC25A1) all belong to the same 
family of solute carriers, that typically catalyse the exchange of one molecule for 
another across the inner mitochondrial membrane and share a similar set of three 
tandem repeats of a SOLCAR domain, each consisting of approximately 100 residues 
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3.2.9. UMAD1 promotes interaction of ESCRT-I with CEP55 
Hierarchical clustering of the 24 proteins identified in the previous section according to 
protein enrichment and reproducibility across cell types and repeats, revealed all ESCRT-
I subunits and CEP55 to form a distinct cluster together, consistent with formation of a 
complex (Figure 36). Reproducibility across the two HeLa∆UMAD1 cell line repeats was 
better than across the two 293T∆UMAD1 cell line repeats. More detailed examination 
of this cluster shows further clustering together of VPS37B and C, with VPS37C above 
VPS37B, suggesting a higher enrichment of VPS37C, as would be consistent with the 
previously observed pairing preference (Figures 27A, 27B, 28 and 34). CEP55 and 
































Following up on the observed decrease in co-precipitation of CEP55 by TSG101 in the 
HeLa∆UMAD1 background, observed by mass spectrometry (Table 3, Figure 35), we 
decided to repeat this co-precipitation and examine this reduced interaction by 
immunoblotting with α-CEP55 (Figure 37A). Four repeats of a side by side comparison 
of CEP55 co-precipitation by stably expressed YFP-TSG101 in HeLa and HeLa∆UMAD1 
cells revealed an obvious decrease in the amount of CEP55 co-precipitated in the 
HeLa∆UMAD1 background compared to the HeLa background, for equal amounts of 
YFP-TSG101 immunoprecipitation. This matched perfectly with results from table 3 and 
figure 35.  
A further co-precipitation assay using YFP-UMAD1 as the bait protein, stably re-
expressed in HeLa∆UMAD1 cells, showed clear co-precipitation of CEP55 (Figure 37B 
bottom panel). Presumably this interaction occurs via TSG101, which binds directly to 
CEP5517,442. However, a direct interaction between CEP55 and UMAD1 cannot be ruled 
out either, and future work would involve testing this. These results strongly suggest a 
role for UMAD1 in ESCRT mediated cytokinetic abscission, potentially by forming a 













Figure 36. Hierarchical clustering analysis of 24 identified potential UMAD1 interaction partners by 
IP-TMT based mass spectrometry 
Hierarchical clustering was applied to the 24 potential UMAD1 interaction partners identified by IP-
TMT based mass spectrometry, ordering proteins according to enrichment and reproducibility across 
the two cell lines and repeats. ESCRT-I subunits and CEP55 form a distinct cluster, consistent with 
formation of a complex. Finer details of clustering within this group are also consistent with the CEP55-
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In this chapter, I have presented strong evidence in the form of co-precipitation assays, 
mass spectrometry and a viral trans-complementation assay that UMAD1 is a genuinely 
expressed novel alternative MVB12 type subunit of ESCRT-I, that forms a functional 
ESCRT-I complex. UMAD1 pairs specifically with VPS37B and C with a preference for 
VPS37C, and its absence leads to reduced binding of TSG101 to CEP55. A picture for 
mammalian ESCRT-I subunit composition is starting to emerge, involving a combination 
of both stochastic and selective subunit pairing. Whilst there is strong evidence for 
selective preferred pairing of VPS37A with UBAP1196,681, the preference of UMAD1 for 
pairing with VPS37C represents the second example of selective MVB12-VPS37 pairing, 
although binding to VPS37B is also observed. Although preferential pairing with VPS37C 
is clear from the experiments presented in this chapter, the ability of UMAD1 to also 
pair with VPS37B to a certain extent could exist to ensure that UMAD1 containing ESCRT-
I complexes are still formed in tissues expressing low levels of VPS37C. Fine tuning of 
Figure 37. TSG101 shows reduced binding to CEP55 in a HeLa∆UMAD1 background. 
A. An immunoprecipitation assay was performed as in A, using lysates from HeLa∆UMAD1 cells that 
stably re-express YFP-UMAD1 or HeLa cells that express YFP-TSG101/YFP as positive/negative controls 
respectively. Immunoblotting using α-GFP and antibodies against each of the proteins shown was 
performed. B. Lysates from HeLa or HeLa∆UMAD1 cells that stably express YFP-TSG101, or YFP alone 
were purified by incubation with GFP trap beads. 1% cell lysates (input) and 10% bead eluates (pull-
down) were resolved by SDS-PAGE and immunoblotting using α-GFP and antibodies against each of 
the proteins shown was performed.  
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VPS37B:VPS37C expression level ratios could also possibly act to determine the level of 
UMAD1 containing ESCRT-I formation in different cell types to accommodate specific 
functions. 
Whilst VPS37A has been shown to preferentially pair with UBAP1 to form a specific 
ESCRT-I complex that is highly adapted for lysosomal sorting of ubiquitinated cargo, 
preferred pairing of the other VPS37 subunits with other MVB12-like subunits has not 
been seen until now. By analogy to ESCRT-I complexes that contain VPS37A with UBAP1, 
it is tempting to speculate that complexes containing UMAD1 with VPS37C could be 
involved in another specific ESCRT mediated process. Since UMAD1 also binds to VPS37B, 
however, like MVB12A and MVB12B667,681, some redundancy in regard to function 
between UMAD1, MVB12A and MVB12B may exist, so future functional studies should 
involve examining the effects of co-depletion of pairs or all three MVB12A, MVB12B and 
UMAD1 subunits in addition to depletion of each individually. The UMAD1 CRISPR/Cas9 
knockout cells generated in this chapter will be an invaluable tool for this, given that 
total abolishment of UMAD1 expression has extremely likely been achieved, thus 
removing the possibility of effects maintained by any residual UMAD1 expression that 
may be been using RNAi depletion. It should be remembered, however, that cells often 
adapt, displaying compensatory effects, when expression of a particular protein is 
knocked out. The UMAD1 knockout cells generated in this chapter were regularly 
checked for absence of the UMAD1 locus by PCR, and absence of protein expression by 
lack of co-precipitation using YFP-TSG101. However, as presented in the following 
chapter, a possible compensatory effect manifested by increased ALIX expression in the 
UMAD1 knockout cells is observed (sections 4.2.3. and 4.2.4.). Future work should also 
involve generation of MVB12A and MVB12B CRISPR knockout cells, to be similarly tested 
side by side in functional studies if these cells are viable. Co-precipitation assays such as 
that presented in Figure 37A could also be performed using lysates from such knockout 
cells to investigate whether depletion of MVB12A and MVB12B also reduce binding of 
TSG101 to CEP55, or whether this is UMAD1 specific. 
I have shown that UMAD1 binds ESCRT-I via a V89P90F91 motif at the start of its UMA 
domain which is conserved with all other MVB12 proteins (Figure 29). This motif appears 
to be both necessary and sufficient for binding using overexpressed tagged ESCRT-I 
subunits. Although residues outside this VPF motif have been found to be important for 
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ESCRT-I binding in other MVB12-like proteins196,658,667, mutations at the equivalent 
positions in UMAD1 (P108A and E130A, which is the UMA domain conserved C-terminal 
signature glutamate residue) did not disrupt binding of UMAD1 to ESCRT-I. It is possible 
that these residues are important for binding but are “accessory/secondary” binding 
sites and our experimental approach using overexpressed proteins masks the 
importance of interactions that are not as strong as that mediated by V89P90F91, but still 
contribute to incorporation of UMAD1 into ESCRT-I. This is further suggested by the 
observation that the E130A mutant shows reduced binding to ESCRT-I, using this system. 
Further work should therefore involve testing the ability of these mutants to co-
precipitate endogenous ESCRT-I, in co-precipitation assays such as those shown in figure 
28 and 37B: immunoprecipitations using lysates from cells that stably express these YFP 
tagged mutants should be performed followed by blotting to detect endogenous ESCRT-
I subunits. If P108A and E130A are found in these assays to be important for the 
incorporation of UMAD1 into ESCRT-I, it is likely that loss of binding mediated by these 
residues was previously masked by overexpression of the other ESCRT-I subunits. 
Alternatively, if these residues are genuinely found to be less crucial for incorporation 
of UMAD1 into ESCRT-I,  it is likely that due to UMA domain structural differences in 
each of the MVB12-like subunits, these residues are more crucial for optimal interaction 
with ESCRT-I in the case of MVB12A, MVB12B and UBAP1. Perhaps binding via the VPF 
motif is enhanced in these subunits by additional VPS37B/VPS37C Mod(r) – TSG101 
dimer contacts mediated by these residues.  
Co-precipitation assays have shown that TSG101 appears to bind less well to CEP55 in 
the absence of UMAD1, and this has been reinforced by mass spectrometry experiments. 
The mechanism by which UMAD1 strengthens interaction of TSG101 with CEP55 
remains to be elucidated. Two possibilities are that it either directly contributes to the 
interaction by providing a binding surface together with TSG101, or that it simply 
stabilises a cytokinesis specific ESCRT-I complex or promotes structural changes in 
TSG101 that favour its direct interaction with CEP55. Although a complete mammalian 
ESCRT-I structure is yet to be solved, structural information would also help clarify the 
relationship between UMAD1 with CEP55, and the reason for the pairing preference 
with VPS37C over VPS37B. Along these lines, another unanswered question is what the 
N-terminal ~85 residues of UMAD1, upstream of the UMA domain is for. Structural 
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information would help show whether this region, predicted to be largely unstructured, 
becomes more structured or stabilises interactions such as those with CEP55 or 
VPS37B/VPS37C-TSG101 dimers upon binding ESCRT-I. In the absence of a structure, 
further co-precipitation assays could also be performed to investigate this issue by side 
by side testing the ability of full-length UMAD1 and the UMA domain alone to co-
precipitate CEP55 and each of the VPS37 proteins. Since a helical region downstream of 
the UMA domain in UBAP1 has been shown to confer specificity of binding to VPS37A, 
specifically by preventing binding of VPS37B and C681, it follows that UMAD1, and 
MVB12A and B, most probably possess regions that prevent pairing with VPS37A. It is 
also worth noting that helical regions are predicted to exist either side of the V89P90F91 
motif in UMAD1, which are not predicted to occur in any of the other MVB12 proteins 
and are instead replaced by a short beta strand overlapping and extending just 
downstream of the VPF motif. It is therefore possible that such helical regions in UMAD1 
could be involved in conferring specific interaction preferences or functions, and 
fragments encompassing these regions should be tested in co-precipitation assays. 
My results suggest that the endogenous levels of VPS37 proteins are tightly regulated in 
cells. The mechanism similar to that of the steadiness box in TSG101, that appears to be 
controlling the total levels of VPS37 proteins further reinforces what is known about the 
inter-dependability of ESCRT-I subunits for stability666, and further adds to the notion 
that subunits show precise levels of control at a post-translational level669,672,694. It is 
likely that specific ubiquitin ligases exist to ubiquitinate and target uncomplexed VPS37 
proteins for degradation. By analogy to TSG101, perhaps sites of ubiquitination are 
located within the Mod(r) domains of VPS37 proteins which are occluded when this 
region binds to the rest of ESCRT-I. To investigate whether targeted proteosomal 
degradation by ubiquitination is regulating VPS37 levels, side by side transfections of 
cells with YFP-tagged VPS37 proteins with and without treatment with a proteasome 
inhibitor could be performed. If ubiquitination is necessary for steady state regulation, 
cells treated with the proteasome inhibitor would be expected not to lose expression of 
endogenous VPS37s upon transfection of increasing amounts of the YFP-tagged proteins. 
The striking difference in enrichment of ESCRT-I proteins compared to other potential 
interaction partners identified in the mass spectrometry screens in this chapter suggests 
that genuine ESCRT-I binding partners other than its own subunits bind with a much 
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lower affinity or transiently. Perhaps a co-precipitation assay more suited to 
identification of weak interaction partners, such as BioID695 would facilitate 
identification of weaker interaction partners such as potential ubiquitin ligases 
necessary for controlling the levels of VPS37 proteins. 
Our mass spectrometry studies of affinity purified UMAD1 containing complexes have 
revealed a number of mitochondrial proteins identified as potential UMAD1 binding 
partners. We can speculate from this that perhaps UMAD1 could be involved in 
mitochondrial clearance. Damaged mitochondria must be promptly degraded to 
prevent their cytotoxicity leading to cell death. A number of pathways for mitochondrial 
clearance have been elucidated, most notably autophagy (mitophagy) regulated by 
Parkin – a ubiquitin ligase that marks damaged mitochondria for degradation. More 
recently, a Parkin mediated autophagy independent pathway for mitochondrial 
clearance has been described, in which damaged mitochondria are sequestered into 
Rab5 positive vesicles by the ESCRT machinery and later delivered to lysosomes for 
degradation696,697. Whether UMAD1 contributes to this pathway can be tested by 
comparing cell death in HeLa and HeLaDUMAD1 cells following treatment with 
trifluoromethoxy carbonyl cyanide phenylhydrazone (FCCP) to depolarise mitochondria 
and stimulate their clearance. An increase in cell death due to accumulation of damaged 
mitochondria in HeLaDUMAD1 cells would suggest a role for UMAD1 in clearance. 
HeLaDUMAD1 cells would be expected to display a slower rate of mitochondrial 
clearance, hence mitochondrial proteins, over time following FCCP treatment. This could 
















Chapter 4 – UMAD1 in cytokinesis 
4.1. Introduction 
CEP55 represents the site-specific adaptor protein that recruits the ESCRT machinery to 
the midbody upon mitotic exit to function in cytokinetic abscission. This is mediated a 
direct interaction with either TSG101 or ALIX at the ‘hinge’ region of CEP5517,442,451. 
Initial testing of cytokinetic defects upon depletion of TSG101 or ALIX, by scoring of 
multinucleation showed the increase in multinucleation to be much greater upon 
depletion of ALIX than TSG101. Multinucleation levels could show as much as a >30-fold 
increase in the case of ALIX depletion, compared to around a 5-fold increase in the case 
of TSG101 depletion17,442. Furthermore, depletion of ESCRT-II appeared to show only 
very minor increases in cytokinetic defects17,55,167,252. Details of the exact pathways 
contributing to the recruitment of ESCRT-III were therefore further probed in a study by 
Christ et al 2016, through a series of more specific microscopy experiments to examine 
both CHMP4B recruitment to the midbody, and the time taken for abscission to occur 
upon knockdown of various ESCRT components93.  
The appearance of CHMP4B at the midbody was unperturbed upon single depletion of 
either TSG101 or ALIX but disappeared upon depletion of TSG101 in a CHMP4B∆ALIX 
binding site background. Although localisation of CHMP4B to the midbody was 
unperturbed, further probing showed that depletion of ALIX or TSG101 displayed a delay 
in CHMP4B recruitment to the midbody, both by around 35 minutes. These initial 
experiments suggested overlapping roles for TSG101 and ALIX in CHMP4B recruitment. 
Experiments to examine effects on successful abscission timing revealed a delay in the 
time taken for midbody resolution upon TSG101 depletion, from approximately 74 
minutes in wild type cells to 98 minutes upon TSG101 depletion, an even greater 
increase in the case of ALIX depletion to around 177 minutes. A synergistic increase upon 
depletion of both TSG101 and ALIX to around 338 minutes was observed. This suggested 
that TSG101 and ALIX constitute parts of two parallel pathways leading to abscission. 
Effects on abscission time were correlated with CHMP4B recruitment by the observation 
that TSG101 depletion in a CHMP4B∆ALIX binding site background showed a much more 
pronounced increase in abscission time than in a wild type CHMP4B background. 
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Importantly, the effects of ESCRT-II depletion were re-visited in this study93. It was found 
that whilst wild type siRNA resistant VPS28 was able to rescue a slight delay in abscission 
seen upon depletion of endogenous VPS28, a rescue was not seen upon expression of 
truncated VPS28 that lacked the C-terminus, responsible for binding EAP45 (ESCRT-II) 
and CHMP6, or a mutant in which just the residues responsible for CHMP6 binding were 
mutated. CHMP6 localisation to the midbody was also not observed in the context of 
these mutant VPS28 constructs, and CHMP4B midbody recruitment was reduced upon 
co-depletion of ALIX and EAP30 (ESCRT-II). This was rescued upon re-expression of siRNA 
resistant EAP30. In another study by Goliand et al 2014, EAP45 was suggested to assume 
a position in between the Flemming body and secondary ingression during late 
cytokinesis, without ever reaching the secondary ingression like ESCRT-III698. This is 
consistent with a role for ESCRT-II in bridging ESCRT-I with ESCRT-III. Taken together, 
these studies point towards potential contribution of ESCRT-II in ESCRT-III recruitment 
for cytokinetic abscission, and suggest a model for ESCRT-III recruitment involving two 
partially redundant pathways that both contribute to ESCRT-III recruitment: A CEP55 – 
TSG101 (ESCRT-I) – ESCRT-II – CHMP6 – ESCRT-III branch and a CEP55 – ALIX – ESCRT-III 
branch (Figure 38). The above study by Christ et al 2016 also suggests interaction 
between VPS28 (ESCRT-I) and CHMP6 to contribute to abscission via a CEP55 – ESCRT-I 










































Aside differences in binding partners described for TSG101 and ALIX that play roles in 
more upstream processes in cytokinesis (Section 1.5.6.), another reason for lack of 
complete redundancy between these proteins in abscission could be related to the 
interaction between them (Sections 3.1.1. and 1.3.5.2.). An earlier study by Carlton et 
al. 2008 of the roles for TSG101 and ALIX in cytokinesis suggested that the interaction 
between TSG101 and ALIX did somewhat contribute to cytokinesis55. This was 
Figure 38. Proposed parallel arms of recruitment for ESCRT-III in cytokinetic abscission 
ESCRT-III recruitment has been proposed by Christ et al 2016 to occur via two partially redundant  parallel 
arms of recruitment involving a direct interaction between ALIX with CEP55 and CHMP4 proteins (ESCRT-
III), or an interaction between CEP55 with TSG101, hence ESCRT-I, which then recruits ESCRT-II and 
CHMP6, which is able to nucleate ESCRT-III filament polymerisation. As part of the latter branch of 
recruitment, experiments using a re-expressed VPS28 mutant in which residues that disrupt CHMP6 
binding were mutated (F206A D207S E209A), showed failure to rescue an observed delay in abscission 
seen upon endogenous VPS28 depletion.  This mutant also displayed impairment of CHMP6 to the 
midbody. These results suggest the direct interaction between VPS28 and CHMP6 contributes to ESCRT-
III recruitment and abscission. In addition to this model, work by Carlton et al. 2008 suggested that 
interaction between TSG101 and ALIX contributed to cytokinesis, as shown by the failure to rescue 
cytokinetic defects caused by endogenous ALIX depletion upon re-expression of ALIX with its TSG101 
binding sites (717PSAP720 and 852PSYP855) mutated. Direct effects on abscission, however, have not been 
investigated here.  
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demonstrated by the incomplete ability of an ALIX construct in which its TSG101 binding 
717PSAP720 and 852PSYP855 motifs were mutated to rescue cytokinetic defects seen upon 
endogenous ALIX depletion. In this way, TSG101 has additionally been proposed to play 
a role in the stabilisation of ALIX during cytokinesis. Along the same lines, another study 
by Okumura et al. 2013 showed the calcium binding protein ALG-2 to mediate a 
potential bridging interaction between TSG101 and ALIX674. ALG-2 is a homodimer, each 
monomer of which contains hydrophobic pockets capable of interacting with the PRR 
regions of TSG101 or ALIX in a calcium dependent manner, thus bridging these 
proteins674–676. Interestingly, this study also showed that VPS37B and VPS37C PRRs also 
interacted with ALG-2, more strongly than TSG101, and that even in the presence of the 
calcium chelating agent EGTA, some interaction with VPS37B and VPS37C was still 
seen674. As further discussed later in ‘General discussion and future work’, a potential 
parallel can be seen here with UMAD1, which specifically pairs with VPS37B and VPS37C 




4.2.1. HeLa∆UMAD1 cells show a growth defect and increase in 
multinucleation  
Experience passaging HeLa∆UMAD1 cells revealed noticeably slower growth compared 
to wild type, parental HeLa cells. We decided to compare the rate of cell growth of 
HeLa∆UMAD1 cells with that of wild type HeLa cells. To investigate this, a clonogenic 
assay was performed, in which an equal number of both HeLa and HeLa∆UMAD1 cells 
were plated and left to grow for 10 days, following which staining with crystal violet was 
performed and the area occupied by colonies on the base of wells was measured (Figure 
39A). This assay allows quantification of cell growth based on the principle that single 
cells grow to form colonies, the size of which, after 10 days, will depend on their growth 
rate. HeLa∆UMAD1 cells displayed close to 4-fold less growth than wild type HeLa cells. 
Following the observation of reduced binding of CEP55 to TSG101 in the UMAD1 
knockout background (Figure 37A) we hypothesised that, although unlikely to be the 
major contributor to defective cell growth of this scale, such defects could also, at least 
in part, be due to problems with cell division: CEP55 is the upstream adaptor required 
for recruitment of the ESCRT machinery to the midbody to function in abscission. In 
order to initially examine a more direct effect of UMAD1 on cytokinesis, HeLa cells and 
HeLa∆UMAD1 cells were plated and fixed on coverslips. Following staining with Hoechst, 
to visualise nuclei, and α-tubulin antibody, to visualise the cytoskeleton, cytokinetic 
defects were measured by scoring the number of cells with more than one nucleus and 
the number of midbody connected cells. Multinucleated cells form upon furrow 
regression. They can result from cytokinesis failure at both an early stage, such as during 
furrow ingression or midbody stabilisation, or a later stage such as abscission, following 
a prolonged period of daughter cell connection by midbodies. An increase in midbody 
connected cells is therefore indicative of a late stage phenotype, closer to abscission. 
HeLa∆UMAD1 cells displayed on average just over a 2-fold increase in multinucleated 
cells compared to wild type HeLa cells (Figure 39B/C). Experiments using siRNA to 
deplete UMAD1 did not display the same growth defect or increase in multinucleation 
(Appendix 1). However due to the lack of an antibody able to detect endogenous levels 
of UMAD1 expression, the efficiency of protein depletion could not be reliably tested, 
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and the lack of a phenotype seen in these experiments could be due to some residual 
UMAD1 expression that would be enough to prevent appearance of such phenotypes. 
Furthermore, the clonogenic assay was performed using only one dose of siRNA, which 
might not have depleted UMAD1 expression to the extent required to observe the 
growth defect.  The reason for transfecting only one dose was to avoid inaccuracy when 
attempting to re-plate an equal number of cells for each condition following a further 
trypsinisation and siRNA transfection: cell counting using such a small volume of cells, 
from wells of a 24 well plate, would have been difficult and innacurate. 
Examination of stably expressed YFP-UMAD1 localisation in fixed cells shows diffuse 
localisation throughout the cytoplasm, however midbody localisation in a pattern 
similar to that of TSG101 is observed: YFP-UMAD1 localises to the midbody at a single 
site at the centre of the Flemming body, as opposed to the concentric rings seen either 
side of the Flemming body as in the case of ESCRT-III proteins17(Figure 39D). This 
localisation is therefore consistent with UMAD1’s identity as an ESCRT-I subunit. Taken 


































































4.2.2. Depletion of VPS37C shows a growth defect and increase in 
multinucleation similar to HeLa∆UMAD1 cells 
Given the pairing preference of UMAD1 for VPS37C, described in the previous chapter, 
further clonogenic and multinucleation assays were performed to compare cell growth 
and cytokinetic defects seen upon siRNA mediated depletion of VPS37C with those in 
HeLa∆UMAD1 cells (Figure 40A/B). Clonogenic assays showed growth of HeLa cells upon 
depletion of VPS37C to be almost identical to that of HeLa∆UMAD1 cells, with both 
displaying > 2-fold less growth than HeLa transfected with siNT control siRNA.  
Although statistically insignificant, quantification of cytokinetic defects also initially 
suggested potentially similar levels of multinucleation in HeLa∆UMAD1 cells, with a 
mean of 7.6% multinucleation, and HeLa cells depleted of VPS37C, with a mean of 8.5% 
multinucleation compared to HeLa cells transfected with siNT control siRNA, which 







Figure 39. HeLa∆UMAD1 cells show a growth defect and an increase in multinucleation 
A. Clonogenic assay using HeLa cells and HeLa∆UMAD1 cells. 3000 HeLa or HeLa∆UMAD1 cells were 
seeded and resuspended in wells of a 6-well plate. Cell colonies were left to grow, following which 
colonies were fixed and stained with 0.5% w/v crystal violet in methanol. The area occupied by 
colonies on the base of each well was then measured. Graph shows the mean number obtained for 
six independent experimental repeats, and error bars represent the standard deviation from the 
mean. Values are normalised to those of wild type HeLa cells, set at 1-fold. HeLa∆UMAD1: 0.27±0.12-
fold. Unpaired t test; ****, P < 0.0001 B. Quantification of cytokinetic defects in HeLa and 
HeLa∆UMAD1 cells. Graph shows the number of fixed cells with more than one nucleus and the 
number of midbody connected cells. The mean percentages for four independent repeats, with error 
bars representing the standard deviation from the mean are shown. n > 1200 cells per condition. HeLa 
multinucleated cells: 2.8±0.4%, HeLa midbodies: 5.7±1.8%, HeLa∆UMAD1 multinucleated cells: 
5.8±0.5%, HeLa∆UMAD1 midbodies: 4.1±1.2%. Unpaired t test; ***, P = 0.0001. C. Representative 
images of Hela cells and HeLa∆UMAD1 cells used in B. Red = tubulin, Blue = Hoechst (Nuclei). Arrows 
indicate multinucleated cells, scale bar = 50µm. D. YFP-UMAD1 shows Flemming body localisation. 
HeLa∆UMAD1 cells that stably re-express YFP-UMAD1 were stained with Hoechst (blue) and α-Tubulin 
(red) to visualise the nucleus and cytoskeleton respectively, together with YFP-UMAD1 (green). 
HeLa∆UMAD1 cells expressing YFP-TSG101, or YFP alone were imaged as positive and negative 






Figure 39. HeLa∆UMAD1 cells show a growth defect and an increase in multinucleation 
A. Clonogenic assay using HeLa cells and HeLa∆UMAD1 cells. 3000 HeLa or HeLa∆UMAD1 cells were 
seeded and resuspended in wells of a 6-well plate. Cell colonies were left to grow, following which 
colonies were fixed and stained with 0.5% w/v crystal violet in methanol. The area occupied by 
colonies on the base of each well was then measured. Graph shows the mean number obtained for 
six independent experimental repeats, and error bars represent the standard deviation from the 
mean. Values are normalised to those of wild type HeL  c lls, s t at 1-fold. HeLa∆UMAD1: 0.27±0.12-
fold. Unpaired t test; ****, P < 0.0001 B. Quantification of cytokinetic defects in HeLa and 
HeLa∆U AD1 cells. Graph shows the number of fixed cells with more than one nucleus and the 
number of midbody connected cells. The mean percentages for four independent repeats, with error 
bars representing the standard deviation from the mean are shown. n > 1200 cells per condition. HeLa 
multinucleated cells: 2.8±0.4%, HeLa midbodies: 5.7±1.8%, HeLa∆UMAD1 multinucleated cells: 
5.8±0.5%, HeLa∆UMAD1 midbodies: 4.1±1.2%. Unpaired t test; ***, P = 0.0001. C. Representative 
images of Hela cells and HeLa∆UMAD1 cells used in B. Red = tubulin, Blue = Hoechst (Nuclei). Arrows 
indicate multinucleated cells, scale bar = 50µm. D. YFP-UMAD1 shows Flemming body localisation. 
HeLa∆UMAD1 c lls that stably re-expr s  YFP-UMAD1 were s ained with Hoechst (blue) and α-Tubulin 
(red) to visualise the nucleus and cytoskeleton respectively, together with YFP-UMAD1 (green). 
HeLa∆UMAD1 cells expressing YFP-TSG101, or YFP alone were imaged as positive and negative 






Figure 39. HeLa∆UMAD1 cells show a growth defect and an increase in multinucleation 
A. Clonogenic assay using HeLa cells and HeLa∆UMAD1 cells. 3000 HeLa or HeLa∆UMAD1 cells were 
seeded and resuspended in wells of a 6-well plate. Cell colonies were left to grow, following which 
colonies were fixed and stained with 0.5% w/v crystal violet in methanol. The area occupied by 
colonies on the base of each well was then measured. Graph shows the mean number obtained for 
six independent experimental repeats, and error bars represent the standard deviation from the 
mean. Values are normalised to those of wild type HeLa cells, set at 1-fold. HeLa∆UMAD1: 0.27±0.12-
fold. Unpaired t test; ****, P < 0.0001 B. Quantification of cytokinetic defects in HeLa and 
HeLa∆UMAD1 cells. Graph shows the number of fixed cells with more than one nucleus and the 
number of midbody connected cells. The mean percentages for four independent repeats, with error 
bars representing the standard deviation from the mean are shown. n > 1200 cells per condition. HeLa 
multinucleated cells: 2.8±0.4%, HeLa midbodies: 5.7±1.8%, HeLa∆UMAD1 multinucleated cells: 
5.8±0.5%, HeLa∆UMAD1 midbodies: 4.1±1.2%. Unpaired t test; ***, P = 0.0001. C. Representative 
images of Hela cells and HeLa∆UMAD1 cells used in B. Red = tubulin, Blue = Hoechst (Nuclei). Arrows 
indicate multinucleated cells, scale bar = 50µm. D. YFP-UMAD1 shows Flemming body localisation. 












































4.2.3. Determination of siRNA quantities suitable for a partial depletion 
of ALIX 
ALIX and ESCRT-I have been proposed to constitute two parallel arms of ESCRT-III 
recruitment during cytokinetic abscission93. Interestingly, although statistically 
insignificant on this occasion, HeLa∆UMAD1 cells appeared to be expressing slightly 
elevated levels of ALIX compared to wild type HeLa cells (Figure 41A), as determined by 
immunoblotting using a-HSP90 and a-ALIX on the same membrane, normalising ALIX 
signal to HSP90 signal. We reasoned that this is likely to be a compensatory effect 
following depletion of UMAD1, under the hypothesis that UMAD1 contributes to the 
CEP55 – ESCRT-I – ESCRT-II – CHMP6 – ESCRT-III branch of ESCRT-III recruitment to the 
midbody whilst CEP55 – ALIX – ESCRT-III forms the second branch. Under this hypothesis 
and given the weak phenotype for cytokinesis defects upon knockout of UMAD1 alone, 
we decided to examine the effects of co-depletion of UMAD1 with ALIX. 
Given the strength of the phenotype previously reported17,183,442,699 and observed 
(Figure 41B) upon siRNA mediated depletion of ALIX using a single dose of 50 pmol, we 
decided to perform a titration using increasing quantities of siALIX to determine 
conditions that would lead to a significant increase in cytokinetic defects without 
reaching maximum levels (Figure 41B/C). This would allow for any synergistic effects of 
co-depletion of UMAD1 with ALIX to be observed. Given the observed elevation in ALIX 
Figure 40. HeLa∆UMAD1 cells show a growth defect and increase in multinucleation comparable 
with that seen upon VPS37C depletion. 
A. Clonogenic assay to compare cell growth upon siRNA mediated depletion of VPS37C with that of 
HeLa∆UMAD1 cells. HeLa and HeLa∆UMAD1 cells were transfected with a single dose of each siRNA 
shown. Cells were diluted 48 hrs later and colonies were left to grow for 10 days in wells of a 6-well 
plate. The mean area occupied by colonies on the base of each well is shown for 6 independent 
repeats, normalised to that of HeLa+siNT, set at 1-fold. Error bars represent the standard deviation 
from the mean. HeLa+siVPS37C: 0.454±0.221-fold, HeLa∆UMAD1+siNT: 0.410±0.153-fold. Unpaired t 
test; ***, P = 0.0001, ****, P < 0.0001 B. Representative image of cell colonies from A, fixed and 
stained with 0.5% w/v crystal violet in methanol following 10 days growth. C. Comparison of 
cytokinetic defects attained upon depletion of VPS37C with those in HeLa∆UMAD1 cells. HeLa cells 
and HeLa∆UMAD1 cells were transfected with two separate doses of each siRNA indicated. Following 
fixation and staining, the number of cells with more than one nucleus and the number of midbody 
connected cells were scored. The mean percentages for three independent experimental repeats are 
shown, with error bars representing the standard deviation from the mean. n > 900 cells per 
condition. HeLa+siNT: 3.3±0.6% multinucleated cells, 4.5±1.2% midbodies, HeLa+siVPS37C: 8.5±2.0% 
multinucleated cells, 3.2±0.4% midbodies, HeLa∆UMAD1+siNT: 7.6±4.0% multinucleated cells, 
4.3±0.6% midbodies. Cell lysates were analysed by immunoblotting using rabbit α-VPS37C and α-
HSP90. One-way ANOVA with Tukey’s multiple comparisons test; ns, P is not significant. D. 
Representative images of fixed cells used in C. Red = Tubulin, Blue = Hoechst. Arrows indicate 
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levels in HeLa∆UMAD1 cells, a second reason for performing a titration was to 
determine two separate quantities of siALIX that could be used side by side in further 
experiments, choosing the quantities that achieved ALIX depletion to the closest levels 
in HeLa and HeLa∆UMAD1 cells, in each experimental repeat. We decided to proceed 







































As further proof of principle for the use of a partial ALIX depletion under these 
conditions, before proceeding with experiments in HeLa and HeLa∆UMAD1 cells, an 
experiment to examine the effects of TSG101 depletion with a 5 pmol siALIX mediated 
partial depletion of ALIX was performed (Figure 42).  Under these conditions, a 
synergistic increase in the number of multinucleated cells was observed, with a mean of 
30.7% multinucleated cells compared to 13.4% in the case of the ALIX partial depletion 
alone, and 10.2% in the case of TSG101 depletion. This result contrasts with similar 
experiments using live cells performed by Christ et al. 2016, who concluded that there 
was no statistically significant increase in the number of cells that underwent 
multinucleation following depletion of TSG101 with ALIX93. These experiments, however, 
were performed with total depletion of ALIX rather than a partial depletion, suggesting 









Figure 41. Titration of siRNA against ALIX to determine quantities to use for a suitable partial 
depletion 
A. Quantification of ALIX levels in non-transfected HeLa and HeLa∆UMAD1 cells. Cell lysates from HeLa 
and HeLa∆UMAD1 cells were resolved by SDS-PAGE and immunoblotting with α-HSP90 and α-ALIX on 
the same gel was performed. ALIX levels in HeLa∆UMAD1 cells normalised to those in HeLa cells were 
then quantified according to band intensity. Graph shows the mean and standard deviation for 4 
independent repeats. HeLa∆UMAD1 ALIX levels: 1.3±0.5-fold. Unpaired t test; ns, P is not significant. 
B. Titration of siALIX in HeLa cells. HeLa cells were transfected with the quantities of siALIX shown, 
using a single transfection per siALIX quantity. Following fixation and staining, the number of cells with 
more than one nucleus and the number of midbody connected cells were scored. The mean 
percentages for 4 independent experimental repeats are shown, with error bars representing the 
standard deviation from the mean. n > 1200 cells per condition. 0 pmol (siNT only): 5.0±1.2% 
multinucleated cells, 5.3±3.3% midbodies, 1.25 pmol siALIX: 9.6±4.3% multinucleated cells, 4.9±1.3% 
midbodies, 2.5 pmol siALIX: 12.6±6.6% multinucleated cells, 7.8±0.6% midbodies, 5 pmol siALIX: 
20.3±7.4% multinucleated cells, 9.8±4.3% midbodies, 50 pmol siALIX: 36.8±4.9% multinucleated cells, 
18.4±2.2% midbodies. Cell lysates were analysed by immunoblotting using α-HSP90 and α-ALIX. C. 
Representative images of fixed cells used in B. Red = Tubulin, Blue = Hoechst. Arrows indicate 







Figure 41. Titration of siRNA against ALIX to determine quantities to use for a suitable partial 
depletion 
A. Quantification of ALIX levels in non-transfected HeLa and HeLa∆UMAD1 cells. Cell lysates from HeLa 
and HeLa∆UMAD1 c lls were resolved by SDS-PAGE and immunoblotting with α-HSP90 and α-ALIX on 
the same gel was performed. ALIX levels in HeLa∆UMAD1 cells normalised to those in HeLa cells were 
then quantified according to band intensity. Graph shows the mean and standard deviation for 4 
independent repeats. HeLa∆UMAD1 ALIX levels: 1.3±0.5-fold. Unpaired t test; ns, P is not significant. 
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Representative images of fixed cells used in B. Red = Tubulin, Blue = Hoechst. Arrows indicate 
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4.2.4. Functional synergy between UMAD1 and ALIX in cytokinesis 
Having determined suitable quantities of siALIX to use for obtaining a partial depletion 
of ALIX, the effects on cytokinesis of co-depletion of UMAD1 with ALIX were investigated. 
HeLa∆UMAD1 cells showed a substantial increase in both the number of multinucleated 
cells and midbodies, at 26.4% and 9.7% respectively, compared to wild type HeLa cells, 
at 13.8% and 7.5%, upon depletion of ALIX to approximately 24% of its normal 
expression level in wild type HeLa cells (Figure 43). This increase in multinucleation is 
not as strong as that seen upon co-depletion of TSG101 with ALIX (Figure 42A). However, 
the increases are significant, particularly given that the mean level to which ALIX is 
depleted for the 4 repeats is extremely close in HeLa and HeLa∆UMAD1 cells, at 24% 
and 23% respectively (Figure 43C). The elevated level of ALIX expression in 
HeLa∆UMAD1 cells is also clearer and statistically significant here, displaying a mean of 









Figure 42. A synergistic increase in multinucleation is seen upon co-depletion of TSG101 with a 
partial depletion of ALIX 
A. Quantification of cytokinetic defects upon co-depletion of TSG101 with a partial depletion of ALIX. 
A single transfection of HeLa cells was performed using the siRNA oligonucleotides shown. 50pmol 
siRNA was used for siNT and siTSG101 whilst 5pmol was used for siALIX, keeping the total volume of 
siRNA used per condition at 100pmol using siNT. Following fixation and staining, the number of cells 
with more than one nucleus and the number of midbody connected cells were scored. The mean 
percentages for 3 independent experimental repeats are shown, with error bars representing the 
standard deviation from the mean. n > 900 cells per condition. siNT: 4.4±1.5% multinucleated cells, 
2.8±0.4% midbodies, siTSG101: 10.2±1.1% multinucleated cells, 2.8±0.9% midbodies, siALIX: 
13.4±3.7% multinucleated cells, 8.9±3.2% midbodies, siALIX+siTSG101: 30.7±6.5% multinucleated 
cells, 5.4±3.7% midbodies. Cell lysates were analysed by immunoblotting using α-HSP90, α-ALIX and 
α-TSG101. One-way ANOVA with Tukey’s multiple comparisons test; ns, P is not significant, **, P < 
0.01 B. Representative images of fixed cells used in A. Red = Tubulin, Blue = Hoechst. Arrows indicate 








Figure 42. A synergistic increase in multinucleation is seen upon co-depletion of TSG101 with a 
partial depletion of ALIX 
A. Quantification of cytokinetic defects upon co-depletion of TSG101 with a partial depletion of ALIX. 
A single transfection of HeLa cells was performed using the siRNA oligonucleotides shown. 50pmol 
siRNA was used for siNT and siTSG101 whilst 5pmol was used for siALIX, keeping the total volume of 
siRNA used per condition at 100pmol using siNT. Following fixation and staining, the number of cells 
with more than one nucleus an  the number of midbody connected cells were scored. The mean 
percentages for 3 independent experimental repeats are shown, with error bars representing the 
standard deviation from the m an. n > 900 cells per condition. siNT: 4.4±1.5% multinucleat d cells, 
2.8±0.4% midbodies, siTSG101: 10.2±1.1% multinucleated cells, 2.8±0.9% midbodies, siALIX: 
13.4±3.7% multinucleated cells, 8.9±3.2% midbodies, siALIX+siTSG101: 30.7±6.5% multinucleated 
cells, 5.4±3.7% midbodies. Cell lysates were analysed by immunoblotting using α-HSP90, α-ALIX and 
α-TSG101. One-way ANOVA with Tukey’s multiple comparisons test; ns, P is not significant, **, P < 
0.01 B. Representative images of fixed cells used in A. Red = Tubulin, Blue = Hoechst. Arrows indicate 








Figure 42. A synergistic increase in multinucleation is seen upon co-depletion of TSG101 with a 
partial depletion of ALIX 
A. Quantification of cytokinetic defects upon co-depletion of TSG101 with a partial depletion of ALIX. 
A single transfection of HeLa cells was performed using the siRNA oligonucleotides shown. 50pmol 
siRNA was used for siNT and siTSG101 whilst 5pmol was used for siALIX, keeping the total volume of 
siRNA used per condition at 100pmol using siNT. Following fixation and staining, the number of cells 
with more than one nucleus and the number of midbody connected cells were scored. The mean 
percentages for 3 independent experimental repeats are shown, with error bars representing the 
standard deviation from the mean. n > 900 cells per condition. siNT: 4.4±1.5% multinucleated cells, 
2.8±0.4% midbodies, siTSG101: 10.2±1.1% multinucleated cells, 2.8±0.9% midbodies, siALIX: 
13.4±3.7% multinucleated cells, 8.9±3.2% midbodies, siALIX+siTSG101: 30.7±6.5% multinucleated 
cells, 5.4±3.7% midbodies. Cell lysates were analysed by immunoblotting using α-HSP90, α-ALIX and 
α-TSG101. One-way ANOVA with Tukey’s multiple comparisons test; ns, P is not significant, **, P < 
0.01 B. Representative images of fixed cells used in A. Red = Tubulin, Blue = Hoechst. Arrows indicate 




















































4.2.5. Further synergy between UMAD1 and ALIX is seen in abscission 
timing 
Having examined changes in cytokinetic defects representative of cytokinesis failure, we 
decided to more specifically examine effects on abscission by measuring abscission time 
in cells that successfully complete abscission. In addition to causing cytokinesis failure, 
depletion of TSG101 and ALIX have each been shown to delay successful abscission, and 
further display a synergistic increase in abscission time upon co-depletion of both 
proteins. Under the hypothesis that UMAD1 represents part of the branch for ESCRT-III 
recruitment including TSG101 (ESCRT-I), a possible prolonging of abscission time could 
be expected upon UMAD1 depletion, in addition to the above described phenotypes in 
cytokinetic failure. HeLa and HeLa∆UMAD1 cells that stably expressed mCherry-tubulin 
were made and sorted for comparable levels of low mCherry-tubulin expression. Live 
cell imaging of these cells was then performed for 24 hours to investigate differences in 
abscission timing upon partial depletion of ALIX with UMAD1. Imaging of asynchronous 
cells was started 12 hours post-transfection to avoid an undesirable number of 
multinucleated cells at the start of the experiment, caused in particular by depletion of 
ALIX, as shown in the previous figure. HeLa and HeLa∆UMAD1 cells were transfected 
Figure 43. Co-depletion of UMAD1 with a partial depletion of ALIX shows increased cytokinetic 
defects 
A. Both HeLa and HeLa∆UMAD1 cells were transfected with siALIX, to obtain a partial depletion to 
equal levels in both cell types, or siNT control using a single dose of siRNA per condition. Following 
fixation and staining, the number of cells with more than one nucleus and the number of midbody 
connected cells were scored for conditions using the quantities of siALIX that showed depletion of ALIX 
to comparable levels in HeLa and HeLa∆UMAD1 cells (approximately 24% as shown in D), as 
determined by immunoblotting, as shown in C and D. The mean percentages for 4 independent 
experimental repeats are shown, with error bars representing the standard deviation from the mean. 
n > 1200 cells per condition. HeLa+siNT: 5.5±0.6% multinucleated cells, 6.4±1.9% midbodies, 
HeLa∆UMAD1+siNT: 8.0±0.1% multinucleated cells, 2.7±0.4% midbodies,  HeLa+siALIX: 13.8±7.4% 
multinucleated cells, 7.5±2.6% midbodies, HeLa∆UMAD1+siALIX: 26.4±6.4% multinucleated cells, 
9.7±1.7% midbodies. One-way ANOVA with Tukey’s multiple comparisons test; *, P < 0.05, ***, P < 
0.001, ns, P is not significant B. Cell lysates were analysed by immunoblotting using α-HSP90 and α-
ALIX. Detection of HSP90 and ALIX signal on the same nitrocellulose membrane by fluorescence rather 
than enhanced chemiluminescence was performed to ensure optimal ALIX level quantification as 
shown in C. C. Quantification of cellular levels of ALIX used in A, as determined by immunoblotting. 
Mean ALIX levels are normalised to HeLa+siNT. Error bars represent the standard deviation from the 
mean. HeLa∆UMAD1+siNT: 1.53±0.42-fold, HeLa+siALIX partial depletion: 0.24±0.06, 
HeLa∆UMAD1+siALIX partial depletion: 0.23±0.08. Unpaired t test; *, P < 0.05 D. Representative 
images of fixed cells used in A. Red = Tubulin, Blue = Hoechst. Arrows indicate multinucleated cells, 
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with siALIX, to obtain a partial depletion of ALIX to equal levels in both cell types (Section 
4.2.3), or siNT control siRNA. Results for depletion of ALIX to comparable levels, of 28% 
and 30% wild type HeLa levels in HeLa and HeLa∆UMAD1 cells respectively, (Figure 
44D/E) are shown, taking abscission time as the time from furrow ingression to midbody 
resolution (Figure 44A-C).  
Abscission times showed a similar pattern to data obtained by Christ et al. 2016 for the 
effect of TSG101 and ALIX depletion on abscission timing93. An increase in median 
abscission time from 150 mins in HeLa cells to 170 mins in HeLa∆UMAD1 cells, 190 mins 
in HeLa cells with the partial ALIX depletion and a clearly synergistic increase to 240 mins 
in HeLa∆UMAD1 cells with the partial ALIX depletion was seen. Statistical analysis 
additionally revealed much higher degrees of confidence in this data, than for previous 
assays to measure cytokinetic defects in fixed cells. Such results are consistent with the 
hypothesis that UMAD1 and ALIX are part of two separate and partially redundant 
pathways for the recruitment of ESCRT-III to mediate abscission, with UMAD1 forming 
an ESCRT-I complex that contributes to cytokinetic abscission. In contrast to the previous 
figure, elevated levels of ALIX are not observed in HeLa∆UMAD1 cells on this occasion. 
A possible explanation for this could be that by this time, further adaptations to the 






































4.2.6. Midbody localisation of CHMP4B upon UMAD1 and ALIX depletion 
Under the hypothesis that UMAD1, as a component of ESCRT-I, and ALIX form parallel 
arms of ESCRT-III recruitment to the midbody, we decided to examine midbody 
localisation of CHMP4B-L-GFP in HeLa cells, initially following depletion of TSG101 or 
ALIX (Figure 45A/B). 
As previously observed for fluorescently tagged ESCRT-III proteins17, CHMP4B-L-GFP 
either displayed its characteristic localisation to two concentric rings at either side of 
the Flemming body or was absent, in cells transfected with non-targeting control siRNA. 
In the case of a partial depletion of ALIX, both localisation to two concentric rings and 
the absence from some midbodies was again observed. However, CHMP4B-L-GFP also 
showed a third type of localisation in 54.4% midbodies, as a single band at the centre of 
the Flemming body, similar to that seen for CEP55 and TSG101. This was also seen for 
TSG101 depletion, accounting for 32.6% midbodies.  
In experiments using HeLa∆UMAD1 cells, a similar pattern of results was seen (Figure 
45A/C). A slight increase from 2.0% in wild type cells transfected with non-targeting 
siRNA to 9.4% in HeLa∆UMAD1 cells transfected with non-targeting siRNA was seen for 
the number of cells showing CHMP4B-L-GFP localisation to a single band at the 
Flemming body. This figure was at 35.6% for cells transfected with 5pmol siALIX. It would 
therefore appear that both ALIX depletion and TSG101/UMAD1 depletion leads to 
Figure 44. A synergistic increase in abscission time is observed upon a partial co-depletion of ALIX 
with UMAD1. 
A. 12 hours post-transfection with siNT or siALIX, to obtain a partial depletion, asynchronous HeLa or 
HeLa∆UMAD1 cells sorted for equal levels of low mCherry-Tubulin expression, were imaged live every 
10 mins for 24 hrs. Midbody resolution times were scored for 3 independent experiments combined 
in the scatter plot shown, selecting for conditions using the quantities of siALIX that showed depletion 
of ALIX to comparable levels in HeLa and HeLa∆UMAD1 cells (approximately 29% as shown in C). 
Abscission times were taken as the interval between furrow ingression and midbody breakage. Bars 
indicate the median and range of abscission times. n = no. of events scored per condition. Kruskal-
Wallis test with Dunn’s multiple comparisons test; **, P < 0.01, ***, P < 0.001, ****, P < 0.0001. B. 
Data from A plotted as a cumulative frequency plot. C. Time-lapse images for HeLa and HeLa∆UMAD1 
cells stably expressing equal levels of low mCherry-Tubulin, as used in A and B. Scale bar = 10µm D. 
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signal on the same nitrocellulose membrane by fluorescence rather than enhanced 
chemiluminescence was performed to ensure optimal ALIX level quantification, as shown in D. E. 
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HeLa+siNT. Error bars represent the standard deviation from the mean. 
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increases in this phenotype, with ALIX depletion showing a stronger phenotype than for 
TSG101/UMAD1 depletion. Whether this localisation represents midbodies that are still 
able to complete abscission or defective in abscission remains to be investigated. 
HeLa∆UMAD1 cells also show a more obvious increase in the number of midbodies in 
which CHMP4B is absent, compared to cells transfected with non-targetting control 


























Figure 45. Effects of TSG101, UMAD1 and ALIX depletion on CHMP4B midbody localisation 
A. Representative images of midbodies in HeLa cells stably expressing CHMP4B-L-GFP, as scored in B 
and C. Blue = Hoechst, Red = Tubulin, Green = CHMP4B-L-GFP. Scale bar = 10µm, Inset = Midbody. B. 
HeLa cells were transfected with one dose of each siRNA oligonucleotide shown. Following fixation 
and staining, the number of midbodies showing each type of CHMP4B-L-GFP localisation pattern were 
scored. The mean percentages for 3 independent experimental repeats is shown, with error bars 
representing the standard deviation from the mean. siNT: 57.5±3.9% Absent, 7.4±1.7% Flemming 
body, n=331, siALIX: 33.1±3.6% Absent, 54.4±7.1% Flemming body, n=829, siTSG101: 58.9±9.6% 
Absent, 32.6±9.8% Flemming body, n=275 C. Both HeLa and HeLaDUMAD1 cells were transfected with 
one dose of each of siRNA oligonucleotides shown, using a partial depletion in the case of siALIX. 
Following fixation and staining, the number of midbodies showing each type of CHMP4B-L-GFP 
localisation pattern was scored. The mean percentages for 3 independent experimental repeats are 
shown, with error bars representing the standard deviation from the mean. HeLa+siNT: 55.9±4.1% 
Absent, 2.0±3.5% Flemming body, n=242, HeLa+siALIX (partial): 36.2±10.9% Absent, 35.6±14.8% 












Following the observation in the previous chapter that UMAD1 knockout reduces 
interaction of TSG101 with CEP55, the results presented in this chapter demonstrate 
that UMAD1 indeed contributes to cytokinesis. Time-lapse experiments have shown 
that UMAD1 functions in cytokinetic abscission. UMAD1 knockout leads to an increase 
in the median time taken for midbody resolution, and a synergistic increase in resolution 
time is observed upon a partial co-depletion with ALIX. Although not always statistically 
significant, results from assays to measure cytokinetic defects have additionally 
suggested a more generalised role for UMAD1 in mediating successful cytokinesis, as 
seen by increased multinucleation upon knockout of UMAD1. This could potentially 
explain some of the reason why retarded growth is seen in HeLa∆UMAD1 cells (Figure 
39A). Despite undergoing increased multinucleation and an increase in time taken for 
abscission, it should be remembered that such cells would still enter G1 and G2 growth 
phases of the cell cycle. Additionally, such modest increases in cytokinetic defects upon 
knockout of UMAD1 alone are unlikely to fully explain the 4-fold growth defect observed. 
It is therefore likely that involvement of UMAD1 in additional cellular processes, 
uncharacterised here, other than cytokinesis could be contributing to the growth defect 
to a greater extent. Depletion of VPS37C shows a growth defect and increase in 
multinucleation similar to that seen upon UMAD1 knockout, consistent with the 
preferred pairing of UMAD1 with VPS37C, in the same ESCRT-I complex (Chapter 3/ 
Figure 40). The biggest question remaining here is whether increases in multinucleation 
upon UMAD1 knockdown occur more precisely at a stage closer to furrow ingression or 
to abscission, representing early or late cytokinetic defects, respectively, or both. This 
can be established by examination of multinucleation events in the time-lapse 
experiments presented in Figure 44, to specifically score the time intervals between 
furrow ingression and regression to form multinucleated cells. 
If multinucleation events occur following a prolonged period of midbody connectivity 
(i.e. longer than the median time interval seen between furrow ingression and 
regression in wild type HeLa cells) involvement of UMAD1 closer to abscission would be 
implied. This would be consistent with the prolonged midbody resolution time seen in 
HeLaDUMAD1 cells that do successfully complete abscission, as scored in time-lapse 
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experiments (Figure 44). Conversely, multinucleation events that occur closer to the 
time of furrow ingression (i.e. shorter than the median time interval seen between 
furrow ingression and regression in wild type HeLa cells) would be indicative of earlier 
failure, in furrow ingression or midbody stability. UMAD1 could also possibly be involved 
at both stages to a certain extent, like MITD1511 (Section 1.5.6.). Interestingly, Morita et 
al. 2007 report both early and late furrow regression events upon depletion of TSG101 
and ALIX17. Also, as presented in the same study and discussed in section 1.5.6., unique 
binding partners involved at early stages of cytokinesis have been identified for both 
TSG101 and ALIX. This suggests a potential dual role for the ESCRT machinery at both 
early and late stages of cytokinesis, coordinating abscission with more upstream events 
in cytokinesis and mitosis. The prolonged midbody resolution time and more statistically 
significant results for such time-lapse experiments, however, potentially suggests a 
more prominent role for UMAD1 in abscission. 
A synergistic increase in midbody resolution time, in cells that successfully complete 
abscission, is seen upon co-depletion of UMAD1 with ALIX. This is consistent with the 
hypothesis that UMAD1 forms part of an ESCRT-I complex involved in abscission as part 
of a CEP55 – ESCRT-I – ESCRT-II – CHMP6 – ESCRT-III pathway of ESCRT-III recruitment 
(Figure 46). This is proposed to form a partially redundant branch of ESCRT-III 
recruitment in a dual axis together with a CEP55 – ALIX – ESCRT-III branch93 (Figure 46). 
This hypothesis is also consistent with the elevated levels of ALIX expression in 
HeLa∆UMAD1 cells, seen most prominently in figure 43C, as a potential compensatory 
mechanism in cytokinesis. It will be interesting to similarly examine potential change in 
ALIX levels upon depletion of TSG101, VPS37B and VPS37C, given that these subunits 
form complexes with UMAD1 (Chapter 3), and VPS37C depletion shows a growth defect 
akin to that in HeLa∆UMAD1 cells (Figure 40A/B). A similar compensatory effect would 
yet again add to the notion that ESCRT proteins show tight regulation of expression and 
would shed light on an area for further investigation of control of ESCRT protein 
expression.  
In addition to midbody resolution time, a synergistic increase is also seen in 
multinucleation upon codepletion of UMAD1 or TSG101 with a partial depletion of ALIX. 
This contrasts with similar experiments using live cells performed by Christ et al. 2016, 
who concluded that there was no statistically significant increase in the number of cells 
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that underwent multinucleation following depletion of TSG101 with ALIX93. These 
experiments, however, were performed with total depletion of ALIX rather than a partial 
depletion, suggesting that a synergistic effect might have been masked due to reaching 
saturated levels of multinucleation. 
Experiments to examine localisation of CHMP4B-L-GFP have shown an increase in the 
localisation of CHMP4B-L-GFP to a single band at the Flemming body upon depletion of 
ALIX, TSG101 and UMAD1. An increase in midbodies in which CHMP4B is absent is also 
seen in HeLaDUMAD1 cells. A possible explanation for this phenotype could be that 
localisation as a single band at the Flemming body might represent an intermediate 
stage of ESCRT-III localisation, prior to re-localisation to the concentric rings. Depletion 
of early ESCRTs such as ALIX, TSG101 and UMAD1 would lead to persistence at this stage, 
if they are required for appropriate positioning of ESCRT-III to the rings.  
The different ratios of CHMP4B localisation to the Flemming body, concentric rings or 
absence from the midbody could also likely be due to differences in time taken for 
CHMP4B recruitment to the midbody and persistence at the midbody before the final 
scission event. For example, perhaps CHMP4B persists at the midbody for longer upon 
ALIX depletion than upon UMAD1 depletion, leading to the increased proportion of 
CHMP4B at the Flemming body and concentric rings compared to when UMAD1 is 
depleted. Time-lapse experiments would greatly help clarify this more accurately, by 
measuring the time interval between CEP55 and CHMP4B appearance at the midbody, 
and also how long CHMP4B persists at the midbody. Similarly, another potential method 
for measuring differences in the kinetics of CHMP4B recruitment to the midbody would 
be to perform fluorescence recovery after photobleaching (FRAP) experiments. In such 
experiments, high-power laser illumination would be used to specifically photobleach 
midbody localised CHMP4B-L-GFP. The time taken for fluorescence recovery, as non-
bleached CHMP4B-L-GFP is recruited back to the midbody, would then be measured for 
wild type HeLa and HeLaDUMAD1 cells. Time-lapse experiments would also help clarify 
whether localisation of CHMP4B to the Flemming body as a single band represents 
midbodies that are defective in abscission, and later undergo multinucleation, or 
represent midbodies that simply resolve later. 
The fact that the phenotypes presented in this chapter are seen upon depletion of 
UMAD1 without codepletion of other MVB12 like subunits, suggests a potentially unique 
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role for UMAD1 in cytokinesis. Partial redundancy with other MVB12 like subunits, 
however, cannot be dismissed yet. Future multinucleation/midbody scoring assays and 
time-lapse experiments to measure abscission time should therefore be performed to 
further investigate whether similar phenotypes are seen upon depletion of MVB12A and 
MVB12B and whether stronger phenotypes are seen upon co-depletion of UMAD1 with 
MVB12A/B.  
To further confirm that the phenotypes seen are genuinely due to UMAD1 knockout, 
future work should involve performing rescue experiments in which multinucleation 
assays and abscission time scoring experiments are performed using HeLa∆UMAD1 cells 
that re-express UMAD1 by lentiviral transduction. Decreases in multinucleation and 
abscission times would be expected in these cases. Also, in order to further attempt to 
discount a clone specific phenotype using a single CRISPR/Cas9 HeLa∆UMAD1 clone, 
experiments using siRNA knockdown of UMAD1 (Appendix 1) should also be 
reattempted for these experiments to measure abscission time. For completeness, time-
lapse experiments to score abscission times upon depletion of UMAD1 binding partners 
VPS37B and VPS37C could also be attempted, to investigate whether abscission times 











































Figure 46. Proposed model for the role on UMAD1 in cytokinetic abscission 
ESCRT-III is recruited by the two parallel partially redundant pathways proposed by Christ et al 2016 
involving a dominant CEP55 – ALIX – ESCRT-III branch and a more subsidiary CEP55 – ESCRT-I – ESCRT-
II – CHMP6 – ESCRT-III branch. UMAD1 contributes to cytokinesis through the more subsidiary branch, 
by incorporation into ESCRT-I complexes involved in cytokinesis containing VPS37B and VPS37C, with 
a preference for VPS37C (as shown by the double solid line, as opposed to the single solid line in the 
case of VPS37B). UMAD1 specifically strengthens the interaction between CEP55 with TSG101 (as 
shown by dashed arrows) 
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Chapter 5 – UMAD1 in viral budding 
5.1. Introduction 
5.1.1. HIV-1 assembly and Gag multimerisation 
HIV-1 is a single-stranded positive-sense enveloped RNA virus that belongs to the 
Lentivirus genus of the Retroviridae family. Retroviruses are characterised by reverse 
transcription of their RNA genome into a double-stranded DNA intermediate by a virally 
encoded reverse transcriptase. The dsDNA provirus is then integrated into the host 
genome by a virally encoded integrase, such that transcription by the host cell 
machinery generates new ssRNA genomes for incorporation into new viral progeny. This 
host transcribed RNA also serves as mRNA for the production of new viral proteins, 
which assemble into the viral progeny.  
The HIV-1 genome encodes 9 proteins: Gag, Env, Pol, Tat, Rev, Vif, Vpu, Nef and Vpr700 
(Figure 47). Gag and Env represent the main structural components of virions, with Gag 
accounting for approximately 50% of the virion mass701. Expression of Gag is sufficient 
for assembly of HIV-1 at the plasma membrane702,703. Env encodes the HIV-1 envelope 
glycoprotein that is processed to form gp120-gp41 that binds the HIV-1 receptor CD4 
and co-receptors CXCR4 and CCR5, on cells of the immune system, via interaction with 
gp120704,705. Pol encodes the viral protease (PR), involved in maturation of the virus to 
form infectious virions, together with the viral reverse transcriptase (RT) and integrase 
(IN). Tat and Rev regulate gene expression, and the remaining Vif, Vpr, Vpu and Nef are 
known as accessory proteins, involved in evasion of host immune responses and fine 
tuning of viral replication706–708. Whilst unspliced RNA forms the viral genome for 
incorporation into progeny virions, it is also translated to form Gag and Gag-Pol 
polyprotein precursors. Singly spliced RNA is translated to produce Env at the ER, which 
is further glycosylated at the Golgi apparatus and cleaved to form gp120-gp41 prior to 
plasma membrane insertion709–711. Multiply spliced RNAs are translated to produce all 
other HIV-1 proteins708.  
Gag (p55) and Gag-Pol (p160) polyproteins (Figure 47) are generated by ribosomal 
frameshifting at the 3’ end of the Gag open reading frame, such that Gag and Gag-Pol 
are produced in an approximately 20:1 ratio, ensuring appropriate stoichiometry of Gag 
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structural proteins and the viral enzymes712. Gag polyproteins consist of matrix protein 
(MA), capsid protein (CA) and nucleocapsid protein (NC) domains (Figure 47) separated 
by the flexible linkers spacer peptide 1 (SP1) and spacer peptide 2 (SP2) and the C-
terminal p6 region which interacts with the ESCRT proteins TSG101 and ALIX to direct L-












Gag and Gag-Pol precursors traffic to the plasma membrane and are incorporated in a 
radial arrangement into domains of the membrane displaying specific lipid raft-like 
compositions (Figure 48). Such domains contain enriched PI(4,5)P2, phosphatidylserine 
(PS), phosphatidylethanol, and cholesterol714–717. Gag MA domains provide interaction 
with the membrane through a basic patch in its N-terminus, which interacts with 
PI(3,4)P2713,718. Further anchorage is mediated via an N-terminal myristoyl group which 
is exposed upon PI(3,4)P2 binding718,719. Gag assembly into a spherical lattice is mediated 
primarily by lateral interactions between the CA-SP1 regions of Gag720. These form 
hexameric rings which curve to form the spherical immature virion721,722. The most inner 
layer of the immature virion contains the NC regions which package the viral genomic 
RNA dimers723–725. Genomic RNA dimers form in the cytoplasm prior to packaging and 
are formed through noncovalent interactions at the 5’UTRs. Packaging is directed 
through an interaction between another 5’ region known as the y site, which forms 
stem loop structures that interact with two zinc finger motifs and basic clusters of 
residues within the NC region of Gag726. Binding to RNA also promotes Gag 
multimerisation727,728. 
Figure 47. HIV-1 genome structure with p55 Gag proteolytic processing products 
The HIV-1 genome encodes 9 proteins, as described in the text. Gag (p55) and Gag-Pol (p160) 
polyproteins are generated by ribosomal frameshifting, such that Gag (p55) and Gag-Pol (p160) are 
produced in an approximately 20:1 ratio. As relevant to this chapter, p55 Gag proteolytic processing 
products are shown. 
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Gag processing to form mature infectious virions occurs concomitantly with budding and 
involves cleavage of the Gag/Gag-Pol precursor proteins at PR cleavage sites, and 
reorganisation of the individual Gag components to form a characteristic HIV-1 conical 
capsid structure enclosing the genome729,730 (Figure 48). Cleavage by PR occurs at 11 
separate sites within Gag/Gag-Pol to produce MA, CA, NC, p6, PR, RT, and IN proteins. 
Whilst MA remains membrane associated, CA forms the capsid shell containing around 
1500 CA copies731,732. The capsid shell encapsidates NC bound RNA, and the PR, RT and 

















5.1.2. Contribution of ESCRT-I subunits to L-domain mediated viral 
budding 
HIV-1 usurps the ESCRT machinery to facilitate its budding from the plasma membrane, 
as detailed in section 1.7. This is mediated primarily through a 7PTAP10 L-domain and 
more auxilliary 35LYPLTSL41 L-domain within p6 Gag, which bind directly to TSG101 and 
ALIX respectively. Accordingly, it comes as no surprise that depletion of TSG101 has 
Figure 48. Arrangement of proteins in immature HIV-1 virions and mature infectious virions 
During HIV-1 budding, Gag and Gag-Pol precursor polyproteins localise to lipid raft-like regions of the 
cell plasma membrane and form a radial arrangement. Whilst MA mediates interaction with the 
membrane, to become the viral envelope, CA-SP1 regions are primarily responsible for interaction 
with neighbouring Gag polyproteins for assembly into a spherical lattice, and NC is responsible for 
packaging of the viral RNA genome. Gag/Gag-Pol processing to form the mature infectious virion 
involves cleavage by the viral protease at 11 separate sites to produce MA, CA, NC, p6, PR, RT, and IN 
proteins. MA remains associated with the viral envelope, whilst CA forms the capsid shell 
encapdisating NC bound RNA, and the PR, RT and IN enzymes. 
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consistently shown a 10-50-fold reduction in infectious virus release from cells12–14,76,734. 
Overexpression of its N-terminus leads to similar reduction in release15. 
The importance of VPS28 in viral budding was initially suggested by the localisation of 
VPS28 to HIV-1 Gag, and later Ebola VP40, at the plasma membrane565,735. This 
interaction was abolished upon mutation of its interaction site on TSG101. It was further 
shown that truncation of the TSG101 C-terminus including the VPS28 binding region 
abolished HIV-1 budding665,734.  
A direct effect on HIV-1 budding upon specific depletion of VPS37A, VPS37B or VPS37C 
has not been examined. However, when an MLV virus was engineered to be dependent 
on ESCRT-I for budding, by replacing its PPPY L-domain with the PTAP L-domain and 
surrounding sequence from HIV-1, depletion of either VPS37B or VPS37C showed partial 
inhibition of viral budding and an even stronger inhibition than TSG101 depletion upon 
co-depletion of both VPS37B and VPS37C657.  
Whilst depletion of UBAP1 has been shown to have no effect on HIV-1 budding, 
consistent with its specific role in endosomal sorting658, depletion of MVB12A or 
MVB12B, or co-depletion of both has been shown to reduce infectious virus release by 
a modest 2-5 fold, but not affect the actual level of budding, i.e. the overall release of 
virions667. Electron microscopy analysis of released virions revealed the reduction in 
infectious virus release to be due to an increase in budding of aberrant virions, that 
appeared electron dense and lacked discernible internal structures. A concomitant 
decrease in mature infectious virions with conical capsids was also seen667. This 
contrasts with depletion of TSG101 which shows a decrease in the overall levels of 
released virus, characteristic of defective ESCRT mediated viral budding. Interestingly, 
overexpression of MVB12A or MVB12B did cause a reduction in overall virus release that 
paralleled that of infectious virus release. Released virions also appeared mature. Unlike 
the phenotype seen upon TSG101 depletion, however, intracellular virions appeared to 
remain cell-associated but not directly connected to the plasma membrane, as seen for 
TSG101 overexpression667. Overall, these observations indicate that whilst MVB12A and 
MVB12B depletion appears to potentially perturb viral budding to a certain extent, the 
weaker phenotype and differences in terms of viral morphology, intracellular 
localisation and overall budding levels compared to TSG101 depletion indicates only a 




5.2.1. The effect of UMAD1 knockout on HIV-1 budding 
Given the importance of ESCRT-I, notably TSG101, for PT/SAP L-domain activity and 
previously described roles for MVB12A and MVB12B in ESCRT mediated viral budding 
(Section 5.1.2.), we decided to examine the effects of UMAD1 knockout on HIV-1 
budding. Also, given that viral budding is largely unperturbed by ESCRT-II depletion, the 
identification of potential bridging factors that link ESCRT-I to ESCRT-III in L-domain 
mediated viral budding is of great interest. An initial TZM-bl assay to measure infectious 
virus release following transfection of producer 293T cells and 293TDUMAD1 cells with 
the commonly used pNL-HxB full-length X4 strain HIV-1 infectious proviral plasmid 
appeared to show a 2-fold decrease in infectious virus release from 293TDUMAD1 cells 
compared to 293T cells (Figure 49A). In this assay, infectious virus release is quantified 
by measuring b-galactosidase activity, since TZM-bl reporter cells express this enzyme 
under the control of an HIV-1 LTR promoter, which is responsive to the HIV-1 tat protein 
upon infection with HIV-1.  
This modest decrease is similar to that previously reported for single depletion of either 
MVB12A or MVB12B667, and immunoblotting using a-Gag revealed that band intensities 
for budded virus appeared to mirror the levels of infectious virus release. However, 
immunoblotting of producer cell lysates appeared to show less cellular Gag for the 
293TDUMAD1 cells (Figure 49A, lane 3) compared to the wild type 293T cells (lane 1), 
suggesting that fewer viable cells were present throughout the period of virus 
production compared to wild type 293T cells. 293TDUMAD1 cells are noticeably more 
fragile than 293T cells, most likely due to the effects of UMAD1 knockout on cell division, 
so it is likely that despite seeding the same number of cells, more cell death occurred 
during seeding and throughout experimental repeats than for wild type 293T cells. This 
would have meant fewer producer cells, hence less virus production. From this it cannot 
be concluded that UMAD1 has an effect on viral budding.  
An experiment performed the same way in HeLa and HeLaDUMAD1 cells (which grow 
more slowly but are not as fragile as 293TDUMAD1 cells) (Figure 49B) showed no 
difference in the levels of infectious virus release from HeLaDUMAD1 cells. 
Immunoblotting of producer cell lysates and budded virions likewise revealed no clearly 
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visible difference in the levels of budded virus, or cellular gag. This finding makes it more 
likely that the decreased level of infectious virus release seen in 293TDUMAD1 cells is 
due to cell death rather than a genuine role of UMAD1 in viral budding.  
In contrast to 293T cells, transfection of HeLa cells with two doses of siTSG101, as a 
negative control, appeared to be considerably more toxic, causing substantial cell death, 
























Figure 49. UMAD1 knockout appears to have to discernible effect on HIV-1 viral budding 
A. The effect of UMAD1 knockout on HIV-1 viral budding is unclear using 293T cells. 293T and 
293TDUMAD1 cells were transfected with two doses of control siRNA (siNT) or siRNA against TSG101 
(siTSG101) with co-transfection of pNL-HxB HIV-1 provirus with the second siRNA transfection. TZM-
bl reporter cells were infected with clarified viral supernatant 48 hours later. TZM-bl cells were lysed 
a further 48 hours post-infection and infectious virus release readout was quantified by b-
galactosidase activity. Graph shows the mean levels of infectious virus release for 5 independent 
repeats normalised to the levels attained using 293T+siNT. Error bars represent the standard deviation 
from the mean. 293T+siTSG101: 0.09±0.06-fold, 293TDUMAD1+siNT: 0.54±0.09-fold, 
293TDUMAD1+siTSG101: 0.05±0.04-fold. Producer cell lysates were resolved by SDS-PAGE and 
immunoblotting using a-HIV-1 gag antibody was performed. Extracellular budded virions were 
purified by centrifugation through a 20% sucrose cushion and similarly analysed by SDS-PAGE and a-
HIV-1 gag immunoblotting. B. UMAD1 knockout appears to be having no effect on HIV-1 budding using 
HeLa producer cells. An experiment performed exactly as in A, using HeLa and HeLaDUMAD1 cells was 
performed. Graph shows mean levels of infectious virus release for 6 independent repeats normalised 
to the levels attained using HeLa+siNT. Error bars represent the standard deviation from the mean. 
HeLa+siTSG101: 0.01±0.01-fold, HeLaDUMAD1+siNT: 0.88±0.43-fold, HeLaDUMAD1+siTSG101: 
0.01±0.01-fold. 
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A. The effect of UMAD1 knockout on HIV-1 viral budding is unclear using 293T cells. 293T and 
293TDUMAD1 cells were transfected with two doses of control siRNA (siNT) or siRNA against TSG101 
(siTSG101) with co-transfection of pNL-HxB HIV-1 provirus with the second siRNA transfection. TZM-
bl reporter cells were infected with clarified viral supernatant 48 hours later. TZM-bl cells were lysed 
a further 48 hours post-infection and infectious virus release readout was quantified by b-
galactosidase activity. Graph shows the mean levels of infectious virus release for 5 independent 
repeats normalised to the levels attained using 293T+siNT. Error bars represent the standard deviation 
from the mean. 293T+siTSG101: 0.09±0.06-fold, 293TDUMAD1+siNT: 0.54±0.09-fold, 
293TDUMAD1+siTSG101: 0.05±0.04-fold. Producer cell lysates were resolved by SDS-PAGE and 
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5.2.2. The effect of UMAD1 knockout on L-domain dependent viral 
budding 
Further viral budding assays were performed to explore the possibility that UMAD1 
could be mediating more modest effects on PT/SAP L-domain dependent viral budding 
that are not so obvious using the experimental setup in figure 49. A side by side 
comparison of viral budding using pNL-HxB together with another full-length R9 HIV-
1NL4-3 provirus, and the same construct with a mutated, non-functional YPxnL ALIX 
binding L-domain (R9DYPxnL) (Figure 50A) was performed, initially using 293T and 
293TDUMAD1 cells (Figure 50B). Since the ALIX binding YPxnL L-domain in R9DYPxnL is 
mutated, is it assumed that L-domain mediated viral budding is rendered entirely 
dependent on the PTAP motif in this case, and its interactions with TSG101, hence 
ESCRT-I. We hypothesised that this would therefore make any potentially more modest 
contributions to PTAP mediated HIV-1 budding by UMAD1 more obvious. 
Whilst the same previously observed approximate 2-fold decrease in viral budding using 
pNL-HxB in 293TDUMAD1 cells compared to 293T cells was recapitulated, the same 
phenotype was not seen using either R9 or R9DYPxnL proviruses (Figure 50B). Far from 
a decrease in viral budding, an increase was seen in 293TDUMAD1 cells, although the 
standard deviations were large, again possibly due to varying amounts of cell death in 
293TDUMAD1 cells. 
A similar experiment using HeLa cells was performed using an additional two R9 proviral 
constructs containing a mutated PTAP motif and both mutated PTAP and YPxnL motifs 
(Figure 50C), as alternative negative controls to use, given the toxicity previously seen 
upon two doses of siTSG101 in HeLa cells (Figure 49B). As expected, viral budding was 
abolished using both of these constructs (Figure 50C lanes 2, 4, 6 and 8 from the left). 
No difference in the levels of infectious virus release was seen for HeLaDUMAD1 
compared to HeLa cells using either R9 or R9DYPxnL proviruses, and the standard 
deviations were lower, showing better reproducibility than in figure 50B, using 293T 
cells. 
Taken together, these assays show UMAD1 to be having no discernible effect on viral 





























































Results presented in this chapter suggest no apparent contribution of UMAD1 to HIV-1 
budding. One potential avenue to explore further, however, is the possibility of 
redundancy with the other MVB12-like proteins. It is likely that any of the MVB12-like 
subunits can be co-opted by HIV-1 for viral budding, so co-depletion of UMAD1 with 
MVB12A, MVB12B, UBAP1 or combinations of more than one of these subunits could 
potentially show more obvious effects. Mass spectrometry data from chapter 3 
suggesting that endogenous levels of UMAD1 expression are lower than that of MVB12A 
and UBAP1 also suggests that effects on viral budding upon co-depletion with other 
MVB12-like subunits could become more apparent. 
Given the effects on cytokinesis upon co-depletion of UMAD1 with ALIX (Chapter 4), 
another exciting area to explore would be the same in HIV-1 budding, especially since 
HIV-1 encodes an auxiliary ALIX binding YPXnL motif in addition to its dominant TSG101 
(ESCRT-I) binding PTAP motif, both of which have been shown to mediate L-domain 
activity (Section 1.7.1). Depletion of ALIX or mutation of the ALIX binding L-domain in 
HIV-1 has not been shown to significantly reduce HIV-1 budding, except in the context 
of a minimal proviral construct lacking the globular domain of MA and the N-terminal 
Figure 50. UMAD1 knockout appears to have no effect on L-domain dependent HIV-1 viral budding 
A. Schematic showing HIV-1 Gag constructs encoded by each of the proviral constructs used in B and 
C. Mutation of the TSG101 binding PTAP L-domain and ALIX binding YPxnL L-domain is shown. B. 
UMAD1 knockout has no effect on PTAP L-domain dependent HIV-1 budding using 293T producer 
cells. 293T and 293TDUMAD1 cells were transfected with two doses of control siRNA (siNT) or siRNA 
against TSG101 (siTSG101) with co-transfection of pNL-HxB, R9 or R9DYPxnL proviruses with the 
second siRNA transfection. TZM-bl reporter cells were infected with clarified viral supernatant 48 
hours later and lysed a further 48 hours post-infection. Infectious virus release readout was quantified 
by b-galactosidase activity. Graph shows the mean levels of infectious virus release for 3 independent 
repeats normalised to the levels attained using 293T+siNT. Error bars represent the standard deviation 
from the mean. pNL-HxB 293TDUMAD1+siNT: 0.62±0.32-fold, R9 293TDUMAD1+siNT: 1.30±1.03-fold, 
R9DYPxnL 293TDUMAD1+siNT: 2.32±1.59-fold. Producer cell lysates were resolved by SDS-PAGE and 
immunoblotting using a-HIV-1 gag antibody was performed. Extracellular budded virions were 
purified by centrifugation through a 20% sucrose cushion and similarly analysed by SDS-PAGE and a-
HIV-1 gag immunoblotting. C. UMAD1 has no effect on L-domain dependent HIV-1 budding using HeLa 
producer cells. HeLa and HeLaDUMAD1 cells were transfected with R9, R9DPTAP, R9DYPxnL and 
R9DPTAPDYPxnL proviruses. TZM-bl reporter cells were infected with clarified viral supernatant 48 
hours later and lysed a further 48 hours post-infection. Infectious virus release readout was quantified 
by b-galactosidase activity. Graph shows the mean levels of infectious virus release for 3 independent 
repeats normalised to the levels attained using R9 provirus. Error bars represent the standard 





domain of CA568. However, it is possible that co-depletion with UMAD1 could show more 
obvious effects, especially since depletion of UMAD1 does not show the same >10-fold 
decrease in budding seen upon TSG101 depletion: depletion of UMAD1 would not show 
a huge decrease in budding, allowing for more modest effects upon co-depletion with 
ALIX to be seen. 
With reference to the study by Morita et al. 2007667, on the effect of MVB12A and 
MVB12B depletion on HIV-1 budding, this study mainly observed a defect in virion 
infectivity, due to aberrant morphology, rather than budding. Similar analysis of virion 
morphology by electron microscopy is therefore another area for potential exploration. 
As for MVB12A/B depletion, a slightly elevated level of virions showing amorphous 
electron-dense morphology may be observed upon UMAD1 depletion, providing 
evidence for some involvement in viral budding in the form of a visual phenotype, that 
would not be clear from the assays to measure infectious virus release presented in this 
chapter. Since overexpression of MVB12A and MVB12B led to a reduction in virion 
release that was at least partially dependent upon ESCRT-I binding ability, similar 
overexpression studies could be performed using UMAD1 overexpression, using wild 
























General discussion and future work 
The ESCRT machinery represents the only cellular apparatus so far identified for 
directing “reverse topology” membrane remodelling events away from the cytoplasm, 
by assembly inside cytoplasm filled stalks. Since their original discovery in MVB 
biogenesis and endosomal sorting, the last two decades have seen a vast expansion in 
the number of mammalian ESCRT mediated processes, ranging from viral budding and 
cytokinesis to nuclear envelope reformation and lysosome membrane repair. Such 
discoveries have reinforced the identity of the ESCRT machinery as a modular system, 
whereby site-specific adaptor proteins ultimately recruit ESCRT-III to target membranes. 
Links to mitosis and the abscission checkpoint, and the potential ability of a hIST1-
CHMP1B polymer to direct ‘normal’ rather than ‘inside-out’ topology membrane 
remodelling have further demonstrated the essential role of ESCRTs as a key player in 
cell biology, and opened up many more avenues for future study. 
The importance of ESCRT-I is clearly demonstrated by the inability of cells to survive 
upon its depletion. ESCRT-I shows precise regulation of its cellular levels, as 
demonstrated by the action of the TSG101 steadiness box. This thesis has demonstrated 
similar regulation of VPS37 subunit levels, as presented in chapter 3, and the increased 
expression of ALIX as a potential compensatory mechanism to account for UMAD1 
knockout during cytokinesis also demonstrates tight control of ESCRT-I expression levels.  
Furthermore, ESCRT-I is conserved across species and is involved in many of the ever 
growing ESCRT mediated processes identified so far: endosomal sorting, cytokinetic 
abscission, viral budding, ARMM formation, lysosome membrane repair, neuron 
pruning, and potentially roles in plasma membrane repair and autophagy. 
In this thesis, I have characterised the conserved protein UMAD1 as a novel MVB12-like 
subunit of ESCRT-I that binds ESCRT-I in a manner similar to other MVB12-like subunits 
via conserved residues within a C-terminal UMA domain. Prior to this work, preferred 
pairing between UBAP1 with VPS37A to form an ESCRT-I complex with a function specific 
to MVB biogenesis and endosomal sorting was well described. UMAD1 represents the 
second example of an MVB12-like subunit that shows a degree of preferred pairing, in 
this case with VPS37C, although pairing with VPS37B is also observed. My work on 
UMAD1 together with previous studies of ESCRT-I composition suggests that VPS37-
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MVB12 pairing is mediated to varying extents in both selective and stochastic manners. 
Although preferred pairings with VPS37 subunits have not been seen for MVB12A and 
MVB12B, such pairings could likely become clearer by performing more finely tuned 
coprecipitation experiments. For example, immunoblotting using antibodies against 
MVB12A and MVB12B to examine levels of coprecipitation of these endogenous 
proteins by each of the VPS37 subunits, as performed for UMAD1 (Figure 34), could 
make any preferred pairing clearer. 
UMAD1 knockout shows reduced binding of TSG101 to the adaptor protein for 
cytokinetic abscission, CEP55. Consistent with this are results for phenotypic studies 
from chapter 4 that show both an increase in time taken for successful midbody 
resolution, and an increase in multinucleation in HeLaDUMAD1 cells. These results are 
indicative of a role in cytokinetic abscission and a more generalised role for UMAD1 in 
mediating successful cytokinesis, respectively. Whilst a similar role in cytokinesis cannot 
yet be excluded for MVB12A and MVB12B, this is equally likely to be a function specific 
role for UMAD1. This would represent a function specific role for UMAD1 in cytokinesis, 
similar to that seen in endosomal sorting for UBAP1. It is tempting in this way to 
speculate that specific MVB12-like subunits help determine function specific roles for 
ESCRT-I, mediated in part by their pairing preferences with VPS37 subunits. The ability 
to pair with more than one VPS37 subunit could potentially be to counteract tissue 
specific differences in expression levels of each of the VPS37 subunits. Alternatively, in 
cases where preferential binding to one VPS37 subunit over another is seen in the same 
cell type, this might be to ensure fine tuning of the levels of different MVB12-like subunit 
containing ESCRT-I complexes for a specific function, according to the ratio of the 
different VPS37 subunit levels.  
Aside strengthening binding of TSG101 to CEP55, a function for UMAD1 in cytokinesis 
could also be conferred by other as yet unidentified binding partners, just as the 
interaction between UBAP1 with HD-PTP helps confer a function in endosomal sorting. 
As mentioned in chapter 3, results to IP-TMT based mass spectrometry experiments 
suggest that ESCRT-I binding partners other than its own subunits bind with a much 
lower affinity or transiently. A technique such as BioID, more suited to identifying weak 
interaction partners could therefore potentially help identify such partners for UMAD1. 
This together with characterisation of regions responsible for binding would help further 
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define the function of UMAD1, and potentially the uncharacterised N-terminus 
upstream of the UMA domain. If proteins known to be involved in cytokinesis are 
identified, this may help provide clues as to whether it is involved at early or late stages 
of cytokinesis, in addition to abscission, and would help direct further study of the role 
of UMAD1 in cytokinesis.  
Other factors that could help define function specific roles for UMAD1 and the other 
MVB12-like proteins could include differences in localisation to specific membranes. 
This could be mediated by specific binding motifs, such as the MABP domains of 
MVB12A and MVB12B, or again via specific interaction partners. 
A synergistic increase in midbody resolution time upon co-depletion of UMAD1 with a 
partial depletion of ALIX suggests that UMAD1 contributes to cytokinetic abscission 
through a CEP55 – ESCRT-I – ESCRT-II – CHMP6 – ESCRT-III pathway for ESCRT-III 
recruitment which acts in parallel with a CEP55 – ALIX – ESCRT-III pathway for ESCRT-III 
recruitment as two partially redundant pathways. Further work will firstly involve 
further characterisation of these phenotypes by determining when multinucleation 
takes place, hence whether UMAD1 is involved at early, late or both stages of cytokinesis, 
in addition to abscission. Further time-lapse experiments to investigate CHMP4B-L-GFP 
localisation upon UMAD1 depletion are also necessary, to examine differences in the 
recruitment kinetics and localisation of ESCRT-III in more detail. Rescue experiments in 
which cytokinetic defects and abscission times are measured upon UMAD1 re-
expression in HeLaDUMAD1 cells will also help strengthen findings. 
Given the expansion of MVB12-like subunits in mammals, to include UBAP1, MVB12A, 
MVB12B and UMAD1, the potential for a degree of redundancy between these subunits 
suggests that similar testing of each of these proteins for roles in contributing to CEP55 
binding and cytokinesis may prove fruitful, as single depletions or co-depletion with 
UMAD1. Whilst UBAP1 appears to be specifically required for endosomal sorting, further 
reason to test co-depletion of MVB12A and MVB12B with UMAD1 stems from the fact 
that MVB12A and MVB12B show only weak phenotypes in endosomal sorting and viral 
budding compared to UBAP1 and TSG101 respectively. Co-depletion with UMAD1 could 
therefore potentially display stronger phenotypes both in cytokinesis and viral budding. 
Consistent with this is the finding that yeast Mvb12 shows the weakest sorting defects 
compared to depletion of other ESCRT-I subunits, suggesting its main role to be in 
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stability of the ESCRT-I heterotetramer, even though more functional roles have been 
suggested.  
As previously mentioned in section 4.1., a study by Okumura et al. 2013 showed a 
specific interaction between VPS37B and VPS37C paralogues with the calcium binding 
protein ALG-2, which had previously been shown to bind TSG101 and ALIX and proposed 
to act as a bridging protein between ESCRT-I and ALIX674. Interaction between ALG-2 
with VPS37B/C appeared to be stronger than with TSG101, particularly the interaction 
with VPS37C674. An interesting parallel can be seen here with UMAD1, which also 
specifically pairs with VPS37B/C with a preference for VPS37C, and with the roles of 
UMAD1 and ALIX in cytokinetic abscission. The importance of an interaction between 
ESCRT-I with ALIX in cytokinesis is perhaps more consistent with the original proposal by 
Carlton et al. 200855 that ESCRT-I simply acts to stabilise ALIX, rather than each protein 
being part of separate pathways for ESCRT-III recruitment to the midbody. Nonetheless, 
such a striking parallel with UMAD1 suggests that UMAD1 could additionally be 
contributing to cytokinesis through stabilisation of ALIX via ALG-2 dimers. Since this 
bridging via ALG-2 requires calcium, further multinucleation and abscission time scoring 
experiments could be performed to examine differences in the effects of depleting each 
of the MVB12-like proteins with and without chelation of calcium, by addition of EGTA.  
Interestingly, the recently described role for the ESCRT machinery in lysosome 
membrane repair suggests involvement of both TSG101 and ALIX in this process, as 
manifested by a delay in recruitment of CHMP4B to damaged lysosome membranes 
upon depletion of TSG101, and abolishment of recruitment upon co-depletion of 
TSG101 and ALIX (Section 1.8.6.). This is similar to the effects of depletion of TSG101 
and ALIX on cytokinetic abscission, although depletion of ALIX has consistently shown 
greater perturbation of cytokinesis than TSG101. Nonetheless, this interesting parallel 
also potentially suggests that testing contribution of UMAD1 to lysosomal repair could 
prove worthwhile, given the synergistic effects observed upon co-depletion of UMAD1 
and ALIX in cytokinesis. 
Although the marked increase in co-precipitated UBAP1 and MVB12A by TSG101 from 
HeLaDUMAD1 cell lysate can be attributed to reduced competition for binding to ESCRT-
I in the absence of UMAD1 (Chapter 3), this competition suggests that UMAD1 could 
potentially be involved in negative regulation of ubiquitin dependent endosomal sorting, 
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or other ESCRT-I mediated processes, as a subsidiary role. Given the comparatively small 
size and structural simplicity of UMAD1 compared to UBAP1, MVB12A or MVB12B, with 
the lack of any obvious ubiquitin binding motifs, one can speculate that UMAD1 could 
behave as a negative regulator by simply taking the place of UBAP1, or MVB12A/B within 
ESCRT-I. Pulse-chase experiments similar to those performed by Stefani et al. 2011196 
could be performed using wild type and UMAD1 knockout cells to compare EGF 
degradation and accumulation over time, to see if there is a decrease in 
accumulation/faster degradation of EGF in UMAD1 knockout cells. The cellular 
localisation of fluorescently tagged UMAD1 upon depletion of VPS4, or expression of 
VPS4 dominant negative catalytically inactive (E228Q) or ATP binding defective (K173Q) 
forms could also be examined for endosomal clustering phenotypes.  
It is often overlooked that MVB12A was originally identified not as an ESCRT-I 
component but as a protein named CFBP (CIN85/CD2AP family binding protein) 
identified in a screen for proteins that are tyrosine-phosphorylated upon EGF 
stimulation686. Phorphorylation was shown to increase binding affinity of CIN85/CD2AP 
to CFBP and promote EGF receptor downregulation through recruitment of Cbl ubiquitin 
ligase to the CD2AP/CIN85 complex. Similar phosphorylation of MVB12B was also later 
observed, in response to EGF stimulation667,685. Such phosphorylations of MVB12A and 
MVB12B perhaps suggests that similar post-translational modifications of UMAD1 could 
be required for its function. Another area of future work could therefore be to identify 
whether this is the case, and if so, test whether abolishment of such modifications has 
an effect on the cytokinesis phenotypes presented in chapter 4, and interaction with 
ESCRT-I.  
Our custom-made a-UMAD1 antibody does not detect endogenous levels of UMAD1 
protein, making it unsuitable for immunofluorescence microscopy experiments. One 
way of examining endogenous UMAD1 localisation more accurately than using cells that 
stably express exogenous fluorescently tagged UMAD1 would be to create CRISPR 
knock-in cells for a fluorescent tag immediately upstream of the first UMAD1 exon. This 
would ensure that fluorescently tagged UMAD1 is expressed at endogenous levels, thus 
minimising any undesirable effects due to overexpression, and UMAD1 localisation 
could be accurately observed in both fixed cells and time-lapse experiments. Time-lapse 
experiments to specifically examine localisation of fluorescently tagged UMAD1 to the 
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midbody would complement those to observe YFP-CHMP4B, as discussed in section 
4.2.6., providing a more detailed profile of the spaciotemporal localisation of both 
proteins in relation to each other in cytokinetic abscission. 
Although UMAD1 appears to be relatively ubiquitously expressed, according to the 
human protein atlas version 19, work could also be expanded to examination of UMAD1 
in a number of other cell lines derived from other tissues. This could potentially uncover 
any cell type specific differences such as perhaps stronger cytokinesis phenotypes, as 
presented in chapter 4.  
In conclusion, this thesis has characterised UMAD1 as a novel MVB12-like subunit that 
shows incorporation into a functional ESCRT-I complex, containing VPS37B or VPS37C 
with a preference for VPS37C. As is the case with the other characterised MVB12-like 
proteins, incorporation of UMAD1 into ESCRT-I is mediated via a conserved UMA 
domain at its C-terminus, through conserved residues. Regions conferring the preferred 
pairing with VPS37C remain to be discovered. The previously characterised interaction 
between TSG101 with CEP55 is reduced upon knockout of UMAD1 expression, and 
consistent with this are results from assays to measure time taken for abscission to occur, 
which demonstrate a role for UMAD1 in cytokinetic abscission. Quantification of 
cytokinetic defects in fixed cells has also demonstrated a more generalised role for 
UMAD1 in mediating successful cytokinesis, as seen by increased multinucleation upon 
UMAD1 knockdown. Synergistic increases in both multinucleated cells and time taken 
for successful abscission to occur are seen upon co-depletion of UMAD1 with ALIX. This 
has led to the hypothesis that UMAD1 contributes to abscission through a subsidiary 
CEP55 – ESCRT-I – ESCRT-II – CHMP6 – ESCRT-III branch of ESCRT-III recruitment to the 
midbody, which operates in conjunction with a more dominant partially redundant 
CEP55 – ALIX – ESCRT-III branch. Further microscopy has additionally demonstrated 
differences in the localisation patterns/presence of CHMP4B at the midbody upon 
UMAD1 depletion, further demonstrating a role for UMAD1 in ESCRT mediated 
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Appendix 1 – Supplementary material 
Oligonucleotides used in this thesis 
Primers for cloning and mutagenesis 
UMAD1 5’ Fwd CTCCTCGAATTCATGTTTCACTTCTTCAG 
UMAD1 3’ Rev ATATATCTCGAGTTATGAATCACAGAGCACTG 
UMAD1 L86S87D88/AAA 5’ Fwd TTAATGGCCGAGCTCGCAGCAGCAGTGCCGTTCACCCTG 
UMAD1 L86S87D88/AAA 3’ Rev CAGGGTGAACGGCACTGCTGCTGCGAGCTCGGCCATTAA 
UMAD1 V89P90F91/AAA 5’ Fwd GCCGAGCTCCTGAGCGATGCAGCAGCAACCCTGGCCCCGCATGTG  
UMAD1 V89P90F91/AAA 3’ Rev CACATGCGGGGCCAGGGTTGCTGCTGCATCGCTCAGGAGCTCGGC 
UMAD1 P108A 5’ Fwd ATCACTGACCTTGCAGACCACTTACTC 
UMAD1 P108A 3’ Rev GAGTAAGTGGTCTGCAAGGTCAGTGAT 
UMAD1 Y125A 5’ Fwd TATCACGGTTTTGGGCAGATTTCACTCTTGAA 
UMAD1 Y125A 3’ Rev TTCAAGAGTGAAATCTGCCCAAAACCGTGATA  
UMAD1 F127A 5’ Fwd CGGTTTTGGTATGATGCAACTCTTGAAAATTCA 
UMAD1 F127A 3’ Rev TGAATTTTCAAGAGTTGCATCATACCAAAACCG 
UMAD1 E130A 5’ Fwd TATGATTTCACTCTTGCAAATTCAGTGCTCTGT 
UMAD1 E130A 3’ Rev ACAGAGCACTGAATTTGCAAGAGTGAAATCATA 
RPA3 5’ Fwd CTCCTCGAATTCATGGTGGACATGATG 
RPA3 3’ Rev ATATATCTCGAGTCAATCATGTTGCACAATC 
 
Primers for sequencing 
pCR3.1 Rev  TAGAAGGCACAGTCGAGG 
pCMS28 Fwd  CTTGAACCTCCTCGTTCGACC 
pCMS28 Rev  GCTTCGGCCAGTAACGTTAGG 
pLKO1 Fwd GACTATCATATGCTTACCGT 
 
siRNA oligos 
Non-targeting siRNA ON-TARGETplus Non-targeting (Cat. No. D-001810-01, Dharmacon) 
siVPS37C CAGUCCUGGUUAUCCUCAAUU Cat. No. S104156096, Qiagen 
siTSG101  CCUCCAGUCUUCUCUCGUC (custom order siRNA, Dharmacon) 
siALIX 
siUMAD1 
GAAGGAUGCUUUCGAUAAAUU (custom order siRNA, Dharmacon) 
GCGAAAACUUAUCACGGUU (Cat. No. N-183515-16, Dharmacon) 
 
All sequences are shown 5’ – 3’ 
Fwd = Forward 
Rev = Reverse  
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Plasmids used in this thesis 
 







pCR3.1 HA EcoRI/XhoI Ampicillin Coprecipitations 
 pCMS28 YFP EcoRI/XhoI Ampicillin/Puro Immunoprecipitations, 
Imaging 




pCR3.1 HA EcoRI/XhoI Ampicillin Coprecipitations 
VPS28  pCR3.1 Myc NotI/NotI Ampicillin Coprecipitations 
VPS37A  pCR3.1 HA EcoRI/XhoI Ampicillin Coprecipitations 
 pCMS28 YFP EcoRI/XhoI Ampicillin/Puro Immunoprecipitations 
VPS37B pCR3.1 HA EcoRI/XhoI Ampicillin Coprecipitations 
 pCMS28 YFP EcoRI/XhoI Ampicillin/Puro Immunoprecipitations 
VPS37C pCR3.1 HA EcoRI/XhoI Ampicillin Coprecipitations 
 pCMS28 YFP EcoRI/XhoI Ampicillin/Puro Immunoprecipitations 
VPS37D pCR3.1 HA EcoRI/XhoI Ampicillin Coprecipitations 
TSG101 pCAGGS GST EcoRI/XhoI Ampicillin Coprecipitations 
 pCMS28 YFP EcoRI/XhoI Ampicillin/Puro Immunoprecipitations, 
Imaging 
 pHxB EcoRI/XhoI Ampicillin Viral trans-complementation 
UBAP1 pHxB NotI/NotI Ampicillin Viral trans-complementation 
HIV-1 Gag p6 pHxB EcoRI/XhoI Ampicillin Viral trans-complementation 
RPA3 pNG72 EcoRI/XhoI Ampicillin/G418 Testing a-RPA3 antibody 
 pNG72 YFP EcoRI/XhoI Ampicillin/G418 Testing a-RPA3 antibody 
Tubulin pCMS28 
mCherry 
NotI/NotI Ampicillin/Puro Imaging 
CHMP4B pNG72-linker 
GFP 






Antibodies used in this thesis 
 
Primary antibodies 
Antibody Species Source Dilution Application 
α-Tubulin Mouse, monoclonal Sigma (DM1a) Cell 
signalling 
1:1000 IF 
α-HA Mouse, monoclonal Covance (HA.11, 
16B12) 
1:1000 WB 




α-GFP Mouse, monoclonal  Roche (7.1/13.1) 1:5000 WB 
α-TSG101  Mouse, monoclonal Abcam (4A10) 1:1000 WB 
α-VPS37A Rabbit, polyclonal Proteintech 11870-1-
AP 
1:1000 WB 
α-VPS37B Rabbit, polyclonal Proteintech 15613-1-
AP 
1:1000 WB 
α-VPS37C Rabbit, polyclonal Gifted from Prof. Philip 
Woodman 
1:1000 WB 
α-CEP55 Mouse, polyclonal Abnova 1:500 WB 
α-HIV-1 p24 Gag Mouse, monoclonal  
 
NIH AIDS Reagent 
Program (183-H12-5C) 
1:100 WB 
α-UBAP1 Rabbit, polyclonal Proteintech 12385-1-
AP 
1:1000 WB 
α-RPA3 Rabbit, polyclonal Proteintech 10692-1-
AP 
1:1000 WB 
α-UMAD1 Rabbit, polyclonal Custom made by 
Lampire Biologicals* 
against residues 6-23 
1:100 WB 













Antibody Conjugation Source Dilution Application 
α-mouse IgG  HRP-linked Cell Signalling 
Technology 
1:1000 WB, LI-COR 
Odyssey 
α-rabbit IgG  HRP-linked Cell Signalling 
Technology 
1:1000 WB, LI-COR 
Odyssey 
Goat α-mouse  
 
680nm IRDye® LI-COR Biosciences 1:10000 WB, LI-COR 
Odyssey 
Goat α-rabbit  
 
800nm IRDye® LI-COR Biosciences 1:10000 WB, LI-COR 
Odyssey 








     
IF = Immunofluorescence 
WB = Western blotting 































































































































Complete list of mass spectrometry data for potential TSG101 interaction partners identified in 
sections 3.2.1. and 3.2.7. 
ESCRT proteins are highlighted in yellow. All proteins identified with >1 peptide are shown. Signal 
values for each identified protein, and the isobaric tandem mass tag (TMT) used for each sample are 
indicated. # Peptides = No. of different tryptic peptides detected. # PSM = Peptide Spectrum 
Matches, i.e. the total number of tryptic peptides identified for a protein (including those identified 





Experiments using siRNA against UMAD1 
 
  
Experiments using siRNA against UMAD1 
A. Clonogenic assay to compare cell growth upon transfection of siRNA against UMAD1. HeLa cells 
were transfected with a single dose of each siRNA shown. Cells were diluted 48 hrs later and colonies 
were left to grow for 10 days in wells of a 6-well plate. The mean area occupied by colonies on the 
base of each well is shown for 3 independent repeats, normalised to that of siNT, set at 1-fold. Error 
bars represent the standard deviation from the mean. siUMAD1: 0.983±0.174-fold. B. Quantification 
of cytokinetic defects attained upon transfection of siUMAD1. HeLa cells were transfected with two 
separate doses of each siRNA indicated. Following fixation and staining, the number of cells with more 
than one nucleus and the number of midbody connected cells were scored. The mean percentages 
for three independent experimental repeats are shown, with error bars representing the standard 
deviation from the mean. n > 900 cells per condition. sihIST1 was used as a positive control. siNT: 
3.400±1.493% multinucleated cells, 1.667±0.723% midbodies, siUMAD1: 4.667±2.312% 
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Review Article
Growing functions of the ESCRT machinery in cell
biology and viral replication
Edward J. Scourfield and Juan Martin-Serrano
Faculty of Life Sciences & Medicine, Department of Infectious Diseases, King’s College London, London, U.K.
Correspondence: Juan Martin-Serrano ( juan.martin_serrano@kcl.ac.uk)
The vast expansion in recent years of the cellular processes promoted by the endosomal
sorting complex required for transport (ESCRT) machinery has reinforced its identity as a
modular system that uses multiple adaptors to recruit the core membrane remodelling
activity at different intracellular sites and facilitate membrane scission. Functional connec-
tions to processes such as the aurora B-dependent abscission checkpoint also highlight
the importance of the spatiotemporal regulation of the ESCRT machinery. Here, we sum-
marise the role of ESCRTs in viral budding, and what we have learned about the ESCRT
pathway from studying this process. These advances are discussed in the context of
areas of cell biology that have been transformed by research in the ESCRT field, including
cytokinetic abscission, nuclear envelope resealing and plasma membrane repair.
Introduction
Seminal work in yeast identified the endosomal sorting complex required for transport (ESCRT)
through a series of studies of ∼40 vacuolar protein sorting (VPS) mutants that showed defective
sorting of proteins to the vacuole [1]. In a subset of these mutants, membrane proteins that were nor-
mally trafficked to the vacuole for degradation did not reach this compartment and accumulated in a
perivacuolar structure termed the class E compartment [1–4]. These class E VPS genes were subse-
quently found to encode components of four ESCRT complexes, ESCRT-0, -I, -II and -III, that are
necessary to recognise the ubiquitinated cargo and sort it into intralumenal vesicles (ILVs) at multive-
sicular bodies (MVBs) through inward invagination and budding of the limiting membrane away
from the cytoplasm [5–10].
The ESCRT proteins are conserved from yeast to humans [8,11,12], although a gene expansion can
be seen in higher eukaryotes. For example, ESCRT-III in humans possesses eight charged multivesicu-
lar body protein (CHMP) families, namely CHMP1–7 and human increased sodium tolerance 1
(hIST1). Additional genes for CHMP1 (CHMP1A and B), CHMP2 (CHMP2A and 2B) and CHMP4
(CHMP4A, 4B and 4C) exist, totalling 12 different ESCRT-III subunits identified so far. A key compo-
nent required for ESCRT function throughout evolution is VPS4, an ATPase that maintains the activ-
ity of ESCRT-III by promoting its disassembly for recycling purposes [13–15].
In addition to their role in MVB formation, ESCRTs were subsequently found to be involved in
topologically equivalent membrane remodelling events, notably facilitation of enveloped virus budding
[16–19] and cytokinetic abscission [20,21]. Over the last decade, the number of discovered
ESCRT-mediated processes has continued to expand to include plasma membrane repair [22,23],
axonal pruning [24–26], nuclear envelope (NE) resealing [27,28] and defective nuclear pore complex
(NPC) removal [29]. In each of these cases, the ESCRT machinery must assemble on the cytosolic
side of the limiting membrane, within membranous stalks, to stabilise negative membrane curvature
and mediate budding and scission away from the cytosol.
This review will first summarise what is known about the role of ESCRTs in viral budding and how
studies in this area have furthered our understanding of the ESCRT pathway. Focus will be paid to
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and NE resealing, together with spaciotemporal regulation of the ESCRTs and their coordination with the
abscission checkpoint. Finally, the role of ESCRTs in plasma membrane repair and modes of ESCRT-III poly-
merisation that may be relevant for membrane remodelling will be discussed.
ESCRTs in viral budding
The pioneering work by Göttlinger et al. [30] showed that the p6 region of the main human immunodeficiency
virus-1 (HIV-1) structural protein, Gag, is essential for viral release. The deletion of p6 resulted in tethering of
nascent virions to the plasma membrane by thin membranous stalks, thus suggesting that membrane remodel-
ling events required at the last step of viral assembly were impaired in these mutants. Subsequent work estab-
lished that this phenotype could be largely attributed to a conserved N-terminal 7PTAP10 motif in p6 [31].
Other conserved short amino acid motifs that were necessary for viral budding were soon identified, notably a
YPxnL motif in equine infectious anaemia virus (EIAV) p9-Gag [32] and a PPxY motif in Rous sarcoma virus
(RSV) p2b-Gag [33,34]. Given their activity in the final events of viral assembly, these motifs were termed late
budding domains (L-domains). The short length and proline-rich nature of these motifs suggested that their
role in viral budding could involve the recruitment of cellular proteins. This notion was further supported by
observations that L-domains were interchangeable and position independent within retroviral Gag proteins
[32,35,36].
The cellular pathway recruited by L-domains was revealed by the identification of the essential interaction
between PT/SAP motifs in HIV-1 and Ebola virus with the ESCRT-I subunit tumour susceptibility gene 101
(Tsg101), via its ubiquitin enzyme variant (UEV) domain [16–19,37,38]. YPxnL motifs on the other hand were
shown to recruit the ESCRT-associated protein ALG-2-interacting protein X (ALIX) via its V domain
[11,12,39,40], whereas PPxY motifs promote viral budding by binding to members of the NEDD4 (neural pre-
cursor cell expressed developmentally down-regulated protein 4)-like HECT domain E3 ubiquitin ligases,
notably WWP1 (WW domain-containing E3 ubiquitin protein ligase 1), WWP2 (WW domain-containing E3
ubiquitin protein ligase 2) and Itch via their WW domains [41,42]. Although functional redundancy between
these ubiquitinases in viral budding was originally suggested, a recent study has shown a preference for
NEDD4-1 and Itch ubiquitin ligases for Ebola virus budding [43], which encodes overlapping PTAP and PPEY
motifs [18,44]. The striking discovery of a primordial ESCRT system in Archae of the genus Sulfolobus has
revealed that the CHMP4 and VPS4 homologues are necessary for Sulphobus turreted icosahedral virus replica-
tion and budding [45–47]. These findings demonstrate an ancient, conserved role for ESCRTs in viral budding.
The widely conserved requirement in the release of enveloped viruses suggested a membrane remodelling
function of the ESCRT machinery, in particular of ESCRT-III. Importantly, ALIX recruitment to YPxnL
L-domains provides a direct link to ESCRT-III by directly binding to the CHMP4 proteins [11,12,40,48,49].
However, definitive pathways for ESCRT-III recruitment for the other two L-domains remain less clear.
ESCRT-II has been suggested as a necessary activity for HIV-1 genomic RNA trafficking [50], and subsequent
work has proposed a role for ESCRT-II as a potential bridging complex between ESCRT-I and ESCRT-III in
PTAP-dependent budding [51,52]. However, these hypotheses remain controversial as other studies do not
observe deleterious effects in viral assembly upon depletion of ESCRT-II [53,54]. Crucially, siRNA approaches
and VPS4 dominant-negative expression have established the essential role of ESCRT-III in each case
[17,37,55–57]. These findings together with the specificity found at the adaptor/L-domain level have given rise
to the concept that the ESCRT pathway operates as a modular machinery that uses different adaptor proteins
to recruit a core membrane remodelling activity at specific sites (Figure 1).
Detailed functional analysis of HIV-1, murine leukaemia virus (MLV) and EIAV assembly has shown that
viral budding requires only a small subset of the 12 mammalian ESCRT-III subunits. In particular, a prominent
role for CHMP2 and CHMP4 family members in L-domain activity has been demonstrated for HIV-1 and
MLV [52,56]. Accordingly, an axis that involves Gag–ALIX–CHMP4B–CHMP2A–VPS4 interactions is required
for EIAV release [57]. The involvement of other ESCRT-III subunits in retroviral budding is less clear, as deple-
tion of CHMP6, CHMP3 and the CHMP1A/B proteins only results in modest phenotypes at best
[52,54,56,57]. These studies strongly suggest that the core membrane remodelling activity only requires the
CHMP4–CHMP2 complex, while other ESCRT-III subunits may play accessory roles that are not required for
retroviral release.
Many viruses such as HIV-1, Ebola virus and MLV encode multiple L-domains. In each case, one appears to
show dominance whilst others seem to play subsidiary roles. For example, HIV-1 Gag has an ALIX-binding
LYPxnL motif in p6, in addition to its PTAP motif [11,39,58]. The PTAP–Tsg101 interaction appears to be its
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dominant mode of ESCRT recruitment, but ALIX overexpression can rescue budding of PTAP mutant HIV-1
[40,49]. A similar phenomenon has been described for MLV, whose Gag encodes PPPY, PSAP and LYPxnL
motifs, although the PPPY L-domain activity shows a clear dominance [59]. Ebola VP40 contains a PTAPPEY
sequence that binds Tsg101 and HECT ubiquitin ligases, and both activities are required for efficient viral
release [18,41,60]. Similar to HIV-1 and MLV, a third L-domain in VP40 interacts with ALIX and plays an
auxiliary function in viral release [61]. Possession of multiple L-domains may have evolved to confer an evolu-
tionary advantage to ensure viral propagation in the event of loss-of-function mutations of the dominant
L-domain, albeit at reduced levels. Another advantage would be to broaden viral tropism such that alternative
L-domains may exhibit differential dominance in multiple cell types, as has been shown for the LYPxnL motif
of HIV-1 in T cells [62].
One intriguing question that still needs to be fully answered is the role of ubiquitin in L-domain activity.
Evidence supporting a role here includes the enrichment of ubiquitin observed in many virus particles [63,64],
the discovery of ubiquitin ligases as host factors for PPXY type L-domains [41,42,65] and the substitution of
L-domain activity by attachment of ubiquitin to Gag [66,67]. Defining the mechanism and most relevant sub-
strates for ubiquitination has proved challenging, perhaps suggesting considerable redundancy in substrate
requirements. The importance of ubiquitination in viral budding is supported by the strong correlation
between viral budding and Gag ubiquitination in those viruses that exhibit PPXY motifs [65,68]. Accordingly,
mutation of ubiquitin acceptor sites in RSV Gag abolishes budding, particularly in the NC-p2 region that lies
close to the L-domains [69]. Importantly, L-domain-deficient EIAV and human T-lymphotropic virus can be
rescued by fusion of ubiquitin to Gag [66]. In the case of HIV-1, ubiquitination of residues in the vicinity of
the PTAP motif increases Tsg101 binding [70]. However, increased ubiquitination of Gag by introduction of a
PPXY motif does not enhance budding in the HIV-1 context [68]. In contrast, NEDD4-2 overexpression can
rescue budding of an HIV-1 that lacks L-domains by conjugating K63-linked polyubiquitin chains, despite the
lack of a PPXY motif [71]. Subsequent work has shown that the truncated C2 domain of NEDD4-2 provides a
natural Gag-targeting module, thus explaining an L-domain-independent recruitment of ubiquitin ligases to
the sites of viral budding [72,73].
One possible scenario contemplates that Gag ubiquitination could serve as a docking site for ubiquitin-
binding activities in ESCRT-I [Tsg101, UBAP1 (ubiquitin-associated protein 1)], ESCRT-II (Eap45) and ALIX
[70,74–77]. Accordingly, Tsg101 depletion abolished the ability of NEDD4-2 to rescue an L-domain-deficient
HIV-1 [73], and residues in the UEV domain of Tsg101 that bind ubiquitin are necessary for rescue of an
L-domain-deficient EIAV [66]. Moreover, mutation of the ubiquitin-binding sites in the V domain of ALIX
impairs retroviral budding [77]. A second scenario involving ubiquitination of trans-acting factors is also sup-
ported by data showing that NEDD4-2 overexpression induces the ubiquitination of ESCRT-I subunits [73].
Conversely, the fusion of a deubiquitinating activity to either Tsg101 or ALIX inhibits HIV-1 budding [78]. A
more compelling example of the importance of trans-acting factor ubiquitination in viral budding has been
provided by studies that used an engineered prototypic foamy virus Gag devoid of its single ubiquitination site,
which was fully functional in viral budding [79]. Ubiquitination-resistant foamy virus Gag was also capable of
budding when the PSAP motif was replaced with a PPPY motif derived from MLV, and viral budding in this
context was also enhanced by a catalytically active YFP-WWP1 in the absence of Gag ubiquitination [67,79].
Thus, a trans-acting factor must be the target of ubiquitination since Gag cannot be ubiquitinated in this
context. Some plausible candidates for ubiquitinated trans-acting factors are the arrestin-related trafficking
(ART) proteins. This family of proteins interacts both with HECT domain ubiquitin ligases (WWP1, WWP2,
Itch and NEDD4) and ESCRT-associated proteins (Tsg101, ALIX and ubiquitin), therefore providing potential
bridging interactions with the ESCRT machinery [41,80]. ARTs can be recruited to sites of viral budding and
they reduce MLV budding when overexpressed, but more definitive evidence is needed to support their role in
PPXY-dependent budding [80]. One related hypothesis is that the identity of the ubiquitinated protein may not
be critical for viral budding to proceed, as long as it is located in close proximity to Gag to allow the recruit-
ment of ubiquitin-binding components in the ESCRT pathway [67].
In addition to the established role in viral particle release at the plasma membrane, ESCRTs have also been
implicated in intracellular viral replication events that include both RNA and DNA viruses. The positive-strand
RNA plant viruses including Tomato bushy stunt virus and Brome mosaic virus recruit ESCRT-III to facilitate
inward invagination of peroxisome or endoplasmic reticulum (ER) membranes, respectively, to form replication
compartments [81,82]. These compartments are thought both to provide a protective environment, away from
viral RNA sensing host defence mechanisms, and to concentrate components necessary for viral replication.
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Unlike other ESCRT-mediated processes, no membrane scission is involved in the formation of the replication
organelles, as this compartment remains attached to the membrane. How this incomplete budding event is con-
trolled remains unknown but potential clues have been provided by the functional characterisation of ESCRT
requirement in flavivirus replication. Propagation of dengue virus and Japanese encephalitis virus was inhibited
by depletion of Tsg101 or ESCRT-III subunits. However, unlike other enveloped viruses, VPS4 is dispensable
for flavivirus replication, perhaps suggesting that unknown viral mechanisms inhibit the recruitment of VPS4
in this context to prevent membrane scission by ESCRT-III [83].
Other uses of the ESCRT machinery in viral replication include herpesviruses. This family of viruses requires
two separate envelopment stages for assembly and egress [84]. Primary envelopment allows nucleocapsids to
exit the nucleus through budding at the inner nuclear membrane (INM) and fusion of the resulting perinuclear
virion with the outer nuclear membrane, subsequently releasing nucleocapsids into the cytoplasm. Secondary
envelopment promotes budding of nucleocapsids, together with viral tegument proteins, into the lumen of
cytoplasmic membrane compartments that contain the viral envelope proteins [84]. Herpesviruses are likely to
use the ESCRT machinery at multiple stages during assembly, as Epstein-Barr virus recruits ALIX through the
viral protein BFRF1 for nuclear egress [85,86], whereas herpes simplex virus-1 (HSV-1) requires ESCRT-III for
secondary envelopment at the trans-Golgi network/endosomal compartments [87]. Although HSV-1 encodes
potential L-domain motifs, the viral mechanisms that recruit ESCRT-III to promote secondary envelopment
remain unclear [88].
ESCRTs in cytokinesis
Cytokinesis begins with the establishment of the spindle midzone, which derives from the metaphase spindle
after mitosis. The central area of the spindle midzone, or central spindle, is formed by microtubules overlap-
ping at their plus ends. The central spindle subsequently acts as a signalling hub from which signals to the cell
cortex emanate to specify the central cleavage plane, where the cleavage furrow is constricted by an actomyosin
ring [89,90]. Two important components of the central spindle orchestrate the cytokinetic process. The central-
spindlin complex is composed of two mitotic kinesin-like protein 1 (MKLP1) kinesin-6 motor subunits and
two cytokeratin-4 (CYK-4) Rho-family GTPase-activating subunits [91]. The chromosomal passenger complex
(CPC) is composed of Aurora B kinase, INCENP (inner centromere protein), Borealin and Survivin [92]. Both
centralspindlin and the CPC play roles in stabilising the central spindle and they are activated by dephosphory-
lation of cyclin-dependent kinase 1 (CDK1) substrate residues [93,94]. Aurora B-mediated phosphorylations of
centralspindlin and other components of the spindle midzone are also important in central spindle mainten-
ance [95]. The guanine-nucleotide exchange factor ECT2 (epithelial cell-transforming sequence 2 oncogene)
binds to the CYK-4 component of centralspindlin and thereby induces localised activation of the GTPase
RhoA at the cell cortex in response to decreasing CDK1 activity [96]. This localised RhoA activity determines
the cleavage plane at which actomyosin ring formation occurs through nucleation of actin and myosin II fila-
ments [97,98]. These filaments contract to eventually form a thin intercellular bridge connecting daughter cells
known as the midbody, with a central electron dense region corresponding to the compacted microtubules of
the central spindle known as the Flemming body [99,100]. Once the midbody is formed, the actomyosin ring is
disassembled through inactivation of RhoA by PKCε [101], and a decrease in membrane associated PI(4,5)P2
levels that result from the action of Rab35 and p50RhoGAP, which are delivered to the midbody by RAB11
(Ras-related protein Rab-11A)/FIP3 (Rab11 family-interacting protein 3)-positive endosomes [102,103].
The final event in cytokinesis is termed abscission and requires the resolution of the midbody to facilitate
the physical separation of the daughter cells [104,105]. The molecular mechanism underlying abscission has
remained elusive until recently as the identity of the membrane remodelling activities involved in this process
was not clear. An important clue to better understand abscission was the identification of centrosomal protein
55 (CEP55) as an essential adaptor protein required for midbody resolution [106,107]. In agreement with this
role, CEP55 stays inhibited during the early stages of cytokinesis via its phosphorylation by Polo-like kinase 1
(PLK-1), which inhibits the interaction with MKLP-1 to prevent the premature recruitment of CEP55 to the
midbody [108]. Towards the end of anaphase, PLK-1 is targeted for proteasomal degradation as a consequence
of its ubiquitination by the anaphase-promoting complex. As the level of PLK1 decreases, cytokinesis progresses
and CEP55 is dephosphorylated to allow the interaction with MKLP-1 at the Flemming body [108].
Functional analogies with viral budding and the interaction with CEP55 were instrumental to uncover the
essential role of the ESCRT machinery in cytokinetic abscission [20,21]. This discovery was quickly followed by
the surprising identification of CHMP4 and VPS4 homologues that are involved in cell division in Archaea of
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the genus Sulfolobus, thus suggesting that abscission is the ancestral role for ESCRT proteins as these organisms
lack endosomal systems [45,46]. In mammalian cells, CEP55 works as the adaptor protein, analogous to viral
Gag proteins, that recruits the ESCRT machinery to the midbody by directly binding to Tsg101 and ALIX
[20,21,109,110]. Like MVB formation and viral budding, ESCRT-III activity is required for abscission, as indi-
cated by the requirement for the ALIX–CHMP4B interaction in this process [21,109]. More recent work has
suggested that ALIX and the Tsg101/ESCRT-II axis constitute parallel arms that promote CHMP4B recruit-
ment [111], although this model requires further validation. Abscission requires midbody maturation and thin-
ning from an approximate diameter of 1.5–2 mm to ∼100 nm (Figure 2). This constriction can occur at either
side of the Flemming body at an approximate distance of 1 mm and it always forms ∼10–20 min before abscission
[112,113]. These secondary ingression zones coincide with the site of abscission and one model suggests that
they are formed by fusion of Golgi and recycling endosomes with the membrane. This is thought to be facili-
tated by members of the exocyst complex and SNAREs [SNAP (soluble NSF attachment protein) receptor],
which localise to the midbody via interaction with centriolin rings [114–116]. Alternatively, it has been pro-
posed that ESCRT-III polymerisation itself drives secondary ingression [117], perhaps facilitated by hIST1 —
an ESCRT-III subunit specific to cytokinesis that can direct polymerisation of filaments large enough to
promote abscission [118–120].
Time-lapse experiments have shown that whilst MKLP-1 and CEP55 are present at the Flemming body from
the time of its appearance, ESCRT proteins localise to the Flemming body at times closer to midbody reso-
lution [112,113]. Importantly, monitoring of fluorescently tagged CHMP4B and CHMP4A shows that closer to
the time of abscission, a separate pool of ESCRT-III appears specifically at the secondary ingression site at
which abscission occurs [113,121]. Here, the membrane appears rippled containing 17 nm diameter filaments,
which are likely to be those of ESCRT-III since they are not observed in CHMP2A-depleted cells [112].
Interestingly, the appearance of this separate ring of ESCRT-III is preceded by an increase in the fluorescence
of CHMP4B at the Flemming body, at the same side as the distal pool. VPS4 shows a similar localisation
pattern, but appears at the secondary ingression just after CHMP4B, consistent with its role in ESCRT disas-
sembly and recycling following abscission [113]. This ESCRT-III localisation pattern is consistent with a model
whereby nucleation of ESCRT-III polymerisation at the Flemming body first occurs followed by
VPS4-mediated breakage and constriction of outer ESCRT-III spirals, thus propelling them away from the
Flemming body to form the secondary ingression at an equilibrium position. VPS4-mediated disassembly
would then mediate the final scission event [121]. Other models have been proposed, such as continuous poly-
merisation and constriction of ESCRT-III spirals away from the Flemming body to deform the membrane and
form the secondary ingression [112]. Schiel et al. propose a model whereby ESCRT-III polymerisation instead
stabilises a pre-formed secondary ingression formed by vesicle fusion, such as by FIP3-positive endosomes
[103,122]. However, the importance of vesicle fusion remains controversial as the addition of vesicle fusion
inhibitors has no effect on abscission [112].
Cytokinesis is characterised by a tight spatiotemporal regulation, perhaps explaining the requirement for
most of the ESCRT-III subunits, in contrast with viral budding which only requires the core membrane remod-
elling subunits of ESCRT-III [123]. Completion of cytokinesis requires a complex coordination with activities
upstream of scission, such as furrow ingression and those involved in membrane binding, midbody stabilisation
and microtubule disassembly. In this context, severing of microtubules derived from the spindle midzone has
been shown to be a rate-limiting essential step in cytokinesis and its occurrence at secondary ingression sites
correlates closely with completion of abscission [112,124]. The microtubule severing AAA-ATPase Spastin
plays an essential role in this process, and when depleted, abscission is delayed [112,124]. All ESCRT-III subu-
nits encode microtubule-interacting and trafficking (MIT) domain-interacting motifs (MIMs) that interact with
MIT domain containing effector proteins, notably VPS4A/B and its effector LYST-interacting protein 5 (LIP5)
[125,126]. In addition to VPS4, Spastin is another MIT domain-containing protein that is specifically recruited
to sites of abscission via the MIMs of CHMP1B and hIST1 [124,127]. These interactions would be consistent
with a role for Spastin in abscission, thus suggesting a mechanism that co-ordinates microtubule severing with
ESCRT-III-mediated scission. An alternative model suggests that buckling of microtubules by spastin contri-
butes to abscission, rather than microtubule severing. This result is based on the disorganisation of the central
spindle microtubules in Spastin-depleted cells [128]. However, subsequent work has shown that Spastin plays
another key role during mitotic exit by coordinating NE sealing and spindle disassembly at NE–microtubule
intersection sites, perhaps explaining the disorganised spindle in Spastin-depleted cells [28].
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The ESCRT-III–Spastin interaction highlights an example of the adaptability of the ESCRT machinery that is
required to facilitate cytokinetic abscission. A second adaptation of the ESCRT machinery is illustrated by MIT
domain containing 1 (MITD1), which binds MIMs encoded by several ESCRT-III subunits, including
CHMP1A, 1B, 2A and hIST1 [129,130]. Whilst the N-terminal MIT domain in MITD1 mediates the interac-
tions with ESCRT-III, the C-terminal domain has a phospholipase D-like fold with a positively charged surface
patch that interacts with PtdIns (phosphatidylinositol)-containing membranes. The phenotypic characterisation
of MITD1-depleted cells suggests multiple roles in cytokinesis as evidenced by premature abscission, increased
cortical blebbing and cytokinesis failure. These phenotypes are consistent with a role of MITD1 in maintaining
the stability of the midbody and coordinating abscission with earlier cytokinetic events, perhaps by stabilising
ESCRT-III filaments and regulating the actin cytoskeleton [129,131].
The different MIT domain-containing proteins involved in abscission could be brought into close proximity
by interacting with the multiple MIMs that are present in the ESCRT filaments to couple activation of VPS4,
membrane scission and microtubule severing (Figure 2). However, despite this progress in our understanding of
abscission, some important questions remain unanswered. For example, the midbody persists from 80 min to
several hours before abscission, depending on the cell type. The events that occur during this time remain largely
unknown. A partial clue comes from the regulation of abscission by midbody tension [132], which can explain
an ∼30 min delay in HeLa cells, but we still do not understand the events that precede abscission in these cells.
It will also be important to understand how the recruitment of each of the ESCRT subunits is co-ordinated,
and the nature of the signal that triggers the polymerisation of ESCRT-III in the final moments of abscission.
ESCRTs and the abscission checkpoint
One of the most striking adaptations of the ESCRT machinery for coordinating cytokinetic abscission comes
from its interaction with the Aurora B-dependent abscission checkpoint, also known as NoCut [104,131]. This
evolutionarily conserved control system ensures that abscission is delayed until anaphase chromatin bridges,
caused by segregation errors, have been removed from the intercellular bridge connecting daughter cells [133–
135]. Such segregation errors are often caused by defects in chromosome architecture, such as impaired decate-
nation of DNA and dicentric chromosomes [136–138]. Failure to restrain abscission until clearance from the
midbody leads to cleavage furrow regression, tetraploidisation and DNA damage. NoCut was originally identi-
fied in yeast, in which the Aurora B homologue, Ipl1 kinase, was shown to inhibit septin-mediated abscission
upon interaction with chromatin [133]. In addition to chromatin bridges, the abscission checkpoint also delays
midbody resolution in response to defective NPC assembly [139] and high levels of midbody tension that
result from cell growth at low densities [140].
Aurora B plays a crucial role in the coordination of cytokinesis [92]. One of its critical functions in this
process is the phosphorylation of MKLP1 to stabilise the cleavage furrow, while the subsequent inactivation of
Aurora B triggers abscission [135]. Crucially, Aurora B activity is sustained in the presence of chromatin
bridges to delay midbody resolution, although how this activity is regulated by chromatin is not known
[133,135,141]. The signal by chromatin, however, is thought to be specific, since asbestos fibres within the
intercellular bridge do not sustain the checkpoint [135]. Intriguingly, the molecular origin of the chromatin
bridges has an important effect on checkpoint induction. Whilst chromatin bridges induced by replication
stress, condensation or decatenation defects sustain the abscission checkpoint, those due to the formation of
dicentric chromosomes are not detected by NoCut, thus resulting in chromosome damage by the abscission
machinery [142].
The physical connection between the abscission checkpoint and the abscission machinery was demonstrated
by the functional interaction between regulatory subunits in the ESCRT pathway and components of the abscis-
sion checkpoint. More specifically, abscission delays induced by nucleopore disruption and chromatin bridges
are abrogated by depletion of CHMP4C [141], a human ESCRT-III subunit that is closely related to the
polymer forming CHMP4B. At a molecular level, CHMP4C engages the CPC by binding to Borealin and this
interaction delays abscission via the Aurora B-dependent phosphorylation of CHMP4C at a unique insertion
that is not present in CHMP4B [141,143]. Importantly, the interaction of ESCRT-III with the CPC is conserved
from Drosophila to humans [143], and human polymorphisms in the CHMP4C gene are associated with
increased risk for ovarian cancer [144], thus highlighting the importance of this damage preventing regulatory
mechanism.
Abscission/NoCut Checkpoint Regulator (ANCHR) has been recently identified as another key component
of the abscission checkpoint [145]. ANCHR encodes two MIM sequences that interact with the MIT domain
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of VPS4 in an Aurora B-dependent manner. This interaction allows the formation of a ternary complex with
CHMP4C that retains VPS4 at the Flemming body, thus inhibiting its localisation to the secondary ingressions
that mark the abscission sites [145]. Unc-51-like kinase 3 (ULK3) was subsequently identified as an essential
regulator of the abscission checkpoint and its kinase activity is required for this function [140]. ULK3 acts
downstream from Aurora B to regulate abscission in a CHMP4C-dependent manner. Accordingly, ULK3 phos-
phorylates CHMP4C at sites distinct from those targeted by Aurora B. A subset of other ESCRT-III subunits is
also phosphorylated by ULK3, although the preferred substrate is thought to be hIST1, which binds ULK3 via
an especially strong MIT–MIM interaction. Critically, ULK3 phosphorylation of hIST1 is required to sustain
the checkpoint in response to lagging chromosomes and nucleopore disruption. However, a mutated version of
hIST1 that cannot be phosphorylated by ULK3 still supports abscission delays when the checkpoint is sustained
by low cell tension, suggesting that some downstream factors involved in maintaining the checkpoint may
differ depending on the stimuli [140]. The exact mechanism by which the various phosphorylation events
inhibit abscission is still unclear. One possible scenario is that the initial phosphorylation of CHMP4C by
Aurora B could be subsequently ‘amplified’ to other ESCRT-III subunits by ULK3 (Figure 3). These
phosphorylations could lock the ESCRT-III subunits such as hIST1 in their ‘closed’ inactive forms. It is also
possible that the various phosphorylations may retain ESCRT-III and VPS4 at the Flemming body, thus
preventing its polymerisation and scission activity at the secondary ingression sites. In agreement with this
model, phosphomimetic mutations enhance the hIST1 interactions with VPS4 and LIP5 [140], a cofactor
that promotes VPS4 oligomerisation and ATP hydrolysis [146–148].
One important question that remains open is the relevant subcellular location where CHMP4C inhibits
abscission. One possibility is that CHMP4C might form an inhibitory complex in the cytoplasm, as suggested
by the distinctive localisation of Aurora B to cytoplasmic foci in cells arrested by the abscission checkpoint
[139]. An independent line of evidence suggests that abscission regulation would require the midbody localisa-
tion of CHMP4C [141], which would be facilitated by ALIX and MKLP1 [111,149]. Once recruited to the
midbody, CHMP4C is initially found in the midbody arms, whereas the phosphorylation of serine 210 by
Aurora B allows its subsequent localisation to the Flemming body [141]. Interestingly, the CHMP4C subset
found at the midbody arms is phosphorylated at residues 214, 215 and 210, whereas the phosphorylation of
residues 214 and 215 is lost in the transition to the Flemming body [149]. In agreement with this notion, the
mitotic phosphorylation of CHMP4C decreases around the time of abscission [140,141], suggesting that a
phosphatase activity of unknown identity may be required to reverse the inhibitory activity of CHMP4C, thus
allowing abscission in midbodies that are arrested by the abscission checkpoint.
ESCRTs at the nuclear envelope
The nuclear envelope (NE) is a double membrane structure continuous with the ER that acts as a barrier,
establishing both nucleo-cytoplasmic compartmentalisation and protection of the genome from cytoplasmic
nucleases [150]. Whilst yeast undergoes a closed mitosis, mammalian cells undergo an open mitosis, in which
the NE and the nuclear lamina that lines the inner nuclear membrane (INM) are disassembled, allowing
chromosomes to access the mitotic spindle at prometaphase [150–153]. Dynein-mediated microtubule tearing
breaks down the NE, co-ordinated by numerous kinases including regulators that are shared with cytokinesis,
such as CDK1, Aurora B and PLK-1 [152]. The broken down NE is incorporated into the mitotic ER, which
remains intact, away from the spindle and segregating chromosomes [154–159]. Opposite events occur during
NE reformation, during which Aurora B and PLK-1 relocate to the central spindle and midbody, to control
cytokinesis, and CDK1 is inactivated [104]. The NE is reformed from the ER by attachment of ER tubules to
decondensing chromosomes [160]. These tubules flatten and enclose chromatin, leaving discontinuities of the
double membrane primarily at sites of mitotic spindle attachment [157,160–162]. Annular fusion must
therefore take place to seal such holes in close coordination with microtubule severing. Two ground breaking
studies have recently established the essential role of the ESCRT machinery in this process.
As observed for other functions of the ESCRT pathway, NE resealing requires the core membrane remodel-
ling activity of ESCRT-III [27,28]. Accordingly, knockdown of ESCRT-III subunits disrupts the integrity of the
NE and this phenotype correlates with increased DNA damage. This function is further supported by the local-
isation of CHMP2A and CHMP4B to the reforming NE into nucleo-cytoplasmic channels that are topologically
equivalent to other membrane tethers resolved by the ESCRT pathway [27,28]. In a striking parallel with
cytokinesis, hIST1 is required in NE reformation to recruit spastin and promote the disassembly of spindle
microtubules [28]. As observed in cytokinesis, microtubule severing is a rate-limiting step of the NE resealing
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process, as CHMP4B–eGFP persisted at unsealed holes upon inhibition of spastin activity [28]. In contrast with
cytokinesis, CHMP1B depletion did not perturb spastin localisation to the nucleus, suggesting differential
routes of recruitment in these two processes [28].
The two most likely candidates identified so far as adaptor proteins responsible for ESCRT-III recruitment
to the NE are ubiquitin fusion degradation protein 1 (UFD1) and CHMP7. UFD1 is an adaptor protein of the
p97/UFD1/NPL4 AAA-ATPase that has previously been implicated in NE resealing [163,164]. Prior to this, a
related complex containing p97 and p47 is involved in ER membrane recruitment to chromatin [163]. P97/
UFD1/NPL4 is also known to facilitate removal of Aurora B from chromatin to allow chromosome deconden-
sation [163,164]. UFD1 was shown to be necessary for ESCRT-III recruitment to the reforming NE, and this
function correlates with its interaction with CHMP2A [27]. CHMP7 is essential for ESCRT-III recruitment to
the NE, and this function correlates with a potential interaction with CHMP4B [28]. Closer examination of its
structure reveals a C-terminus similar to CHMP6 that is necessary for binding to CHMP4B, whereas the
extended N-terminus contains tandem winged-helix domains that resemble the ESCRT-II subunit
ELL-associated protein of ∼20 kDa (EAP20) [165,166]. The first of these tandem domains contains an
extended loop between the β2–β3 hairpin that is important for the specific localisation of CHMP7 at the ER
membrane [166]. The continuity of the ER with the NE suggests a model whereby CHMP7 provides a platform
that orchestrates the recruitment of ESCRT-III to the reforming NE.
The emerging role of the ESCRT pathway in establishing NE integrity has been extended beyond the mitotic
nuclear regeneration. NE breakdown is thought to be a rare event outside mitosis [167], but recent work has
shown that NE rupture occurs during migration of cells of the immune system, and similar nuclear ruptures
have been observed in cancer cells during metastasis [168,169]. Studies monitoring cell migration through con-
fined spaces have shown that NE blebbing occurs at the leading end of the cell in response to increased nuclear
hydrostatic pressure, and the NE is forced through ruptures in the nuclear lamina [168]. These blebs eventually
burst resulting in nucleo-cytoplasmic mixing and DNA damage. The rapid localisation of ESCRT-III to the site
of NE rupture is associated with a repair function that results in nucleo-cytoplasmic re-compartmentalisation
and reduced DNA damage. Following the repair by ESCRT-III, the accumulation of lamin A forms ‘lamin
scars’ that increase the local resistance of the NE to protect against subsequent rupture at the same sites [169].
The quality control of nuclear pore complexes (NPCs) has been identified as another function of the ESCRT
pathway to maintain nucleo-cytoplasmic compartmentalisation [170]. NPCs are central to maintaining nuclear
identity by controlling entry and exit of proteins and RNA, and consist of ∼600–700 individual subunits from
a repertoire of ∼30 different nucleoporins (Nups) [171–173]. Epistasis screens in yeast have uncovered a role
for ESCRT-III in the clearance of defectively assembled early NPC intermediates [29,174]. Since yeast
undergoes a closed mitosis, involving asymmetric division in which the NE is not broken down and
reassembled, such a quality control mechanism is thought to be essential to re-establish a fully functional NE
[29,170,175]. As yet, there is no evidence for an equivalent role for ESCRT-III in mammals, perhaps due to
less demand as a consequence of the open mitosis in these cells.
The initial clue to uncovering the role of ESCRTs in NPC surveillance was provided by the conserved
genetic interaction in fission and budding yeast between Vps4 and the transmembrane nucleoporin POM152
[174]. Additional genetic interactions were subsequently observed between POM152, Nup170 and the
ESCRT-III subunits sucrose nonfermenting protein 7 (Snf7) (CHMP4), Vps24 (CHMP3) and Vps2 (CHMP2)
[29]. Snf7 and, more recently, Chm7 (CHMP7) [176], were also found to interact with the INM LEM (LAP2,
emerin, MAN1) domain proteins Heh1 and Heh2, both of which interact with Nup170, perhaps during NPC
assembly [177]. Chm7 was shown to be recruited to sites of incomplete NPC assembly [176], and its recruit-
ment was shown to require Heh1/2 [176]. This strongly suggests that Heh1/2 acts as putative adaptors for
ESCRT-III recruitment to the NPC [29]. In agreement with this model, deletion of Heh2, ESCRT-III or Vps4
leads to clustering of malformed NPCs in a structure termed the storage of improperly assembled NPCs
(SINCs) [29]. Conversely, Chm7 deletion prevents SINC formation suggesting a role in defective NPC clearance
[176]. This storage structure forms at a single location at the NE and is therefore not inherited by the daughter
cells, thus representing an additional level of quality control of the NE in yeast [29,170]. Importantly, Chm7 is
also required for sealing of the NE over the top of malformed NPCs [176]. This demonstrates a conserved
mode of action in both NE resealing/repair and defective NPC removal through sealing of the NE to maintain
nucleo-cytoplasmic compartmentalisation.
How ESCRT-III and Vps4 could also potentially direct removal of defective NPCs is not clear. The catalytic
activity of Vps4 has been suggested to disassemble the defective intermediates, either directly or through the
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removal of NPC-bound ESCRT-III [29,170,178]. An alternative model would involve the ESCRT-III-dependent
budding of vesicles that contain the defective NPCs into the intermembrane space, a process that may resemble
the nuclear egress of Epstein–Barr virus [85,86].
ESCRTs at the plasma membrane
A direct role of the ESCRT pathway in remodelling the plasma membrane in diverse functional contexts has
emerged in the last few years. One of these processes bears striking resemblance to viral budding, namely the
formation of arrestin domain containing 1 (ARRDC1)-mediated microvesicles (ARMMs) [179,180]. A central
PSAP motif in ARRDC1 mediates interaction with Tsg101, as in viral budding, whereas localisation to the
plasma membrane is directed via an N-terminal arrestin domain. Furthermore, two C-terminal PPXY motifs
mediate interaction with WWP2 ubiquitin ligase, which ubiquitinates ARRDC1 and confers optimal ARMM
release [179]. ARMM formation is likely to require the core ESCRT machinery since vesicle release is inhibited
by catalytically inactive VPS4. However, the subset of ESCRT-III units required for this process needs to be
determined [179]. Whilst the function of ARMM release remains uncharacterised, ARRDC1 can be transferred
from donor to recipient cells, suggesting a role for ARMM contents or membrane-bound proteins in intercellu-
lar communication [179]. This transfer of material between cells also raises the question of how the released
vesicles fuse with the target cells. It is tempting to speculate that cellular fusogens may resemble the fusion
activity of viral envelope proteins, to deliver the microvesicle content into the target cells. ESCRTs have also
been implicated in shedding of ubiquitinated T-cell receptor (TCR) containing microvesicles from T cells at
immunological synapses, although the involvement of ARRDC1 in this budding event is not clear. This mech-
anism facilitates the interaction of TCRs with major histocompatibility complex-bound antigens on antigen-
presenting cells and promotes signal transduction [181].
Another ESCRT-mediated event at the plasma membrane is the microvesicle shedding induced by depletion
of the lipid flippase TAT-5 [182]. Loss of this P4-ATPase disrupts phosphatidylethanolamine symmetry leading
to accumulation of this lipid on the exterior side of the plasma membrane (PM). This lipid asymmetry in turn
triggers loss of cell adhesion and increased vesicle shedding, leading to a thickened appearance of the mem-
brane, which contains components of the ESCRT machinery [182]. Although the relevant adaptor protein is
unknown, ESCRT-0 and ESCRT-I are thought to be necessary for membrane thickening, but the role of
ESCRT-III in ectosome release needs to be established [182].
In addition to formation and shedding of microvesicles, ESCRTs have been implicated in PM repair by an
analogous process that involves pinching out of the damaged regions of membrane followed by scission and
shedding [22]. The plasma membrane can be damaged by exposure to bacterial pore forming toxins [183,184]
and mechanical stress, such as that seen in muscle tissue [185,186]. Experimental approaches to induce mem-
brane wounding include laser ablation, detergents and micropipettes. All membrane repair mechanisms
described so far share a dependence of calcium influx into the cytoplasm following wounding [186,187]. Such
mechanisms include clotting, patching and endocytosis or exocytosis of damaged regions [188–191]. Likewise,
the rapid recruitment of ESCRT-III to sites of wounding is calcium-dependent [22,23]. Whilst ESCRT-0 and
ESCRT-II are not involved in PM repair, Tsg101, ALIX, CHMP3, 2A, 2B, 1A and importantly 4B have all been
shown to localise to the PM upon wounding, and wound closure correlates with maximum CHMP4B levels at
the repair site [22,23]. ALIX is thought to play an important role in wound repair by bridging the calcium-
sensing protein apoptosis-linked gene-2 (ALG-2) with ESCRT-III at the PM, perhaps nucleating ESCRT-III
polymers via its interaction with CHMP4B [22,23]. ALG-2 therefore appears to act as the adaptor for ESCRT
recruitment to the PM. This model is consistent with the sequential recruitment of ALG-2, ALIX, ESCRT-III
and VPS4 to sites of wounding, as shown by confocal microscopy and TIRF imaging [22,23].
Finally, ESCRTs also play indirect roles at the plasma membrane, for example, by promoting the release of
exosomes [192]. This function requires binding of the intracellular adaptor protein syntenin and ALIX, and
this interaction promotes the release of exosomes as ILVs into multivesicular bodies by remodelling the endoso-
mal membranes [193,194]. These late endosomal compartments subsequently fuse with the plasma membrane
in an ESCRT-independent manner, thus releasing the exosomes to the extracellular medium.
ESCRT-III and membrane remodelling
In contrast with ESCRT-0, -I and -II, ESCRT-III does not form a stable complex, instead forming a transient
assembly at sites of membrane remodelling to direct scission [195]. The domain organisation and structure of
CHMP proteins has been well characterised [120,196], and studying MVB formation and viral budding has
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helped define the core CHMP proteins required for all ESCRT-mediated processes. Despite this progress, a
defined, unified mechanism for membrane sculpting and severing by ESCRT-III remains to be established.
Likewise, functional studies in cytokinesis indicate that each of the CHMP proteins may play differential roles
and cannot compensate for one another [117,131,197]. However, precise roles for each of the CHMPs in
ESCRT-III polymerisation and membrane remodelling remain to be defined.
Crystal structures for CHMP1B, 3, 4 and hIST1 have revealed that all CHMPs share a similar structure
[120,196,198–200]. In their ‘closed’ soluble autoinhibited conformation, they consist of a highly structured
N-terminal 4-helix bundle and an unstructured C-terminus, containing another two helices
[120,196,199,201,202]. In their ‘open’ polymerisation competent forms, the second and third helices from the
N-terminal bundle form a single elongated helix which forms a positively charged hairpin, together with helix
one [198], which binds acidic lipids to promote membrane binding [120,196]. Interactions between ESCRT-III
subunits are also mediated by this hairpin, particularly at the tip [120,196,199]. Other regions involved in inter-
subunit interactions remain to be confirmed but are likely to include other surfaces of the first four helices that
together comprise the core structure [56,198,200] and the fifth helix [120,196,201,203,204]. The fifth helix is,
however, more commonly associated with an autoinhibitory function, maintaining CHMPs in their ‘closed’
monomeric conformation in the cytoplasm when not in use. The fifth helix folds back on the four helix bundle
forming numerous contacts with the helices [120,196,201,202,204,205]. MIM domains are present in the
C-terminus of all CHMPs except CHMP3 [199,202,206]. MIT domain-containing proteins can stabilise the
open conformation of the CHMPs by binding to the conserved C-terminal MIM [201].
Studies in yeast initially showed the highly ordered assembly of CHMPs in a sequence that starts with Vps20
(CHMP6) and follows with Snf7 (CHMP4), Vps24 (CHMP3) and Vps2 (CHMP2), which recruits Vps4 to
promote ESCRT-III disassembly [9,195]. According to this model, Vps20 would act as the nucleator for initial
polymerisation of Snf7, which is thought to be the main constituent of the ESCRT-III filaments [204,207].
These polymers would be capped by the Vps24/Vps2 dimer that in turn recruits Vps4 for filament disassembly
[125,195,208]. The specific roles of these core subunits are thought to be conserved in mammals [209,210],
although additional proteins, such as ALIX and CHMP7, may also have nucleating activity in higher eukaryotes
[28,40,165,211]. Nucleation of ESCRT-III involves transition of CHMPs from ‘closed’ to ‘open’ forms as a
result of structural reorganisation upon binding to ESCRT-II/ALIX [195,207,212–214]. Membrane curvature
has also been shown to promote nucleation [213,215]. One interesting feature observed in some of the nucleat-
ing factors is their ability to dimerise. For example, ESCRT-II contains two EAP20 subunits which are each
able to bind separate CHMP6 molecules and therefore nucleate two ESCRT-III filaments
[207,212,214,216,217]. ALIX can also dimerise through its V domain and bind two CHMP4 subunits [211].
Such pairing of ESCRT-III filaments is likely to account for some of the diversity in filament width that is
observed in vitro and in vivo [112,200,203,218,219]. In fact, ALIX has been shown to bundle pairs of 3 nm
CHMP4B filaments in vitro [205,211], whereas the spiral filaments formed in vivo when CHMP4B is overex-
pressed have an approximate width of 6 nm [203], perhaps suggesting that bundling of two ESCRT-III fila-
ments could underlie the formation of these structures. Similar observations have been made in the context of
yeast Snf7, whereby bundling produces proto-filaments wider than 9 nm [204].
Electron microscopy has shown a variety of structures, both in vitro and in vivo for various ESCRT-III fila-
ments, including spirals, tubes, coils, cones and domes [200,204,208,218–220]. The overexpression of CHMP4A
in COS-7 cells forms flat spirals, which form tubes projecting from the plasma membrane when a VPS4
dominant-negative mutant is expressed, consistent with membrane budding away from the cytoplasm [203].
Yeast Snf7 forms a variety of filaments, rings and sheets in vitro [205,211]. A recent study showed that, when
incubated with membranes, Snf7 forms spirals in which the inner ring is over bent, hence storing less energy
than outer rings which are underbent [221]. Such spirals showed spring-like buckling activity when they even-
tually covered the entire membrane, pushing ESCRT-III outwards, suggesting that lateral compression causes
the spirals to deform into tubes, releasing stored elastic energy to remodel membranes [221]. Like CHMP4,
CHMP2A also forms spirals when the C-terminal autoinhibitory region is removed [208,219], whereas
CHMP2B forms tubes of varying diameters when overexpressed [222]. Importantly, coexpression of CHMP2A
and CHMP3 forms heteropolymeric tubes that end in dome-shaped caps [203,208,223]. Another fascinating
study has recently determined a high-resolution hIST1–CHMP1B structure by cryo-electron microscopy [200].
The tubular structure of this straight heteropolymer revealed an outer surface of ‘closed’ hIST1 that is
negatively charged, whilst CHMP1B assumed an ‘open’ state in the inner surface that forms a cationic interior
[200]. Remarkably, the inner surface was able to bind membranes and promote scission of membrane tubules
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with normal topology, i.e. scission from the outside of the membrane rather than from the inside, as commonly
associated with the ESCRT machinery [200]. This study raises the question of whether closed CHMP confor-
mations always correspond to autoinhibited incompetent forms, or just membrane-binding forms. Secondly, it
raises the surprising possibility that CHMPs are indeed capable of directing membrane scission in diverse topo-
logical contexts, a model supported by increased endosomal tubulation in hIST1-depleted cells [224].
Various models for ESCRT-III action have been proposed based on the structures observed so far [225]. These
models take also into account the importance of CHMP4 and CHMP2/3 subunits, energetic considerations and
localisation of subunits in relation to cargo in MVB formation, as well as observations in the context of viral
budding. The ‘whorl’ model of ESCRT-III assembly was proposed to accommodate the initial role of ESCRT-I
and -II in initial membrane stabilisation at bud necks of ILVs [226]. ESCRT-I and -II form a crescent-shaped
supercomplex that is believed to facilitate initial membrane bending that aids ESCRT-III nucleation. Pairs of
ESCRT-III filaments are proposed to form spokes that extend away from each ESCRT-I–ESCRT-II complex,
meeting at the site of scission [226]. The natural propensity for filaments to bend would allow the ESCRT-III
filaments to form a ‘whorl’ shaped structure that would constrict the membrane towards the site of scission.
VPS4 has been suggested to play an organisational role in this context by clustering the ends of the spokes at the
site of scission [226]. Dome models have gained more plausibility given the strong experimental evidence that
supports dome-shaped caps at the ends of tubular structures formed by CHMP2/CHMP3 [208,227]. Crucially,
this model has the potential to explain how ESCRT-III could remodel membrane necks of different diameters
ranging from 50 nm, as required for viral budding, to 1 mm in cytokinesis. Dome models involve binding of
membrane to the outside of dome-shaped caps of tubules, which pull opposing membranes together to constrict
bud necks and drive scission [208,225,227,228]. Whether membrane scission requires VPS4 in this context is
unclear at present [200,228]. It is also unclear whether CHMP2 and 3 are incorporated into growing CHMP4
filaments or whether they form a separate dome-shaped cap on the end of the tubes [112,204,208,229]. This
Figure 1. Site specific adaptors and pathways for ESCRT-III recruitment.
Schematic depicting adaptor proteins necessary for recruitment of ESCRT-III to sites of membrane remodelling and pathways
for ESCRT-III recruitment that are both well established and speculative/require further validation. Adaptors are boxed, adjacent
to their relevant ESCRT-mediated process. Solid lines represent established interactions. Dashed lines represent interactions
that are either speculative or require further validation, such as the role of ESCRT-II in viral budding/cytokinetic abscission.
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aspect could have profound implications in this model as a switch from CHMP4 homopolymerisation to hetero-
polymerisation of CHMP2/3 would be required to achieve membrane scission.
In addition to ‘whorl’ and ‘dome’ models, inverse buckling of ESCRT-III cones/domes has been suggested to
drive membrane scission [221,230]. In this model, over bent filaments at the tip of the cones are severed from
upstream ESCRTs, such as ESCRT-I, ESCRT-II and ALIX, by the action of VPS4, causing stored energy to be
released by inverse buckling, back into 2D spirals [225,230]. Release of energy stored in the bent membranes
would simultaneously drive scission. This model would require outward growth of filaments from the narrow
tip towards the wider end of the cone, consistent with tapering of the cone towards HIV-1 Gag seen by
deep-etch electron microscopy (DEEM) [220]. However, it would be difficult to apply this model to cytokinesis,
where ESCRT-I, ESCRT-II and ALIX localise to the Flemming body and have not been observed at the abscis-
sion sites [112,113]. The orientation of ESCRT-I and -II complex-bound cargo in relation to the ESCRT-III
cones also makes this model attractive in terms of providing an explanation for how MVB sorted cargo is
sorted into ILVs whilst ESCRT-III monomers are recycled to the cytoplasm [225,231].
Whilst the role of VPS4 in disassembly and recycling of ESCRT-III is well established, it is still unclear
whether or not it plays a direct role in membrane deformation and/or the actual membrane scission event.
Neither Vps4 nor Vps2 appears to be required for scission of ILVs in yeast, but both are required for
Figure 2. Localisation and action of the ESCRT machinery during cytokinetic abscission.
The adaptor protein CEP55 recruits ALIX and Tsg101 to the Flemming body — an electron dense structure formed at the centre of the midbody,
where microtubules derived from the central spindle overlap. ALIX–CHMP4B and Tsg101 (ESCRT-I)-ESCRT-II-CHMP6 have been proposed to form
parallel arms of recruitment for ESCRT-III to the midbody. Prior to abscission, ESCRT-III and VPS4 appear both at the sides of the Flemming body
and in distal pools as 17 nm filaments ∼1 mm away from the Flemming body, where the membrane appears rippled. These distal sites correspond
to the sites of abscission and are known as secondary ingressions because the membrane tube is thinned from 1.5–2 mm to ∼100 nm here,
possibly by vesicle fusion with the membrane prior to ESCRT-III arrival, or directly by ESCRT-III constriction. The ‘cut and slide’ model for
abscission proposes VPS4-mediated breakage of ESCRT-III filaments at the initial pool at the sides of the Flemming body, followed by constriction,
leading to propulsion away from the Flemming body to form/reach pre-formed secondary ingression sites. Here, continued polymerisation would
mediate scission. Alternatively, continuous ESCRT-III polymerisation from the Flemming body to the secondary ingression sites has been proposed,
as has independent nucleation of ESCRT-III at pre-formed secondary ingression sites. Microtubule severing is a rate-limiting step of abscission and
is performed by spastin that binds CHMP1B and hIST1 via MIT–MIM interactions.
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subsequent rounds of scission, arguing for an ESCRT-III recycling role for Vps4 [229,232]. Furthermore, the
hIST1–CHMP1B helical tubes discussed above could be formed in the absence of VPS4, suggesting a dispens-
able role for polymer assembly, at least in vitro [200]. Despite this evidence, the role of VPS4 remains an open
question, and a more direct role in membrane remodelling is possible, given its localisation to sites of mem-
brane scission such as the stalks of budding HIV-1 virions [233,234] and abscission sites during cytokinesis
prior to scission [113]. One simple model that could unify several observations is the sequential removal of
ESCRT-III subunits by VPS4, which could drive membrane constriction perhaps by constricting the ESCRT-III
filaments up to a point where spontaneous membrane scission can occur [227,235].
As summarised in this section, there has been spectacular progress over the last few years in our understanding
of the molecular mechanisms employed by ESCRT-III to promote membrane scission. However, the mechanism of
ESCRT-III polymerisation should be treated with caution at this stage due to the overexpressed nature of some of
the experimental systems, as well as the limitation posed by the lack of the entire set of ESCRT-III subunits that are
found in physiological conditions. In these respects, greater effort should be devoted to better understanding the
structure of the ESCRT-III filaments assembled under strict physiological conditions. Cytokinetic abscission
Figure 3. The ESCRT machinery in the NoCut Aurora B-dependent abscission checkpoint.
Aurora B kinase, a component of the CPC, is activated by phosphorylation. Activated Aurora B phosphorylates MKLP1, which ensures cleavage
furrow stabilisation. Aurora B also phosphorylates CHMP4C which is brought into the proximity of Aurora B via its interaction with Borealin, another
CPC component. Phosphorylation at residue 210 of CHMP4C is important here, within an insertion specific to CHMP4C between the MIM- and
ALIX-binding regions. CHMP4C acts upstream of and is necessary for ULK3 kinase activity. ULK3 also phosphorylates CHMP4C, at separate sites
within the MIM, and other ESCRT-III subunits. However, its best characterised substrate is hIST1, with which it interacts via a strong C-terminal
MIT–MIM interaction. These phosphorylations have been proposed to halt abscission by potentially binding to VPS4 and retaining it at the
Flemming body and/or preventing VPS4 activation through inhibition of assembly, and/or maintaining ESCRT-III subunits in ‘closed’ inactive forms
incapable of polymerisation. ANCHR is another component of the checkpoint that has been proposed to act in concert with CHMP4C to bind and
retain VPS4 at the midbody in an Aurora B-dependent manner. Question marks represent speculative interactions that have not been validated.
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perhaps represents an interesting area that could benefit from such work, given the large size of the polymeric
ESCRT-III structures that are proposed to promote the physical separation of daughter cells.
Concluding remarks
The co-option of the ESCRT machinery by an increasing number of intracellular processes, together with the
identification of various adaptors for recruitment of ESCRT-III to specific sites, has reinforced the modular
nature of the ESCRT machinery. The control in cytokinesis by the abscission checkpoint, as well as the role of
ESCRTs in multiple events at the NE, has demonstrated the interplay and precise spatiotemporal coordination
of the ESCRT machinery with cellular processes that are involved in quality control.
The binding partners of the different L-domains and the essential ESCRT-III subunits required for viral
budding are well established. However, the biggest remaining question in this field is exactly how ESCRT-III is
recruited to the sites of viral budding, and how membrane remodelling is achieved in this context. Whilst
ALIX provides direct bridging of viral structural proteins with ESCRT-III, we still lack a clear consensus regard-
ing ESCRT-III recruitment in PTAP and PPXY-dependent budding. Questions that remain unanswered in
cytokinetic abscission include how ESCRT-III is recruited to the sites of abscission that are adjacent to the
Flemming body, and how the membrane tube of ∼1 mm is severed, given that the diameters resolved in other
ESCRT-mediated processes are much smaller, in the range of 50–100 nm. Why the midbody persists for so
long before abscission occurs, and what triggers the final cut is also unclear. Intriguing connections between
the nucleus and the midbody are suggested by the delays in abscission that are induced upon disruption of the
nucleopores, and the nature of this signal needs to be uncovered. This connection is further highlighted by the
recent discoveries that demonstrate the essential role of the ESCRT machinery in establishing and maintaining
the integrity of the NE, suggesting that a tight coordination of the ESCRT complexes is needed at multiple
steps during the final events of cell division. In fact, this coordination might be required in other cellular com-
partments, as the localisation of CHMP7 in interphase strongly suggests potential roles of the ESCRT pathway
at the ER.
The variety of structures seen for homo and heteropolymers of CHMP proteins in vitro and in vivo has pro-
vided the basis to better understand the dynamic conformation of ESCRT-III and the mechanism that pro-
motes membrane scission. However, a better characterisation of the polymers formed in vivo is required to
understand membrane remodelling by ESCRT-III; it is even possible that different structures might be adopted
by ESCRT-III at different sites of action. Further insights into the mechanism of ESCRT-III action is likely to
come from higher resolution microscopy techniques, such as the DEEM employed so far, and newly developed
super-resolution microscopy will be better suited to address these issues.
In terms of the clinical implications of ESCRTs, their role in viral maturation and budding presents potential
avenues for therapeutic intervention in HIV-1, Ebola, Hepatitis C and other emerging viral infections. Changes
in expression levels of several ESCRT proteins have also been linked to various forms of cancer, and the con-
nection between polymorphisms in human CHMP4C and increased risk for ovarian cancer is particularly excit-
ing. Other relevant connections with human disease that need to be further explored include the link between
CHMP2B and neurodegenerative diseases such as frontotemporal dementia and Alzheimer’s disease [236–238].
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